<SEC-DOCUMENT>0000950170-24-034672.txt : 20240321
<SEC-HEADER>0000950170-24-034672.hdr.sgml : 20240321
<ACCEPTANCE-DATETIME>20240321160537
ACCESSION NUMBER:		0000950170-24-034672
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240321
DATE AS OF CHANGE:		20240321

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MiNK Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001840229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40908
		FILM NUMBER:		24771299

	BUSINESS ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		212-994-8250

	MAIL ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AgenTus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20210112
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>inkt-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-21T12:40:03.8977+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:inkt="http://minktherapeutics.com/20231231" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_d6829c8e-0a86-431c-914d-fc56ded86e08" name="dei:AmendmentFlag" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247">false</ix:nonNumeric><ix:nonNumeric id="F_56a93653-5ac0-43e1-a736-13ae28d9d6c5" name="dei:DocumentFiscalPeriodFocus" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247">FY</ix:nonNumeric><ix:nonNumeric id="F_b33ac35d-4c62-4f3b-8d5a-c4723b47fa1e" name="dei:EntityCentralIndexKey" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247">0001840229</ix:nonNumeric><ix:nonFraction id="F_1579128d-7e6a-4a6e-9792-dbbae8282bd9" name="us-gaap:CommitmentsAndContingencies" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_136c5469-8cc9-4126-a3dc-d9ccade676d2" name="us-gaap:CommitmentsAndContingencies" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" unitRef="U_USD" xsi:nil="true"/><ix:nonNumeric id="F_bf9d2624-e5f8-4332-8ece-0d2f7a8edc9c" name="us-gaap:OpenTaxYear" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247">2018 2019 2020 2021</ix:nonNumeric><ix:nonNumeric id="F_e22d9b5d-ce5f-4f3e-922e-62300307dbb9" name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247">2037-12-31</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="inkt-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_dc1f8474-7a37-45c5-a06a-9ca912012dca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a95821e-13b6-49df-9115-37827f9a727f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a5913b2-d4ec-4aae-bf25-d4732ba15bdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">inkt:NasdaqMvlsNoticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-23</xbrli:startDate><xbrli:endDate>2024-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df7ebdbc-60ae-490c-baef-5224675cbc1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4dec32d-a6b7-4422-b38c-c1ea75f485c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a02edeb-2a2b-41a7-856e-4ba72582b120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6874be7-da49-437b-ba93-4e3f9f01d838"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8de82880-160e-43df-8a06-7bd23e1206fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6d89eba-0f82-40fd-b984-843734274884"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b633005e-91ea-43eb-97fa-7e4b54c42a57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inkt:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c2d616e-4ddf-4064-8944-7301eb485567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ce3db47-5730-4c1e-bcf4-44053fd9ff21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:WolfGreenfieldSachsPCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51eb493f-bc2b-4fd9-b5aa-efa55fc34f2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f88878f-2cfe-43e5-b0ca-654e225c9a1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AtlantClinicalLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26d61948-a095-4072-b5b4-5cab95d54532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae710cfd-3658-456e-8236-9910244a165d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1cce805-eca1-48ac-8a3e-95ff6ff8052a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b187843-724c-4035-a8bd-2721f3e23008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4568e37-46c0-4e69-b2ec-5733ed214cac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_346638e3-eec6-429f-b5ff-617610cdae8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84ae0517-023d-4ec4-b8be-679864cc08aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e054ad4-ee65-43e9-bf29-ab336dac222b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inkt:PaymentForServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab635f33-5c9a-416d-95b3-be4679d91964"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inkt:NonVestedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92993aa5-8d2c-43e1-861d-dafd88c0d11f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inkt:NewIntercompanyServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_732341c7-957d-4682-9e02-69f3f41bc8cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f948c4b-dbf7-4fe1-80de-c2e6ec8ad0c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandAndEighteenEIPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0766000b-7486-4271-8d7f-0f025af31180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30bfebaf-513a-4ffd-92f3-96640e11b431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:WolfGreenfieldSachsPCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_74e50261-4062-42c1-85a6-53221008391a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0acbebda-ba84-4b3e-97b5-988e9d80a5aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25dc845e-01ae-44d3-831b-9b8aed9e8e67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">inkt:PurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inkt:ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-12</xbrli:startDate><xbrli:endDate>2024-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0540306-0080-4f2c-8d4d-23d53f4564e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">inkt:PurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inkt:ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8cc928c1-4773-48cd-b025-3a741ebaaee1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb7f200e-d650-4621-9cdf-076793f5da15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92fa1c95-ab93-4332-a14e-01ee475bc615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95392f28-5e39-4fdd-bb55-5bba87d291c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6bed87a6-106d-428e-a478-dc518b3adca0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70150baa-d209-420b-b3f0-9727e2e8e91b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AtlantClinicalLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-12</xbrli:startDate><xbrli:endDate>2022-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5eaab94b-6260-4a4a-a00c-52210c750bbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ed8c189-5338-453a-9f58-24dd7ab9d275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">inkt:DirectorsOrOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_419eb5b2-74d7-426a-8de0-6ec785c7a7e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inkt:PaymentForServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_174c7e6c-f05b-4cd6-b218-630f2cf7c135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b96f833e-9e89-4940-890a-3ad3066d1a3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30769c45-3fd9-4704-8227-5041637f5332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9607a901-9bb0-4a3b-a4c9-d3098e66534e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c81ea76b-898a-4328-bab5-6699b445169a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_268ec649-4cb5-49c6-a775-45044d13d5a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee885642-fc14-4425-b334-06fb0a0d1eea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d36c7999-649a-4daf-ab6e-976ec054bb05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inkt:EmployeeBonusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cefd892b-5378-4271-adcd-95443a008fca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a1ac15f-c735-4f88-9b7d-d2ba5526a4fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e412c6c7-5f47-4066-aab4-7147f2d0c3b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inkt:NonVestedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_514af47c-c76d-45ca-bffb-56d9b5ff3b74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed60fc07-4280-4084-b339-04048dfe71c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">inkt:NasdaqMvlsNoticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b3b3dc2-5df1-42cf-b22c-651f9e7e2441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcf77660-1f56-4511-acbc-a3e5c157ebe0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e66d751-8e58-4e0e-9b7c-eba65cf04289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7f39df2-940c-4946-a3d9-f259147aae28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b28e3d23-d775-4bbd-9547-580645e3901f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b57bd5bc-4306-4671-aabe-7907cd2bac83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inkt:EmployeeBonusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbf44c3c-afb7-4d6d-ae4b-5bcbfa6eb60d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cdfdfaeb-561e-445c-ae5b-25b64f9aebd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53b8ed07-cd44-46c7-8c61-16a3a18d3787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_442d530a-bd9b-4549-9f81-dfaba599e462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inkt:EmployeeBonusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12d6f787-9426-4e92-85b0-11024f100689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AtlantClinicalLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1fff5c2a-d559-4ece-acb2-fc94ed1c220d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inkt:IndividualServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b863875-076d-407c-9f20-f71f59c308af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb24caa1-2baa-4a9a-bc97-8c26392c5c44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_957e80a8-d4b5-459b-8ae0-7824ad63cf97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">inkt:NasdaqMvlsNoticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb216ed3-85fe-4453-894a-011e3ac6dfb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e13b52a1-81e9-4212-b833-7812073181d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">inkt:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e90aa4c-d975-4aee-8b77-ed3c9b0a38c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42c15bdd-fb56-4487-acc5-a92fa8762921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c28b56ad-700c-422d-b0b5-3496a8befd3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24cbce9b-fd20-4704-9a75-a6a645e49d55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_477e462d-66f4-4337-b1ec-ca7e1946fed2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8ef24c4-afb3-478b-a8f5-beceae45922e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bacbc03f-bcdc-458e-bcf7-0544b65ce927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ac170bb-03d4-44e8-b39d-948d34f91995"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:DrBuellMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9103c720-7b6a-415f-96e7-4b1a21557321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0c522b1-1207-430a-a24a-68c5917435b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandAndEighteenEIPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb159f01-5c87-4f27-ae80-397834ee1e9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandAndTwentyOneEIPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43fdd5bf-5e30-46cf-b276-ce4dac22ec86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AtlantClinicalLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc88111c-fde0-4875-b17d-3dcd2f81ff4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e994016-9f6a-4ddc-a1f5-464cebf76b9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42074970-bc84-4a58-b664-9c0013d5b65b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88fdd179-67f1-4d6b-afcb-9aa725675bbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56e9f88d-c09c-467c-a477-e97ed4507f16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">inkt:NasdaqMinimumBidPriceNoticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_637388a5-8881-487e-b1c7-e3b9f34f5c6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">inkt:NasdaqMinimumBidPriceNoticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-26</xbrli:startDate><xbrli:endDate>2024-02-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_396bcb04-2fa1-44c0-ba48-210a76d1239a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inkt:BusinessServicesAndOccupancyCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0247a7d4-1c63-48a2-b771-84ce9fed7ccf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:DrBuellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>inkt:Segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55350a1c-7232-4d1e-b476-1bbff8635a5d" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> (Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_e790b1b0-18b0-4dc1-9e78-439d673acd9a" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51b54b92-074d-48ab-a6bf-3c4e6c713300" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ad87a5c-98ad-4396-b52c-caa3b5d7bcfa" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f402a65e-3ae9-4571-b46e-5fc99fcdb352" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_61e6bb7a-06b2-4598-8d40-d63b00c62b0a" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf56e26b-5257-417a-acfd-ee0fd95d5d0c" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-40908</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:22pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2442111-b6cc-4282-b58c-748bc4116464" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:22pt;font-family:Times New Roman;min-width:fit-content;">MiNK Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_9642aa3f-c403-4d5c-98df-67e5bc9819ff" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_1fed25d3-2ecf-461e-a2f3-f1c69fc289fd" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">82-2142067</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_8975397e-b916-465d-a602-e0e226c2d3fe" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">149 Fifth Avenue</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_0dd2602b-5ff6-4007-a0ae-18751d75b5fa" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 500</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_56358a06-59fe-46a9-b917-912fce3f7780" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">New York</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;min-width:fit-content;">, </span><span style="font-size:8.5pt;"><ix:nonNumeric id="F_d55a3ae6-10d2-4f4d-9b38-472c8a02f25b" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">NY</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_70ed9cc6-e2a7-4ea4-98fa-17e684781563" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">10010</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f54e8596-e84f-4e4a-b43b-9d73c73189c1" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">212</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fcc688a-af73-4894-9200-8cf8540a0d22" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">994-8250</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.32%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:39%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
    <td style="width:1%;"/>
    <td style="width:39%;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_10b79cab-2903-4867-8494-3f550a6c94bb" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, par value $0.00001 per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_c4a8363a-75d5-4007-a85d-a5abdb39764e" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">INKT</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_373eb3f0-6dab-47e0-8a73-6202c3e653fc" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;Capital Market</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a91a1519-5bf1-4169-8918-a8b722e7fe7c" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_94c0b34c-1273-42a0-b831-3e9c74cc251b" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ff3b8ec7-0c5b-46df-a62c-66a0a0f0a84a" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d449b71a-53c4-45f1-ab03-68a0c6d179eb" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:15.477%;"/>
    <td style="width:1%;"/>
    <td style="width:60.988%;"/>
    <td style="width:1%;"/>
    <td style="width:19.476%;"/>
    <td style="width:1%;"/>
    <td style="width:1.06%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_672b964f-9810-4062-a2dc-3c2b7c258b66" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_f81ba5af-172f-4704-a0fe-5aba398dabc8" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_2b0eb2f6-a093-4732-b60a-bb01d79c28c2" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_75097a20-8444-46e9-98e9-83b2a7a81f55" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_bbbc28c7-ce01-4b50-b558-b4351e1fc495" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_66a00e68-bf59-45c1-b8a3-7f05c5703c97" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> No </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_3fa4c5c1-8aee-40e1-a640-f8b76dde7bb9" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2023, the last business day of the Registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of Common Stock held by non-affiliates of the registrant was: $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35f1bb67-7c22-4ab6-9737-6462f6a211fa" contextRef="C_bacbc03f-bcdc-458e-bcf7-0544b65ce927" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The number of shares of Registrant&#8217;s Common Stock outstanding as of March 15, 2024 was </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3edcb77-7c67-45e2-b1e6-12e8713fad13" contextRef="C_514af47c-c76d-45ca-bffb-56d9b5ff3b74" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">34,699,056</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_159d9bd8-0785-4ba2-8f04-ebbda25e7c1c" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the 2024 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2023, are incorporated by reference into Part III of this Report.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.429%;"/>
    <td style="width:11.905%;"/>
    <td style="width:16.667%;"/>
    <td style="width:16.667%;"/>
    <td style="width:11.905%;"/>
    <td style="width:21.429%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditor Firm Id:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_dc3937d1-0255-4145-a9a7-2b8283dd0f75" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditor Name:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_82f1997b-1bf5-4c8e-83aa-de041b85a085" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditor Location:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_1dce7d61-4987-491f-abbb-b90b8e553cdd" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Boston, Massachusetts</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.1%;"/>
    <td style="width:82.82%;"/>
    <td style="width:7.08%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0563c1;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART I</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0563c1;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART II</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign_jur"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0563c1;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART III</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0563c1;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16</span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">i</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note Regarding Forward Looking Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K and other written and oral statements we make from time to time contain forward-looking statements. You can identify these forward-looking statements by the fact they use words such as &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;may,&#8221; &#8220;project,&#8221; &#8220;guidance,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;potential,&#8221; &#8220;opportunity,&#8221; &#8220;future&#8221; and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Certain forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes to differ materially from current expectations. These statements relate to, among other things, our business strategy, our research and development, our product development efforts, our ability to commercialize our product candidates, our prospects for initiating partnerships or collaborations, the timing of the introduction of products, the effect of new accounting pronouncements, uncertainty regarding our future operating results and our profitability, anticipated sources of funds as well as our plans, objectives, expectations, and intentions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we believe we have been prudent in our plans and assumptions, no assurance can be given that any goal or plan set forth in forward-looking statements can be achieved, and readers are cautioned not to place undue reliance on such statements, which speak only as of the date of this report. We undertake no obligation to release publicly any revisions to forward-looking statements as a result of new information, future events or otherwise, except as required by law.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risks identified in this Annual Report on Form 10-K, including, without limitation, the risks set forth in Part I-Item 1A. &#8220;Risk Factors,&#8221; could cause actual results to differ materially from forward-looking statements contained in this Annual Report on Form 10-K. We encourage you to read those descriptions carefully. Such statements should be evaluated in light of all the information contained in this document.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T I</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Bu</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">siness.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK Therapeutics, Inc. (&#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;) is a clinical-stage biopharmaceutical company pioneering a novel platform of living medicines based on a rare and potent class of immune cells called invariant natural killer T (&#8220;iNKT&#8221;) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (&#8220;NK&#8221;) cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease (&#8220;GvHD&#8221;). Our proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, we believe that our approach represents a highly versatile application for therapeutic development in cancer and immune diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our goal is to discover, develop and commercialize novel allogeneic, off-the-shelf, iNKT cell therapies to treat cancer and other immune-mediated diseases with high unmet need. We are employing iNKT cells in their native form, through our lead program agenT-797, in diseases where iNKT cells have demonstrated activity and accelerated approval pathways exist. These indications include but are not limited to solid tumor cancers, acute respiratory distress (&#8220;ARDS&#8221;) and other severe immune-related diseases, such as GvHD. Our discovery efforts are focused applying our proprietary technologies to build a broad pipeline of engineered iNKT cells, including TCRs, CAR-INKTS (such as, MiNK-215, FAP-CAR-iNKT and MiNK-413. BCMA-CAR-iNKT), and engager technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our current product development pipeline:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img206969693_0.jpg" alt="img206969693_0.jpg" style="width:708px;height:243px;"/>&#160;</p>
  <p style="margin-left:1.133%;text-indent:-3.561%;padding-left:3.4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agenus Inc, therapeutic candidates botensilimab (BOT, Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our most advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Our Phase 1 clinical trial has enrolled 34 patients and is evaluating agenT-797 in refractory solid tumor cancers, as a monotherapy and in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab and nivolumab. Encouraging early activity was seen with agenT-797 monotherapy and combination, with reductions in target and non-target lesions and disease stabilization, which included a durable partial response in a PD-1 refractory gastric cancer patient. AgenT-797 also showed long-term persistence (detected in the periphery for up to 6 months), which was independent of human leukocyte antigen ("HLA") matching and in absence of lymphodepletion. These data were presented at Society of Immunotherapy for Cancer (&#8220;SITC&#8221;) in 2023. In addition, a case study on the gastric cancer response was published in Oncogene in January 2024. Most recently, a Phase 2 investigator sponsored trial led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center was launched. This study will evaluate the clinical safety and efficacy of the combination of agenT-797, Agenus Inc.'s ("Agenus") botensilimab (a novel fc-enhanced CTLA-4 inhibitor (plus balstilimab (anti-PD-1) with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction ("GEJ") adenocarcinoma. The study aims to enroll around 38 patients with advanced, unresectable, or metastatic forms of these cancers who have experienced disease progression after initial treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With the unique circumstances of the COVID-19 pandemic, we commenced a Phase 1 clinical trial to investigate agenT-797 in moderate to severe viral ARDS, a setting where there are currently no approved therapies. In a cohort of 21 patients with mechanical ventilation, survival rates exceeded 70%, with an 80% survival rate among those patients (5) on veno-venous extracorreal membrane oxygenation (&#8220;VV ECMO"). These data compared favorably to the 10% survival rate in the in-hospital control group at the same time. The full results from this study were published in Nature Communications in February 2024 and data from the subset of patients on VV ECMO were presented at the American Thoracic Society Annual Meeting in 2023. We plan to further advance agenT-797 in viral ARDS through an externally funded, large platform trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we are advancing a pipeline of next-generation allogeneic, engineered iNKT programs. Our two most advanced preclinical engineered programs are (1) MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (&#8220;BCMA), and (2) MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program. MiNK-413 has demonstrated tumor clearance and improved persistence in preclinical models, as well as manufacturing and logistical improvements over current BCMA cell therapies. These data were presented at SITC in 2022. MiNK-215 reported therapeutic activity in non-small cell lung cancer models, which resulted in substantial tumor elimination and improved survival compared to T cells alone. Data were reported at the American Society of Gene and Cell Therapy Annual Meeting.  Investigational new drug application (&#8220;IND&#8221;) enabling studies for MiNK-215 are underway.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have achieved notable strides in the delivery of allogeneic iNKT cells, successfully treating nearly 100 patients across various immune-related diseases, including severe respiratory distress and solid tumor cancers. Moreover, our efforts have led to significant insights into the crucial mechanisms driving the activity of allo-iNKTs. With our vertically integrated capabilities and experienced leadership team, we remain fully dedicated to pioneering accessible and transformative cell therapy solutions to make a significant impact in the healthcare sector.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our foundational leadership team has recruited and assembled a team who bring extensive industry expertise to our company, including decades of experience in manufacturing autologous and off-the-shelf products. We believe the expertise of our management team, and the established current Good Manufacturing Processes ("cGMP") site, greatly de-risks the challenges often associated with capital-intensive cell therapy companies. The combined team has a strong track record in discovering and developing immuno-oncology and cell therapies as well as executing on value-accretive business development opportunities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our goal is to discover, develop and commercialize novel allogeneic, off-the-shelf, iNKT cell therapies to treat cancer and other immune-mediated diseases with high unmet need. We believe that allogeneic iNKT cells exhibit highly adaptable properties for broad therapeutic development, and we plan to achieve our goal by executing a strategy with the following key elements:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advance agenT-797, native iNKT cells, in cancer, including solid tumors, as monotherapy and in combination with checkpoint antibodies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Validate broad applicability of iNKT cells through our opportunistic development of agenT-797 in severe respiratory distress, and other immune related diseases such as GvHD.</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Apply our proprietary technologies to build a broad pipeline of engineered iNKT cells, starting with MiNK-215, FAP-CAR-iNKT, with IND enabling activities actively underway.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Continue to scale up our in-house manufacturing processes and build our capability to cost-efficiently optimize speed, control, flexibility and scalability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selectively explore additional strategic partnerships that can enhance the potential of our iNKT cell product candidates and combination therapies. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We appreciate that there may be significant potential over time to enhance the efficacy and addressable population of our products through combination of our iNKT cells with other classes of therapeutics. In December 2023, we entered into a collaboration agreement with Immunoscape to discover and develop next-generation T-cell receptor ("TCR") therapies against novel targets in solid tumors. The collaboration aims to accelerate the development of TCR-based therapies against novel targets in T cells, iNKT cells, and other modalities, potentially offering new therapeutic approaches for diverse cancer indications. In September 2021,we entered into an Intellectual Property Assignment and License Agreement with Agenus (the &#8220;Agenus License Agreement&#8221;), which provides us with access to Agenus therapeutic candidates and adjuvants for use in our development activities, subject to rights retained by Agenus. We continue to explore further potential collaborations with third parties, either to bring in access to products or expertise to advance the development and further differentiate of our pipeline. Furthermore, if therapeutics areas of interest reveal themselves beyond our core areas of focus we may look to partner with appropriately qualified partners. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Approach to Cell Therapy &#8211; iNKT Cells</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T cells engineered with CARs have changed the paradigm of treatment for patients with B-cell malignancies with high response rates in previously intractable cancers, yet there are limitations to CAR-T cell therapy in both the autologous and evolving allogeneic settings, including practical, logistical and toxicity issues. As a result of these limitations, there is rapidly growing interest in other immune effector cells for CAR engineering, including NK cells, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">&#61543;&#61540;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> T cells and macrophages. We believe our approach, harnessing iNKT cells, offers significant advantages over existing cell therapies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are advancing a novel approach through the deployment of iNKT cells, a select subset of T cells with the capabilities to orchestrate both innate and adaptive immunity and the potential to deliver durable memory responses associated with T cell therapies with the cytolytic power of NK cells. The immune system is a complex network of soluble factors and cellular components that defends the body against cancer and infection, with two main lines of defense: innate immunity (e.g. NK cells) and adaptive immunity (T and B cells).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T cells are key to the adaptive immune response to cancer and infections, and through expression of specific TCRs they recognize antigens displayed on the surface of target cells. The diversity of TCRs arising from gene rearrangements allows TCRs to be generated against a virtually unlimited number of antigens and is the hallmark of adaptive immunity. Remarkably, this mechanism has also led to the evolution of specialized &#8220;innate-like&#8221; T cell populations which, akin to the cells of the innate immune system, detect molecular markers common among pathogens, infected cells, and cancer, such as lipids or metabolites. Such specialized innate-like T cells demonstrate additional innate characteristics underscoring their hybrid phenotype, such as the expression of innate immuno-receptors and the ability to rapidly respond to cell stress caused by cancer and infections.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mechanistically, we have observed that agenT-797:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Homes to tumors; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Activates dendritic cells (signalers that help the immune system recognize tumor cells);</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Kills M2 macrophages (immunosuppressive cells that constrain the body&#8217;s ability to fight tumors);</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restores tumor killing capacity of exhausted T cells;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Persists beyond our measurement period of 35 days;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Are activated by CD1d, the key ligand for the invariant TCR, and by stress ligands for potent tumor killing; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Can secrete a wide array of inflammatory cytokines to clear infections and tumors; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recruit and activate NK and T cells to regulate the immune response; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dampen inflammatory donor T cell activity to naturally suppress GvHD. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iNKT cells use an invariant TCR &#945;-chain and recognize the glycolipid &#945;-GalCer, as well as other exogenous and endogenous glycolipids presented by monomorphic major histocompatibility complex (&#8220;MHC&#8221;)-I-like CD1d. iNKT cells contribute to natural anti-tumor responses through their IFN-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">&#61543;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-production and the subsequent activation of DCs, NK cells and cytotoxic T lymphocytes, and their presence within tumors correlates with favorable prognosis in multiple cancers. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress GvHD. Additionally, we have observed persistence of over 35 days in some of our preclinical models, making iNKT cells well-suited for therapeutic application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Key Features of iNKT Cells</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Combine Key Features of Innate and Adaptive Immunity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iNKT cells offer significant advantages compared to other allogeneic cell types as they can directly attack tumor cells through both TCR-mediated as well as NK-receptor-mediated mechanisms. In addition to their direct cancer targeting and killing properties, iNKT cells are also powerful orchestrators of the immune responses within the tumor microenvironment (&#8220;TME&#8221;). iNKT cells directly attack suppressive myeloid cells in the TME and recruit and activate NK cells and T cells, a distinguishing feature not shared by other innate lymphocytes such as NK cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Potent Cancer Killing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iNKT cells are largely tissue-resident, and a small percentage (less than 1% of circulating T cells) are present in the blood. We believe iNKT cells&#8217; tissue homing properties make them highly suitable for therapeutic application in solid tumor indications. Like NK cells, they respond with wide-ranging effector potential, and express a specific invariant TCR that recognizes CD1d, a key monomorphic HLA-related molecule expressed in a wide range of cancers. iNKT cells have the capacity to mount strong anti-tumor responses both directly and by activating other immune cells, potentiating endogenous NK cells and T cells within the TME.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In preclinical and clinical studies, iNKT cells have been observed to home to tumor tissues and target CD1d-, NKG2D-, and other NK-receptor ligands expressed on solid and liquid tumors to mediate tumor killing and modification of the TME. The invariant TCR can recognize glycolipids presented by CD1d, arming the iNKT cells with the ability to respond to lipid antigenic stimulation within minutes by secreting a wide variety of cytokines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Naturally Suited for Allogeneic Approaches</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GvHD is an important driver of toxicity with most cell therapy approaches. Unlike conventional &#945;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">&#61538;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> T cells, iNKT cells do not require gene editing of the TCR to eliminate risk of GvHD due to the monomorphic nature of the CD1d ligand of the iNKT cell TCR. Although no allogeneic iNKT cell therapy has been approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) or any comparable regulatory authority, in both clinical and preclinical studies, iNKT cells have been observed not to cause, but instead to actively suppress, GvHD, lowering the safety risks associated with other allogeneic immune cells. Higher iNKT cell counts following hematopoietic stem cell transplantation (&#8220;HSCT&#8221;) for acute leukemia correlates with lower risk for GvHD, and vice versa.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Enhanced Tolerability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lymphodepletion is a requirement for most cell therapies and leads to significant side effects. Since iNKT cells are largely resident in non-lymphoid tissue, we believe that allogeneic iNKT cells may engraft better than other allogeneic cell types and thus require less lymphodepletion. We believe reducing or eliminating lymphodepletion would significantly improve patients&#8217; quality of life, increase their ability and willingness to undergo treatment, and potentially increase long-term anti-tumor immunity. Reduced or no lymphodepletion leaves the patient&#8217;s immune system in a better condition. A healthy and intact immune system is a key requirement for long-term cancer control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ability to Scale and Manufacture Effectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iNKT cells can be induced to grow exponentially for an extended period of time in our manufacturing process, whilst retaining full immunomodulatory and cytotoxic features and metabolic fitness. This is enabled by a combination of intrinsic proliferative properties of iNKT cells and the proprietary process conditions we use to expand and condition the cells. In our current process we are able to expand iNKT cells over 10,000-fold without inducing exhaustion, and our internal research indicates that we can further increase these yields.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our iNKT Cell Platform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our platform builds on the unique features of native iNKT cells and our advanced capabilities for manufacturing and engineering. We believe this enables us to develop a portfolio of robust, highly pure, off-the-shelf, allogeneic products that can be delivered to patients worldwide for treatment of a wide array of indications in cancer and other immune-mediated diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Allogeneic iNKT cell therapy is an adoptive cell therapy that involves the infusion of cells derived from healthy donors. We believe that iNKT cell therapies have the potential to address many of the key limitations of current cell therapy approaches, particularly through the ability to (1) rapidly treat patients real-time after diagnosis, (2) improve response rates and the durability of responses, (3) address more indications and a broader patient population, (4) improve tolerability, (5) be administered without lymphodepletion and (6) scale at a favorable cost profile. Below are the key elements that constitute our platform.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img206969693_1.jpg" alt="img206969693_1.jpg" style="width:684px;height:339px;"/>&#160;</p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Novel cell type bridging innate and adaptive immunity: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are advancing a novel platform based on a rare and potent class of immune cells, iNKTs. These cells have the unique ability to bridge the innate and adaptive immune system, with the killing power of NK cells and memory of T cells, as well as the ability to recruit host immunity and reshape the TME. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Broad therapeutic capability: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our pipeline of native and engineered iNKT cell candidates has opportunity across a range of disease settings, including in oncology and immune-mediated diseases. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical proof of concept: Our Phase 1 clinical trials have demonstrated the tolerability and immune-modulating activity of allogeneic iNKT cells in multiple cancer types and ARDS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Proprietary cell engineering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: Our engineering platforms enable the discovery of CARs, TCRs, and bispecific engagers. This includes CARDIS, our novel CAR discovery and engineering platform developed fully in house over the last five years. It is a hybrid of phage and mammalian display technologies, enabling direct functional selection from cellular immune libraries. This yields a higher frequency of candidate hits with improved pharmaceutical quality and eliminates tonic signaling at an early stage. The use of fully human single-chain fragment variable libraries lowers risk of immunogenicity, and optimized intracellular signaling domains are designed to synergize with the invariant TCR and the array of other native iNKT signaling receptors in driving tumor killing and limiting off-tumor toxicity. Our technology also includes the development of bispecific engagers, where we utilize IgG-based, proprietary highly selective iNKT engager arms and a fully human antibody discovery suite for developing targeting arms. Our experienced team of molecular biologists, genetic engineers and manufacturing experts has a track record of success in delivering now Biologics License Application (&#8220;BLA&#8221;)-stage antibodies and we are now focused on delivering iNKT engagers. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Proprietary manufacturing at scale: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our manufacturing process takes place using an existing expert cGMP grade manufacturing infrastructure, using our own in-house production team of cell manufacturing experts. Our manufacturing capabilities include a proprietary closed-system process, minimizing contamination risk. This efficient isolation and expansion process from healthy donors can generate &gt;5,000 doses per donor. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Access to validated Immuno-oncology therapies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We have access to Agenus&#8217; pipeline of immuno-oncology antibodies, both monospecific and bispecific, and immune stimulating adjuvants for our development activities, which creates the potential for rapid development of combinations and commercial flexibility. Agenus will not be obligated to provide us access to their biological material in certain limited circumstances. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Product Candidate</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">agenT-797</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">agenT-797, our allogeneic, native iNKT cell therapy, is our most advanced product candidate and is currently in clinical development across multiple different trials and indications, constituting a pipeline within a single product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">agenT-797 &#8211; Oncology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In preclinical studies, we have observed that agenT-797 cells have the potential to reduce or eliminate hematologic and solid tumor cancers as a monotherapy and in combination with checkpoint modulating antibodies, as they (1) home to sites of disease via CD1d and NK related ligands; (2) attack suppressive myeloid cells in the TME to eliminate tumor escape mechanisms; (3) recruit and activate NK cells and T cells for enhanced tumor killing (a distinguishing feature not shared by other innate lymphocytes such as NK and gamma delta T cells); and (4) promote tumor killing without lymphodepletion. 34 solid tumor patients have been enrolled in our Phase 1 clinical trial. The data demonstrated that agenT-797 appeared to overcome resistance to immune checkpoint inhibitors, with durable disease stabilization and a confirmed response in chemotherapy and anti-PD-1 refractory gastric cancer. A Phase 2 investigator sponsored trial is underway, evaluating agenT-797 in second-line gastroesophageal cancers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">agenT-797 &#8211; ARDS Secondary to Infectious Disease (i.e. COVID-19, Influenza)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In preclinical models, iNKT cells have been shown to promote viral clearance and increase secondary anti-viral responses, offering the potential to control inflammation and limit lung tissue damage resulting from ARDS secondary to infectious disease in humans. We completed a Phase 1 clinical trial of agenT-797 for the treatment of ARDS secondary to COVID-19, which was initiated during the height of the COVID-19 pandemic, and we subsequently expanded the trial to investigate viral ARDS secondary to other life-threatening infectious diseases, such as influenza In a cohort of 21 patients with mechanical ventilation, the survival rates from this study exceeded 70%, with a 80% survival rate among those patients (5) on VV ECMO. These data compared favorably to the 10% survival rate in the in-hospital control group at the same time.  In addition to survival benefit, we demonstrated that we can dose the cells to 1x109 cells/dose with no related cytokine release syndrome or neurotoxicity and importantly, observed signals that the cells may prevent secondary infections.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">agenT-797 &#8211; GvHD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iNKT cells have the potential to provide the following benefits in relation to GvHD: (1) promoting engraftment success; (2) mitigating or suppressing GvHD; and (3) promoting durable responses in patients with cancer. Our near-term plans are to advance the administration of allogeneic iNKT cells in patients undergoing HSCT to enable a successful engraftment and prevention/suppression of acute GvHD. HSCT is a well-established treatment for more than 50,000 adults and children with malignancies, autoimmune</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conditions and other serious diseases. The most common life-threatening complication, which occurs in approximately 50% of HSCTs, is graft failure and GvHD driven by immunocompetent T cells in the graft recognizing host tissues. Current pre-conditioning therapies such as cytotoxic chemotherapies produce inferior responses in patients over 65 years old. Furthermore, failure to engraft and downstream GvHD are associated with cancer recurrence or death.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Enhance iNKT Activity and Expand Targeting through Engineering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are advancing a pipeline of allogeneic, engineered iNKT cell product candidates that leverage our proprietary technologies to enhance iNKT activity and expand tumor targeting through CARs, TCRs and bispecific iNKT engagers. Our two most advanced engineered programs are (1) MiNK-413, a BCMA-CAR-iNKT, and (2) MiNK-215, a FAP-CAR-iNKT. These programs are both in preclinical development with IND enabling underway for MiNK-215.In addition, we plan to utilize our bispecific iNKT engagers, TCRs and CAR technologies, as well as our access to a large portfolio of proprietary targets, to further expand our pipeline of novel allogeneic, engineered iNKT cell product candidates. We entered into a collaboration agreement with Immunoscape to discover and develop next-generation TCR therapies against novel targets in solid tumors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our CARs are designed to work in conjunction with the invariant TCR and the array of innate receptors expressed natively by iNKT cells. They increase the range of tumor targets that can be addressed by iNKT cells and carry optimized intracellular domains that augment and expand native signaling. The resulting CAR-iNKT cells exhibit an augmented and finely integrated response to the tumor through a combination of CAR target recognition, TCR activation and innate receptor activation by CD1d or stress ligands in the TME.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to genetically engineered CAR-expressing iNKT products, we are developing bispecific iNKT cell engagers. Our bispecific iNKT cell engagers are designed to expand tumor targeting in tumors that are difficult to treat due to immunologic or biologic factors, which may include low CD1d expression. Our engagers bind to the invariant TCR with one arm, and to tumor targets with the other arm. They extend the range of tumor targets that can be engaged by iNKT cells and are designed to work in conjunction with allogeneic iNKT cells, CAR-iNKT cells as well as endogenous iNKT cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">iNKT Cell Therapy Combinations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proof of concept of iNKT cells as a cancer treatment has been established in extensive public preclinical </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> data sets. Such data has shown that iNKT cells can decrease tumor burden and improve survival in multiple animal models, including through prophylactic and interventional administration of iNKT cells using xenograft, syngeneic and spontaneous tumor models of solid and hematologic tumors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have observed from our in-house research that infused native human iNKT cells are persistent (detectable and active) in mice for over 35 days. This persistence enables flexible clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have also observed that allogeneic human iNKT cells are beneficial in reducing tumor burden in an aggressive human leukemia xenograft model. In this model we observed that our human iNKT cells were present in all tissues that contain tumor cells, and also were detected in blood throughout the treatment window. We believe this indicates that iNKT cells home to and are activated at sites with tumor cells, which is different from the observations in healthy mice. This is in line with published data and supports that iNKT cells recognize and actively seek out tumor cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img206969693_2.jpg" alt="img206969693_2.jpg" style="width:304px;height:174px;"/>&#160;</p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="margin-left:6pt;text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;	Nalm6-CD1d human leukemia xenograft model</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="margin-left:6pt;text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;	10 million agenT-797 cells injected</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="margin-left:6pt;text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;	Stay in circulation with tumor cells</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="margin-left:6pt;text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;	Home to all tissues with tumor cells</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="margin-left:6pt;text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;	iNKT cells present and active for &gt;21 days</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="margin-left:6pt;text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#149;	Reduce tumor burden</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A further active area of our internal research focuses on the combination of iNKT cell therapy and checkpoint inhibitors such as anti-PD-1 and anti-CTLA4 antibodies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our internal preclinical research indicates expanded anti-tumor activity of iNKT cells when used in combination with immuno-oncology antibodies, including anti-PD-1 and anti-CTLA-4 antibodies. These increase the ability of iNKT cells to control tumors by further increasing immune cell infiltration and reducing metastases. In a highly checkpoint inhibitor-resistant metastatic murine tumor model we have observed nearly complete tumor clearance when the mice are treated with a combination of anti-PD-1 and Fc-enhanced CTLA4 antibodies, and endogenously expanded and activated murine iNKT cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img206969693_3.jpg" alt="img206969693_3.jpg" style="width:653px;height:307px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have capitalized on our internal research findings and actively pursued clinical development of iNKT cells in combination with immuno-oncology antibodies for treatment of cancer. Our Phase 1 study in refractory solid tumors investigated agenT-797 monotherapy and in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab and nivolumab. In addition, an investigator sponsored Phase 2 study was launched to evaluate agenT-797 in combination with Agenus&#8217; antibodies botensilimab (a novel fc-enhanced CTLA-4 inhibitor) and balstilimab (PD-1 inhibitor) with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or GEJ adenocarcinoma.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our close relationship with Agenus is a key enabler for development flexibility.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Proprietary Manufacturing Process and Capabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our experienced management team and fully operational cGMP manufacturing suite directly address and greatly de-risk the challenges often associated with capital intensive cell therapy companies. We believe this site pioneered the industrialization and international distribution of autologous cancer vaccines and later the customization of synthetic, off-the-shelf cancer vaccines, immune stimulating adjuvants and antibodies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our allogeneic iNKT manufacturing platform allows for cell manufacturing at step function improvement in scale cost, and availability. We are in the process of scaling up our internal manufacturing process to ensure stable, robust and scalable production for advanced clinical trials and commercialization. Our process is designed to scale up &gt; 5,000 doses per donor. We plan to conduct all manufacturing for native iNKT cells and the engineered programs with our in-house capabilities in 2023, with the exception of lentiviral vector manufacturing. Our automated, closed-system allogeneic cell product batch production is designed to provide rapid, scalable, production with rigorous quality control and consistent and reproducible product release with minimal risk of batch failure. This closed-system process reduces hands-on time and optimizes personnel usage and facility qualification and validation processes. Our proprietary reagents and process generate a product that is over 99% pure iNKT cells that can be stably cryopreserved with full retention of functional properties. We believe this will enable us to further increase reproducibility, minimize run failures and greatly increase scalability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immuno-Oncology Combination Therapy Collaboration with Agenus</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have retained the rights to develop our wholly owned or exclusively licensed pipeline independent of Agenus, we have entered into Agenus Agreement which provides us with access to immuno-oncology antibodies, adjuvants and other potential synergistic combinations, and intend to pursue the development of combination products between our allogeneic iNKT cell product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">candidates and products in Agenus&#8217; immuno-oncology portfolio. The Agenus License Agreement would require us to enter into a separate agreement governing the transfer of Agenus&#8217; biological material and allows for Agenus to refuse such a transfer in certain circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iNKT cell therapy adds critical new immune system functionality to cancer patients whose immune system cannot effectively combat the tumor. Infused iNKT cells home to the tumor, where the iNKT cells attack the cancer cells and reshape the TME, attracting additional endogenous immune cells to the tumor, such as T cells and NK cells, and diminishing the suppressive effect of infiltrating myeloid cells. Due to their allogeneic nature, infused iNKT cells disappear over time, at which point the endogenous immune system must continue to provide effective immune surveillance to prevent relapse. While there is significant development opportunity for iNKT cells as a monotherapy, we have also demonstrated the benefits of these cells in combination with anti-PD-1 and/or enhanced anti-CTLA-4 antibodies in preclinical models. We believe current cancer therapy developments indicate that anti-PD-1 and anti-CTLA-4 immuno-oncology antibodies have the potential to become the standard of care for many tumor indications and will form the basis for most, if not all, future combination therapies in cancer. Access to Agenus&#8217; immuno-oncology products allows us to combine our iNKT cells with immuno-oncology antibodies, creating more flexibility in our clinical strategy, a better window for optimization dosing and timing, and more control over commercial pricing of the combinations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our collaboration with Agenus, we are evaluating agenT-797 in combination with Agenus&#8217; botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or GEJ adenocarcinoma through a Phase 2 investigator sponsored study. The study is led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We protect our intellectual property rights and proprietary technology with a combination of patent rights, trademark rights, proprietary procedures and contractual provisions. We seek to protect our intellectual property rights and proprietary technology in select key global markets. Further, in order to supplement our existing intellectual property protection and support commercialization of current and future product candidates, we continue to seek protection for our technological innovations and branding efforts by filing new patent and trademark applications when and where appropriate. As of December 31, 2023, we own three issued U.S. patents and 25 pending patent applications in the U.S. and other major jurisdictions worldwide. One of the issued U.S. patents is directed to a process for the discovery of TCRs and the term of the patent will expire in 2041. The other two issued U.S. patents are intended to protect intellectual property relating to a TCR for cell therapy targeting NY-ESO-1 and a TCR for cell therapy targeting Phosphopeptides. The term of these two patents will expire in 2039.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our process to manufacture iNKT cells at scale from healthy donor PBMCs, using cGMP-grade proprietary resources, including a humanized iNKT-TCR mAb to enable iNKT cell isolation and an &#945;-GalCer lipid ligand to enable iNKT cell expansion, is proprietary technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to proprietary processes and patents on individual assets, we anticipate achieving a 12-year regulatory exclusivity period for agenT-797 upon receiving BLA approval from the FDA, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a biopharmaceutical company, we are subject to extensive regulation. Our iNKT cell product candidates, if approved, will be regulated as biologics. With this classification, commercial production of our products will need to occur in registered and licensed facilities in compliance with cGMPs for biologics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human immunotherapy products are a new category of therapeutics. The FDA categorizes human cell- or tissue-based products as either minimally manipulated or more than minimally manipulated, and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy and the submission of a BLA for marketing authorization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacturing, packaging, labeling, storage, record keeping, reimbursement, advertising, promotion, distribution, post-approval monitoring and reporting and import and export, pricing and reimbursement of pharmaceutical products, including biological products. In the United States, the FDA regulates biological products under the Public Health Service Act (the &#8220;PHSA&#8221;), the Federal Food, Drug and Cosmetic Act (the &#8220;FDCA&#8221;) and implementing regulations. Failure to comply with the applicable regulatory requirements at any time during the product development process or post-approval may subject an applicant for marketing approval to delays in development or approval, as well as administrative and judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters and similar public notice of alleged non-compliance with laws, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, fines, refusals of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">government contracts, restitution, disgorgement of profits or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions and compliance with applicable statutes and regulatory requirements, both pre- and post-approval, require the expenditure of substantial time and financial resources. The regulatory requirements applicable to drug and biological product development, approval and marketing are subject to change, and regulations and administrative guidance often are revised or reinterpreted by the agencies in ways that may have a significant impact on our business. Ethical, social and legal concerns about gene therapy, genetic testing and genetic research could result in additional regulations restricting or prohibiting the processes we may use. We cannot predict whether legislative changes will be enacted or if regulatory authorities&#8217; guidance or interpretations will change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Product Development Process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain FDA approval of a product candidate, we must, among other things, submit clinical data providing substantial evidence of safety and efficacy of the product for its intended use, as well as detailed information on product composition, its manufacture and controls, and proposed labeling. The testing and collection of data and the preparation of necessary applications are expensive and time-consuming. The FDA may not act quickly or favorably in reviewing these applications, and we may encounter significant difficulties or costs in our efforts to obtain FDA approvals that could delay or preclude us from marketing our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our biological product candidates must be approved by the FDA through the BLA process before they may be legally marketed in the United States. The process required before a biologic may be marketed in the United States generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of preclinical laboratory tests and animal studies according to Good Laboratory Practices (&#8220;GLPs&#8221;), and applicable requirements for the humane use of laboratory animals or other applicable regulations; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval by an independent institutional review board (&#8220;IRB&#8221;), representing each clinical site before each clinical trial may be initiated; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as Good Clinical Practices (&#8220;GCPs&#8221;), and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation and submission to the FDA of a BLA, for marketing approval that includes substantive evidence of safety, purity and potency from results of nonclinical testing and clinical trials; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment of user fees for FDA review of the BLA; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities where the drug or biological product is produced to assess compliance with cGMP to assure that the facilities, methods and controls used in product manufacture are adequate to preserve the drug or biological product&#8217;s identity, strength, quality and purity and, if applicable, the FDA&#8217;s current Good Tissue Practices (&#8220;GTPs&#8221;), for the use of human cellular and tissue products; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA acceptance, review and approval, or licensure, of the BLA, which might include review by an advisory committee, a panel typically consisting of independent clinicians and other experts who provide recommendations as to whether the application should be approved and under what conditions. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Studies and Investigational New Drug Applications</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before testing any drug or biological product candidate, including our product candidates, in humans, the product candidate must undergo rigorous preclinical testing. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations as well as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and animal studies to assess the potential safety and efficacy of the product candidate. After sufficient preclinical testing has been conducted, the conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical trial sponsor must submit an IND to the FDA before clinical testing can begin in the United States. An IND must contain the results of the preclinical tests, manufacturing information, analytical data, any available clinical data or literature, a proposed clinical protocol, an investigator&#8217;s brochure, a sample informed consent form, and other materials. Some preclinical testing, such as toxicity studies, may continue even after the IND is submitted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An IND is an exemption from the FDCA that allows an unapproved drug or biological product to be shipped in interstate commerce for use in an investigational clinical trial. The IND seeks FDA authorization to test the drug or biological product candidate in humans and automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In that case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trials can begin. Preclinical or nonclinical testing typically continues even after the IND is submitted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA may, at any time during the initial 30-day IND review period or while clinical trials are ongoing under the IND, impose a partial or complete clinical hold based on concerns for patient safety and/or noncompliance with regulatory requirements. This order issued by the FDA would delay the initiation of a proposed clinical trial or cause suspension of an ongoing trial until all outstanding concerns have been adequately addressed, and the FDA has notified the company that investigations may proceed. Imposition of a clinical hold could cause significant delays or difficulties in completing planned clinical studies in a timely manner. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that require the suspension or termination of such trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expanded Access to an Investigational Drug for Treatment Use</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no requirement for a manufacturer to provide expanded access to an investigational product. However, if a manufacturer decides to make its investigational product available for expanded access, FDA reviews requests for expanded access and determines if treatment may proceed. Expanded access may be appropriate when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere with initiation, conduct or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the FDCA, sponsors of one or more investigational products for the treatment of a serious disease(s) or condition(s) must make publicly available their policy for evaluating and responding to requests for expanded access for individual patients. Sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 study, or 15 days after the investigational drug or biologic receives designation as a breakthrough therapy, fast track product or regenerative medicine advanced therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides an additional mechanism for patients with a life-threatening condition who have exhausted approved treatments and are unable to participate in clinical trials to access certain investigational products that have completed a Phase 1 clinical trial, are the subject of an active IND, and are undergoing investigation for FDA approval. Unlike the expanded access framework described above, the Right to Try Pathway does not require FDA to review or approve requests for use of the investigational product. There is no obligation for a manufacturer to make its investigational products available to eligible patients under the Right to Try Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Human Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials involve the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research patients provide informed consent. Clinical trials are conducted under study protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the trial complies with certain FDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory requirements in order to use the trial as support for an IND or application for marketing approval in the United States. Specifically, the FDA requires that such trials be conducted in accordance with GCP requirements intended to ensure the protection of human subjects and the quality and integrity of the study data, including requirements for review and approval by an independent ethics committee and obtaining subjects&#8217; informed consent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For clinical trials conducted in the United States, an IND is required, and each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, and the possible liability of the institution. An IRB must operate in compliance with FDA regulations. Clinical trials must also comply with extensive GCP rules and the requirements for obtaining subjects&#8217; informed consent. The FDA, IRB or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements, including GCP, or the subjects or patients are being exposed to an unacceptable health risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group may recommend continuation of the study as planned, changes in study conduct, or cessation of the study at designated checkpoints based on access to certain data from the study. Finally, research activities involving infectious agents, hazardous chemicals, recombinant DNA and genetically altered organisms and agents may be subject to review and approval of an Institutional Biosafety Committee (IBC), in accordance with National Institute of Health (NIH) Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients with the target disease or condition. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency and safety in an expanded patient population, generally at geographically dispersed clinical trial sites. These clinical trials are intended to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk to benefit profile of the product and to provide an adequate basis for product labeling. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some cases, the FDA may approve a BLA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety or effectiveness after approval. Such post approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of drugs or biologics approved under accelerated approval regulations. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA, the NIH and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> testing that suggest a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. The FDA or the sponsor or its data safety monitoring board, an independent group of experts that evaluates study data for safety and makes recommendations concerning continuation, modification or termination of clinical trials, may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product has been associated with unexpected serious harm to patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because this is a relatively new and expanding area of novel therapeutic interventions, there can be no assurance as to the length of the trial period, the number of patients the FDA will require to be enrolled in the trials in order to establish the safety, efficacy, purity and potency of immunotherapy products, or that the data generated in these trials will be acceptable to the FDA to support marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Pediatric Research Equity Act of 2003 (the &#8220;PREA&#8221;), a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must submit a pediatric study plan to FDA outlining the proposed pediatric study or studies they plan to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The FDA must then review the information submitted, consult with the sponsor and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For products intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of an applicant, meet to discuss preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments. In addition, FDA will meet early in the development process to discuss pediatric study plans with sponsors and FDA must meet with sponsors by no later than the end-of-phase 1 meeting for serious or life-threatening diseases and by no later than 90 days after FDA&#8217;s receipt of the study plan. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements, under specified circumstances. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website. Similar requirements for posting clinical trial information in clinical trial registries exist in the European Union and in other countries outside the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrently with clinical trials, companies usually complete additional nonclinical studies and must also develop additional information about the physical characteristics of the drug or biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Review and Approval Processes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the product. The BLA must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the premarketing application for filing and, even if filed, that any approval will be granted on a timely basis, if at all as the FDA has significant discretion to approve or reject BLAs and to require additional preclinical or clinical studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Prescription Drug User Fee Act, as amended (&#8220;PDUFA&#8221;), each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for approved prescription biological products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission has been accepted for filing, the FDA begins an in depth review of the application. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months from filing in which to complete its initial review of a standard application and respond to the applicant, and six months for a priority review application. A major amendment to a BLA submitted at any time during the review cycle, including in response to a request from the FDA, may extend the goal date by three months. The FDA does not always meet its PDUFA goal dates for standard and priority applications. The FDA reviews the application to determine, among other things, whether</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proposed product is safe, potent and/or effective for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During its review of a BLA, the FDA may refer the application to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved and under what conditions. In particular, the FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions about a BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. For immunotherapy products, the FDA also will not approve the product if the manufacturer is not in compliance with the GTPs, to the extent applicable. These are FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue based products (&#8220;HSCT/Ps&#8221;), which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA GTP regulations also require tissue establishments to register and list their HSCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND and GCP requirements. To assure cGMP, GTP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, recordkeeping, production and quality control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. If the agency decides not to approve the BLA in its present form, the FDA will issue a Complete Response Letter, which generally outlines the specific deficiencies in the application identified by the FDA and may require additional clinical or other data or impose other conditions that must be met in order to secure final approval of the application. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Even with the submission of additional information, the FDA may ultimately decide that the application does not satisfy the regulatory criteria for approval. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA approves a new product, it may limit the approved indications for use of the product. It may also require that contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require post approval studies, including Phase 4 clinical trials, to further assess the product&#8217;s safety or efficacy after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;), to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use (&#8220;ETASU&#8221;). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has several programs designed to expedite the development and approval of drugs and biological products intended to treat serious or life-threatening diseases or conditions. These programs include fast track designation, breakthrough therapy designation, priority review designation, accelerated approval, and regenerative medicine advanced therapy (&#8220;RMAT&#8221;) designation. These designations are not mutually exclusive, and a product candidate may qualify for one or more of these programs. While these programs are intended to expedite product development and approval, they do not alter the standards for FDA approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">First, the FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have more frequent interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">remaining information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Second, a product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third, the FDA may designate a product for priority review if it is a product that treats a serious disease or condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fourth, a product may be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&#8220;IMM&#8221;), that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials to confirm efficacy using a clinically meaningful endpoint, thereby confirming efficacy observed pre-approval using a surrogate endpoint. If the FDA concludes that a drug or biologic shown to be effective can be safely used only if distribution or use is restricted, it will require such post-marketing restrictions, as it deems necessary to assure safe use of the product. If the FDA determines that the conditions of approval are not being met, the FDA can withdraw its accelerated approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fifth, a product may receive RMAT designation, which provides for an expedited program for the advancement and approval of regenerative medicine therapies that are intended to treat, modify, reverse or cure a serious condition and where preliminary clinical evidence indicates the potential to address unmet medical needs for life-threatening diseases or conditions. Similar to Breakthrough Therapy designation, the RMAT designation allows companies developing regenerative medicine therapies to work earlier, more closely, and frequently with the FDA, and RMAT-designated products may be eligible for priority review and accelerated approval. Regenerative medicine therapies include cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products, except for those regulated solely under section 361 of the PHS Act and Title 21 of the Code of Federal Regulations Part 1271. The FDA confirmed that gene therapies, including genetically modified cells that lead to a sustained effect on cells or tissues, may meet the definition of a regenerative medicine therapy. For product candidates that have received a RMAT designation, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. The timing of a sponsor&#8217;s request for designation and FDA response are the same as for the Breakthrough Therapy designation program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be sure that any of our product candidates will qualify for any of these expedited development, review and approval programs, or that, if a product candidate does qualify, that it will be approved, will be accepted as part of any such program or that the review time will be shorter than a standard review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon FDA approval of a BLA, the sponsor must comply with extensive post approval regulatory requirements applicable to drugs and biological products, including any additional post approval requirements that the FDA may impose as part of the approval process. These post-approval requirements include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">record keeping requirements; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reporting of certain adverse experiences with the product and production problems to the FDA; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission of updated safety and efficacy information to the FDA; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">drug sampling and distribution requirements; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">notifying FDA and gaining its approval of specified manufacturing and labeling changes; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with requirements concerning advertising, promotional labeling, industry-sponsored scientific and educational activities and other promotional activities. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the sponsor and its third-party manufacturers are subject to periodic unannounced regulatory inspections for compliance with ongoing regulatory requirements, including cGMP and pharmacovigilance regulations. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA strictly regulates the advertising and labeling of prescription drug products, including both prescription drugs and biological products. Promotional claims about a drug&#8217;s safety or effectiveness are prohibited before the drug is approved. In addition, the sponsor of an approved drug in the United States may not promote that drug for unapproved, or off-label, uses, although a physician may prescribe a drug for an off-label use in accordance with the practice of medicine. If a company is found to have promoted off-label uses, it may become subject to administrative and judicial enforcement by the FDA, the DOJ, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After approval, some types of changes to the approved product, such as adding new indications or dosing regimens, manufacturing changes, or additional labeling claims, are subject to further FDA review and approval. In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may withdraw product approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency or issues with manufacturing processes, may result in revisions to the approved labeling to add new safety information; imposition of post market studies or clinical trials to assess new safety signals; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of the product; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, warning letters or holds on post approval clinical trials; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product recall, seizure, or detention or refusal to permit the import or export of products; or </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Drug Designation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan drug designation in the United States is designed to encourage sponsors to develop drug and biological products intended for the treatment of rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available for the disease or condition will be recovered from sales of the product in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan drug designation qualifies a company for certain tax credits. In addition, if a drug candidate that has orphan drug designation subsequently receives the first FDA approval for that drug for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years following product approval unless the subsequent product candidate is demonstrated to be clinically superior. Absent a showing of clinical superiority, the FDA cannot approve the same product made by another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor or the sponsor is unable to provide sufficient quantities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug or biologic. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation. To qualify for orphan exclusivity, however, the drug must be clinically superior to the previously approved product that is the same drug for the same condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pediatric Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatric exclusivity is another type of non-patent regulatory exclusivity in the United States. Specifically, the Best Pharmaceuticals for Children Act provides for the attachment of an additional six months of exclusivity, which is added on to the term of any remaining regulatory exclusivity or patent periods at the time the pediatric exclusivity is granted. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data, even if the data do not show the product to be effective in the pediatric population studied.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Biosimilars and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2010 Patient Protection and Affordable Care Act (the "PPACA"), which was signed into law in March 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009 (the "BPCIA"). The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars. FDA has approved over 20 biosimilar products for use in the United States to date. No interchangeable biosimilars, however, have been approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the BPCIA, a manufacturer may submit an application for licensure of a biological product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was first licensed. This 12-year exclusivity period is referred to as the reference product exclusivity period and bars approval of a biosimilar but notably does not prevent approval of a competing product pursuant to a full BLA (i.e., containing the sponsor&#8217;s own preclinical data and data from adequate and well controlled clinical trials to demonstrate the safety, purity and potency of the product). The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. The law also includes an extensive process for the innovator biologic and biosimilar manufacturer to litigate patent infringement, validity and enforceability prior to the approval of the biosimilar.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been ongoing federal legislative and administrative efforts as well as judicial challenges seeking to repeal, modify or invalidate some or all of the provisions of the PPACA. While none of those efforts have focused on changes to the provisions of the PPACA related to the biosimilar regulatory framework, if those efforts continue and if the PPACA is repealed, substantially modified or invalidated, it is unclear what, if any, impact such action would have on biosimilar regulation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Term Restoration and Extension</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A patent claiming a new drug or biological product may be eligible for a limited patent term extension under the Hatch Waxman Act, which permits a patent restoration of up to five years for a single patent for an approved product as compensation for patent term lost during product development and FDA regulatory review. The restoration period granted on a patent covering a product is typically one half the time between the effective date a clinical investigation involving human beings is begun and the submission date of a marketing application less any dime during which the applicant failed to exercise due diligence, plus the time between the submission date of an application and the ultimate approval date less any dime during which the applicant failed to exercise due diligence. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved product is eligible for the extension, only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biopharmaceutical industry, and particularly the immuno-oncology field, is characterized by rapidly advancing and changing technologies with intense competition. Cell therapy is one of the most active areas for the discovery and clinical development of new anti-cancer therapies. It involves the delivery of immune cells to the site of the tumor to mediate killing. We face substantial competition from many different entities, including large pharmaceutical companies, small and midsize biotechnology companies, and academic research institutions. These competitors are focused on engineering multiple immune cell types including NK cells, &#945;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> T cells and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">gd</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> T cells, in addition to iNKT cells. These products are both autologous and allogeneic (i.e., derived from a healthy donor) in nature and are unmodified or genetically engineered to target ligands with CARs or TCRs. Several companies are also using induced pluripotent stem cells as an allogeneic cell source, which could theoretically have enhanced scalability. Other modalities such as bispecific antibodies, antibody drug conjugates, as well as novel immuno-oncology antibodies, are also capable of enabling infiltration of immune cells to the site of the tumor. For example, many bispecific approaches simultaneously bind one immune cell antigen and one tumor cell antigen, thereby redirecting a patient&#8217;s endogenous NK or T cells to the site of a tumor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Key competitor companies developing autologous CAR-T or TCR cell therapies include, but are not limited to, Bristol-Myers Squibb Company (Celgene/Juno Therapeutics), Gilead Sciences, Inc. (Kite Pharma), Johnson &amp; Johnson, Novartis AG, AstraZeneca and BioNTech.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Key competitors developing iNKT cell therapies include Arovella Therapeutics (previously known as Suda Pharmaceuticals), Appia Bio, Inc., Brightpath Biotherapeutics and Ambicion Co. We are also aware of competitors advancing glycolipid formulations or small molecules designed to activate endogenous iNKT cells, including Portage Biotech LLC, Abivax SA and Gri Bio.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Key competitors developing allogeneic T cell therapies include, but are not limited to, Allogene Therapeutics, Inc., Atara Biotherapeutics, Inc., Cellectis S.A., Celyad Oncology SA, CRISPR Therapeutics AG, Poseida Therapeutics, Inc. and Precision BioSciences, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Key competitors in the NK cell therapy space include, but are not limited to, Celularity, Inc, Fate Therapeutics, Inc., Gamida Cell, Glycostem Therapeutics B.V., Nkarta, Inc., Artiva Biotherapeutics, Sanofi and Takeda Pharmaceutical Company Limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other key competitors in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">gd</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> T cell therapy space include, but are not limited to, Adicet Bio, Inc., GammaDelta Therapeutics Limited, In8bio, Inc. and TC BioPharm Limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our competitors have initiated clinical trials for solid tumors, hematological malignancies and autoimmune indications, settings in which our iNKT cell therapy platform is currently being investigated. We are also aware of competitors pursuing cell therapy drug candidates, including but not limited to stem cell-based approaches, for the treatment of ARDS secondary to COVID-19. Competitors may compete with us in hiring scientific and management personnel, establishing clinical trial sites, recruiting patients for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Many of our current or potential competitors have significantly greater financial, technical, and human resources, as well as more expertise in research and development, manufacturing, conducting clinical trials and commercializing and marketing approved products. Early-stage companies may also prove to be significant competitors, either alone or through collaborative arrangements with large established companies. Our commercial opportunity could be reduced if our competitors develop and commercialize products that are safer, more effective, more convenient or less expensive. Our competitors also may obtain regulatory approval more rapidly than we may obtain approval for ours, which could result in them establishing a dominant market position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human Capital Resources and Employees</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 15, 2024, we had 31 full-time employees, 52% of whom have Ph.D. degrees. Our ability to manage growth effectively will require us to continue to implement and improve our management systems, recruit and train new employees and select qualified independent contractors. Functions in legal, finance, information technology and human resources are provided by Agenus pursuant to our services agreement.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our existing and additional employees. We provide compensation and benefit programs to attract and retain employees. In addition to salaries, these programs include potential annual discretionary bonuses, various stock awards under our equity incentive plans, a 401(k) Plan, healthcare and insurance benefits, flexible spending accounts, paid time off, family leave, and flexible work schedules, among others.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK Website</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Internet website address is www.minktherapeutics.com. The contents of the websites referred to above are not incorporated into this filing. Further, our references to the URLs for these websites are intended to be inactive textual references only.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">k Factors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is subject to a number of risks and uncertainties. The following is a summary of the principal risk factors described in this section:</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Financial Position and Need for Additional Capital</span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to raise capital, we would be forced to delay, reduce, or eliminate certain projects.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our short history as an independent company may make it difficult to evaluate the success of our business and to assess our future viability.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future ability to utilize certain tax attributes may be limited.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and its financial condition and results of operations.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited financial statements.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Discovery, Development and Commercialization of Our Allogeneic iNKT Cells and Other Product Candidates</span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is highly dependent on the success of our lead product candidate, agenT-797, and we may fail to develop agenT-797 successfully or be unable to obtain regulatory approval for it.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Allogeneic iNKT cells represent a novel approaches to immunotherapy, which may result in significant challenges to the development, regulatory approval, and commercialization of product candidates.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is highly dependent on our iNKT cell platform, and our product candidates will require significant additional testing before we can seek regulatory approval.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Serious adverse events, undesirable side effects or unexpected characteristics caused by our product candidates could delay or prevent regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The data produced in our clinical trials is at an early stage and future data may not show responses in patients treated or support continued development. </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to submit INDs or the foreign equivalent to commence additional clinical trials for cell therapies on the timeframes we expect.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if any product candidates we may develop receive marketing approval, they may fail to achieve commercial success.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant competition and there is a possibility that our competitors may achieve regulatory approval before us or develop adoptive cell therapies that are safer or more advanced or effective than ours. </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidates we develop may be complex and difficult to manufacture. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Regulatory Review and Other Legal Compliance Matters</span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our clinical trials fail to demonstrate safety and efficacy, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of product candidates.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience delays or difficulties in the enrollment of patients in our clinical trials.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulatory landscape that will govern any product candidates we may develop is uncertain and may change.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any failure to comply with laws and regulations could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare and other reform legislation may increase the difficulty and cost for us and any collaborators we may have to obtain marketing approval of and commercialize any product candidates.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, or we may fail to satisfy certain arrangements with governmental authorities.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Laws and regulations governing our international operations may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us implement costly compliance programs.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to stringent privacy and information security laws, regulations, policies and contractual obligations and changes in such laws, regulations, policies and contractual obligations could adversely affect our business.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Relationship with Agenus</span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience difficulty in separating our resources from Agenus. </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agenus owns a majority of our common stock and will be able to exert control over specific matters subject to stockholder approval.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with Agenus.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Relationships with Third Parties</span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third parties, which may not perform satisfactorily, including failing to meet deadlines for the completion of trials, research, or testing.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reliance on third parties increases the risk that we will not have sufficient quantities of materials, product candidates, or any medicines that we may develop and commercialize, or that it will not be available at an acceptable cost.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to establish collaborations, we may have to alter our development and commercialization plans.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to obtain and maintain satisfactory patent and other intellectual property protection for any product candidates we develop and for our cell-based immunotherapies.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our rights to develop and commercialize our cell-based immunotherapies and product candidates are subject, in part, to the terms and conditions of assignments and licenses granted to us by others, including Agenus.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be successful in acquiring or in-licensing necessary rights to key technologies or any product candidates we may develop.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not obtain patent term extension (&#8220;PTE&#8221;) and data exclusivity for any product candidates we may develop.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to protect the confidentiality of our proprietary knowledge.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Employee Matters, Managing Growth, Information Technology and Our Operations</span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to retain our key executives and to attract, retain and motivate qualified personnel.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may encounter difficulties in managing our growth, which could disrupt our operations.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our internal computer systems, or those of our third-party vendors, collaborators or other contractors or consultants, may fail or suffer security breaches.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A market for our common stock may not be sustained. We may be delisted from the Nasdaq Capital Market if we are unable to comply with Nasdaq Listing Rules.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions in our organizational documents and Delaware law may have anti-takeover effects.</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our organizational documents designate courts within the State of Delaware as the exclusive forum for certain types of actions and proceedings, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Financial Position and Need for Additional Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, we have incurred operating losses associated with our research, clinical development and manufacturing efforts. We have devoted substantially all of our efforts and financial resources in building our iNKT cell platform, identifying our current product candidates, conducting preclinical development and initiating clinical trials of agenT-797. Our net loss was $22.5 million and $28.0 million for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $133.4 million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue our clinical and preclinical development of product candidates; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek to develop our iNKT cell platform further and identify additional research programs and additional product candidates; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiate preclinical testing and clinical trials for any product candidates we identify and develop from our current research programs; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain, expand, enforce, defend and protect our intellectual property portfolio; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek marketing approvals for any of our product candidates that successfully complete clinical trials; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a sales, marketing, manufacturing and distribution infrastructure to commercialize any biologics for which we may obtain marketing approval; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hire additional research and development personnel; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hire clinical and commercial personnel; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support our product development; and</span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acquire or in-license product candidates, intellectual property and technologies.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have initiated three Phase 1 clinical trials for our lead product candidate, agenT-797, and all of our other product candidates remain in preclinical development. We do not have any products approved for sale and have not generated any revenue from product supplies or royalties. Based on our current plans, we do not expect to generate product or royalty revenues unless and until we obtain marketing approval for a product candidate. We expect that it will be many years, if ever, before we have a product candidate that receives such approval. To become and remain profitable, we must develop and, either directly or through collaborators, eventually commercialize a medicine or medicines with significant market potential. This will require us to be successful in a range of challenging activities, including identifying product candidates, completing preclinical testing and clinical trials of product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those medicines for which we may obtain marketing approval, and satisfying any post-marketing requirements. Even if one or more of the product candidates we may develop are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA or other regulatory authorities to perform clinical and other studies in addition to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved product candidates, we may not become profitable and may need to obtain additional funding to continue operations and, even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease our value and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate our research and product development programs or future commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our expenses to increase in connection with the maturation of our programs and ongoing activities, particularly as we identify, continue the research and development of, initiate and continue clinical trials of, and seek marketing approval for, our product candidates, including agenT-797. In addition, if we obtain marketing approval for any product candidates we may develop, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of a collaborator. Furthermore, we incur significant costs associated with operating as a standalone public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our primary source of funding prior to our initial public offering was through Agenus. As of December 31, 2023, our cash balance was $3.4 million. We expect that our cash as of December 31, 2023, along with the additional funding received subsequent to year end from our parent, Agenus, and funding planned from a third party, will be sufficient to satisfy our liquidity requirements for more than one year from when these financial statements were issued. However, our operating plan may change as a result of factors currently unknown to us, and we may need to seek funding sooner than planned.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and, if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Our license agreements and any future collaboration agreements may also be terminated if we are unable to meet payment or other obligations under such agreements. We could be required to seek collaborators for product candidates we may develop at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, or relinquish or license on unfavorable terms our rights to product candidates we may develop in markets where we otherwise would seek to pursue development or commercialization ourselves. In addition, any fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends and possibly other restrictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates we may develop, or we may have to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our short operating history as an independent company may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were formed in 2017 as a subsidiary of Agenus and have operated as a majority-owned subsidiary of Agenus since that time. Our operations to date have been limited to organizing and staffing our company, business planning, identifying potential product candidates and undertaking clinical trials and preclinical studies, and some of these activities have been performed by Agenus pursuant to services agreements between the parties. We have initiated three Phase 1 clinical trials for agenT-797 and our other programs are still in the preclinical or research stage of development, where the risk of failure is high. We have not yet demonstrated an ability to successfully complete any clinical trials, including large-scale, pivotal clinical trials; obtain marketing approvals; manufacture a commercial-scale medicine, or arrange for a third party to do so on our behalf; or conduct sales and marketing activities necessary for successful commercialization. It takes many years to develop a new medicine from the time it is discovered to when it is available for treating patients. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer independent operating history.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our limited independent operating history, particularly in light of rapidly evolving cell therapies, may make it difficult to evaluate our technology and industry and predict our future performance, and to make any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by very early stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as a new business, we may encounter other unforeseen expenses, difficulties, complications, delays and other known and unknown factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred substantial net operating losses (&#8220;NOLs&#8221;) during our history. U.S. federal and certain state NOLs generated in taxable years beginning after December 31, 2017 are not subject to expiration. Federal NOLs generally may not be carried back to prior taxable years except that, under the Coronavirus Aid, Relief, and Economic Securities Act, federal NOLs generated in 2018, 2019 and 2020 may be carried back to each of the five taxable years preceding the taxable year in which the loss arises. Additionally, for taxable years beginning after December 31, 2020, the deductibility of federal NOLs generated in taxable years beginning after December 31, 2017 is limited to 80% of our taxable income in such taxable year. NOLs generated in tax years beginning before January 1, 2018 may still be used to offset future taxable income without regard to the 80% limitation, although they have the potential to expire without being utilized if we do not achieve profitability in the future. In addition, in general, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to use its pre-change NOLs to offset future taxable income. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. We may experience ownership changes in the future as a result of future transactions in our stock, some of which may be outside our control. For these reasons, we may not be able to use a material portion of our NOLs, even if we attain profitability.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and its financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We regularly maintain cash balances at third-party financial institutions, such as Silicon Valley Bank (&#8220;SVB&#8221;), in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limit. In March 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. Although all depositors of SVB retained access to all of their money, including funds held in uninsured deposit accounts, if another depository institution is subject to other adverse conditions in the financial or credit markets, it could impact access to our invested cash or cash equivalents and could adversely impact our operating liquidity and financial performance. In addition, if any parties with whom we conduct business are unable to access funds pursuant to such instruments or lending arrangements with such a financial institution, such parties&#8217; ability to pay their obligations to us or to enter into new commercial arrangements requiring additional payments to us could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited financial statements, and it is possible that such report on our financial statements may include such an explanation again in the future.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe we have sufficient capital, including the additional funding received subsequent to year end from our parent, Agenus, and funding planned from a third party to satisfy our liquidity requirements for more than one year from when the financial statements in this Annual Report on Form 10-K were issued. Going forward, if we are unable to obtain sufficient funding to support our operations, we could be forced to delay, reduce or eliminate all of our research and development programs, or product portfolio expansion, our financial condition and results of operations will be materially and adversely affected, and we may be unable to continue as a going concern. In the future, reports from our independent registered public accounting firm may also contain statements expressing substantial doubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms, if at all.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Discovery, Development and Commercialization of Our Allogeneic iNKT Cells</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business is highly dependent on the success of our lead product candidate, agenT-797, which is our only product candidate in clinical development. We have a limited history of conducting clinical trials and may fail to develop agenT-797 successfully or be unable to obtain regulatory approval for it.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot guarantee that agenT-797 will be safe and effective, or will be approved for commercialization on a timely basis or at all. Although certain of our employees and consultants have prior experience with clinical trials, regulatory approvals and cGMP manufacturing, we have not previously completed any clinical trials or submitted a BLA to the FDA, or similar regulatory approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that agenT-797 will be successful in clinical trials or receive regulatory approval. The FDA and other comparable global regulatory authorities can delay, limit or deny approval of a product candidate for many reasons. Any delay in obtaining, or inability to obtain, applicable regulatory approval will delay or harm our ability to successfully commercialize agenT-797 and materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because agenT-797 is our most advanced product candidate and our only product candidate in a clinical trial, and because our other product candidates are based on similar technology, if our clinical trials of agenT-797 encounter safety, efficacy or manufacturing problems, development delays, regulatory issues or other problems, our development plans for agenT-797 and our other product candidates in our pipeline could be significantly impaired, which could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to develop our product candidates both as monotherapy and potentially as combination therapy, a common form of cancer treatment, with one or more currently approved cancer therapies. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the combination therapy used with our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also evaluate our product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval, or if safety, efficacy, manufacturing or supply issues arise with the drugs we choose to evaluate in combination with any product candidate we develop for our combination therapy, we may be unable to obtain approval of or market our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Utilizing allogeneic iNKT cells represents a novel approach to immunotherapy, and we must overcome significant challenges to develop, commercialize and manufacture our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have concentrated our research and development efforts on utilizing allogeneic iNKT cells as an immunotherapy. To date, the FDA has approved only a few adoptive cell therapies for commercialization and no allogeneic iNKT cell therapy has been approved for commercial use by any regulatory authority. The processes and requirements imposed by the FDA or other applicable regulatory authorities may cause delays and additional costs in obtaining approvals for marketing authorization for our product candidates. Because our allogeneic iNKT cell platform products are novel, and adoptive cell therapies are relatively new, regulatory agencies may lack experience in evaluating product candidates like our iNKT cell product candidates, including our lead product candidate, agenT-797. This novelty may heighten regulatory scrutiny of our therapies or lengthen the regulatory review process, including the time it takes for the FDA to review our INDs if and when submitted, increase our development costs and delay or prevent commercialization of our allogeneic iNKT cell platform products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, advancing novel cell therapies involve significant challenges for us, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">educating medical personnel regarding the potential side-effect profile of our product candidates and, as the clinical program progresses, on observed side effects with the therapy; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">training a sufficient number of medical personnel on how to properly administer our product candidates; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">enrolling sufficient numbers of patients in clinical trials; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing a reliable, safe and effective means of genetically modifying certain of our cells; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing a cost-effective and large-scale manufacturing capacity suitable for the manufacture of our product candidates in line with expanding enrollment in our clinical trials and our projected commercial requirements; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sourcing starting material suitable for clinical and commercial manufacturing; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing sales and marketing capabilities to successfully launch and commercialize our product candidates if and when we obtain any required regulatory approvals, and risks associated with gaining market acceptance of a novel therapy if we receive approval, as well as developing a manufacturing process and distribution network to support the commercialization of any approved products. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We must be able to overcome these challenges in order for us to develop, commercialize and manufacture our product candidates utilizing allogeneic iNKT cells. Failure to do so could materially adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are very early in our development efforts and only have one product candidate in early stage clinical development. It will be many years before we commercialize a product candidate, if ever.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are very early in our development efforts. Our future success depends heavily on the successful development of our product candidates. Currently, with the exception of agenT-797, which is in three Phase 1 clinical trials, all of our other product candidates are in preclinical development or in discovery. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur. We currently generate no revenue from sales of any product and we may never be able to develop or commercialize a marketable product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commercialization of our product candidates will require additional preclinical and/or clinical development; regulatory and marketing approval in multiple jurisdictions, including by the FDA and the European Medicines Agency (&#8220;EMA&#8221;); obtaining manufacturing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">supply, capacity and expertise; building of a commercial organization; and significant marketing efforts. The success of product candidates we may identify and develop will depend on many factors, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sufficiency of our financial and other resources to complete the necessary preclinical studies, IND-enabling studies and clinical trials; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful enrollment in, and completion of, clinical trials; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receipt of marketing approvals from applicable regulatory authorities; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishment of arrangements with third-party manufacturers for clinical supply and commercial manufacturing and, where applicable, commercial manufacturing capabilities; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful development of our internal manufacturing processes and transfer to larger-scale facilities operated by either a contract manufacturing organization (&#8220;CMO&#8221;) or by us; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining and maintaining patent, trade secret and other intellectual property protection and non-patent exclusivity for our medicines; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">launching commercial sales of the medicines, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance of the products, if and when approved, by patients, the medical community and third-party payors; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effectively competing with other therapies and treatment options; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a continued acceptable safety profile of the medicines following approval; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">enforcing and defending intellectual property and proprietary rights and claims; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">supplying the products at a price that is acceptable to the pricing or reimbursement authorities in different countries. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we do not successfully achieve one or more of these activities in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any product candidates we may develop, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business is highly dependent on our iNKT cell platform, and our product candidates will require significant additional testing before we can seek regulatory approval. We may not be successful in our efforts to identify and develop additional product candidates. Additional product candidates include, but are not limited to, iNKT cell products genetically engineered to express CARs and other modifications that are designed to enhance safety and efficacy. They may also include combinations with other drug substances such as small molecules and immuno-oncology antibodies. If these efforts are unsuccessful, we may never become a commercial stage company or generate any revenues.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The success of our business depends primarily upon our ability to identify, develop and commercialize product candidates based on our iNKT cell platform. All of our product development programs are still in clinical research or in the preclinical stage of development. The process for obtaining marketing approval for any candidate is very long and risky and there will be significant challenges for us to address in order to obtain marketing approval, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no guarantee that the results obtained in current Phase 1 and anticipated clinical trials for agenT-797 will be sufficient for us to plan one or more pivotal clinical trials and obtain regulatory approval or marketing authorization, or that preclinical development of our other product candidates or agenT-797 in other indications will be successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research programs may also fail to identify additional potential product candidates for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying potential product candidates, our potential product candidates may be shown to have harmful side effects in preclinical </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> experiments or animal model studies, they may not show promising signals of therapeutic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable or unlikely to receive marketing approval. In addition, although we believe our iNKT cell platform will allow us to expand our portfolio of product candidates beyond our current product candidates, we have not yet successfully developed any product candidate and our ability to expand our portfolio may never materialize.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of these events occur, we may be forced to abandon our research or development efforts for a program or programs, which would have a material adverse effect on our business, financial condition, results of operations and prospects. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful, which would be costly and time-consuming.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If any of the product candidates we may develop, or the delivery modes we rely on to administer them, cause serious adverse events, undesirable side effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have completed and published preliminary data from clinical trials for agenT-797. Moreover, there have been only a limited number of clinical trials involving the use of iNKT cells and none involving therapies similar to our therapies. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. In the adoptive cell therapy field, there have been significant adverse events from allogeneic cell treatments in the past, including cytokine release syndrome, peripheral neuropathies and adverse events linked to lymphodepleting chemotherapy regimens used in the field prior to administration of cell therapy products. While in our trials to date, there have been no observations of neurotoxicity or cytokine release syndrome. There can be no assurance that our product candidates will not cause undesirable side effects in the future, which may include serious adverse effects that are related to our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any product candidates we develop are associated with serious adverse events, undesirable side effects or unexpected characteristics, we may need to abandon their development or limit development to certain uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, any of which would have a material adverse effect on our business, financial condition, results of operations and prospects. Many product candidates that initially showed promise in early stage testing for treating cancer or life-threatening diseases have later been found to cause side effects that prevented further clinical development of the product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If in the future we are unable to demonstrate that any of the above adverse events were caused by factors other than our product candidate, the FDA, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, any product candidates we are able to develop for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of any product candidate we may develop, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to identify and develop product candidates, and may harm our business, financial condition, result of operations and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if we successfully develop a product candidate and it receives marketing approval, the FDA could require us to adopt a REMS, to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. The FDA has required REMS programs for other cell therapies, including autologous CAR-T cell therapies. Furthermore, if we or others later identify undesirable side effects caused by any product candidate that we develop, several potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may suspend or withdraw approvals of such product candidate; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require additional warnings on the label or limit the approved use of such product candidate; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to conduct additional clinical trials; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of any product candidates we may identify and develop and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The data produced in our clinical trials of agenT-797 is at an early stage and future data may not show responses in patients treated or support continued development. In addition, the results ultimately obtained from our preclinical studies or other clinical trials for agenT-797 or any of our other product candidates may not be predictive of future results.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we published data from our clinical trial for ARDS secondary to COVID-19; such interim data, and any future interim data from clinical trials that we may conduct, including the clinical trials for agenT-797 for the treatment of cancer and, potentially, other life-threatening infectious diseases, are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. We cannot provide any assurance that additional data will be provided frequently or that data updates will be available at any particular time. Furthermore, while patients with who have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">been treated with our product candidates may have a positive response, there can be no assurance that their progress or recovery will be sustained.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously announced. Negative differences between preliminary or interim data and final data could materially adversely affect the prospects of any product candidate that is impacted by such data updates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the results of any preclinical studies of agenT-797 or for our other product candidates may not be predictive of the results of clinical trials. For example, preclinical models as applied to cell therapy in oncology do not adequately represent the clinical setting, and thus cannot predict clinical activity nor all potential risks and may not provide adequate guidance as to appropriate dose or administration regimen of a given therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to submit INDs or the foreign equivalent outside of the United States to commence additional clinical trials for cell therapies on the timeframes we expect, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the regulatory authorities will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if any product candidates we may develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The commercial success of any of the product candidates we may develop will depend upon its degree of market acceptance by physicians, patients, third-party payors and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and safety of such product candidates as demonstrated in clinical trials; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential and perceived advantages compared to alternative treatments; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the limitation to our targeted patient population and limitations or warnings contained in approved labeling by the FDA or other regulatory authorities; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to offer our medicines for sale at competitive prices; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">convenience and ease of administration compared to alternative treatments; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which the product candidate is approved by the FDA, the EMA or other regulatory agencies; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of the target patient population to try novel therapies and of physicians to prescribe these therapies; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product labeling or product insert requirements of the FDA, the EMA or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">relative convenience and ease of administration; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of competitive products; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">publicity concerning our products or competing products and treatments; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength of marketing and distribution support; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sufficient third-party coverage or reimbursement; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of the product candidates we develop are approved, but do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any approved medicine for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of the product candidates we may develop if and when they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Factors that may inhibit our efforts to commercialize the product candidates we may develop on our own include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs and other support personnel; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future medicines; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and other acceptance by payors; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restricted or closed distribution channels that make it difficult to distribute the product candidates we may develop to segments of the patient population; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the lack of complementary medicines to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent commercialization organization. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we enter into arrangements with third parties to perform sales, marketing, commercial support and distribution services, our product revenues or the profitability of these product revenues to us may be lower than if we were to market and sell any medicines we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize the product candidates we may develop or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our medicines effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing the product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop adoptive cell therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development and commercialization of new adoptive cell therapy products is highly competitive. We face competition from existing and future competitors with respect to each of our product candidates currently in development, and will face competition with respect to other product candidates that we may seek to develop or commercialize in the future. Our competitors include major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide, as well as academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no guarantee that our product candidates will be able to compete with potential future products being developed by our competitors including those described under &#8220;Item 1. Business &#8211; Competition.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of our competitors have initiated clinical trials for GvHD, solid tumors and multiple myeloma, settings in which our iNKT cell therapy platform is currently being investigated. We are also aware of competitors pursuing cell therapy drug candidates, including but not limited to stem cell-based approaches, for the treatment of ARDS secondary to COVID-19. Any product candidates that we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future that are approved to treat the same diseases for which we may obtain approval for the product candidates we may develop. This may include other types of therapies, such as bispecific T cell engagers, oncolytic viruses and antibody drug conjugates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our current or potential competitors, either alone or with their collaboration partners, may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and adoptive cell therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize product candidates that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop or that would render any product candidates that we may develop obsolete or non-competitive. Our competitors also may obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as a result of the expiration or successful challenge of our patent rights, we could face more litigation with respect to the validity and/or scope of patents relating to our competitors&#8217; products. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any product candidates that we may develop and commercialize.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which would harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulations that govern marketing approvals, pricing and reimbursement for new medicines vary widely from country to country. Some countries require approval of the sale price of a medicine before the product can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a medicine in a particular country, but then be subject to price regulations that delay or might even prevent our commercial launch of the medicine, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the medicine in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates we may develop, even if any product candidates we may develop obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to commercialize any medicines successfully also will depend in part on the extent to which reimbursement for these medicines and related treatments will be available from government authorities or healthcare programs, private health plans and other organizations. Government authorities and third-party payors, such as private health plans, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are challenging the prices charged for medical products and requiring that drug companies provide them with discounts from list prices. Novel medical products, if covered at all, may be subject to enhanced utilization management controls designed to ensure that the products are used only when medically necessary. Such utilization management controls may discourage the prescription or use of a medical product by increasing the administrative burden associated with its prescription or creating coverage uncertainties for prescribers and patients. We cannot be sure that reimbursement will be available for any medicine that we may commercialize or, if reimbursement is available, that the level of reimbursement will be adequate. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There may be significant delays in obtaining reimbursement for newly approved medicines, and coverage may be more limited than the purposes for which the medicine is approved by the FDA, the EMA or other regulatory authorities outside the United States. Coverage by one payor does not mean that other payors will also provide coverage. Moreover, eligibility for reimbursement does not imply that any medicine will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new medicines, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the medicine and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost medicines and may be incorporated into existing payments for other services. Net prices for medicines may be reduced by mandatory discounts or rebates required to be provided to government</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of medicines from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved medicines we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize any medicines we may develop, and our overall financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to successfully identify patients who are likely to benefit from therapy with any product candidates we develop, or experience significant delays in doing so, we may not realize the full commercial potential of any medicines we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success may depend, in part, on our ability to identify patients who are likely to benefit from therapy with any medicines we may develop. If we, or any third parties that we engage to assist us, are unable to successfully identify such patients, or experience delays in doing so, then:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to develop any product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our clinical trials; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not realize the full commercial potential of any product candidates we develop that receive marketing approval if, among other reasons, we are unable to appropriately select patients who are likely to benefit from therapy with our medicines. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidates we develop may require use of a companion diagnostic to identify patients who are likely to benefit from therapy. If safe and effective use of any of the product candidates we may develop depends on a companion diagnostic, we may not receive marketing approval, or marketing approval may be delayed, if we are unable to or are delayed in developing, identifying or obtaining regulatory approval or clearance for the companion diagnostic product for use with our product candidate. Identifying a manufacturer of the companion diagnostic and entering into an agreement with the manufacturer could also delay the development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of these factors, we may be unable to successfully develop and realize the commercial potential of any product candidates we may identify and develop, and our business, financial condition, results of operations and prospects would be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any medicines that we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing in clinical trials of any product candidates we may develop and will face an even greater risk if we commercially sell any medicines that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or medicines caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for any product candidates or medicines that we may develop; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation and significant negative media attention; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant time and costs to defend the related litigation; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize any medicines that we may develop. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although Agenus maintains product liability insurance coverage for us, it may not be adequate to cover all liabilities that we may incur. In the future, we may need to procure our own insurance coverage. Additionally, we anticipate that we will need to increase our insurance coverage when we begin additional clinical trials and if we successfully commercialize any medicine. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adoptive cell therapy treatments are novel, and any product candidates we develop may be complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or production problems that result in delays in our development or commercialization programs, limit the supply of our product candidates we may develop or otherwise harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidates we may develop will likely require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as the product candidates we intend to develop generally cannot be fully characterized. As a result, assays of the finished product candidate may not be sufficient to ensure that the product candidate will perform in the intended manner. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims, insufficient inventory or potentially delay progression of our potential IND filings. If we successfully develop product candidates, we may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, EMA or other comparable applicable foreign standards or specifications with consistent and acceptable production yields and costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the FDA, the EMA and other regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We, or our CMOs, also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to manage our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the nature of biologics manufacturing, there is a risk of contamination during manufacturing. Any contamination could materially harm our ability to produce product candidates on schedule and could harm our results of operations and cause reputational damage. Some of the raw materials that we anticipate will be required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of any product candidates we may develop could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially harm our development timelines and our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any problems in our manufacturing process or the facilities with which we contract could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in third-party manufacturing process or facilities also could restrict our ability to ensure sufficient clinical material for any clinical trials we may be conducting or are planning to conduct and meet market demand for any product candidates we develop and commercialize.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we may be unable to find sufficient healthy donors for isolation of the iNKT cells that form the basis of our products to meet clinical or market demands, or we may be unable to timely access our donor pool due to events outside of our control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Regulatory Review and Other Legal Compliance Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our ongoing clinical trials of agenT-797 or any of our future trials fail to demonstrate safety and efficacy to our satisfaction and the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidates we develop may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and our collaborators, if any, may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize any product candidates we may identify and develop, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching a consensus with regulators on trial design; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators, institutional review boards (&#8220;IRBs&#8221;), or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching or failing to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective contract research organizations ("CROs") and clinical trial sites; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials of any product candidates we may develop may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development or research programs; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty in designing well-controlled clinical trials due to ethical considerations which may render it inappropriate to conduct a trial with a control arm that can be effectively compared to a treatment arm; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty in designing clinical trials and selecting endpoints for diseases that have not been well-studied and for which the natural history and course of the disease is poorly understood; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of patients required for clinical trials of any product candidates we may develop may be larger than we anticipate, enrollment of suitable participants in these clinical trials may be delayed or slower than we anticipate or patients may drop out of these clinical trials at a higher rate than we anticipate; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators, IRBs or independent ethics committees may require that we or our investigators suspend or terminate clinical research or clinical trials of any product candidates we may develop for various reasons, including noncompliance with regulatory requirements, a finding of undesirable side effects or other unexpected characteristics, or that the participants are being exposed to unacceptable health risks or after an inspection of our clinical trial operations or trial sites; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of clinical trials of any product candidates we may develop may be greater than we anticipate; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the supply or quality of any product candidates we may develop or other materials necessary to conduct clinical trials of any product candidates we may develop may be insufficient or inadequate, including as a result of delays in the testing, validation, manufacturing and delivery of any product candidates we may develop to the clinical sites by us or by third parties with whom we have contracted to perform certain of those functions; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in having patients complete participation in a trial or return for post-treatment follow-up; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trial sites dropping out of a trial; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurrence of serious adverse events associated with any product candidates we may develop that are viewed to outweigh their potential benefits; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, or additional administrative burdens associated with foreign regulatory schemes; or </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of ourselves or any third-party manufacturers, contractors or suppliers to comply with regulatory requirements, maintain adequate quality controls or be able to provide sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we experience delays in the initiation, enrollment or completion of any preclinical study or clinical trial of our product candidates, or if any preclinical studies or clinical trials of our product candidates are canceled, the commercial prospects of our product candidates may be materially adversely affected, and our ability to generate product revenues from any of these product candidates will be delayed or not realized at all. In addition, any delays in completing our clinical trials may increase our costs and slow down our product candidate development and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our collaborators are required to conduct additional clinical trials or other testing of any product candidates we may develop beyond those that we currently contemplate, if we or our collaborators are unable to successfully complete clinical trials or other testing of any product candidates we may develop, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we or our collaborators may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be delayed in obtaining marketing approval for any such product candidates we may develop or not obtain marketing approval at all; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be subject to changes in the way the product is administered; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a REMS or through modification to an existing REMS; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be sued; or </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">experience damage to our reputation. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product development costs will also increase if we or our collaborators experience delays in clinical trials or other testing or in obtaining marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize any product candidates we may develop, could allow our competitors to bring products to market before we do, and could impair our ability to successfully commercialize any product candidates we may develop, any of which may harm our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we experience delays or difficulties in the enrollment of patients in our clinical trials for agenT-797 or any future trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our collaborators may not be able to continue our current and anticipated clinical trials for agenT-797 or initiate trials for any product candidates we identify or develop if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, the EMA or other analogous regulatory authorities outside the United States, or as needed to provide appropriate statistical power for a given trial. In addition, if patients are unwilling to participate in our clinical trials because of negative publicity from adverse events related to the biotechnology, adoptive cell therapy, competitive clinical trials for similar patient populations, clinical trials in competing products or for other reasons, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of any product candidates we may develop may be delayed. Moreover, some of our competitors may have ongoing clinical trials for product candidates that would treat the same indications as any product candidates we may develop, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patient enrollment is also affected by other factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">severity of the disease under investigation; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">size of the patient population and process for identifying patients; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">design of the trial protocol; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">availability and efficacy of approved medications for the disease under investigation; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ability to obtain and maintain patient informed consent; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">risk that enrolled patients will drop out before completion of the trial; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eligibility and exclusion criteria for the trial in question; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">perceived risks and benefits of the product candidate under trial; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">perceived risks and benefits of adoptive cell therapy as a therapeutic approach; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">efforts to facilitate timely enrollment in clinical trials; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patient referral practices of physicians; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ability to monitor patients adequately during and after treatment; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">proximity and availability of clinical trial sites for prospective patients, especially for those conditions which have small patient pools. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As COVID-19 vaccination rates have increased in the general population, fewer patients have been hospitalized with ARDS secondary to COVID-19, which has slowed our ability to enroll patients in our clinical trial for ARDS secondary to COVID-19. We are preparing a protocol to expand this trial to include ARDS secondary to other life-threatening infectious diseases, including influenza.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty in establishing or managing relationships with CROs and physicians; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">different standards for the conduct of clinical trials; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">different standard-of-care for patients with a particular disease; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty in locating qualified local consultants, physicians and partners; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatments and of cell-based immunotherapies. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our clinical trials may also compete to recruit patients with other clinical trials for product candidates that are in a similar adoptive cell therapy area as our product candidates, and this competition could reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enrollment delays in our clinical trials may result in increased development costs for any product candidates we may develop, which would cause the value of our company to decline and limit our ability to obtain additional financing. If we or our collaborators have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because adoptive cell therapy is novel and the regulatory landscape that will govern any product candidates we may develop is uncertain and may change, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulatory requirements that will govern any novel cell-based immunotherapies we develop are not entirely clear and may change. Within the broader adoptive cell therapy field, we are aware of a limited number of adoptive cell therapies and products that have received marketing authorization from the FDA and the EMA. Even with respect to more established products that fit into the categories of adoptive cell therapy, the regulatory landscape is still developing. Regulatory requirements governing adoptive cell therapy products have changed frequently and will likely continue to change in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adverse developments in post-marketing experience or in clinical trials conducted by others of adoptive cell therapy may cause the FDA, the EMA and other regulatory bodies to revise the requirements for development or approval of any product candidates we may develop or limit the use of products utilizing adoptive cell therapy, either of which could materially harm our business. In addition, the clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as the product candidates we may develop can be more expensive and take longer than for other, better known or more extensively studied pharmaceutical or other product candidates. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing adoptive cell therapy in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays or other impediments to our research programs or the commercialization of resulting products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulatory review committees and advisory groups described above and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates, or lead to significant post-approval limitations or restrictions. As we advance our research programs and develop future product candidates, we will be required to consult with these regulatory and advisory groups and to comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of any product candidates we identify and develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we complete the necessary trials for agenT-797 or any other product candidates we may develop, the marketing approval process is expensive, time-consuming and uncertain. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, product candidates we may develop, and our ability to generate revenue will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidates we may develop and the activities associated with their development and commercialization, including their design, testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale, import, export and distribution, are subject to comprehensive regulation by the FDA, the EMA and other regulatory authorities in the United States and by comparable authorities in other countries or jurisdictions. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the biological product candidate&#8217;s safety, purity and potency. Securing regulatory approval also requires the submission of extensive information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if approval is obtained at all and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Regulatory authorities may also approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a REMS. These regulatory authorities may require labeling that includes precautions or contra-indications with respect to conditions of use, or they may grant approval subject to the performance of costly post-marketing clinical trials. Regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of any product candidates we may develop. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments as described above, which could render the approved medicine not commercially viable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we may develop, the commercial prospects for those product candidates may be harmed and our ability to generate revenues will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to obtain marketing approval in foreign jurisdictions would prevent any product candidates we may develop from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To market and sell any product candidates we may develop in the European Union, the United Kingdom, and other foreign jurisdictions, we or our third-party collaborators must obtain separate marketing approvals (a single one for the European Union) and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product candidate be approved for reimbursement before the product candidate can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our medicines in any jurisdiction, which would materially impair our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we, or any collaborators we may have, obtain marketing approvals for any product candidates we develop, the terms of approvals and ongoing regulation of our product candidates could require the substantial expenditure of resources and may limit how we, or they, manufacture and market our product candidates, which could materially impair our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such medicine, will be subject to continual requirements of and review by the FDA, EMA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, facility registration and drug listing requirements, cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the medicine may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, assuming we, or any collaborators we may have, receive marketing approval for one or more product candidates we develop, we, and such collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we and such collaborators are not able to comply with post-approval regulatory requirements, we and such collaborators could have the marketing approvals for our products withdrawn by regulatory authorities and our, or such collaborators&#8217;, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our business, operating results, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any product candidate for which we obtain marketing approval could be subject to restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our medicines, when and if any of them are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA, the EMA and other regulatory agencies closely regulate the post-approval marketing and promotion of medicines to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA, the EMA and other regulatory agencies impose stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we market our medicines for off-label use, we may be subject to enforcement action for off-label marketing by the FDA and other federal and state enforcement agencies, including the Department of Justice. Violation of the FDCA and other statutes, including the False Claims Act, and equivalent legislation in other countries relating to the promotion and advertising of prescription products may also lead to investigations or allegations of violations of federal and state and other countries&#8217; health care fraud and abuse laws and state consumer protection laws. Even if it is later determined we were not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our actions and have to divert significant management resources from other matters.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, later discovery of previously unknown problems with our medicines, manufacturers, or manufacturing processes, or failure to comply with regulatory requirements, may yield various negative consequences, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on such medicines, manufacturers or manufacturing processes; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the labeling or marketing of a medicine; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the distribution or use of a medicine; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements to conduct post-marketing clinical trials; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receipt of warning or untitled letters; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of the medicines from the market; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recall of medicines; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, restitution or disgorgement of profits or revenue; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on future procurements with governmental authorities; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension or withdrawal of marketing approvals; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension of any ongoing clinical trials; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to permit the import or export of our medicines; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any product candidates we may develop and adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our relationships with healthcare providers, third-party payors and patients as well as our activities generally will be subject to a broad range of healthcare laws and regulations and any failure to comply with such laws and regulations could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain federal and state healthcare laws and regulations pertaining to product promotion, fraud and abuse, privacy and price reporting and payment constrain the activities of pharmaceutical companies and their interactions with healthcare providers, third-party payors and patients. Those laws and regulations, including certain laws and regulations applicable only if we have marketed products, include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal healthcare program anti-kickback law, which prohibits, among other things, persons from soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products for off-label use and regulates the distribution of samples; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the so-called &#8220;federal sunshine&#8221; law under the Healthcare Reform Act, which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with certain healthcare providers to the Center for Medicare &amp; Medicaid Services within the U.S. Department of Health and Human Services for re-disclosure to the public, as well as ownership and investment interests held by physicians and their immediate family members; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">analogous state and foreign laws and regulations, such as state anti-kickback, anti-bribery and false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private insurers. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some state laws also require pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to health care providers or marketing expenditures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Given the breadth of the laws and regulations, limited guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, governmental authorities may possibly conclude that our business practices may not comply with healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">physicians is also governed by the national anti-bribery laws of European Union Member States, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare and other reform legislation may increase the difficulty and cost for us and any collaborators we may have to obtain marketing approval of and commercialize any product candidates we may develop and affect the prices we, or they, may obtain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been and continue to be ongoing efforts to implement legislative and regulatory changes regarding the healthcare system. Such changes could prevent or delay marketing approval of any product candidates that we may develop, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Although we cannot predict what healthcare or other reform efforts will be successful, such efforts may result in more rigorous coverage criteria, in additional downward pressure on the price that we, or our future collaborators, may receive for any approved products or in other consequences that may adversely affect our ability to achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Within the United States, the federal government and individual states have aggressively pursued healthcare reform, as evidenced by the passing of the Healthcare Reform Act and the ongoing efforts to modify or repeal that legislation, as well as to implement new reforms. The Healthcare Reform Act substantially changed the way healthcare is financed by both governmental and private insurers and contains a number of provisions that affect coverage and reimbursement of drug products and/or that could potentially reduce the demand for pharmaceutical products such as increasing drug rebates under state Medicaid programs for brand name prescription drugs and extending those rebates to Medicaid managed care and assessing a fee on manufacturers and importers of brand name prescription drugs reimbursed under certain government programs, including Medicare and Medicaid. Other aspects of healthcare reform, such as expanded government enforcement authority and heightened standards that could increase compliance-related costs, could also affect our business. There are, and may continue to be judicial challenges to the various reform efforts. We cannot predict the ultimate content, timing or effect of any changes to the Healthcare Reform Act or other federal and state reform efforts. There is no assurance that federal or state health care reform will not adversely affect our future business and financial results, and we cannot predict how future federal or state legislative, judicial or administrative changes relating to healthcare reform will affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal and state governments have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, waivers from Medicaid drug rebate law requirements, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. The private sector has also sought to control healthcare costs by limiting coverage or reimbursement or requiring discounts and rebates on products. We are unable to predict what additional legislation, regulations or policies, if any, relating to the healthcare industry or third-party coverage and reimbursement may be enacted in the future or what effect such legislation, regulations or policies would have on our business. Any cost-containment measures could significantly decrease the available coverage and the price we might establish for our potential products, which would have an adverse effect on our net revenues and operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may seek fast track, breakthrough or regenerative medicine advanced therapy designation by the FDA for product candidates but may be unable to obtain such designations. Even if such a designation is granted, it may not actually lead to a faster development or regulatory review or approval process, and does not assure FDA approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA&#8217;s fast track, breakthrough and regenerative medicine advanced therapy ("RMAT") programs are intended to expedite the development of certain qualifying products intended for the treatment of serious diseases and conditions. If a product candidate is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the product&#8217;s potential to address an unmet medical need for this condition, the sponsor may apply for FDA fast track designation. A product candidate may be designated as a breakthrough therapy if it is intended to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. A product candidate may receive RMAT designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening condition, and preliminary clinical evidence indicates that the product candidate has the potential to address an unmet medical need for such condition. While we may seek fast track, breakthrough and/or RMAT designation, there is no guarantee that we will be successful in obtaining any such designation. Even if we do obtain such designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. A fast track, breakthrough or RMAT designation does not ensure that the product candidate will receive marketing approval or that approval will be granted within any particular timeframe. In addition, the FDA may withdraw fast track, breakthrough</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or RMAT designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track, breakthrough and/or RMAT designation alone do not guarantee qualification for the FDA&#8217;s priority review procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may seek priority review designation by the FDA, but we may not be able to obtain such designation and, even if obtained, priority review may not lead to a faster regulatory review or approval process and, in any event, would not assure FDA approval of any product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA determines that a product candidate is intended to treat a serious disease or condition and, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of such disease or condition, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review a marketing application is six months from filing of the application, rather than the standard review period of ten months. We may request priority review for certain of our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may disagree and decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or thereafter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to obtain orphan drug exclusivity for one or more of our product candidates which we may develop, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan product candidates by the EMA in the European Union. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for another product candidate for the same orphan therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA&#8217;s standards for granting orphan drug exclusivity in the cell-based immunotherapies context are unclear and evolving. In order for the FDA to grant orphan drug exclusivity to one of our product candidates, the agency must find that the product candidate is indicated for the treatment of a condition or disease that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product candidate available for the disease or condition will be recovered from sales of the product in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different product candidates can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same product candidate for the same condition if the FDA concludes that the later product candidate is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care compared with the product that has orphan exclusivity. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA&#8217;s policies related to orphan drug exclusivity, including for adoptive cell therapies, are subject to ongoing evaluation. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, or we may fail to satisfy certain arrangements with governmental authorities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, consultants, commercial partners and our principal investigators. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, provide accurate information to the FDA, the EMA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA, the EMA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research and product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance through Agenus to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws, regulations and permitting requirements. These current or future laws, regulations and permitting requirements may impair our research, development, or production efforts. Failure to comply with these laws, regulations and permitting requirements also may result in substantial fines, penalties or other sanctions or business disruption, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any third-party contract manufacturers and suppliers we engage will also be subject to these and other environmental, health and safety laws and regulations. Liabilities they incur pursuant to these laws and regulations could result in significant costs or an interruption in operations, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Laws and regulations governing any of our international operations or those we may have in the future may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate. The creation, implementation and maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The Securities and Exchange Commission (the &#8220;SEC&#8221;) is involved with enforcement of the books and records provisions of the FCPA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similarly, the U.K. Bribery Act 2010 has extra-territorial effect for companies and individuals having a connection with the United Kingdom. The U.K. Bribery Act prohibits inducements both to public officials and private individuals and organizations. Compliance with the FCPA and the U.K. Bribery Act is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expansion outside of the United States has required, and will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain drugs and drug candidates outside of the United States, which could limit our growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies and contractual obligations could adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States and the European Union. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. For example, HIPAA and its implementing regulations establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. We have also assumed contractual obligations related to protecting the privacy and security of personal information. While we have determined that we are neither a &#8220;covered entity&#8221; nor a &#8220;business associate&#8221; directly subject to HIPAA, many of the U.S. health care providers, including U.S. clinical trial sites, with which we interact are subject to HIPAA, and we have assumed contractual obligations related to protecting the privacy of personal information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to properly protect the privacy and security of protected health information, we could be found to have breached our contracts and we could face civil and criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may be subject to privacy and security laws in the various jurisdictions in which we operate, obtain or store personally identifiable information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. For example, the processing of personal data in the European Economic Area (the &#8220;EEA&#8221;), is subject to the General Data Protection Regulation (the "GDPR"), which took effect in May 2018. The GDPR increases obligations with respect to clinical trials conducted in the EEA, such as in relation to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the provision of fair processing notices, responding to data subjects who exercise their rights and reporting certain data breaches to regulators and affected individuals. The GDPR also requires us to enter certain contractual arrangements with third parties that process GDPR-covered personal data on our behalf. The GDPR also increases the scrutiny applied to transfers of personal data from the EEA (including from clinical trial sites in the EEA) to countries that are considered by the European Commission to lack an adequate level of data protection, such as the United States. The July 2020 invalidation by the Court of Justice of the European Union of the EU-U.S. Privacy Shield framework, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States, has led to increased scrutiny on data transfers from the EEA to the United States generally and may increase our costs of compliance with data privacy legislation. If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to &#8364;20.0 million or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill. Additionally, following Brexit, we must comply with the GDPR and the United Kingdom GDPR, each regime having the ability to fine up to the greater of &#8364;20.0 million or 4% of global turnover for violations. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk. In addition, we may be the subject of litigation and/or adverse publicity, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our ongoing efforts to comply with evolving laws and regulations may be costly and require ongoing modifications to our policies, procedures and systems. Our efforts to comply may also be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the European Union and elsewhere and carries with it the potential for significant penalties if we are found to be non-compliant. Similarly, failure to comply with federal and state laws in the United States regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages by data subjects, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Relationship with Agenus</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may experience difficulty in separating our resources from Agenus.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 2, 2022, Agenus and MiNK entered into the Amended and Restated Services Agreement effective April 1, 2022 (the &#8220;Services Agreement&#8221;).  Pursuant to the terms of the Services Agreement, Agenus provides MiNK with certain general and administrative support, including, without limitation, financial, facilities management, human resources and information technology administrative support (the &#8220;Agenus Services&#8221;), and MiNK and Agenus provide each other with certain research and development services (the "R&amp;D Services") and other support services, including legal and regulatory support (the &#8220;Shared Services&#8221;). MiNK pays 10% of Agenus&#8217; costs related to the Agenus Services, and the costs of R&amp;D Services are based upon pass-through costs related to such services plus an allocation of the costs of the employees performing the services. No payment is due from either party for the Shared Services, provided that the services provided by each party are proportional in scope and volume.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Services Agreement also covers MiNK&#8217;s use of Agenus&#8217; business offices and laboratory space and equipment, provided we pay  Agenus a proportionate amount for the use of such facilities and equipment.  We currently utilize business offices, laboratory space and equipment in Agenus&#8217; Lexington, Massachusetts and Cambridge, UK facilities and office space in Agenus&#8217; New York City office.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because our operations have not been fully separated from Agenus, we may have difficulty doing so in the future. We may need to acquire resources in addition to, and eventually in lieu of, those provided by Agenus to us, and may also face difficulty in separating our resources from Agenus&#8217; resources and integrating newly acquired resources into our business. At present, we have prioritized separating our research and development functions from Agenus while continuing to rely on Agenus to provide human resources, finance, information technology, legal and other general and administrative functions. We plan to internalize such functions in the future as our business evolves. We continue to rely on, and plan to continue relying on, access to Agenus&#8217; facilities for our research and development and the eventual manufacturing of our product candidates, which, among other things, presents challenges in maintaining the confidentiality of our intellectual property and proprietary information due the proximity of our employees in their workspace to Agenus&#8217; employees and third party providers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, Agenus may prioritize its own needs ahead of the services Agenus has agreed to provide us or could terminate the Services Agreement. Agenus employees who conduct services for us may prioritize Agenus&#8217; interests over our interests, Agenus employees we rely upon to provide certain services may leave Agenus or Agenus ceases to provide services that are critical to our business. Our business, financial condition and results of operations could be harmed if we have difficulty operating as a standalone company, fail to acquire resources that prove to be important to our operations or incur unexpected costs in separating our resources from Agenus&#8217; resources or integrating newly acquired resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If Agenus or MiNK terminates the Services Agreement, we will need to replicate or replace certain functions, systems and infrastructure to which we will no longer have the same access after our initial public offering. We may also need to make investments or hire additional employees to operate without the same access to Agenus&#8217;s existing operational and administrative infrastructure. These initiatives may be costly to implement. Due to the scope and complexity of the underlying projects relative to these efforts, the amount of total costs could be materially higher than our estimate, and the timing of the incurrence of these costs is subject to change.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to replace these services or enter into appropriate third-party agreements on terms and conditions, including cost, comparable to those that we will receive from Agenus under the Services Agreement. Additionally, after the Services Agreement terminates, we may be unable to sustain the services at the same levels or obtain the same benefits as when we were receiving such services and benefits from Agenus. When we begin to operate these functions separately, if we do not have our own adequate systems and business functions in place, or are unable to obtain them from other providers, we may not be able to operate our business effectively or at comparable costs, and our profitability may decline. In addition, we have historically received informal support from Agenus, which may not be addressed in the Services Agreement and may diminish or be eliminated at any time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agenus owns a majority of our common stock and will be able to exert control over specific matters subject to stockholder approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agenus beneficially owns approximately 63% of our outstanding common stock. Therefore, Agenus has the ability to substantially influence us through this ownership position. For example, Agenus may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. Agenus&#8217; interests may not always coincide with our corporate interests or the interests of other stockholders, and they may act in a manner with which you may not agree or that may not be in the best interests of us or our other stockholders. So long as Agenus continues to own a significant amount of our equity, it will continue to be able to strongly influence or effectively control our decisions. Agenus could remain our controlling stockholder for an extended period of time or indefinitely. Even if Agenus were to control less than a majority of the voting power of our outstanding common stock, it may be able to influence the outcome of our corporate actions so long as it owns a significant portion of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are a &#8220;controlled company&#8221; within the meaning of the applicable rules of Nasdaq and, as a result, qualify for exemptions from certain corporate governance requirements. If we rely on these exemptions, you will not have the same protections afforded to stockholders of companies that are subject to such requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agenus controls a majority of the voting power of our outstanding common stock. As a result, we are a &#8220;controlled company&#8221; within the meaning of the Nasdaq corporate governance requirements. Under these rules, a company of which more than 50% of the voting power for the election of directors is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance requirements, including the requirements:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that a majority of the board of directors consists of independent directors; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for an annual performance evaluation of the nominating and corporate governance and compensation committees; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that we have a nominating and corporate governance committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that we have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibility. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use these exemptions and may continue to use all or some of these exemptions in the future. As a result, you may not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq corporate governance requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If Agenus sells a controlling interest in our company to a third party in a private transaction, you may not realize a change of control premium on shares of our common stock, and we may become subject to the control of a presently unknown third party. In</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">addition, Agenus may distribute a portion of the shares of our common stock it currently holds to its stockholders, which could impact our share price or volatility.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agenus owns a significant equity interest in our company. This means that Agenus could choose to sell some or all of its shares of our common stock in a privately negotiated transaction, which, if sufficient in size, could result in a change of control of our company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agenus&#8217; ability to sell its shares of our common stock privately, with no requirement for a concurrent offer to be made to acquire your shares of our common stock, could prevent you from realizing any change of control premium on your shares of our common stock that may otherwise accrue to Agenus on its private sale of our common stock. Additionally, if Agenus privately sells its significant equity interest in our company, we may become subject to the control of a presently unknown third party. Such third party may have conflicts of interest with those of other stockholders. In addition, if Agenus sells a controlling interest in our company to a third party, such a sale could negatively impact or accelerate any future indebtedness we may incur, and negatively impact any other commercial agreements and relationships, all of which may adversely affect our ability to run our business as described herein and may have a material adverse effect on our operating results and financial condition. Furthermore, Agenus may elect to distribute to its stockholders a portion of the shares of our common stock that it holds. Such Agenus stockholders may then sell the shares of our common stock into the public market. Such sales may not be subject to the volume, manner of sale, holding period and other limitations of Rule 144 and, therefore, may adversely impact our stock price or volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with Agenus.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Garo H. Armen, Ph.D. (Chairman of the Board), Jennifer S. Buell, Ph.D. (President, Chief Executive Officer and Director), Brian Corvese (Director) and Ulf Wiinberg (Director) are all current or former officers and/or directors of Agenus. These individuals own Agenus equity and Agenus equity awards. Their relationship with Agenus and the ownership of any Agenus equity or equity awards creates, or may create the appearance of, conflicts of interest when we ask these individuals to make decisions that could have different implications for Agenus than the decisions have for us. In addition, our certificate of incorporation provides for the allocation of certain corporate opportunities between us and Agenus. Under these provisions, neither Agenus or its other affiliates, nor any of their officers, directors, agents or stockholders, will have any obligation to present to us certain corporate opportunities. For example, a director of our company who also serves as a director, officer or employee of Agenus or any of its other affiliates may present to Agenus certain acquisitions, in-licenses, potential development programs or other opportunities that may be complementary to our business and, as a result, such opportunities may not be available to us. To the extent attractive corporate opportunities are allocated to Agenus or its other affiliates instead of to us, we may not be able to benefit from these opportunities. Additionally, conflicts of interest and certain other disputes may arise between us and Agenus, and we may not be able to resolve favorably such disputes with respect to our past and ongoing relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Relationships with Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, or testing.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend upon independent investigators, such as medical institutions, universities, CROs, clinical data management organizations and clinical investigators to conduct our ongoing clinical trials for agenT-797 and expect to rely on third parties for future clinical trials. We also currently rely and expect to continue to rely on third parties to conduct some aspects of our research and preclinical testing. Any of these third parties may terminate their engagements with us at any time under certain criteria. If we need to enter into alternative arrangements, it may delay our product development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials for agenT-797 is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA, EMA and other regulatory authorities require us to comply with standards, commonly referred to as Good Clinical Practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. In the United States, we also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we designed clinical trials for agenT-797, and will design any future clinical trials for our product candidates, independent investigators, and third parties may also conduct our future clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, are outside of our direct control. Our reliance on third parties to conduct future preclinical studies and clinical trials will also result in less direct control over the management of data developed through preclinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have staffing difficulties; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fail to comply with contractual obligations; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">experience regulatory compliance issues; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">undergo changes in priorities or become financially distressed; or </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">form relationships with other entities, some of which may be our competitors. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. If third-party investigators do not perform preclinical studies and clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates, or our development programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by third parties, we could be required to repeat, extend the duration of or increase the size of any preclinical studies or clinical trials we conduct and this could significantly delay commercialization and require greater expenditures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, producing additional losses and depriving us of potential product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We contract with third parties for the manufacture of materials for our research programs, preclinical studies and clinical trials and expect to do so for commercialization of any product candidates that we may develop. This reliance on third parties increases the risk that we will not have sufficient quantities of such materials, product candidates, or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have any manufacturing facilities at the present time. We currently rely on third-party manufacturers for the manufacture of our materials for preclinical studies and clinical trials. We do not have a long-term supply agreement with any of the third-party manufacturers, and we purchase our required supply on a purchase order basis. Additionally, we are in the process of transferring our manufacturing to an in-house facility pursuant to the Intercompany General &amp; Administrative Services Agreement with Agenus, and we may experience delays or other difficulties associated with such a transition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possible breach of the manufacturing agreement by the third party; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reliance on the third party for regulatory compliance, quality assurance, safety and pharmacovigilance and related reporting. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures or recalls of product candidates or medicines, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any medicines that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply for bulk drug substances. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer. Although we believe that there are several</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential alternative manufacturers who could manufacture any product candidates we may develop, we may incur added costs and delays in identifying and qualifying any such replacement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we utilize third parties to manufacture any product candidates or medicines we may develop, it may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If conflicts arise between our corporate or academic collaborators or strategic partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Some of our academic collaborators and strategic partners are conducting multiple product development efforts within each area that is the subject of the collaboration with us. Our collaborators or strategic partners, however, may develop, either alone or with others, products in related fields that are competitive with the product candidates we may develop that are the subject of these collaborations with us. Competing products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for the product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of our collaborators or strategic partners could also become our competitors in the future. Our collaborators or strategic partners could develop competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the development and commercialization of products. Any of these developments could harm our product development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product development and research programs and the potential commercialization of any product candidates we may develop will require substantial additional cash to fund expenses. For some of the product candidates we may develop, we may decide to collaborate with other pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, the EMA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also be restricted under future collaboration agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to develop product candidates or bring them to market and generate product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain patent and other intellectual property protection for any product candidates we develop and for our cell-based immunotherapies, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and therapies similar or identical to ours, and our</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ability to successfully commercialize any product candidates we may develop, and our cell-based immunotherapies may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success will depend in large part on our ability to obtain and maintain patent, trademark, trade secret and other intellectual property protection of our cell-based immunotherapies, product candidates and other therapies, methods used to manufacture them and methods of treatment, as well as successfully defending our patent and other intellectual property rights against third-party challenges. It is difficult and costly to protect our cell-based immunotherapies and product candidates, and we may not be able to ensure their protection. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, importing or otherwise commercializing the product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We seek to protect our proprietary position by in-licensing intellectual property relating to our platform technology and filing patent applications in the United States and abroad related to our cell-based immunotherapies and product candidates that are important to our business. If we or our licensors are unable to obtain or maintain patent protection with respect to our cell-based immunotherapies and product candidates we may develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours and our ability to commercialize any product candidates we may develop may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patents or patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all desired markets or in a particular market. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be deemed patentable over the prior art. Furthermore, publications of discoveries in the scientific literature lag behind the discoveries per se and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all before the grant of patent rights. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in any licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has been the subject of much litigation in recent years. As a result, whether patent rights will be granted and the scope, validity, enforceability and commercial value of our patent rights are highly uncertain, and we may become involved in complex and costly litigation. Our pending and future patent applications intended to protect our cell-based immunotherapies and product candidates we may develop may not be granted, and if granted may not effectively prevent others from commercializing competitive technologies and products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No consistent policy regarding patentability in the field of cell-based immunotherapies has emerged in the United States. Patentability in this field outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, enforce and defend our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our licensed patent rights. With respect to our in-licensed intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will be deemed valid and enforceable and provide sufficient protection from competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the scope of claims being pursued in a patent application can be significantly reduced before a patent is issued, and the scope of claims can be reinterpreted after issuance. Even if patent applications we in-license or own currently or in the future were to issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Any patents that we own or in-license may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not know whether any of our platform advances and product candidates we may develop will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Moreover, some of our future in-licensed patents and patent applications may in the future be co-owned by our licensors with third parties. If we are unable to obtain an exclusive license to the rights of such third-party co-owners in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our rights to develop and commercialize our cell-based immunotherapies and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others, including Agenus.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend on intellectual property licensed from third parties, and our licensors may not act in our best interest. If we fail to comply with our obligations under our intellectual property licenses, if the licenses are terminated, or if disputes regarding these licenses arise, we could lose significant rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have in-licensed and are dependent on certain rights and proprietary technology from third parties that are important or necessary to the development of some of our cell-based immunotherapies and product candidates. If we fail to comply with our obligations under any license, the licensor may have the right to terminate the license, in which event we would not be able to develop or market our cell-based immunotherapies or any other therapies or product candidates covered by the licensed intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our in-licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our cell-based immunotherapies and product candidates in the future. Some licenses granted to us may be expressly subject to certain preexisting rights held by the licensor or certain third parties. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in certain territories or fields. If we determine that rights to such excluded fields are necessary to commercialize our product candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to continue developing, manufacturing or marketing our product candidates. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms or at all, which could prevent us from commercializing our product candidates or allow our competitors or others the chance to access technology that is important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will not have complete control in the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications intended to protect the technology that we license from third parties in the future. It is possible that our licensors&#8217; enforcement of patents against infringers or defense of such patents against challenges to validity or enforceability may be less vigorous than if we had conducted the proceedings ourselves. We cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced or defended in a manner consistent with the best interests of our business. If our future licensors fail to prosecute, maintain, enforce and defend such patents, or if they lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, our right to develop and commercialize any of the product candidates we may develop that rely in any way on such licensed rights could be adversely affected, and we may not be able to prevent competitors from making, using, selling and importing competing products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future licensors may rely on third-party consultants or collaborators or on funds from third parties and may not be the sole and exclusive owners of the intellectual property we have in-licensed. If other third parties have ownership rights to our in-licensed patents, the license granted to us in jurisdictions where the consent of a co-owner is necessary to grant such a license may not be valid and such co-owners may be able to license such patents to our competitors, and our competitors could market competing products and technology. If one or more of such joint owners breaches any pertinent inter-institutional or operating agreements, our rights to in-licensed patents and patent applications may be adversely affected. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event any of our third-party licensors takes the position that, in spite of our efforts, we have materially breached a license agreement or have failed to meet certain obligations thereunder, it may elect to terminate the applicable license agreement or, in some cases, one or more license(s) under the applicable license agreement and such termination would result in our no longer having the ability to develop and commercialize product candidates and technology covered by that license agreement or license. In the event of such termination of a third-party in-license, or if the underlying patents under a third-party in-license fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our patent, patent applications and any future patents may not provide sufficient protection of our cell-based immunotherapies, our product candidates and our future product candidates or result in any competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agenus has assigned to us a U.S. patent and a U.S. patent application directed to T cell receptor discovery technologies, as well as a number of U.S. and foreign patent applications directed to T cell receptors. Agenus has also assigned to us know-how that supports our cell-based immunotherapies and uses with respect to treatment of particular diseases and conditions and that may provide us with the opportunity to obtain additional patent protection. U.S. provisional patent applications do not themselves mature into granted patent rights, but a non-provisional U.S. and other applications that can result in granted patent rights may claim the benefit of a provisional application if filed within 12 months of the filing date of the provisional application. In any particular case, the failure to file a non-provisional patent application claiming the benefit of the provisional application within the 12-month period could cause us to lose the ability to obtain patent protection for the inventions disclosed in the provisional application. We cannot be certain that any patent applications that we file will issue as patents, and if they do, that such patents will protect our cell-based immunotherapies or our product candidates, or that such patents will not be challenged, narrowed, circumvented, invalidated or held unenforceable. Any failure to obtain or maintain patent protection with respect to our cell-based immunotherapies and product candidates could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Claims to therapeutic methods in a patent do not prevent a competitor or other third party from developing or marketing an identical product for an indication that is outside the scope of such claims. Moreover, even if competitors or other third parties do not actively promote their product to treat the indications recited in such patent claims, health care providers may recommend that patients use the competitor products off-label, or patients may do so themselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license in the future may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or other countries. For example, during the pendency of any of our patent applications, we may be subject to a third party pre-issuance submission of prior art to the United States Patent and Trademark Office (the &#8220;USPTO&#8221;), or we may become involved in interference or derivation proceedings, or various pre-grant third-party challenges in foreign jurisdictions. Even if patents are issued, third parties may challenge the inventorship, validity, enforceability or scope thereof, including through opposition, revocation, reexamination, post-grant review and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review proceedings, and litigation. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or one of our licensors, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or our licensor&#8217;s priority of invention or other features of patentability with respect to our in-licensed patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection for our technology and product candidates. Furthermore, even if they are unchallenged, our current and future patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patent applications we own with respect to our cell-based immunotherapies and product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in development, testing and regulatory review of new product candidates, the period of time during which we could market our product candidates under patent protection would be reduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given that patent applications in the United States and other countries are confidential for a period of time after filing, at any moment in time, we cannot be certain that we or our licensors were in the past or will be in the future the first to file any patent application related to our cell-based immunotherapies or product candidates. In addition, some patent applications in the United States may be maintained in secrecy until the patents are issued. As a result, there may be prior art of which we or our licensors are not aware that may affect the validity or enforceability of a patent claim, and we or our licensors may be subject to priority disputes. For our in-licensed patent portfolios, we will rely on our licensors to determine inventorship, and to obtain and file inventor assignments of any given priority application before the filing of a subsequent PCT or other application claiming the benefit of the priority application. The failure to do so in a timely fashion may give rise to a challenge as to entitlement of priority for such subsequent applications in jurisdictions outside the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be required to disclaim part or all of the term of certain patents or patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we or our future licensors are aware, but which we or our future licensors do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that, if challenged, our current or future patents would be declared by a court, patent office or other governmental authority to be valid or enforceable or that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">even if found valid and enforceable, a competitor&#8217;s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in relation to our product candidates, but our competitors may obtain issued claims, including in patents we consider to be unrelated, that block our efforts or potentially result in our product candidates or our activities being found to infringe such claims. It is possible that our competitors may have filed, and may in the future file, patent applications with claims covering our products or technology similar to ours. Those patent applications may have priority over our in-licensed patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. The possibility also exists that others will develop on an independent basis products that have the same effect as our product candidates and that do not infringe our patent or other intellectual property rights, or will design around the claims of our patent applications or our in-licensed patents or patent applications that cover our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Likewise, our patent applications directed to our proprietary cell-based immunotherapies and our product candidates, if issued, would result in patents expected to expire from 2038 through 2042, without taking into account any possible patent term adjustments or extensions. Our potential future patents may expire before, or soon after, our first product candidate achieves marketing approval in the United States or foreign jurisdictions. Additionally, no assurance can be given that the USPTO or relevant foreign patent offices will grant any of the pending patent applications we own currently or in the future. Upon the expiration any patents, we would lose the right to exclude others from practicing the respective claimed inventions. The expiration of these patents could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of foreign countries do not protect intellectual property rights to the same extent as federal and state laws of the United States. Further, our intellectual property license agreements may not always include worldwide rights. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent such competition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property rights, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products by third parties in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our patents and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Moreover, the initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to enforce or defend our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may need to obtain additional licenses from third parties to advance our research or allow commercialization of product candidates we may develop. It is possible that we may be unable to obtain any additional licenses at a reasonable cost or on reasonable terms, if at all. In either event, we may be required to expend significant time and resources to redesign our technology, product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations and prospects significantly. We cannot provide any assurances that there are no third-party patents that might be enforced against our current therapies, including our cell-based immunotherapies, manufacturing methods, product candidates, or future methods or products, resulting in either an injunction prohibiting our manufacture or future sales, or an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In spite of our efforts, our licensors might conclude that we have materially breached our obligations under our license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of or cell-based immunotherapies or product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and growth prospects. Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sublicensing of patent and other rights to third parties under our collaborative development relationships; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our diligence obligations under the license agreement with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates and what activities satisfy those diligence obligations; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the priority of invention of patented technology. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the agreement under which we currently license intellectual property or technology from Agenus is complex, and certain provisions in such agreement may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or broaden what we believe to be the scope of Agenus&#8217; rights to our intellectual property and technology, or increase what we believe to be our financial or other obligations under the agreement, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. As a result, any termination of or disputes over our intellectual property licenses could result in the loss of our ability to develop and commercialize our cell-based immunotherapies or other product candidates or we could lose other significant rights, any of which could have a material adverse effect on our business, financial conditions, results of operations and prospects. It is also possible that a third party could be granted limited licenses to some of the same technology, in certain circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in acquiring or in-licensing necessary rights to key technologies or any product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The future growth of our business will depend in part on our ability to in-license or otherwise acquire the rights to additional product candidates and technologies. We cannot assure you that we will be able to in-license or acquire the rights to any product candidates or technologies from third parties on acceptable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, there has been extensive patenting activity in the field of cell-based immunotherapies, and pharmaceutical companies, biotechnology companies and academic institutions are competing with us or are expected to compete with us in the field of cell-based immunotherapies and are filing patent applications potentially relevant to our business, and there may be certain third-party patent applications that, if issued, may allow the third party to limit our activities. To market our product candidates, we may find it necessary or prudent to obtain licenses from such third-party intellectual property holders. However, we may be unable to secure such licenses or otherwise acquire or in-license the rights to any compositions, methods of use, processes or other technology from third parties that we identify as necessary for product candidates we may develop and cell-based immunotherapies. We may also require licenses from third parties for certain other cell-based immunotherapies including certain delivery methods that we are evaluating for use with product candidates we may develop. Some institutions may receive funding that obligates the institution to require certain</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terms from collaborators or that creates rights in the funding body, such as a government, that cannot be waived. The obligations and rights may limit the scope or exclusivity of a potential patent right arising from the collaboration. For example, if a patent right is created as part of a collaboration with an entity funded by the United States government, the government may have rights under the Bayh-Dole Act, including &#8220;march-in&#8221; rights to allow use of the patent right by the government or third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we may collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Even if we hold such an option, we may be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the licensing or acquisition of third-party intellectual property rights is a highly competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The intellectual property landscape around cell-based immunotherapies is highly dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery and development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The field of cell-based immunotherapies is still in its infancy. Due to the intense research and development being conducted in this field by several companies, including us and our competitors, the intellectual property landscape is evolving and in flux, and it may remain uncertain for the coming years. There may be significant intellectual property-related litigation and proceedings relating to our in-licensed, and other third-party, intellectual property and proprietary rights in the future, or any such intellectual property we may own in the future. Our commercial success depends upon our ability and the ability of our collaborators and licensors to develop, manufacture, market and sell any product candidates that we may develop and to use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights, as well as administrative proceedings for challenging patents, including interference, derivation, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, post grant review and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be subject to and may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our cell-based immunotherapies and any product candidates we may develop, including interference proceedings, post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European Patent Office (&#8220;EPO&#8221;). Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist in the fields in which we are developing our product candidates and such third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of the merits thereof.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the biotechnology and pharmaceutical industries expand and more patents are issued, this increases the risk that our cell-based immunotherapies and product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover which of various types of therapies, products or their methods of use or manufacture. We are aware of certain third-party patent applications that, if issued, may be construed to cover our cell-based immunotherapies and product candidates. There may also be third-party patents of which we are currently unaware with claims to technologies, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon those patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A large number of patents and patent applications exist in our field. Third parties may allege that they have patent rights encompassing our product candidates, technologies or methods. Third parties may assert that we are employing their proprietary technology without authorization and may file patent infringement lawsuits against us, and if we are found to infringe such third-party patents, we may be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">required to pay damages, cease commercialization of the infringing technology or obtain a license from such third parties, which may not be available on commercially reasonable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to commercialize any product candidates we may develop in the United States and abroad may be adversely affected if we cannot obtain a license on commercially reasonable terms to relevant third-party patents that cover our cell-based immunotherapies and product candidates. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability or priority. A court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize any product candidates we may develop and any other product candidates or technologies covered by the asserted third party patents. To successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe a third party&#8217;s intellectual property rights, and we are unsuccessful in demonstrating that such patents are invalid or unenforceable, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing any product candidates we may develop and our technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our cell-based immunotherapies or product candidates or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business. We also could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidates. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Defense of third-party claims of infringement, misappropriation or other violation of intellectual property rights involves substantial litigation expense and would be a substantial diversion of management and employee time and resources from our business. Some third parties may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, financial condition, results of operations and prospects. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Any of the foregoing events could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our present or future patents or the patents of our licensors, which could be expensive, time-consuming, and unsuccessful and could result in a finding that such patents are unenforceable or invalid.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors may infringe our present or future patents or the patents of our licensing partners, or we may be required to defend against claims of infringement. In addition, our present or future patents or the patents of our licensing partners also are, and may in the future become, involved in inventorship, priority, validity or enforceability disputes. Countering or defending against such claims can be expensive and time-consuming. In an infringement proceeding, a court may decide that a patent is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our present patent, or potential future owned patents, do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our present, or potential future, owned or in-licensed patents at risk of being invalidated or interpreted narrowly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. These types of mechanisms include re-examination, post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). These types of proceedings could result in revocation or amendment to our patents such that they no longer cover our product candidates. The outcome for any particular patent following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our future licensors, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our therapies and/or product candidates. Defense of these types of claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conversely, we may choose to challenge the patentability of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in re-examination, post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). We are currently challenging, and in the future may choose to challenge, third party patents in patent opposition proceedings in the EPO or another foreign patent office. Even if successful, the costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates, cell-based immunotherapies or other proprietary therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and applications must be paid to the USPTO and foreign patent agencies outside of the United States over the lifetime of our present, or potential future, owned or licensed patents and applications. In certain circumstances, we rely on our licensing partners to pay these fees. The USPTO and foreign patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during and after the patent application process. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. While an inadvertent lapse can be cured in some instances by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in a partial or complete loss of patent rights in the relevant jurisdiction. Were a non-compliance event to occur, our competitors might be able to enter the market with similar or identical products or therapies, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in patent law in the United States and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our cell-based immunotherapies and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with other biotech and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of our issued patents. For example, under the Leahy-Smith America Invents Act (the &#8220;America Invents Act&#8221;), the United States changed from a &#8220;first to invent&#8221; to a &#8220;first-inventor-to-file&#8221; patent system. Under a &#8220;first-inventor-to-file&#8221; system, assuming that other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on an invention regardless of whether another inventor made the invention earlier. For example, under the first-inventor-to-file system, if we and a third party independently make the same invention, and the third party files a patent application in the USPTO before we do, the third party could be awarded the patent and we could be denied the patent even if we were the first to make the invention. U.S. patent law requires us to be cognizant going forward of the time from invention to the filing of a patent application seeking to protect the invention. Since patent applications in the United States and most other countries are confidential for at least a period of time after filing and in some cases until issuance, we cannot be certain that we or our licensors were the first to file any patent application related to our therapies or product candidates or the first to invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. The America Invents Act also included a number of other significant changes to U.S. patent law, including provisions affecting the way patent applications are prosecuted, allowing third party submission of prior art and establishing post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review and derivation proceedings. The full effects of these changes are still unclear because the USPTO continues to promulgate new regulations and procedures in connection with the America Invents Act, and many of the substantive changes to patent law, including the &#8220;first-inventor-to-file&#8221; provisions, only became effective</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in March 2013. In addition, the courts have yet to address many of these provisions, and the applicability of the act and new regulations on the specific patents discussed in this filing have not been determined and would need to be reviewed. Generally, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change further in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict how recent and future decisions or actions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Similarly, any adverse changes in the patent laws or practice of other jurisdictions could also have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents have a limited lifespan. The term of a patent in any particular jurisdiction depends on the law governing patent term in the jurisdiction. In most countries, including the United States, the basic term of a utility patent expires 20 years from the earliest effective non-provisional filing date, if all necessary maintenance fees are paid on time. The nature and duration of protection afforded by a patent varies from country to country and depends upon many factors, including the type of patent, the scope of its claims, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Some countries, including the United States, provide for patent term adjustment (&#8220;PTA&#8221;), which increases the term of a patent beyond its basic term to compensate for certain delays in prosecution of the underlying patent application. PTE may also be available when a patent claims certain kinds of inventions requiring regulatory approval in order to market, including certain pharmaceutical-related inventions, and can also increase the term of a patent beyond its basic term. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after we or our partners commercialize those candidates. As a result, our present, or potential future, owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we do not obtain PTE and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited PTE under the Drug Price Competition and Patent Term Restoration Act of 1984 (the &#8220;Hatch-Waxman Amendments&#8221;). The Hatch-Waxman Amendments provide for a PTE term of up to five years as compensation for patent term that could not be enjoyed during the FDA regulatory review process. PTE cannot extend the remaining term of a patent such that the patent would expire beyond 14 years from the date of product approval, only one patent per product may be extended and only those claims covering the approved drug or a method for using it may be extended. Even if we were to seek PTE, it may not be granted because of, for example, the failure to exercise due diligence during the testing phase or regulatory review process, the failure to apply within applicable deadlines, the failure to apply prior to expiration of relevant patents, or any other failure to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain PTE at all or the term of any such obtained extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our proprietary knowledge, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to seeking patents for our technology and product candidates, we also rely on know-how, as well as confidentiality agreements, non-disclosure agreements and invention assignment agreements with our employees, consultants and third parties, to protect our confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is our policy to require our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties to execute confidentiality agreements upon the commencement of employment, consulting or other relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed by or made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties, except in certain specified circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and that are related to our current or planned business or research and development or made</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In the case of consultants and other third parties, the agreements provide that all inventions conceived in connection with the services provided are our exclusive property. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our proprietary technology and processes. Additionally, the assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of these parties may breach the agreements and disclose our proprietary information and we may not be able to obtain adequate remedies for such breaches.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to contractual measures, we try to protect the confidential nature of our proprietary information through other appropriate precautions, such as physical and technological security measures. However, know-how can be difficult to protect. These measures may not provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our proprietary knowledge and providing it to a competitor, and any recourse we might have for this type of misconduct may not result in an adequate remedy. In addition, our proprietary technology and processes may be independently developed by others in a manner that could prevent us from receiving legal recourse. If any of our confidential or proprietary information were to be disclosed or misappropriated, or if any of that information was independently developed by a competitor, our competitive position could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third parties may assert that our employees, consultants or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is common in the biotechnology and pharmaceutical industries, we employ individuals that are currently or were previously employed at universities, research institutions or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Also, we may in the future be subject to claims that these individuals are violating non-compete agreements with their former employers. We may then have to pursue litigation to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities, and we may not have sufficient financial or other resources to adequately conduct this type of litigation or proceedings. For example, some of our competitors may be able to sustain the costs of this type of litigation or proceedings more effectively than we can because of their substantially greater financial resources. In any case, uncertainties resulting from the initiation and continuation of intellectual property litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any product candidates we may develop will eventually become commercially available in generic or biosimilar product forms; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to make adoptive cell therapy products that are similar to any product candidates we may develop or utilize similar cell-based immunotherapies but that are not covered by the claims of the patents that we license or may own in the future; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by issued patents or pending patent applications that we license or own, currently or in the future; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we, or our license partners or current or future collaborators, may fail to meet our obligations to the U.S. government regarding any patents and patent applications funded by U.S. government grants, leading to the loss or unenforceability of patent rights; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our pending or potential future owned or licensed patent applications or those that we may own in the future will not lead to issued patents; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that there are prior public disclosures that could invalidate our patent, or parts of our patent; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later be issued with claims covering our product candidates or therapies similar to ours; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our current and future patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents that we hold rights to may be held invalid, unenforceable or narrowed in scope, including as a result of legal challenges by our competitors; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the claims of our patent or patent applications, if and when issued, may not cover our product candidates; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the laws of foreign countries may not protect our proprietary rights or the proprietary rights of license partners or current or future collaborators to the same extent as the laws of the United States; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inventors of our current and future patents or patent applications may become involved with competitors, develop products or processes that design around our patents, or become hostile to us or uncooperative as to the patents or patent applications on which they are named as inventors; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we have engaged in scientific collaborations in the past and will continue to do so in the future and our collaborators may develop adjacent or competing products that are outside the scope of our patents; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patents of others may harm our business; or </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may choose not to file a patent application in order to maintain certain subject matter as trade secrets or know-how, and a third party may subsequently develop and file a patent application disclosing the same subject matter. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Employee Matters, Managing Growth, Information Technology and Our Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We currently have a limited number of employees, and our future success depends on our ability to retain our key executives and to attract, retain and motivate qualified personnel.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are highly dependent on the principal members of our management and scientific teams, as well as our majority stockholder. Such principal members are employed &#8220;at will,&#8221; meaning we or they may terminate the employment at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors, including our scientific co-founders, may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The inability to recruit, or loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We expect to expand our development, regulatory and future sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the growth and advancement of our pipeline and becoming a public company, we expect to increase the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs, and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational, and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel. Moreover, the expected physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a growing biotechnology company, we are actively pursuing new platforms and product candidates in many therapeutic areas and across a wide range of diseases. Successfully developing product candidates for and fully understanding the regulatory and manufacturing pathways to all of these therapeutic areas and disease states requires a significant depth of talent, resources and corporate processes in order to allow simultaneous execution across multiple areas. Due to our limited resources, we may not be able to effectively manage this simultaneous execution and the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, legal or regulatory compliance failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to compete effectively and commercialize our product candidates, if approved, will depend in part on our ability to effectively manage the future development and expansion of our company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our internal computer systems, or those of our third-party vendors, collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our internal computer systems and those of our current and any future third-party vendors, collaborators and other contractors or consultants are vulnerable to damage or interruption from computer viruses, computer hackers, malicious code, employee theft or misuse, denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we seek to protect our information technology systems from system failure, accident and security breach, if such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our proprietary information or other disruptions. For example, the loss of clinical trial data from ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. If we were to experience a significant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cybersecurity breach of our information systems or data, the costs associated with the investigation, remediation and potential notification of the breach to counter-parties and data subjects could be material. In addition, our remediation efforts may not be successful. If we do not allocate and effectively manage the resources necessary to build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that any disruption or security breach were to result in a loss of, or damage to, our or our third-party vendors&#8217;, collaborators&#8217; or other contractors&#8217; or consultants&#8217; data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability including litigation exposure, penalties and fines, we could become the subject of regulatory action or investigation, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. Any of the above could have a material adverse effect on our business, financial condition, results of operations or prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not know whether a market for our common stock will be sustained or what the market price of our common stock will be, we may be delisted from the Nasdaq Capital Market if we are unable to comply with Nasdaq Listing Rules, and, as a result, it may be difficult for you to sell your shares of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a market for our common stock is not sustained, it may be difficult for you to sell your shares of common stock at an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations may be below the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to raise the value of our common stock, our securities may be delisted. We were notified by the Nasdaq Stock Market Listing Qualifications Department on February 23, 2024 that we had failed to comply with the minimum value of listed securities requirement for the Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(2) for the previous 30 consecutive trading days. Nasdaq Listing Rule 5550(b)(2) requires a listed company maintain a minimum value of listed securities of $35.0 million. We were given 180 calendar days, or until August 21, 2024, to regain compliance with this rule. In order to regain compliance, our minimum value of listed securities must meet or exceed $35.0 million for a minimum of ten consecutive trading days. In the event we are unable to regain compliance with this rule prior to the expiration of the compliance period, we will receive written notification that our securities are subject to delisting. At that time, we may appeal the delisting determination to a Hearings Panel. If we are not successful appealing a delisting determination, our securities may be delisted.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 26, 2024, we received a notification from the Nasdaq Stock Market Listing Qualifications Department letting us know that our common stock failed to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) for the previous 30 consecutive trading days. We have been provided an initial compliance period of 180 calendar days, or until August 26, 2024, to regain compliance with this rule which requires that the closing bid price of our common stock meet or exceed $1.00 per share for a minimum of ten consecutive trading days. If we are unable to regain compliance with rule during the initial compliance period, we may be eligible for an additional 180-day compliance period.  To qualify, we will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market and will need to provide written notice to Nasdaq of our intention to cure the deficiency during the second compliance period. If we are unable to qualify for the second compliance period or we fail to regain compliance during the second 180-day period, we will receive notification from Nasdaq of its determination to delist our common stock, at which point we would have an opportunity to appeal the delisting determination to a Hearings Panel. If we are not successful appealing a delisting determination, our securities may be delisted.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our common stock, the price of our common stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. We do not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our common stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our common stock, the price of our common stock could decline. If one or more of these analysts cease to cover our common stock, we could lose visibility in the market for our common stock, which in turn could cause our common stock price to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A significant portion of our total outstanding shares is restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. We also plan to register all shares of common stock that we may issue under our equity compensation plans or that are issuable upon exercise of outstanding options. Once we register these shares, they can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. We have begun the process of documenting, reviewing and improving our internal controls and procedures for compliance with Section 404 of the Sarbanes-Oxley Act of 2002 (&#8220;SOX Section 404&#8221;), which will require annual management assessment of the effectiveness of our internal control over financial reporting. While we continue to outsource our finance and accounting personnel, we have begun recruiting additional finance and accounting personnel with certain skill sets that we need as a public company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. In addition, investors&#8217; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm our common stock price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of SOX Section 404, not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide stockholders will be different than the information that is available with respect to other public companies. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our common stock price may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation, our amended and restated by-laws and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation, amended and restated by-laws and Delaware law contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. Our amended and restated</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">certificate of incorporation and by-laws, which became effective upon the closing of our initial public offering, include provisions that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">create a classified board of directors whose members serve staggered three-year terms; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">specify that special meetings of our stockholders can be called only by our board of directors, the Chairman of our board of directors or our Chief Executive Officer; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prohibit stockholder action by written consent; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that vacancies on our board of directors may, unless and until filled by our stockholders, be filled only by a majority of directors then in office, even though less than a quorum; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that our directors may be removed only for cause; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">do not permit any stockholder to cumulate votes at any election of directors; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expressly authorized our board of directors to make, alter, amend or repeal our amended and restated by-laws; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated by-laws. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;), which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any provision of our amended and restated certificate of incorporation, amended and restated by-laws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated by-laws designate the state or federal courts within the State of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, subject to limited exceptions, the state or federal courts within the State of Delaware will be exclusive forums for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action asserting a claim against us arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated by-laws, (4) any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated by-laws or (5) any other action asserting a claim against us that is governed by the internal affairs doctrine. Under our amended and restated certificate of incorporation, this exclusive forum provision will not apply to claims that are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction and explicitly not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or the rules and regulations thereunder. Furthermore, our amended and restated by-laws also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation and amended and restated by-laws described above. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation or amended and restated by-laws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The market price of our common stock may be volatile, which could result in substantial losses for investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of the factors that may cause the market price of our common stock to fluctuate include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of existing or new competitive product candidates or technologies; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and results of preclinical studies or clinical trials for any product candidates that we may develop; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure or discontinuation of any of our product development and research programs; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">results of preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments or changing views regarding the use of allogeneic cell therapies; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commencement or termination of collaborations for our product development and research programs; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory or legal developments in the United States and other countries; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of expenses related to any of our research programs, clinical development programs or product candidates that we may develop; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of our efforts to develop additional product candidates or products; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcement or expectation of additional financing efforts; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of our common stock by us, our insiders or other stockholders; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expiration of market stand-off or lock-up agreement; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic, industry and market conditions; and </span></div></div>
  <div style="margin-left:6.787%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.645414266250416%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the other factors described in this &#8220;Risk Factors&#8221; section. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Although we have director and officer liability insurance, the coverage provided by our policy may be insufficient if we are the target of securities litigation.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not expect to pay any dividends for the foreseeable future. Investors may never obtain a return on their investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">You should not rely on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment. As a result, investors seeking cash dividends should not purchase our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, and particularly after we are no longer an emerging growth company, we do and will in the future incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that we will need to hire additional accounting, finance and other personnel in connection with our efforts to comply with the requirements of being, a public company, and our management and other personnel devote a substantial amount of time towards maintaining compliance with these requirements. These requirements increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, we expect that the rules and regulations applicable to us as a standalone public company may make it more difficult and more expensive for us to retain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B. Unresolved</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Staff Comments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. Cybersecurity.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We design and assess our program based on the Information Systems Audit and Control Association&#8217;s Control Objectives for Information Technologies framework and National Institute of Standards and Technology cybersecurity framework, as well as threat trends identified by multiple external and internal cybersecurity intelligence reports.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We contract with external firms to assess our cybersecurity controls. We have processes in place to identify and evaluate risks associated with third party vendors and suppliers. In addition, we have systems in place to maintain business continuity and disaster recovery. Some or all of this work is done through our services agreement with Agenus.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have not experienced any material cybersecurity incidents.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We describe whether and how risks from cybersecurity threats are reasonably likely to affect our business, results of operations and financial condition, under the heading &#8220;Our internal computer systems, or those of our third-party vendors, collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business&#8221; included as part of our Item 1A. Risk Factors of this Annual Report on Form 10-K, which is incorporated by reference into this Item 1C.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cybersecurity Governance</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Audit Committee of the Board of Directors has oversight responsibility for risks and incidents related to cybersecurity threats. As part of our services agreement with Agenus, Agenus&#8217; Chief Information Officer provides the Audit Committee and the Board of Directors periodic reports on our cybersecurity risks and any material cybersecurity incidents.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our team of cybersecurity professionals is led by Agenus&#8217; Chief Information Officer, who has over 20 years of experience in cybersecurity in regulated industries. Our cybersecurity team monitors the prevention and detection of cybersecurity events and is responsible for incident response and remediation.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently utilize a combined 3,500 square feet of Agenus&#8217; facilities in Lexington, MA, New York, NY and Cambridge, United Kingdom. The space supports our research, clinical, manufacturing and administrative functions. There is current capacity to expand our operations within existing Agenus facilities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are not currently a party to any material legal proceedings. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Regardless of the outcome, litigation can have a material adverse effect on us because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Safe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ty Disclosures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stoc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">kholder Matters and Issuer Purchases of Equity Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is currently listed on the Nasdaq Capital Market under the symbol &#8220;INKT.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 1, 2024, there were approximately 193 holders of record of our common stock. This number does not reflect the beneficial holders of our common stock who hold shares in street name through brokerage accounts or other nominees.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Proceeds</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 19, 2021, we closed the initial public offering of our common stock pursuant to which we issued and sold 3,333,334 shares of our common stock at a price to the public of $12.00 per share for aggregate gross proceeds of approximately $40.0 million, before deducting underwriting discounts and commissions and offering expenses payable by us. On November 3, 2021, we sold an additional 500,000 shares of our common stock pursuant to the underwriters&#8217; option to purchase additional shares in the initial public offering at the public offering price for an additional $6.0 million in gross proceeds.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the shares issued and sold in the initial public offering were registered under the Securities Act pursuant to a Registration Statement on Form S-1 (File No. 333-259503), which was declared effective by the SEC on October 14, 2021. Evercore Group L.L.C and William Blair &amp; Company, L.L.C. acted as joint book-running managers and B. Riley Securities, Inc. and Robert W. Baird &amp; Co. Incorporation acted as co-managers of our initial public offering.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We received net proceeds of approximately $42.8 million after deducting underwriting discounts and commissions. None of the underwriting discounts and commissions or offering expenses were incurred or paid to directors or officers of ours or their associates or to persons owning 10 percent or more of our common stock or to any of our affiliates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been no material change in our planned use of the net proceeds from the offering as described in our Registration Statement on Form S-1.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reserved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK Therapeutics, Inc. (&#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;) is a clinical-stage biopharmaceutical company pioneering a novel platform of living medicines based on a rare and potent class of immune cells called invariant natural killer T (&#8220;iNKT&#8221;) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (&#8220;NK&#8221;) cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease (&#8220;GvHD&#8221;). Our proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, we believe that our approach represents a highly versatile application for therapeutic development in cancer and immune diseases. We are leveraging our platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of both native and engineered iNKT cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business activities include product research and development, manufacturing, regulatory and clinical development, corporate finance, and support of our collaborations. To be successful, our product candidates require clinical trials and approvals from regulatory agencies, as well as acceptance in the marketplace. We are a party to an Amended and Restated Intercompany Services Agreement and an Intellectual Property Assignment and License Agreement with Agenus. Under the Amended and Restated Intercompany Services Agreement, Agenus provides us with certain general and administrative support, including, without limitation, financial, facilities management, human resources and information technology administrative support, and we and Agenus provide each other with certain research and development services and other support services, including legal and regulatory support. We are also entitled to use Agenus&#8217; business offices and laboratory space and equipment in exchange for us contributing a proportionate payment for the use of such facilities and equipment, and we will be covered by certain Agenus insurance policies, subject to certain conditions, including us paying the cost of such coverage. Under the Intellectual Property Assignment and License Agreement, Agenus exclusively assigned patent rights and know-how related to our technology to us. We also have a field-limited exclusive license under certain Agenus patents and know-how; and we retain the rights to expand a proprietary pipeline of products and technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our most advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. iNKTs are a potent class of immune cells and serve as master regulators of immune response, possessing the killing power of NK cells and the memory of T-cells. Our proprietary manufacturing platform allows these cells to be infused in billion-fold numbers, arming the immune system against cancer and other life-threatening diseases. We have established and launched in-house iNKT cell manufacturing and product release capacity to supply more than 5,000 doses per year through a U.S. Food and Drug Administration (&#8220;FDA&#8221;)-cleared scalable, fully closed, and automatic process. Our Phase 1 clinical trial studying agenT-797 in solid tumor cancers, as a monotherapy and in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab and nivolumab, is currently advancing as a priority program. Encouraging activity was seen with agenT-797 monotherapy and combination, with durable responses and disease stabilization in patients, which was presented at the American Association for Cancer Research and more recently at the Society of Immunotherapy for Cancer (&#8220;SITC&#8221;) conference in November 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our Phase 1 clinical trial, most recently presented at SITC 2023, agenT-797 demonstrated a durable clinical benefit and a tolerable safety profile across various heavily pre-treated solid tumors. This includes non-small cell lung cancer (&#8220;NSCLC&#8221;), testicular cancer, and gastric cancer. Notably, the median progression-free survival (&#8220;PFS&#8221;) exceeded six months. Approximately 30% of patients experienced durable disease stabilization, even in cancers that were refractory to all prior therapies, such as pembrolizumab and nivolumab. This was observed in multiple cancer types, including but not limited to NSCLC and testicular cancer. Significantly, a patient with metastatic gastric cancer, who had not responded to anti-PD-1 therapy and standard chemotherapy, achieved a partial response when treated with agenT-797 in combination with nivolumab. This response was ongoing at 10 months. The safety profile of agenT-797 was tolerable, both as a standalone treatment and in combination with PD-1 inhibitors. Treatment doses up to one billion cells showed no neurotoxicity, dose-limiting toxicities, or severe cytokine release syndrome (above grade 3).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Building on these encouraging results, we plan to conduct a randomized phase 1/2 expansion trial. This trial will assess the efficacy of agenT-797 in combination with standard-of-care chemotherapy and immune therapy (pembrolizumab/nivolumab), with or without Agenus&#8217; multifunctional anti-CTLA-4 agent, botensilimab, in relapsed/refractory gastric cancer.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We reported updated data from our Phase 1 clinical trial of agenT-797 in viral acute respiratory distress syndrome (&#8220;ARDS&#8221;) at the 2023 American Thoracic Society International Conference. We reported an encouraging survival benefit of 75%, compared to ~10-22% in an in-hospital control and time-matched data from the Centers for Disease Control and Prevention. Notably, in addition to a survival benefit, we reported observations that agenT-797 improved lung function and significantly reduced inflammation and secondary infections in the population. There are currently no approved therapies for ARDS and secondary infections are a significant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">contributor to comorbidity and death in intensive care units; our data contribute favorably as a potential therapeutic and we plan to advance agenT-797 in viral ARDS through strategic collaborations and non-dilutive external financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we completed a Phase 1 clinical trial of agenT-797 for the treatment of multiple myeloma and reported at SITC in 2022 that agenT-797 was tolerable to a billion cells/dose and suppressed biomarkers associated with disease progression. This proof of concept Phase 1 underscores the potential application of INKT cells in multiple myeloma and we believe supports the advancement of our armored B cell maturation antigen (&#8220;BCMA&#8221;)-CAR-INKT program as a potential best in class next generation allogeneic BCMA cell therapy for these patients. Strategic discussions to advance this program are underway.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also advancing a pipeline of next-generation allogeneic, engineered iNKT programs. Our two most advanced engineered programs are (1) MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT and (2) MiNK-413, an IL-15 armored CAR-iNKT program targeting BCMA program. MiNK-413 has demonstrated tumor clearance and improved persistence in preclinical models, as well as manufacturing and logistical improvements over current BCMA cell therapies. MiNK-215 has demonstrated efficacy in NSCLC and melanoma preclinical models, promoting curative responses, eliminating tumor burden in the lungs, and enhancing tumor specific CD8+ T cell infiltration through tumor stroma. These data and programs were presented at SITC in 2022 with more recent translational data presented at the American Society of Cell and Gene Therapy Conference in 2023. Investigational new drug (&#8220;IND&#8221;) enabling activities are underway we expect to submit an IND to the FDA in 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development expenses for the years ended December 31, 2023 and 2022 were $15.5 million and $23.1 million, respectively. We have incurred losses since our inception. As of December 31, 2023, we had an accumulated deficit of $133.4 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Historical Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">For the Year Ended December 31, 2023 Compared to the Year Ended December 31, 2022</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development (&#8220;R&amp;D&#8221;) expense</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">R&amp;D expense includes the costs associated with our internal research and development activities, including compensation and benefits, occupancy costs, manufacturing costs, costs of expert consultants, and administrative costs. R&amp;D expense decreased 33% to $15.5 million for the year ended December 31, 2023 from $23.1 million for the year ended December 31, 2022. This decrease is primarily due to decreased costs associated with the timing of our clinical trials and decreased costs associated with allocated Agenus services. These decreases were partially offset by increased personnel costs associated with increased headcount.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and administrative (&#8220;G&amp;A&#8221;) expense</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G&amp;A expense consists primarily of personnel costs, facility expenses, and professional fees. G&amp;A expense decreased 5% to $7.4 million for the year ended December 31, 2023 from $7.8 million for the year ended December 31, 2022. This decrease is primarily due to decreased professional fees, primarily attributable decreased legal and consulting fees, and decreased costs associated with allocated Agenus services. These decreases were partially offset by increased personnel costs, including stock-based compensation expense, associated with increased headcount.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other income (expense), net</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income decreased $2.7 million for the year ended December 31, 2022, from income of $2.7 million for the year ended December 31, 2022 to de minimis expense for the year ended December 31, 2023, due to the recognition of a $2.7 million gain on the partial forgiveness of the advance received under our research and development agreement with the Belgium Walloon Region Government (the &#8220;Walloon Region&#8221;), in the year ended December 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest income (expense), net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income increased $210,000 for the year ended December 31, 2023, from income of $253,000 for the year ended December 31, 2022 to income of $463,000 for the year ended December 31, 2023, primarily due to increased interest earned on our money market funds.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Programs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">R&amp;D program costs include compensation and other direct costs plus an allocation of indirect costs, based on certain assumptions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For the years ended December 31,</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payroll and personnel costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,814,210</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,729,235</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,283,439</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,607,709</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allocated services</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">500,280</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,284,920</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Materials and other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,892,068</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,493,259</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,489,997</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,115,123</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are in various stages of development and significant additional expenditures will be required if we start new clinical trials, encounter delays in our programs, apply for regulatory approvals, continue development of our technologies, expand our operations and/or bring our product candidates to market. The total cost of any particular clinical trial is dependent on a number of factors such as trial design, length of the trial, number of clinical sites, number of patients and trial sponsorship. The process of obtaining and maintaining regulatory approvals for new products is lengthy, expensive and uncertain. Because of the current stage of our product candidates, among other factors, we are unable to reliably estimate the cost of completing our research and development programs or the timing for bringing such programs to various markets or substantial partnering or out-licensing arrangements, and, therefore, when, if ever, material cash inflows are likely to commence.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred annual operating losses since inception, and we had an accumulated deficit of $133.4 million as of December 31, 2023. We expect to incur losses over the next several years as we continue development of our technologies and product candidates, manage our regulatory processes, initiate and continue clinical trials, and prepare for potential commercialization of products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, we completed an initial public offering of 3,333,334 shares of our common stock, at a public offering price of $12.00 per share. The gross proceeds from the offering, before deducting underwriting discounts, commissions and other offering expenses, were approximately $46.0 million, which includes the exercise of the underwriters option to acquire an additional 500,000 shares at the public offering price, which shares were delivered in November 2021. Underwriting discounts, commissions and other offering expenses, were approximately $6.2 million, resulting in net proceeds of approximately $39.8 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2018, we entered into an agreement with the Walloon Region in which the Walloon Region agreed to provide a grant of up to &#8364;1.3 million and an advance of up to &#8364;8.3 million for the development of one of our research programs. As of December 31, 2023, we had received $881,000 of the grant portion and $5.2 million of the advance. During 2020, we discontinued research efforts related to this program, and in 2021 we provided additional information as requested by the Walloon Region to terminate the agreement. We recognized the grant portion received as income during the years ended December 31, 2019 and 2020. We learned in the second quarter of 2022 that the Walloon Region had obtained a default judgment in the amount of &#8364;2,086,712 for repayment of the advance. In view of the default judgment, we reduced the recorded liability and recorded a gain of approximately $2.7 million in our consolidated statement of operations for the year ended December 31, 2022. We have included the remaining balance of $2.3 million in other current liabilities in our condensed consolidated balance sheet at December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cash and cash equivalents balance as of December 31, 2023 was $3.4 million. We believe that our cash and cash equivalents balance along with the additional funding received subsequent to year end from our parent, Agenus, and funding planned from a third party will be sufficient to satisfy our liquidity requirements for more than one year from when these financial statements were issued. Because the additional funding is influenced by external uncertainties, in accordance with the relevant accounting guidance, we are required to disclose that substantial doubt exists about our ability to continue as a going concern for a period of one year after the date of filing of this Annual Report on Form 10-K. The financial statements have been prepared on a basis that assumes we will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management continually monitors our liquidity position and adjusts spending as needed in order to preserve liquidity. Potential sources of additional funding include: (1) seeking strategic partnerships and collaborations, as well as out-licensing opportunities, for our portfolio programs and product candidates, (2) exploring avenues for securing non-dilutive financing, such as grants and collaborations to strengthen our balance sheet, and (3) potential of equity or debt financing options. If additional funding is not obtained through these sources, Agenus has indicated a willingness to loan us additional funds to finance our operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities for the years ended December 31, 2023 and 2022 was $15.8 million and $18.9 million, respectively. Our future ability to generate cash from operations will depend on achieving regulatory approval and market acceptance of our product candidates, and our ability to enter into collaborations. Please see the &#8220;Note Regarding Forward-Looking Statements&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of this Annual Report on Form 10-K and the risks highlighted under Part I-Item 1A. &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The SEC defines &#8220;critical accounting policies&#8221; as those that require the application of management&#8217;s most difficult, subjective, or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We base those estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our significant accounting policies are described in Note 2 of the notes to our consolidated financial statements contained elsewhere in this Annual Report on Form 10-K. In many cases, the accounting treatment of a particular transaction is dictated by U.S. GAAP, with no need for our judgment in its application. There are also areas in which our judgment in selecting an available alternative would not produce a materially different result.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 2 to our consolidated financial statements included within Item 8 of this Annual Report on Form 10-K for a description of recent accounting pronouncements applicable to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">JOBS Act</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We qualify as an &#8220;emerging growth company&#8221; as defined in the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies, including reduced disclosure about our executive compensation arrangements, exemption from the requirements to hold non-binding advisory votes on executive compensation and golden parachute payments and exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may take advantage of these exemptions until the last day of the fiscal year following the fifth anniversary of our initial public offering or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company earlier if we have more than $1.235 billion in annual revenue, we have more than $700.0 million in market value of our stock held by non-affiliates (and we have been a public company for at least 12 months and have filed one annual report on Form 10-K) or we issue more than $1.0 billion of non-convertible debt securities over a three-year period. For so long as we remain an emerging growth company, we are permitted, and intend, to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. We may choose to take advantage of some, but not all, of the available exemptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualify as an emerging growth company. Therefore, the reported results of operations contained in our consolidated financial statements may not be directly comparable to those of other public companies</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ve Disclosures About Market Risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This item is not required for smaller reporting companies.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Financial Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s and Supplementary Data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.42%;"/>
    <td style="width:7.58%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheet"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheet as of December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statement_operations_compre"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statement of Operations and Comprehensive Loss for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statement_stockholders_defi"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statement of Stockholders&#8217; Deficit for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statement_cash_flows"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statement of Cash Flows for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Regist</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ered Public Accounting Firm</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and Board of Directors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK Therapeutics, Inc.:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of MiNK Therapeutics, Inc. and subsidiaries (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; deficit, and cash flows for each of the years in the two-year period ended December 31, 2023, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Going Concern</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ KPMG LLP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2020.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 21, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK THERAPEUTICS, INC. AND SUBSIDIARIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheet"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALANCE SHEET</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ASSETS</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd69bdda-bdf7-4c91-861e-740c19afaa94" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,367,229</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93ff6a29-0ef1-40ac-9354-02ad7436db22" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">19,635,725</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ea555e2-4c9c-4c60-9cbb-4c0361abee5c" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">53,111</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb5c6414-f452-4331-a60a-d85e67cf5355" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">298,667</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e55019b-cb66-4c60-baf0-b7ccf75e1c02" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">177,964</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_471d2c76-f28e-434c-b7a0-2008c5af407c" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">470,300</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4cefbfd-2f05-4e0e-9d67-40495285e977" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:AssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,598,304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2550720d-3923-4999-b8ff-a7448031545a" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:AssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">20,404,692</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equipment, net of accumulated depreciation of $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a2d591c-b327-40b1-8639-3b65b9d9f2a5" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">495,638</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b5a4f53-d3b6-4bd3-ac4a-69667895cee3" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">283,682</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;as of <br/>&#160;&#160;&#160;December 31, 2023 and 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_add793b5-1628-4358-8a85-1b5b6073a916" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">953,977</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f48e5af-1e16-44c1-a798-ade3968d5ad7" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,066,910</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a7ccf3f-ae31-4dfe-93b1-74285fda7359" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:Assets" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">4,552,281</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41897028-9a47-473c-b4c6-694a0fbf3fc4" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:Assets" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">21,471,602</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73f21bbd-cb1b-41b5-88fa-982a5f58dba2" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,911,973</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fdccf34-1fa3-40bd-a123-209185ab439c" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,823,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d87caa01-5894-4d1b-a4cb-7f827515f88f" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,037,361</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ea7a5bf-fe5b-4984-8534-93437badc12a" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">4,238,555</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e582aca6-a02d-4208-b8d4-1aec825887eb" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,453,251</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0c4d164-79fc-402b-9ba4-c26a52e8176b" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,621,611</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94b4e06a-c0bc-4c69-8595-31a0e19f1455" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">11,402,585</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_698125a2-15e3-4dbf-abea-c7abbac96c01" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">12,683,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47582a7d-349d-44ab-81ad-bebbd55f359c" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">48,072</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41ebf6e5-2dd2-49f6-bca5-760081c9ec9b" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">108,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due to related parties</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc1550ab-d035-4955-91a0-52ed306cdf13" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="inkt:DueToRelatedParty" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">11,157,073</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_014b4794-a532-42dd-ac99-653807fccc23" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="inkt:DueToRelatedParty" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">9,081,239</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_1579128d-7e6a-4a6e-9792-dbbae8282bd9;"><span style="-sec-ix-hidden:F_136c5469-8cc9-4126-a3dc-d9ccade676d2;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; deficit</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, par value $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_333d0ddc-8bb0-4fca-be62-51f7fd3521e4" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="5"><ix:nonFraction id="F_338907ea-c72b-442c-be1d-65846c5573de" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="5">0.00001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;per share, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acb5a297-c73e-4776-bed7-d9799098ae5f" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_37c7670b-f89d-448b-b16d-bfbcc6036364" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">150,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares<br/>&#160;&#160;&#160;authorized, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16d73fc3-f2b0-4a82-82af-1efd429f51fb" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3f0e5e72-4e33-4f70-b8e9-cd5f6e2375d7" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,599,119</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98340c61-5dc4-4e63-bdd2-791195740f32" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_55efc0cf-572a-4296-ab03-c05bdcd58b5b" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">33,856,428</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding as of <br/>&#160;&#160;&#160;December 31, 2023 and 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_176382a9-e2b6-46fc-a851-e7b1fd757cb6" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:CommonStockValue" unitRef="U_USD" decimals="0">346</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d20c4fdb-e022-40a8-8fcd-5467e276c120" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:CommonStockValue" unitRef="U_USD" decimals="0">339</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1588f373-1ec7-4e8a-888a-598e0aa17c82" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">115,772,085</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ad63aec-3136-4ef9-846c-a20cd0353f55" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">110,829,900</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fd5ee32-113b-4eae-b676-526469d14e74" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">430,947</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07b699ea-924e-4cc6-b754-9ad9a94be75b" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">292,468</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd51a222-a838-4b16-abe8-11bbc3f6998b" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">133,396,933</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4dc8fb2-95f9-4285-91c7-11ecdf205974" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">110,939,074</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf8d8b33-8db4-4bb0-904b-728599cc7716" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">18,055,449</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b295d57-e45c-486b-be66-ca1f3f64b1be" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">401,303</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2629f79e-6d5e-44b7-b91c-b41fd3a8740c" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">4,552,281</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c20583ca-3e29-417c-bd6d-6fd7a3c15ff0" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">21,471,602</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK THERAPEUTICS, INC. AND SUBSIDIARIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statement_operations_compre"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENT OF OPER</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATIONS AND COMPREHENSIVE LOSS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a72664b-8a0b-49aa-a7e7-cdcfff9febe9" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,489,997</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed795e6d-17ac-4603-a9e2-012627e35762" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">23,115,123</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9f8c42c-010f-4dec-a5fc-2b430c26fd92" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">7,431,108</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_192ed667-af3a-4527-86a0-3330bc2756f1" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">7,834,155</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7edfe247-6b9c-4ad6-be48-7edb1eade498" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">22,921,105</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_006367ef-7bee-42f9-b3fe-70677996cf33" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">30,949,278</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68e5ea3c-df4d-40aa-96b7-ebffd530cd69" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">463,256</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48107b0d-3ff2-42fa-b443-d85fad52fa73" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">253,323</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (loss), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e18b97e6-2afc-4ffc-9993-f3cebc4d5fc7" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99bea7e4-2f3d-4687-89ea-d7d95cfbe3f8" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,704,743</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a0ee101-d485-44a0-b0fc-3a288b8d78d7" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">22,457,859</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_590e816f-d111-4daa-bded-a56057ac3aac" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">27,991,212</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Per common share data:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic and diluted net loss per common share</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5481acc9-0008-4b89-915d-cf8903463a2e" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-"><ix:nonFraction id="F_005d259b-3894-4070-8937-dd227608d615" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">0.65</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_897361ad-ffb0-4551-be27-71d710a1be18" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-"><ix:nonFraction id="F_ccc6e582-9060-43f0-b463-07394e081509" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">0.83</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average number of common shares outstanding</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4314942-afc5-48c7-b985-2c0a0eac7832" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4c49cb50-90b3-4361-b903-68fb4e184eb3" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">34,359,945</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0031e83-edd7-4827-ba31-1d445f7d0fbd" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9d69bdd4-de1b-4708-942d-4308068485fb" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">33,672,927</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive gain (loss)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation gain (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6913bf67-c156-4245-aedf-963f938165bb" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">138,479</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb5479d1-df69-4859-b814-0b916eb2aad4" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">332,801</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a22d3f6b-dfd5-4c61-958d-0c7691d87003" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">22,596,338</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98c5ebc7-50fc-48ab-912d-b956508f558d" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">27,658,411</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK THERAPEUTICS, INC. AND SUBSIDIARIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statement_stockholders_defi"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENT OF</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> STOCKHOLDERS&#8217; DEFICIT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:16.817%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.698%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:7.239000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:6.879%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.698%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:7.239000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:7.239000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:7.239000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:7.239000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Treasury Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>shares</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Par<br/>Value</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In<br/>Capital</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>shares</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Par<br/>Value</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other<br/>Comprehensive<br/>Income (Loss)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Deficit</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69f78996-5d0d-4ef5-bb3b-978d280be5cc" contextRef="C_b4568e37-46c0-4e69-b2ec-5733ed214cac" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">33,476,523</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_078755be-cc18-43c7-9852-d0ff06208cf6" contextRef="C_b4568e37-46c0-4e69-b2ec-5733ed214cac" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0">335</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74f08238-a74e-4ffa-9d1d-88f1e0f81053" contextRef="C_fb24caa1-2baa-4a9a-bc97-8c26392c5c44" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">107,349,265</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_093d72b5-2b58-4031-b86f-16e547f90c56" contextRef="C_9607a901-9bb0-4a3b-a4c9-d3098e66534e" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">625,269</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_833183b1-ad94-4d0f-a0c3-674226d2412f" contextRef="C_cdfdfaeb-561e-445c-ae5b-25b64f9aebd2" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">82,947,862</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eaf9f8ce-c50a-4288-a0ab-c6daafbc7dc4" contextRef="C_8de82880-160e-43df-8a06-7bd23e1206fe" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">23,776,469</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net Loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47614913-4583-475a-b813-3922b5cd8bec" contextRef="C_0766000b-7486-4271-8d7f-0f025af31180" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">27,991,212</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9b0ce2c-d855-4b27-a38a-6648090d232e" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">27,991,212</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive gain</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b21f4a6-3227-4209-a964-09edef719d3d" contextRef="C_dc1f8474-7a37-45c5-a06a-9ca912012dca" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">332,801</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_216119d3-6f5a-49d6-a46d-cf1056a00e4f" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">332,801</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of nonvested shares</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af9647ed-60d6-4f46-a8f1-a7c4e1cd0384" contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,595</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_025dd20d-479c-4052-b1a2-bb7473d124ba" contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec2a3122-e99a-4dbf-aaa3-1a45a70866e9" contextRef="C_477e462d-66f4-4337-b1ec-ca7e1946fed2" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" decimals="0" sign="-">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3d4aa56-8c19-4c84-bd37-8715c823130e" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4121279-022b-4587-9329-d723c0a8d8ac" contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">258,648</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c920117e-935a-4aa7-83d8-517e52a9a7ef" contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bca4319-1940-411f-a107-55b87b7d4ed8" contextRef="C_477e462d-66f4-4337-b1ec-ca7e1946fed2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,593</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71ce9c15-f2ae-4661-b95b-372d16694f0d" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,595</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeiture of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5792dfa-6b86-407b-8306-5b5793c5b953" contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">20,872</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa4490e8-afe0-4fa5-9ef6-e1e4189f8047" contextRef="C_477e462d-66f4-4337-b1ec-ca7e1946fed2" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e4b49d1-5e6c-4f9b-b98b-3d0d4eb93fc9" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grant and recognition of<br/>&#160;&#160;&#160;stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fe0640c-b54a-4633-aff9-9ea886a88e85" contextRef="C_477e462d-66f4-4337-b1ec-ca7e1946fed2" name="inkt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,089,583</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b554306f-b2e0-4cce-b2eb-729796505e8c" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="inkt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,089,583</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Recognition of parent stock<br/>&#160;&#160;&#160;options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06fd159a-7ff8-438f-865c-5888fd47198a" contextRef="C_477e462d-66f4-4337-b1ec-ca7e1946fed2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">96,013</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cada9be-05c0-46bf-8789-950fb493eb83" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">96,013</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of shares for employee<br/>&#160;&#160;&#160;bonuses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78516f39-6dcc-4b17-8fc9-440e6baa3735" contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">125,199</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe907362-9d1b-4d45-b9da-3ccf6f74d20b" contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edcbd20b-69d4-45de-8a5a-5480b7e2a0fe" contextRef="C_477e462d-66f4-4337-b1ec-ca7e1946fed2" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">293,522</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6926898f-00c8-4a93-8fca-56cf14d34d00" contextRef="C_dc88111c-fde0-4875-b17d-3dcd2f81ff4a" name="inkt:TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">43,665</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d27f319b-9775-43fa-b255-f9ea9b032206" contextRef="C_dc88111c-fde0-4875-b17d-3dcd2f81ff4a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">157,194</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34b9d9ea-6d38-4f84-87a3-ef8d0521b869" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">136,329</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Retirement of treasury shares</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74380b1f-26bf-4d91-8d88-1bef72f66db6" contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b" name="us-gaap:TreasuryStockSharesRetired" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">43,665</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4eab3950-888e-4385-b4fd-03ccb2c52b4e" contextRef="C_dc88111c-fde0-4875-b17d-3dcd2f81ff4a" name="us-gaap:TreasuryStockSharesRetired" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">43,665</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21c0bfb7-856f-4ed9-95b3-e34fc644b65d" contextRef="C_dc88111c-fde0-4875-b17d-3dcd2f81ff4a" name="us-gaap:TreasuryStockRetiredCostMethodAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">157,194</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af79edf6-bdc2-44d4-bb8a-d3baa78ab5be" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:TreasuryStockRetiredCostMethodAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">157,194</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da39c648-feaf-4e86-b299-749c8016110a" contextRef="C_b7f39df2-940c-4946-a3d9-f259147aae28" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">33,856,428</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d6187d4-d685-47f2-8be1-622a2e91fd8e" contextRef="C_b7f39df2-940c-4946-a3d9-f259147aae28" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0">339</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2512bb95-9d01-45a6-84e9-20dfb1049403" contextRef="C_b6874be7-da49-437b-ba93-4e3f9f01d838" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">110,829,900</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4aa5a08a-1f60-4d21-a6e1-789104c7340e" contextRef="C_c28b56ad-700c-422d-b0b5-3496a8befd3a" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">292,468</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6e1c56e-0086-43b9-a7e7-4abb5bd16ece" contextRef="C_5eaab94b-6260-4a4a-a00c-52210c750bbd" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">110,939,074</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2592d471-104d-4364-a340-87994d458235" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">401,303</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net Loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_358d8cad-6922-42d9-99b2-3df25325020b" contextRef="C_8e90aa4c-d975-4aee-8b77-ed3c9b0a38c0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">22,457,859</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f722f23-7c6b-4bcb-be42-cec67b4b5540" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">22,457,859</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00c1bf81-3257-4bdf-901e-5b583847b550" contextRef="C_b1cce805-eca1-48ac-8a3e-95ff6ff8052a" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">138,479</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_904f11f8-50a4-4c47-abf7-160f9dd30ae0" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">138,479</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of nonvested shares</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d83d4e00-024e-4d35-a617-49b118153a3f" contextRef="C_30769c45-3fd9-4704-8227-5041637f5332" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">175,196</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c1a8732-268e-4544-8347-a283f83d54e8" contextRef="C_30769c45-3fd9-4704-8227-5041637f5332" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98878cc9-2ede-4fad-a7fe-fc97ff8ca678" contextRef="C_9a95821e-13b6-49df-9115-37827f9a727f" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options and<br/>&#160;&#160;&#160;employee share purchases</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b561304-6a63-49d7-a509-c3a59bdbceb4" contextRef="C_30769c45-3fd9-4704-8227-5041637f5332" name="inkt:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">144,527</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a41c8787-983a-43f5-9843-aed3bb122a59" contextRef="C_30769c45-3fd9-4704-8227-5041637f5332" name="inkt:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db744a6a-2c98-498d-a738-54bd9c791b6f" contextRef="C_9a95821e-13b6-49df-9115-37827f9a727f" name="inkt:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">70,465</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bff3e799-070a-4b07-b58f-fc251d22350e" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="inkt:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">70,466</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share retirement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee78ea52-2e7c-4531-82ec-e175c58f8502" contextRef="C_30769c45-3fd9-4704-8227-5041637f5332" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">192</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of shares for services</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40f2049c-336d-4770-8eee-a93b8aeb887a" contextRef="C_30769c45-3fd9-4704-8227-5041637f5332" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">25,209</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df789775-af71-4594-a8ca-053ba94a6d50" contextRef="C_9a95821e-13b6-49df-9115-37827f9a727f" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_726f93f4-98a8-4292-9d8d-6a256a73ad30" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grant and recognition of<br/>&#160;&#160;&#160;stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c1a4494-f2c9-44f2-b6ba-071120c81e45" contextRef="C_9a95821e-13b6-49df-9115-37827f9a727f" name="inkt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,698,436</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c63a7cd9-2e78-4f17-a075-cc2ca73ea804" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="inkt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,698,436</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Recognition of parent stock<br/>&#160;&#160;&#160;options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddf35436-b499-479e-89bf-ef36daddf8f7" contextRef="C_9a95821e-13b6-49df-9115-37827f9a727f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">131,930</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16e3274d-5222-4025-871f-76509f456734" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">131,930</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of shares for employee<br/>&#160;&#160;&#160;bonuses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fc0d9b8-fbc6-49ea-a887-4e4df9715842" contextRef="C_30769c45-3fd9-4704-8227-5041637f5332" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">603,830</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4b8e88a-1af2-43c9-aa4c-1538e24db430" contextRef="C_30769c45-3fd9-4704-8227-5041637f5332" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" unitRef="U_USD" decimals="0">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b00f7b2b-4978-4950-85b6-0c27103c3130" contextRef="C_9a95821e-13b6-49df-9115-37827f9a727f" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,011,356</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67eebc98-fec3-4f93-8f22-9ebcc3bbaa4e" contextRef="C_92fa1c95-ab93-4332-a14e-01ee475bc615" name="inkt:TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">205,879</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e540c983-e19c-41ed-9e0f-fc7ee81b0f32" contextRef="C_92fa1c95-ab93-4332-a14e-01ee475bc615" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">477,639</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c8fd558-869c-427b-998b-9c46a88e1b9c" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">533,723</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Retirement of treasury shares</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1e26a67-8f7f-48f9-bfc8-fb2be83ac661" contextRef="C_30769c45-3fd9-4704-8227-5041637f5332" name="us-gaap:TreasuryStockSharesRetired" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">205,879</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ecd572d-504e-4eed-82c8-6358732aab7e" contextRef="C_30769c45-3fd9-4704-8227-5041637f5332" name="us-gaap:TreasuryStockRetiredCostMethodAmount" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c062b36b-12f4-430c-8026-f8c9aa573936" contextRef="C_92fa1c95-ab93-4332-a14e-01ee475bc615" name="us-gaap:TreasuryStockSharesRetired" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">205,879</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5204c675-589d-46d8-9501-a1d7bf13dab4" contextRef="C_92fa1c95-ab93-4332-a14e-01ee475bc615" name="us-gaap:TreasuryStockRetiredCostMethodAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">477,639</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c702246-c797-4446-bc22-fce017e36431" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:TreasuryStockRetiredCostMethodAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">477,637</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c85bcb76-9dc8-4749-a95a-d7fb9327daa2" contextRef="C_eb216ed3-85fe-4453-894a-011e3ac6dfb1" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,599,119</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b08d0721-06f2-41e4-b40e-403da170f3c4" contextRef="C_eb216ed3-85fe-4453-894a-011e3ac6dfb1" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0">346</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1fa4f07-d4d1-43e1-adfb-f7d05eed35c5" contextRef="C_7e66d751-8e58-4e0e-9b7c-eba65cf04289" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">115,772,085</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00fa648e-834d-4afd-a0d9-f61d504f0ff2" contextRef="C_42c15bdd-fb56-4487-acc5-a92fa8762921" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">430,947</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ce49b4d-a78e-45c2-b17c-4b393eb39887" contextRef="C_b96f833e-9e89-4940-890a-3ad3066d1a3f" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">133,396,933</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c9f9297-4da9-4709-a44c-32878133a6a2" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">18,055,449</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK THERAPEUTICS, INC. AND SUBSIDIARIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statement_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ENT OF CASH FLOWS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59220876-8bab-4519-aa66-3218d0890bdf" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">22,457,859</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ceeeb0c4-fc0a-44e4-bd33-2a3f9b518c4f" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">27,991,212</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_786627a7-da57-4968-973a-6c7748e1d05b" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:Depreciation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">204,617</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0950b8ad-dbff-4ec4-bc40-7dd0797d662c" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:Depreciation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">121,749</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c57c0091-fbd5-461a-9d30-5a4068fdaf41" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,860,366</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_427e6c47-6f76-4a84-909a-38635b7a57aa" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,026,846</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gain on forgiveness of liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_183f152b-e388-4dc2-ab55-c3b491f00f17" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="inkt:GainOnForgivenessOfLiability" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">266,780</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1517be72-e7f5-450a-8686-ad14468cb60c" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="inkt:GainOnForgivenessOfLiability" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,790,809</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_614734fc-8851-4841-9a2d-e9308c19181b" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">245,589</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40127bdb-3cef-4c32-8cad-fbec9d0979cf" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">296,945</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d72af638-a465-494e-8153-e792742d5399" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">1,917,557</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_510ee884-f707-4cb5-be9b-49e3fc3f698d" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,660,769</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities and other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0f2a7b2-7e12-45a7-ada7-414cb4e3fe47" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,025,124</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ebc53ab-a36b-4a73-840f-ecaa01982367" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,424,921</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other operating assets and liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9a57a35-ba90-49c0-b196-d2bfb6b56b24" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">2,543,988</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_896b2fe9-68e6-43fc-9e7c-38534a3b9bbe" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">2,977,838</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35e32c59-801d-484c-8fd6-060faf305b42" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">15,762,512</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17094891-3f32-4f05-8f94-e0da8b3d45a1" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">18,866,843</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f04885c-87f4-41ee-a769-5031a368141d" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">73,561</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a13e172e-1245-47f5-96f8-8b757b47e955" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">250,046</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a962d829-95cd-40e7-88c1-f024c13c25f3" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">73,561</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64beb46a-df06-4217-9614-0e2001b85fe8" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">250,046</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of treasury shares to satisfy tax withholdings</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2296ee7d-3039-4938-8058-6d276d771bbf" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="inkt:PurchaseOfTreasurySharesToSatisfyTaxWithholdings" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">477,639</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12f412e5-2b0c-412c-80c4-72431d764ada" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="inkt:PurchaseOfTreasurySharesToSatisfyTaxWithholdings" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">157,194</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from employee stock purchases and option exercises</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d9586b8-4c5b-4d15-90ce-6b69c5a92246" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="inkt:ProceedsFromEmployeeStockPurchasesAndOptionExercises" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">70,466</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0406c280-b076-45b1-a99d-ab8c4dfa509e" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="inkt:ProceedsFromEmployeeStockPurchasesAndOptionExercises" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,595</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_100713a2-acbf-410a-85c3-1dff7776d27f" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">407,173</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea9ff608-cdb8-408d-a0f2-e9e89b90f434" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">155,599</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of exchange rate changes on cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec9cd058-8039-4e2c-b693-70b5113893df" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">25,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8dc15de-1f17-4021-bef9-a5be67f3626c" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">19,385</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08fe6876-5c1b-4e97-89f1-890d8994df01" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">16,268,496</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8702cd7-57ee-47c8-b6ac-11d538035182" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">19,253,103</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c1c7d42-cb7e-4c2f-b570-6eef1d337eb1" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">19,635,725</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_154b9c4b-0d39-4d83-b391-f394e94e043a" contextRef="C_8de82880-160e-43df-8a06-7bd23e1206fe" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">38,888,828</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb8704a5-34d1-46a3-9e0a-a52b06884265" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,367,229</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a45ad5d7-1397-4d86-bc4e-ce2ac3398330" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">19,635,725</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Supplemental cash flow information:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1c0fbed-89a4-478e-8ae9-840a4c988ee2" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:InterestPaidNet" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">27,509</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f3aa5aa-a854-434d-8710-bfb111ffe0e5" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:InterestPaidNet" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">10,820</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Supplemental disclosures - non-cash activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of plant and equipment in accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd81e407-17bd-4525-84c8-113ec534a452" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="inkt:PurchasesOfPlantAndEquipmentInAccountsPayable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">177,680</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Insurance financing agreement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_783ae20b-f56a-4fff-9ba7-9436a5db81e3" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="inkt:InsuranceFinancingAgreement" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">109,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a094fed5-4299-4b7e-98cb-595a4af8c660" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="inkt:InsuranceFinancingAgreement" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">444,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20cca5b2-11bd-459f-8d1b-cd54b377320b" contextRef="C_442d530a-bd9b-4549-9f81-dfaba599e462" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.00001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, for payment of employee bonuses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f10aa0b2-29c1-45f7-b782-0d12532576ad" contextRef="C_d36c7999-649a-4daf-ab6e-976ec054bb05" name="us-gaap:StockIssued1" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,011,360</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7d0f0e6-1967-4767-b23a-b449dd047414" contextRef="C_b57bd5bc-4306-4671-aabe-7907cd2bac83" name="us-gaap:StockIssued1" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">293,523</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9751d715-0231-4f9e-b3cd-795962b360ce" contextRef="C_9e054ad4-ee65-43e9-bf29-ab336dac222b" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.00001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, in connection with payment for services</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77f14baa-0fca-4679-b6f7-1ad90bf011e2" contextRef="C_419eb5b2-74d7-426a-8de0-6ec785c7a7e5" name="us-gaap:StockIssued1" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK THERAPEUTICS, INC. AND SUBSIDIARIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b6a18f9-ed7a-4b43-b342-e92a568ce556" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:NatureOfOperations" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK Therapeutics, Inc. (&#8220;MiNK&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company pioneering a novel platform of living medicines based on a rare and potent class of immune cells called invariant natural killer T (&#8220;iNKT&#8221;) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. MiNK's proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, MiNK believes that its approach represents a highly versatile application for therapeutic development in cancer and immune diseases. MiNK is leveraging its platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of both native and engineered iNKT cells.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its inception in 2017, MiNK has incurred losses and expects to continue incurring operating losses and negative cash flows in the future until it is able to generate sales and profits. As of December 31, 2023, MiNK had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea7d9ae4-c0f5-41df-9900-dbf8bb362e01" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">133.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and cash and cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_853c1fdb-19f5-475d-a175-8f2cacc1c548" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK believes that its cash and cash equivalents balance along with the additional funding received subsequent to year end from its parent, Agenus Inc. (&#8220;Agenus&#8221;), and funding planned from a third party will be sufficient to satisfy its liquidity requirements for more than one year from when these financial statements were issued. Because the additional funding is influenced by external uncertainties, in accordance with the relevant accounting guidance, the Company is required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Annual Report on Form 10-K. The financial statements have been prepared on a basis that assumes MiNK will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management continually monitors MiNK's liquidity position and adjusts spending as needed in order to preserve liquidity. Potential sources of additional funding for the Company include: (1) seeking strategic partnerships and collaborations, as well as out-licensing opportunities, for the Company's portfolio programs and product candidates, (2) exploring avenues for securing non-dilutive financing, such as grants and collaborations to strengthen the Company's balance sheet, and (3) potential of equity or debt financing options. If additional funding is not obtained through these sources, Agenus has indicated a willingness to loan MiNK additional funds to finance its operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK&#8217;s product candidates are in various stages of development and additional expenditures will be required if the Company starts new trials, encounters delays in its programs, applies for regulatory approvals, continues development of its technologies, expands its operations, and/or brings its product candidates to market. The eventual total cost of each clinical trial is dependent on a number of factors such as trial design, length of the trial, number of clinical sites, and number of patients. The process of obtaining and maintaining regulatory approvals for new therapeutic products is lengthy, expensive, and uncertain. Because all of the Company&#8217;s programs are at an early stage of clinical development, the Company is unable to reliably estimate the cost of completing its research and development programs or the timing for bringing such programs to various markets or substantial partnering or out-licensing arrangements, and, therefore, when, if ever, material cash inflows are likely to commence</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_d6dd51c9-5aa1-4881-88f6-af7956155eb3" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2) Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d3edb34-d5a6-4892-a29f-dc184b26f5f3" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(a) Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and include the accounts of MiNK and its subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aad095a0-5f49-45c3-b0d0-ff74b238572e" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(b) Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK is managed and operated as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87e5951a-eca2-429d-bd33-573d16e52adb" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> business segment. The entire business is managed by a single executive operating committee that reports to the chief executive officer. The Company does not operate separate lines of business with respect to any of its product candidates or geographic locations. Accordingly, the Company does not prepare discrete financial information with respect to separate product areas or by location and does not have separately reportable segments as defined by Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 280, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4ebe5bd-2761-446d-922d-44cf1fba7475" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(c) Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases those estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3774819-5a5d-47e4-a7a0-707ade9045ea" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(d) Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments purchased with maturities at acquisition of three months or less to be cash equivalents. Cash equivalents consist primarily of money market funds.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9acbe38-e5ed-41e7-a751-040ca5e72139" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(e) Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equipment is carried at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, typically </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0aec5014-44cd-4e62-af37-e2b225f8f82f" contextRef="C_26d61948-a095-4072-b5b4-5cab95d54532" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb59c53d-359a-44ae-a369-47a3113dc257" contextRef="C_42074970-bc84-4a58-b664-9c0013d5b65b" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Additions are capitalized, while repairs and maintenance are charged to expense as incurred. Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a6492e7-b8c9-41c0-8be3-d500d0444ce6" contextRef="C_8b187843-724c-4035-a8bd-2721f3e23008" name="inkt:DepreciationExpenseOnPropertyPlantAndEquipment" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">205,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_646548c3-6074-49b2-8ab1-62c9685253c1" contextRef="C_84ae0517-023d-4ec4-b8be-679864cc08aa" name="inkt:DepreciationExpenseOnPropertyPlantAndEquipment" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">122,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89f23d92-ea5f-44a4-80c3-9c3b88d3b2d8" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(f) Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:0.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.3553803871825076%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities. </span></div></div><div style="margin-left:0.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.3553803871825076%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></div></div><div style="margin-left:0.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.3553803871825076%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s cash and cash equivalents are carried at fair value (a Level 1 measurement), determined according to the fair value hierarchy described above. The carrying values of the Company&#8217;s, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c55850dd-6d82-4790-b234-45d627836f8d" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(g) Foreign Currency Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gains and losses from the Company&#8217;s foreign currency-based accounts and transactions, such as those resulting from the remeasurement and settlement of receivables and payables denominated in foreign currencies, are included in the consolidated statements of operations within other income (expense). The Company recorded de minimis foreign currency losses for the years ended December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b479ebe-c8a9-4faf-aa11-750d2078233f" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(h) Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include the costs associated with the Company&#8217;s internal research and development activities, including salaries and benefits, share-based compensation, occupancy costs, clinical manufacturing costs, related administrative costs and research and development conducted for the Company by outside advisors. Research and development expenses also include the cost of clinical trial materials shipped to the Company&#8217;s research partners. Research and development costs are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6d7f527-a14d-40de-99a6-4a14a2005c98" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(i) Share-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK accounts for share-based compensation in accordance with the provisions of ASC 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Share-based </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compensation expense is recognized based on the estimated grant date fair value. Compensation cost is recognized on a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">straight-line </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">basis over the requisite service period of the award. Forfeitures are recognized as they occur. See Note 8 for further discussion on share-based compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48089223-12ce-4638-9d4e-09e2d23b2a29" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(j) Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the asset and liability method with deferred tax assets and liabilities recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and net operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such items are expected to be reversed or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statement of operations in the period that includes the enactment date. Deferred tax assets are recognized when they are more likely than not expected to be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9226f532-95e4-4609-ac21-65f8db6a5aeb" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(k) Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic income or loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted income per common share is calculated by dividing net income attributable to common stockholders by the weighted average number of common shares outstanding plus the dilutive effect of outstanding instruments such as stock options. Because the Company reported a net loss attributable to common stockholders for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_711528de-011f-493c-8e6b-acaed1a9966b" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_711528de-011f-493c-8e6b-acaed1a9966b_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of December 31, 2023 and 2022, as they would be anti-dilutive: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_711528de-011f-493c-8e6b-acaed1a9966b_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.78%;"/>
          <td style="width:1.6%;"/>
          <td style="width:1%;"/>
          <td style="width:13.2%;"/>
          <td style="width:1%;"/>
          <td style="width:1.6%;"/>
          <td style="width:1%;"/>
          <td style="width:12.82%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02ba42c1-9394-4cda-81bc-6cf8237032ef" contextRef="C_dcf77660-1f56-4511-acbc-a3e5c157ebe0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,945,716</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0927b3a7-f4e5-43c4-8dc9-ce93875790d7" contextRef="C_f8ef24c4-afb3-478b-a8f5-beceae45922e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,148,447</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested shares</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bd383b0-c5ab-4da2-a4e8-ec0249741e14" contextRef="C_ab635f33-5c9a-416d-95b3-be4679d91964" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">789,503</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1064ab54-0e85-42dd-bc36-b76a85797d13" contextRef="C_e412c6c7-5f47-4066-aab4-7147f2d0c3b8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">726,163</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_602a7e2a-a90d-4eec-a34d-9fd6a3aad355" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(l) Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. As the Company has a single reportable segment, MiNK expects the adoption of this standard to result in increased disclosures in the notes to its consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. For the Company, ASU 2023-09 is effective for fiscal years beginning after December 15, 2025. Early adoption is permitted for any annual periods for which financial statements have not been issued or made available for issuance. The Company is currently evaluating the impact that ASU 2023-09 will have on its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No other new accounting pronouncement issued or effective during the year ended December 31, 2023 had or is expected to have a material impact on the Company&#8217;s consolidated financial statements or disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_318661fa-5e13-4eb7-95a1-55467c3269db" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3) Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e5e8264-a86f-4eb0-b54b-b69424362761" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents consisted of the following as of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:58.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.268%;"/>
        <td style="width:1.719%;"/>
        <td style="width:1%;"/>
        <td style="width:13.715%;"/>
        <td style="width:1%;"/>
        <td style="width:1.719%;"/>
        <td style="width:1%;"/>
        <td style="width:13.715%;"/>
        <td style="width:1%;"/>
        <td style="width:1.719%;"/>
        <td style="width:1%;"/>
        <td style="width:13.715%;"/>
        <td style="width:1%;"/>
        <td style="width:1.719%;"/>
        <td style="width:1%;"/>
        <td style="width:13.715%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Institutional money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbe4b86f-9326-4f08-b2b0-724b193ca968" contextRef="C_c81ea76b-898a-4328-bab5-6699b445169a" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,899</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e00464a-ee1c-4902-85ef-2888154a2e66" contextRef="C_c81ea76b-898a-4328-bab5-6699b445169a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,899</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23bba271-250c-48b4-b4a7-136122189151" contextRef="C_6bed87a6-106d-428e-a478-dc518b3adca0" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,664</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a655a88-6fe4-4313-941c-4e6cb4864706" contextRef="C_6bed87a6-106d-428e-a478-dc518b3adca0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,664</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e1dce775-1464-4135-b15a-c4c06ea07ceb" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4) Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65d948d1-939e-455e-9acd-6a6b581e04d2" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equipment, net, consisted of the following as of December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.627%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:13.377%;"/>
        <td style="width:1%;"/>
        <td style="width:1.46%;"/>
        <td style="width:1%;"/>
        <td style="width:13.036999999999999%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c13b02ab-7646-4965-9ed4-8c1cc5bf1b9b" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,450</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43ff30b4-d943-4873-8b86-582db88e34c0" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,351</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5584c452-5211-4384-a338-f9d0ba958b3f" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">496</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16b357de-f7b8-4abf-8547-8d90a33e56d5" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">284</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa5b00a9-0717-49c1-9ecb-141ce21da128" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">954</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3823d474-fbea-4435-b1ce-3466a658e067" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,067</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_691d2950-8235-4771-abd8-8a53001b3591" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5) Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to taxation in the United States and in various state, local and foreign jurisdictions. The Company remains subject to examination by U.S. Federal, state, local and foreign tax authorities for tax years </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bf9d2624-e5f8-4332-8ece-0d2f7a8edc9c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2019 through 2022</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. With few exceptions, the Company is no longer subject to U.S. Federal state, and foreign examinations by tax authorities for the tax year 2019. However, net operating losses from the tax year 2017 would be subject to examination if and when used in a future tax return to offset taxable income. The Company&#8217;s policy is to recognize income tax related penalties and interest, if any, in its provision for income taxes and, to the extent applicable, in the corresponding income tax assets and liabilities, including any amounts for uncertain tax positions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had available net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a923d698-506c-4bda-9de3-fbb49125d504" contextRef="C_9103c720-7b6a-415f-96e7-4b1a21557321" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_299b2a14-8e69-433c-a55a-647bbd05f968" contextRef="C_df7ebdbc-60ae-490c-baef-5224675cbc1f" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">52.3</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for Federal and state income tax purposes, which are available to offset future Federal and state taxable income, if any. $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc8aea58-fc9c-4719-835a-18e7a7ef35d9" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">52.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of these Federal net operating loss carryforwards do not expire, while the remaining net operating loss carryforwards expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e22d9b5d-ce5f-4f3e-922e-62300307dbb9;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2037</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company&#8217;s ability to use these net operating losses is limited by change of control provisions under Internal Revenue Code ("IRC") Section 382 and may expire unused. The Company also has foreign net operating loss carryforwards, which do not expire, available to offset future foreign taxable income of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4268e1e-51bb-44a6-a4be-55f887f59fd5" contextRef="C_24cbce9b-fd20-4704-9a75-a6a645e49d55" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million generated in the United Kingdom and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd74f36c-f0af-46de-9ca3-64dbd6dac909" contextRef="C_b28e3d23-d775-4bbd-9547-580645e3901f" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in Belgium. The potential impacts of these provisions are among the items considered and reflected in the Company&#8217;s assessment of its valuation allowance requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beginning January 1, 2022, the Tax Cuts and Jobs Act (the "Tax Act") eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to IRC Section 174. The capitalized expenses are amortized over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9558d9f1-d76b-45c8-bef1-b0bab16109de" contextRef="C_ee885642-fc14-4425-b334-06fb0a0d1eea" name="inkt:CapitalizedExpensesAmortizationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period for domestic expenses and a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e9954d7-fc3f-48e1-a627-a0c77aaf4949" contextRef="C_6a1ac15f-c735-4f88-9b7d-d2ba5526a4fb" name="inkt:CapitalizedExpensesAmortizationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period for foreign expenses. We have included the impact of this provision, which results in additional deferred tax assets of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24a2fad6-0644-4e92-8ce6-9f4a4432336f" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a228c03b-9b28-4b98-ad27-2f9554d992b5" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 and 2022 respectively.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35801499-bf4f-4e62-a60c-df0c98602444" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax effect of temporary differences and net operating loss carryforwards that give rise to significant portions of the deferred tax assets and deferred tax liabilities as of December 31, 2023 and 2022 are presented below (in thousands).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Federal and state net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_344c9df8-5d8b-4aec-80bd-62e0d0a67c0f" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,804</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_531170fe-b478-47ba-8f03-d6a55d02a65c" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,411</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_243a514f-55d4-40fc-9b59-5a282e5e0a0a" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,819</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edcd5e61-2eaa-4c32-94b9-65126a594afc" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,224</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01fff03b-363c-4069-aeb6-cb3c72bf9f4e" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="inkt:DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">341</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c32f0caf-d12e-4a98-beca-4e6507792e15" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a418154f-9e75-465c-b8d1-82e89540d28f" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">441</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_686776dd-b54e-4acf-a75b-d6058ad8933f" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,515</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b681f85b-a277-40b2-a0aa-ccc39919483f" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,154</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f0ea508-f2c9-402b-8f00-cbec8dfba4f4" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">926</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a482fc3-cf74-4852-a3a1-a82ee2df71c9" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">427</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e75f5891-f3c4-4479-8962-0ec7d0e19513" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,674</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16d5ce12-ad2b-4f9c-830e-3b171cdbffe8" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,657</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfacce62-ea69-4d8e-9338-48ee4175c319" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,674</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13b13bd6-e530-4174-8eab-602d0db98848" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,657</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the net operating loss and tax credit carryforwards can be utilized or the temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. To fully realize the deferred tax asset, the Company will need to generate future taxable income sufficient to utilize net operating losses prior to their expiration. Based upon the Company&#8217;s history of not generating taxable income, the Company believes that it is more likely than not that deferred tax assets will not be realized through future earnings. Accordingly, a valuation allowance has been established for the full value of the deferred tax assets. The valuation allowance on the deferred tax assets increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7f1e4a6-9586-4738-a883-4b045631744e" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c223909-914b-4ac2-b704-95f0632afed3" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax benefit was nil for the years ended December 31, 2023 and 2022. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2014581-8ed3-4915-91ec-2f047a3fd2e2" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_c2014581-8ed3-4915-91ec-2f047a3fd2e2_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes recorded differed from the amounts computed by applying the U.S. Federal income tax rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_136947dc-fcec-4adc-943c-d1cc1e3496f9" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cbe56b93-6ece-4f23-a141-a56aceda366c" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">21</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% in 2023 and 2022 to loss before income taxes as a result of the following (in thousands). </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_c2014581-8ed3-4915-91ec-2f047a3fd2e2_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computed &#8220;expected&#8221; Federal tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f787dd91-ca1f-4913-ade7-759fc9332a0e" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,716</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_634bc5dd-ec00-482c-b8d1-c7be41a09501" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,878</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Increase) reduction in income taxes benefit resulting from:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05aa33dc-d8b2-4ff4-87c5-134bfe698bfa" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,987</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afc335d4-aaca-4555-a939-ce0cd179de2d" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,028</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign rate change</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8234358-63ba-4ded-8ee9-61d24e74d4b2" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="inkt:EffectiveIncomeTaxRateReconciliationForeignRateChange" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">842</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign income inclusion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d75e5a9-d115-4c3d-a514-a24a98b6ec37" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="inkt:EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_859eaf50-9f50-4878-ba9b-d3651a236687" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="inkt:EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">530</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State and local income benefit, net of Federal income tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43749af1-1b68-4448-a078-8dfd5a13469a" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,693</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a001fee-3238-4a3d-ba99-f94267fa2884" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">104</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Return-to-provision adjustment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_604b1013-e8c9-49b7-96a4-fb1181013888" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="inkt:IncomeTaxReconciliationReturnToProvisionAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,393</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign rate differential</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8e344c0-09ba-47df-87c9-2dbea10d79cc" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">286</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edfdc3d5-bf1e-44a0-9668-1da7546b0db7" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">840</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bab35099-5468-47c1-acb1-9a6bf1c7e9ef" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">348</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eef8131c-9c16-40aa-b383-28844e83ebad" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">397</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f51c27d4-31d3-42e0-bf8f-3c72cc9addf5" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2397572f-c0a1-4211-b90c-6d5ef4581f32" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(6) Accrued Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7461430e-1345-42ba-afc1-54f3d62689f3" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consist of the following as of December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payroll</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08b3b4ec-27ae-4cde-81d3-6a4cc8ccbfbd" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,831</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97b505db-a363-4815-bba3-52b6cde1fbb8" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,655</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c66b5713-f03d-4488-b510-6f61808dcbfa" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">398</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d90d11c0-3322-4830-83e2-0f26854e1779" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">642</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe06921a-57c9-4a39-bdc9-571d32caa4b5" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="inkt:AccruedResearchServicesCurrent" unitRef="U_USD" scale="3" decimals="-3">302</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ffb5689-0501-40c4-b89f-2882c3455c66" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="inkt:AccruedResearchServicesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,681</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract manufacturing costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f6b9868-fd51-4d21-b457-51521fcc94cf" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="inkt:AccruedContractManufacturingExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,430</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31eaaf19-e5da-4d83-a091-3b09a94065f1" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="inkt:AccruedContractManufacturingExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_febe64fd-c9c8-4923-9c1d-2942d5b535b7" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9741885-df69-4dcc-a8e1-ea2c75f01e46" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,037</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7755227a-f388-476b-8530-a219e81f8cd8" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,239</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7b584dd-f1c1-4a9d-a6f4-22ff2584aa5c" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7) Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s authorized capital stock consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03993ac9-c2ac-49ee-a619-f073694b9935" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="inkt:AuthorizedCapitalStockIncreased" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">155,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, all with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a9129de-5404-4290-a2b8-bb15919525f1" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.00001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, of which:</span></p><div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44734f6d-e75b-44b6-9603-b6389fe38365" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">150,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares are designated as common stock; and</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19088dbe-7fec-4b12-9c8c-4bafa5c97a7f" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares are designated as preferred stock.</span></div></div></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_eac12b90-420d-4050-8333-d5af6cb1fef2" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(8) Share-based Compensation Plans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) provided for the grant of incentive stock options intended to qualify under Section 422 of the IRC, nonstatutory stock options, restricted stock, unrestricted stock and other equity-based awards, such as stock appreciation rights, and stock units including restricted stock units for up to approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfc601ed-bfc7-4f79-9d34-2abef4702402" contextRef="C_f0c522b1-1207-430a-a24a-68c5917435b0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">13.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of the Company&#8217;s common stock (subject to adjustment in the event of stock splits and other similar events). As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f48fc724-6949-47d0-b5f3-50f81c6a85f5" contextRef="C_3f948c4b-dbf7-4fe1-80de-c2e6ec8ad0c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares remain available for issuance under the 2018 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Company&#8217;s initial public offering (&#8220;IPO&#8221;), MiNK&#8217;s board of directors adopted the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan provides for the grant of incentive stock options intended to qualify under Section 422 of the Code, nonstatutory stock options, restricted stock, unrestricted stock and other equity-based awards, for an initial share pool of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f19d17f2-cd71-49e1-928a-bbc75151464d" contextRef="C_cb159f01-5c87-4f27-ae80-397834ee1e9e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of the Company&#8217;s common stock (subject to adjustment in the event of stock splits and other similar events). The initial share pool will automatically increase on January 1st of each year from 2024 to 2031 by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dab9a481-00a4-47aa-bc95-6c2a0623644f" contextRef="C_ae710cfd-3658-456e-8236-9910244a165d" name="inkt:PercentageOfSharesOfCompanySCommonStockOutstanding" unitRef="U_pure" scale="-2" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> percent of the number of shares of the Company&#8217;s common stock outstanding as of the close of business on the immediately preceding December 31st and (ii) the number of shares determined by the Company&#8217;s board of directors on or prior to such date for such year. In January 2022 and 2023, the 2021 Plan share pool increased by approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61f1c750-fb49-42e3-b388-865766e8dfc9" contextRef="C_53b8ed07-cd44-46c7-8c61-16a3a18d3787" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_661c1c3e-7656-40b8-a994-f17e17162594" contextRef="C_b4dec32d-a6b7-4422-b38c-c1ea75f485c6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares, respectively. As of December 31, 2023, there were approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcfcd7db-bfc2-4b82-a887-8e3b818f4ba4" contextRef="C_cb159f01-5c87-4f27-ae80-397834ee1e9e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares reserved for issuance under the 2021 Plan.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Company&#8217;s IPO, MiNK&#8217;s board of directors adopted the MiNK Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP provides eligible employees the opportunity to acquire the Company&#8217;s common stock in a program designed to comply with Section 423 of the Code. There are approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ba7a0ac-20a0-4038-a6d2-3572425a5446" contextRef="C_8b3b3dc2-5df1-42cf-b22c-651f9e7e2441" name="inkt:SharesReservedForIssuanceUnderEmployeeStockPurchasePlan" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares reserved for issuance under the ESPP, plus an automatic annual increase on January 1st of each year from 2024 to 2031 equal to the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6eae9ef8-4a61-4a30-9dcd-81e07f6380bb" contextRef="C_4e994016-9f6a-4ddc-a1f5-464cebf76b9f" name="inkt:RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding" unitRef="U_pure" scale="-2" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> percent of the number of shares of the Company&#8217;s common stock outstanding as of the close of business on the immediately preceding December 31st and (ii) the number of shares determined by the Company&#8217;s board of directors on or prior to such date for such year, up to a maximum of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd42ca1a-cedd-43f7-837e-354b6955732b" contextRef="C_4e994016-9f6a-4ddc-a1f5-464cebf76b9f" name="inkt:SharesReservedForIssuanceUnderEmployeeStockPurchasePlan" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares in the aggregate.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company primarily uses the Black-Scholes option pricing model to value options granted to employees and non-employees, as well as options granted to members of the Company&#8217;s Board of Directors. All stock option grants have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e16cfd15-fb48-46ad-87e0-3bb32fe334e2" contextRef="C_268ec649-4cb5-49c6-a775-45044d13d5a1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> terms, service conditions, and generally vest ratably over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b99b56cb-1e64-4c6c-8a92-670d44a857cc" contextRef="C_cbf44c3c-afb7-4d6d-ae4b-5bcbfa6eb60d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7bdc51c-e365-47db-af4b-f62859af49de" contextRef="C_8a02edeb-2a2b-41a7-856e-4ba72582b120" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-year period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cabe2a5b-946b-4e74-91a7-ba0cb2df68ce" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each option granted during the period was estimated on the date of grant using the following weighted average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.343%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.343%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45d09931-e409-4123-a83e-717c4c78b1d1" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc32c639-44d2-42cc-b999-a2118fab9458" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term in years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_5013ef72-4096-4fc8-951c-649c05943620" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_9b6c88c6-02bd-4bf9-8a18-f27f417dbfa4" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7e20017-4239-4b0e-b2ea-6fbeb68b2691" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_114bbe09-ad6e-4655-b69c-a7bc4da6ef8b" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94f41025-7e12-4799-b07a-12effd2e0e0b" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d28789ee-57f6-4c83-b62d-24aec375c7a2" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected term of stock options granted is based on historical data and other factors and represents the period of time that stock options are expected to be outstanding prior to exercise. The risk-free interest rate is based on U.S. Treasury strips with maturities that match the expected term on the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_422d6b87-af60-4ef1-a148-78a118e93b4d" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of option activity for 2023 is presented below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:8.942%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_147da777-496a-448c-8f59-143b2156f502" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,148,447</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa44486a-a9bd-4ffe-8426-49ec18f4b374" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.97</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cb810e5-6c2c-431c-aca8-70608ae2535f" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,002,743</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c49b47b-3233-448e-b96a-27942e194c1f" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.28</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a5e551a-a3f8-453e-b4da-fb5ec06b67ed" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">105,187</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4be0b16-1f36-490f-b7d4-20c22bd0db94" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.22</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d16ba530-28e5-4c19-9dec-07515d77f718" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">61,883</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_045a0d32-335c-4c05-8285-d94bb1331669" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.94</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89283e89-6a96-4e67-880f-e86fc3ceac94" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">38,404</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb5154f1-da10-4eeb-b1e5-2dd09c6c49b9" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.01</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0017ca7-86f6-48f3-bf5b-aefa48556ad8" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,945,716</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8349789c-4a81-46e2-a0ee-9e8bf2c563c1" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.03</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_16c2ad19-013e-4cc9-8e87-9043efe64660" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.32</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d81ba79-afe8-4f64-958f-83d93a99459e" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,227,555</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested or expected to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0243e63e-7b68-4c71-93d9-c970c58b3981" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,945,716</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f48cf83-2439-4dea-be5d-b7c8eefb1978" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.03</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_916e7b39-be44-40d2-a653-290754649c7f" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.32</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99b64933-e9c8-4703-a23d-ad3f0a761230" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,227,555</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9424adfa-1e92-4e0d-bb0d-af791ac12ff7" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,999,908</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1965395-d965-41ca-a8b7-db20e0c51c11" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.44</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_73ec8a8f-a661-4e58-b19b-5cb865e25789" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.56</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8af86954-48b0-4bc6-8511-9ed2eed04fc4" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,227,545</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant-date fair values of options granted during the years ended December 31, 2023 and 2022, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83c2d7c0-7094-452f-9eaf-7f2dfeab414c" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.78</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and  $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee9da499-f688-4260-a6f4-c34ff1c0b647" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. During both 2023 and 2022, all options were granted with exercise prices equal to the market value of the underlying shares of common stock on the grant date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value in the table above represents the difference between the Company's closing stock price on the last trading day of fiscal 2023 and the exercise price, multiplied by the number of in-the-money options that would have been received by the option holders had all option holders exercised their options on December 31, 2023 (the intrinsic value is considered to be zero if the exercise price is greater than the closing stock price). This amount changes based on the fair market value of the Company's stock. The total intrinsic value of options exercised during the year ended December 31, 2023, determined on the dates of exercise, was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_577a6fd0-f55c-422b-af01-f4a985a473d0" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_317292bf-eb0c-4590-be8c-fd31a0dc9bd8" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized share-based compensation expense related to stock options granted to employees, consultants and directors which, if all milestones are achieved on outstanding performance based awards, will be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d3d5c50-a2b9-47f5-9ee3-da40b6aabee0" contextRef="C_268ec649-4cb5-49c6-a775-45044d13d5a1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.9</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. For awards with performance conditions, expense is recognized if the achievement of underlying performance conditions is deemed probable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3cc48fc8-c45e-407c-ade3-6327632d94a4" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of non-vested stock activity for 2023 is presented below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.36%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.88%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nonvested<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f115ee0-141f-4033-93d6-c690bdefff33" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">726,163</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec3ec18e-c9b0-48df-8bf3-71eef7c10060" contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.01</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4ba0cd8-6c7e-4f95-a27b-81e662580964" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,563,324</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f878ad20-40eb-4c95-9c9b-e05161491a7c" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.66</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_beddd8b3-ba23-4adf-b5ad-a3a98b204933" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">804,234</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29fc83ca-d21e-4e53-a6e2-1b0975b7d139" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.15</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba310a90-f6c3-4286-bbbe-fb2e3d8f03be" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">695,750</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69700751-ea88-43c4-8ea4-aadac439e279" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.03</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b62e779c-55a3-4be4-80a6-72c998b8abf3" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">789,503</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f502738-4868-4808-ac81-433ce3b301d4" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.18</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_243354b4-a7ec-4124-8ebc-9bc0defeb78b" contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized share-based compensation expense related to these non-vested shares which will be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2699b8a0-a507-48d8-aebe-0dbceac4496a" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. The total intrinsic value of shares vested during the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab3a55ea-3d7f-4848-9e8a-c72a90ac8de4" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company issues new shares upon option exercises the vesting of non-vested stock and purchases under the ESPP. During the years ended December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99101aae-5517-4ac0-a8bc-dd2524c5c019" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">105,187</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f7d9d1e-d529-419f-a96c-0aa5e6cef5cc" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">258,648</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively, were issued as a result of stock option exercises. During the years ended December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_081d168f-974e-4a67-b671-efb585bf90e5" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">175,196</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e2f597e-b939-4337-9283-5ff763265631" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,595</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively, were issued as a result of the vesting of non-vested stock. During the year ended December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34a2522e-46db-479a-bc9c-54bdf95eecc5" contextRef="C_b6d89eba-0f82-40fd-b984-843734274884" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">39,340</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were issued under the ESPP. Additionally, during the years ended December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c97a4672-e7df-436a-a7a0-ea988c28fda8" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">603,830</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce551908-4bc1-4e1c-9e9e-170da22393bd" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">125,199</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were issued as payment for certain employee bonuses, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff1eef5b-b825-4448-b18c-4cc5533642f2" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">205,879</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa649482-39bf-401c-bbf7-f325d4c2133c" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,665</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of those shares being withheld to cover taxes, resulting in a net share issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd907069-12a5-4d72-a9bd-58d47eb96f91" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="inkt:StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">397,951</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53fbf697-e509-46c3-be1d-adafb8aafdd5" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="inkt:StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">81,534</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock based compensation expense also includes expense related to awards granted to employees of the Company from the Agenus 2019 Equity Incentive Plan. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88110e64-a768-4166-9f92-275b6a95019e" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true" continuedAt="F_88110e64-a768-4166-9f92-275b6a95019e_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The impact on the Company&#8217;s results of operations from share-based compensation for the year ended December 31, 2023 and 2022, was as follows (in thousands): </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_88110e64-a768-4166-9f92-275b6a95019e_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:13%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:13%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aeddaf04-4c84-4066-9a87-f64041fe9171" contextRef="C_5c2d616e-4ddf-4064-8944-7301eb485567" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">541</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffec692a-0b06-4cc4-9267-d5100954c75c" contextRef="C_95392f28-5e39-4fdd-bb55-5bba87d291c1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">435</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c46c0cbb-fd7e-44e2-a31e-b3a0bc8333e4" contextRef="C_346638e3-eec6-429f-b5ff-617610cdae8c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,289</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3677402e-61bd-4ee5-8ba9-f57a4c5a0d45" contextRef="C_cefd892b-5378-4271-adcd-95443a008fca" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,592</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90dac4d6-ea7d-44c5-9c8d-3e10c81c5293" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,830</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59c879d7-bd7c-439c-81d6-8f40e9e01fef" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,027</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04df2868-7aa4-46f2-b545-59a22be5a96d" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(9) Research and Development Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2018, the Company entered into an agreement with the Belgium Walloon Region Government ("Walloon Region") in which the Walloon Region agreed to provide a grant of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8845241-924c-48e7-83c8-c2a3525c797a" contextRef="C_74e50261-4062-42c1-85a6-53221008391a" name="inkt:RepayableAdvanceOfDevelopmentGranted" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and a repayable advance of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a350d64-47a1-4100-9ee8-7247d1c3e5d6" contextRef="C_74e50261-4062-42c1-85a6-53221008391a" name="inkt:RepayableAdvanceOfDevelopment" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the development of one of the Company&#8217;s research programs. During 2020, the Company discontinued research efforts related to this program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other current liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a35cbb6-4d9a-42e2-bae8-72c68a58ffda" contextRef="C_51eb493f-bc2b-4fd9-b5aa-efa55fc34f2c" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7333fb1-cfb4-4ef7-ab59-554697f010dc" contextRef="C_0acbebda-ba84-4b3e-97b5-988e9d80a5aa" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 and December 31, 2022, respectively, represent the remaining amount of the advance received.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2022, the Company received notice that the Walloon Region had obtained a default judgment seeking repayment of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d253712-df60-4a8e-bec9-b848d0efd972" contextRef="C_8cc928c1-4773-48cd-b025-3a741ebaaee1" name="inkt:RepayableAdvanceReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the advance based upon the Company allegedly not providing required notification that research and operations in the region were discontinued. In the year ended December 31, 2022, the Company reduced the recorded liability from the prior total of all amounts received under the advance from the Walloon Region, to the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0179b70d-4c2b-4d38-8dea-c76f27adcae1" contextRef="C_8cc928c1-4773-48cd-b025-3a741ebaaee1" name="inkt:RepayableAdvanceReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million repayment that would be due based on the default judgment, and recorded a gain of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96d59295-a7e1-47b6-ad2b-a951897b6dc4" contextRef="C_e13b52a1-81e9-4212-b833-7812073181d6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in &#8220;other income (expense), net&#8221; on its consolidated statement of operations.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_740c8ef9-8af2-4635-81cd-9aab3c6d9c64" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(10) Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until the completion of its IPO, the Company relied on Agenus for all of its working capital requirements. For the periods presented, certain of the Company&#8217;s operations were fully integrated with Agenus, including, but not limited to, corporate functions such as finance, human resources, information technology and legal functions. The Company&#8217;s consolidated financial statements reflect all costs of doing business related to these operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 2021, the Company entered into an Intellectual Property Assignment and License Agreement with Agenus (the &#8220;New Assignment and License Agreement&#8221;), upon which the prior intercompany agreement between Agenus and MiNK was terminated. Pursuant to the New Assignment and License Agreement, Agenus assigned to the Company certain patent rights and know-how related to its iNKT cell platform, product candidates and other patents and know-how related to its business. In addition to the patent rights assigned to the Company by Agenus, the Company also received an exclusive, royalty-free, sublicensable license to research,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacture and commercialize certain licensed technology in the field. The New Assignment and License Agreement further provides for the Company to grant Agenus a field-limited, non-exclusive, royalty-free license under the assigned patent rights, subject to MiNK&#8217;s discretion and provided such access would not reasonably result in a disruption of planned MiNK activities. Agenus has also agreed to provide the Company with Agenus&#8217; biological material upon written request in order for the Company to use such material in its development activities of a combination therapy. Agenus may withhold the transfer of biological material, including, but not limited to, checkpoint modulating antibodies, for various reasons, including if such transfer would reasonably result in a disruption of planned Agenus activities. For any materials Agenus does share with the Company, the parties have agreed to enter into a separate agreement governing the transfer and providing for joint ownership of the data. Agenus has agreed that during the full term of the New Assignment and License Agreement, and for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b60e1f49-9dc9-413f-978b-a81be9cca043" contextRef="C_88fdd179-67f1-4d6b-afcb-9aa725675bbd" name="inkt:PeriodOfLicenseAgreement" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thereafter, it will not develop, manufacture or commercialize an iNKT cell therapy, directly or indirectly by transferring such technology. The Company has the sole responsibility to develop, manufacture and commercialize products under this New Assignment and License Agreement. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6d1a54f-6c4a-40d1-aaf1-28b24d39b68e" contextRef="C_88fdd179-67f1-4d6b-afcb-9aa725675bbd" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may terminate the New Assignment and License Agreement without cause upon </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a31fb919-9aa4-4dc4-bafe-d4bbff75d991" contextRef="C_88fdd179-67f1-4d6b-afcb-9aa725675bbd" name="inkt:TerminateLicenseAgreementPeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days&#8217; prior written notice to Agenus. Either party may terminate if they believe there has been a material breach which has not been cured within 90 days (or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0094a9f-58ae-47f3-be0c-82e628723eb6" contextRef="C_88fdd179-67f1-4d6b-afcb-9aa725675bbd" name="inkt:PeriodForBreachOfPaymentObligations" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days for breach of payment obligations) of receiving such notice.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective April 1, 2022, the Company entered into an Amended and Restated Intercompany Services Agreement (the &#8220;New Intercompany Agreement&#8221;) with Agenus, which amended and restated the Intercompany General &amp; Administrative Agreement between the Company and Agenus dated September 10, 2021 (the &#8220;Prior Intercompany Agreement&#8221;). Under the New Intercompany Agreement, Agenus provides the Company with certain general and administrative support, including, without limitation, financial, facilities management, human resources and information technology administrative support (the &#8220;Agenus Services&#8221;), and the Company and Agenus provide each other with certain research and development services (the &#8220;R&amp;D Services&#8221;) and other support services, including legal and regulatory support (the &#8220;Shared Services&#8221;). The Company is required to pay </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee5dab80-3f84-4fe1-9d62-e2fe3126d34b" contextRef="C_92993aa5-8d2c-43e1-861d-dafd88c0d11f" name="inkt:PercentageOfServiceCost" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of Agenus&#8217; costs related to the Agenus Services, and the costs of R&amp;D Services are based upon pass-through costs related to such services plus an allocation of the costs of the employees performing the services. No payment will be due from either party for the Shared Services, provided that the services provided by each party are proportional in scope and volume. The Company is also entitled to use Agenus&#8217; business offices and laboratory space and equipment (inclusive of a cGMP site) in exchange for the Company contributing a proportionate payment for the use of such facilities and equipment, and the Company will be covered by certain Agenus insurance policies, subject to certain conditions, including the Company paying the cost of such coverage. Either party may terminate the New Intercompany Agreement upon </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25c6b887-ca72-4f3b-9658-5093061b3281" contextRef="C_92993aa5-8d2c-43e1-861d-dafd88c0d11f" name="inkt:ServiceAgreementNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days&#8217; prior written notice and individual services upon </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_60af964f-49de-4660-b211-987fcab30eb1" contextRef="C_1fff5c2a-d559-4ece-acb2-fc94ed1c220d" name="inkt:ServiceAgreementNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days&#8217; prior written notice.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Allocated Agenus services primarily include payroll related expenses, facility costs, insurance and stock-based compensation, and are included in the accompanying financial statements based on certain estimates and allocations described above. Under the Prior Intercompany Agreement, the allocation methods primarily included time devoted to activities and headcount-based allocations. Agenus business services and occupancy costs were allocated to the Company based on the Company&#8217;s headcount as a percentage of Agenus&#8217; and the Company was required to pay </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9edde705-ba77-4d95-af96-9dfc082b0539" contextRef="C_396bcb04-2fa1-44c0-ba48-210a76d1239a" name="inkt:PercentageOfServiceCost" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">105</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of Agenus&#8217; costs for these business services and occupancy costs. Research services were charged between the entities based on hours recorded by Agenus employees as time spent on specific projects, applied to hourly wage rates, and the Company paid </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fc7f7d2-3827-43fc-bbaa-e54a16bdfdd7" contextRef="C_b633005e-91ea-43eb-97fa-7e4b54c42a57" name="inkt:PercentageOfServiceCost" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">110</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of Agenus&#8217; costs for these research services. As such, these allocations may not be indicative of the actual amounts that would have been recorded had the Company operated as an independent, publicly traded company for the periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Allocation of Agenus Services, net, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2072e3bd-cb72-4e95-b61b-bb9a7a4cf34e" contextRef="C_88fdd179-67f1-4d6b-afcb-9aa725675bbd" name="inkt:IntercompanyAllocationIncludedInExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86dc3a1d-7fed-42db-98f3-471d328f8bad" contextRef="C_732341c7-957d-4682-9e02-69f3f41bc8cb" name="inkt:IntercompanyAllocationIncludedInExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023 and 2022, respectively, is included in Operating expenses in the Company&#8217;s statement of operations and comprehensive loss and Due to related parties, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95296c96-3856-4faf-99e5-d04c2db90891" contextRef="C_174c7e6c-f05b-4cd6-b218-630f2cf7c135" name="inkt:DueToRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023, in the Company&#8217;s consolidated balance sheet. Agenus has agreed to not require repayment of this balance prior to March 31, 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, the Company's CEO (&#8220;Dr. Buell&#8221;), became an employee of Agenus in the role of Chairman of the Executive Council. As an employee of Agenus, Dr. Buell is paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a9e9a84-05a6-44f4-aeff-b947cdc63846" contextRef="C_0247a7d4-1c63-48a2-b771-84ce9fed7ccf" name="us-gaap:SalariesWagesAndOfficersCompensation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">150,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> annually and was granted an option to acquire </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79208c37-63a6-4fc2-a997-76423d1dc234" contextRef="C_6ac170bb-03d4-44e8-b39d-948d34f91995" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">750,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Agenus common stock that vest over a period of four years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective April 12, 2022, the Company entered into a Master Services Agreement with Atlant Clinical Ltd. (&#8220;Atlant&#8221;), a subsidiary of Agenus, to provide clinical trial support services to the Company, including an eTMF platform, medical monitoring and data manager services. The Company&#8217;s Audit and Finance Committee approved the engagement under its related-party transactions policy for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c59e66a-22b9-4f78-a1fd-9a87840be4fc" contextRef="C_70150baa-d209-420b-b3f0-9727e2e8e91b" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in services. As of December 31, 2023, the Company had entered into work orders with Atlant totaling approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46217aaa-fcd8-40fd-8b49-83d8af75b62d" contextRef="C_7f88878f-2cfe-43e5-b0ca-654e225c9a1c" name="inkt:WorkOrderReceivedFromRelatedParty" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">167,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, plus out of pocket expenses which are to pass through to Company at cost. For the years ended December 31, 2023 and 2022, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99ef4ade-d4c4-4033-99c8-474521f97c8e" contextRef="C_12d6f787-9426-4e92-85b0-11024f100689" name="inkt:ClinicalResearchServices" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">30,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0ad08a4-96eb-4870-9426-51054cf221d7" contextRef="C_43fdd5bf-5e30-46cf-b276-ce4dac22ec86" name="inkt:ClinicalResearchServices" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">106,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> related to these services is included in &#8220;Research and development&#8221; expense in the Company&#8217;s consolidated statements of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Buell's spouse is a partner in the law firm of Wolf, Greenfield &amp; Sachs, P.C. (&#8220;Wolf Greenfield&#8221;), which provided legal services to the Company during the years ended December 31, 2023 and 2022, and continues to do so. In the years ended December 31, 2023 and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company expensed Wolf Greenfield fees totaling approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69f5ad00-e0da-4247-85d6-6a22890d2c05" contextRef="C_4ce3db47-5730-4c1e-bcf4-44053fd9ff21" name="us-gaap:LegalFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">225,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ff0146e-423a-4e38-8023-28161e86b680" contextRef="C_30bfebaf-513a-4ffd-92f3-96640e11b431" name="us-gaap:LegalFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">343,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Dr. Buell&#8217;s spouse does not receive direct compensation from the fees paid to Wolf Greenfield by the Company and the fees paid by the Company to Wolf Greenfield in the period was an insignificant amount of Wolf Greenfield&#8217;s revenues. The Company&#8217;s Audit and Finance Committee approved these services under its related-party transactions policy.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_656f80b8-8c34-477b-9e7d-e4f9930f4caa" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:LossContingencyDisclosures" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(11) Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may currently be, or may become, a party to legal proceedings. While the Company currently believes that the ultimate outcome of any of these proceedings will not have a material adverse effect on its financial position, results of operations, or liquidity, litigation is subject to inherent uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_607bd66a-8f55-4c09-960d-9f5a776dae6c" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:DefinedBenefitPlanTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(12) Benefit Plans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s employees are eligible to participate in the Agenus Inc. 401(k) Savings Plan in the United States and a defined contribution Group Personal Pension Plan in the United Kingdom (the &#8220;Plans&#8221;) for all eligible employees, as defined in the Plans. Participants may contribute a portion of their compensation, subject to a maximum annual amount, as established by the applicable taxing authority. Each participant is fully vested in his or her contributions and related earnings and losses. For the years ended December 31, 2023 and 2022, the Company expensed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8645872-ff41-4d3e-bf63-7c9581e99f3f" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">172,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e616447-ecbc-4ebd-8674-582dd055ab7d" contextRef="C_7b863875-076d-407c-9f20-f71f59c308af" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">131,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, related to the discretionary contribution to the Plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f79e023-3282-4e0c-a7e0-2af98a79785c" contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(13) Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Note</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 12, 2024, the Company and Agenus entered into a Convertible Promissory Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) pursuant to which the Company issued to Agenus a Convertible Promissory Note in the principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91061339-6525-479f-be66-ee5633c24a79" contextRef="C_25dc845e-01ae-44d3-831b-9b8aed9e8e67" name="us-gaap:DebtInstrumentIssuedPrincipal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the &#8220;Note&#8221;). The Purchase Agreement sets forth the terms and conditions, including representations and warranties, for the Company&#8217;s issuance and sale of the Note to Agenus.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may draw down on the principal amount of the Note from time to time with Agenus&#8217;s consent in any increment, either in the form of advancements or payments made by Agenus on the Company&#8217;s behalf. The Note carries an annual rate of interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78b27e6e-d0bc-4fe7-8bf2-6c828ac6f20c" contextRef="C_25dc845e-01ae-44d3-831b-9b8aed9e8e67" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% (the &#8220;Interest Rate&#8221;) that accrues from the date funds are paid or advanced by Agenus to the Company. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e7c9e7e-cbd2-4719-8074-0607ce3b3d94" contextRef="C_25dc845e-01ae-44d3-831b-9b8aed9e8e67" name="us-gaap:DebtInstrumentInterestRateTerms"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest shall accrue and not be payable until converted or paid in connection with the repayment in full of the principal amount of the Note. The Note provides that the Company will pay Agenus on demand the principal amount outstanding, together with any unpaid interest, on or after January 1, 2026.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In the event of a qualified financing event, as described in the Note, at Agenus&#8217;s election, the Company must pay the principal amount outstanding and any unpaid interest, either in full or in the form of equity securities. In March 2024 MiNK received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_547ead0f-ad34-421d-88d4-cf5b95495dd6" contextRef="C_e0540306-0080-4f2c-8d4d-23d53f4564e5" name="us-gaap:ConvertibleDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from Agenus and the Note was fully drawn.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nasdaq MVLS Notice</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 23, 2024, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying it that for the previous </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27534214-3a7d-4597-b80f-511edca75fca" contextRef="C_5a5913b2-d4ec-4aae-bf25-d4732ba15bdf" name="inkt:MinimumValueOfListedSecuritiesPeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consecutive trading days the Company&#8217;s Minimum Value of Listed Securities (&#8220;MVLS&#8221;) was less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb76f5a2-dbd3-454f-a179-eb649d7bd83b" contextRef="C_957e80a8-d4b5-459b-8ae0-7824ad63cf97" name="inkt:MinimumValueOfListedSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, as required by Nasdaq Listing Rule 5550(b)(2) (the &#8220;MVLS Rule&#8221;).  Nasdaq has provided the Company with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5bf23cda-25f0-4af0-ab06-e467875fab63" contextRef="C_5a5913b2-d4ec-4aae-bf25-d4732ba15bdf" name="inkt:AdditionalPeriodForMinimumValueOfListedSecurities" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">180</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> calendar days, or until August 21, 2024, to regain compliance. To regain compliance, the Company&#8217;s MVLS must meet or exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a75307ff-d712-4a42-9cc8-478f33e7290e" contextRef="C_ed60fc07-4280-4084-b339-04048dfe71c4" name="inkt:MinimumValueOfListedSecuritiesForTenTradingDays" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for a minimum of ten consecutive trading days.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event the Company does not regain compliance with the MVLS Rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Hearings Panel. The Company will continue to monitor its MVLS and consider its available options to regain compliance with the MVLS Rule. However, there can be no assurance that the Company will be able to regain compliance with the MVLS Rule.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nasdaq Minimum Bid Price Notice</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 26, 2024, the Company received a letter (the &#8220;Minimum Bid Price Notice&#8221;) from Nasdaq notifying the Company that its common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbf74ece-de20-4bfe-9de6-779857e11113" contextRef="C_56e9f88d-c09c-467c-a477-e97ed4507f16" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.00001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value per share (the &#8220;Common Stock&#8221;), failed to comply with the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f6d68d8-ccd8-4396-a0ae-3b57a4c011b5" contextRef="C_637388a5-8881-487e-b1c7-e3b9f34f5c6e" name="inkt:MinimumBidPrice" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Price Rule&#8221;) based upon the closing bid price of the Common Stock for the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37b17795-6295-4eae-82bf-b823488524ea" contextRef="C_637388a5-8881-487e-b1c7-e3b9f34f5c6e" name="inkt:NumberOfConsecutivetradingDays" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consecutive trading days prior to the date of the Minimum Bid Price Notice from Nasdaq.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has been provided an initial compliance period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_954fa9f3-c03a-4d1e-a097-eedc5e60cebc" contextRef="C_637388a5-8881-487e-b1c7-e3b9f34f5c6e" name="inkt:InitialCompliancePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">180</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> calendar days, or until August 26, 2024, to regain compliance with the Minimum Bid Price Rule which requires that the closing bid price of the Common Stock meet or exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4032214-aed1-48eb-9286-36ef8993bc06" contextRef="C_637388a5-8881-487e-b1c7-e3b9f34f5c6e" name="inkt:ClosingBidPriceForTenTradingDays" unitRef="U_USD" scale="0" decimals="2" format="ixt:num-dot-decimal">1.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for a minimum of ten consecutive trading days.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the Company is unable to regain compliance with the Minimum Bid Price Rule, the Company may be eligible for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e93e705-c8df-484c-91e9-5c852c039212" contextRef="C_637388a5-8881-487e-b1c7-e3b9f34f5c6e" name="inkt:AdditionalCompliancePeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">180-day</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Rule, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for the second compliance period or fails to regain compliance during the second </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e098b545-e4aa-4134-8a7a-b0332d0e2fc9" contextRef="C_637388a5-8881-487e-b1c7-e3b9f34f5c6e" name="inkt:SecondCompliancePeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">180-day</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period, Nasdaq will notify the Company of its determination to delist the Common Stock, at which point the Company would have an opportunity to appeal the delisting determination to a Hearings Panel.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will continue to monitor the bid price of the Common Stock and consider its available options to regain compliance with the Minimum Bid Price Rule. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Rule.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9. Changes in and Disagreements With Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act. Based on this evaluation, our Chief Executive Officer and our Principal Financial Officer concluded that our disclosure controls and procedures were functioning effectively as of the end of the period covered by this Annual Report on Form 10-K to provide reasonable assurance that the Company can meet its disclosure obligations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a non-accelerated filer and an emerging growth company, management&#8217;s assessment of internal control over financial reporting was not subject to attestation by our independent registered public accounting firm.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trading Plans of Our Directors and Officers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the quarter ended December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6d43e60-2abc-41d6-98bf-f136d7ce256d" contextRef="C_4ed8c189-5338-453a-9f58-24dd7ab9d275" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_70045169-f010-4eea-adc3-3fad7e9f2d5c" contextRef="C_4ed8c189-5338-453a-9f58-24dd7ab9d275" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_abc358ef-bbdb-4f0c-81df-3a16184fcb87" contextRef="C_4ed8c189-5338-453a-9f58-24dd7ab9d275" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_f9342393-323f-4c82-8943-7abcedeae425" contextRef="C_4ed8c189-5338-453a-9f58-24dd7ab9d275" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">none</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of our directors or executive officers adopted or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each item is defined in Item 408 of Regulation S-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign_jur"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign J</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">urisdictions that Prevent Inspections.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this item is incorporated herein by reference to the Company&#8217;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#8217;s fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this item is incorporated herein by reference to the Company&#8217;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#8217;s fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this item is incorporated herein by reference to the Company&#8217;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#8217;s fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Transactions, and Director Independence.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this item is incorporated herein by reference to the Company&#8217;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#8217;s fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14. Principal Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ting Fees and Services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this item is incorporated herein by reference to the Company&#8217;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#8217;s fiscal year ended December 31, 2023.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ial Statement Schedules.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements are listed under Item 8 of this Annual Report on Form 10-K.</span></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The financial statement schedules required under this Item and Item 8 are omitted because they are not applicable, or the required information is shown in the consolidated financial statements or the footnotes thereto.</span></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits:</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.14%;"/>
    <td style="width:1.68%;"/>
    <td style="width:89.18%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521303045/d134002dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-40908) filed on October 20, 2021).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521303045/d134002dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated By-laws (Incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-40908) filed on October 20, 2021).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521296215/d111280dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Specimen stock certificate evidencing shares of common stock (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-259503), as amended, filed on October 12, 2021).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inkt-ex4_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Convertible Promissory Note by and between the Registrant and Agenus Inc., dated February 12, 2024.</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000156459022011026/inkt-ex42_268.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Securities (Incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 (File No. 001-40908) filed on March 18, 2022).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521271914/d111280dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Intellectual Property Assignment and License Agreement, by and between Agenus Inc. and MiNK Therapeutics, Inc., dated September 10, 2021 (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-259503) filed on September 14, 2021).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000156459022029503/inkt-ex101_191.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Intercompany Services Agreement, by and between Agenus Inc. and MiNK Therapeutics, Inc., dated August 2, 2022 (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (File No. 001-40908) filed on August 15, 2022 ).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521296215/d111280dex106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (Incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-259503), as amended, filed on October 12, 2021).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521296215/d111280dex107.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">MiNK Therapeutics, Inc. 2021 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-259503), as amended, filed on October 12, 2021).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521296215/d111280dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">MiNK Therapeutics, Inc. 2021 Cash Incentive Plan (Incorporated by reference to Exhibit 10.8 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-259503), as amended, filed on October 12, 2021).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521296215/d111280dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Unit Agreement under the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (Incorporated by reference to Exhibit 10.9 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-259503), as amended, filed on October 12, 2021).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521296215/d111280dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Non-Statutory Stock Option Agreement under the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (Incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-259503), as amended, filed on October 12, 2021).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521296215/d111280dex1011.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Incentive Stock Option Agreement under the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (Incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-259503), as amended, filed on October 12, 2021).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521271914/d111280dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">AgenTus Therapeutics, Inc. 2018 Equity Incentive Plan (Incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-259503) filed on September 14, 2021).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521271914/d111280dex1011.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Award Agreement under the AgenTus Therapeutics, Inc. 2018 Equity Incentive Plan (Incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-259503) filed on September 14, 2021).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521271914/d111280dex1012.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Non-Qualified Stock Option Award Agreement for Employees under the AgenTus Therapeutics, Inc. 2018 Equity Incentive Plan (Incorporated by reference to Exhibit 10.12 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-259503) filed on September 14, 2021).</span></a></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.14%;"/>
    <td style="width:1.68%;"/>
    <td style="width:89.18%;"/>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521271914/d111280dex1013.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Non-Qualified Stock Option Award Agreement for Non-Employees under the AgenTus Therapeutics, Inc. 2018 Equity Incentive Plan (Incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-259503) filed on September 14, 2021).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521271914/d111280dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Incentive Stock Option Award Agreement under the AgenTus Therapeutics, Inc. 2018 Equity Incentive Plan (Incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-259503) filed on September 14, 2021).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000119312521296215/d111280dex1020.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement, to be entered into by and between the Registrant and each of its directors and officers (Incorporated by reference to Exhibit 10.20 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-259503), as amended, filed on October 12, 2021).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000156459022011026/inkt-ex1016_207.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Employment Agreement between the Registrant and Jennifer Buell, dated March 3, 2022 (Incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 (File No. 001-40908) filed on March 18, 2022).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16+</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000156459022011026/inkt-ex1017_206.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Employment Agreement between the Registrant and Marc van Dijk, dated March 2, 2022 (Incorporated by reference to Exhibit 10.17 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 (File No. 001-40908) filed on March 18, 2022).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840229/000095017023009762/inkt-ex10_18.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Master Services Agreement between the Registrant and Atlant Clinical Ltd., dated April 12, 2022 (Incorporated by reference to Exhibit 10.18 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022 (File No. 001-40908) filed on March 24, 2023).</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inkt-ex10_18.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Convertible Promissory Note Purchase Agreement by and between the Registrant and Agenus Inc., dated February 12, 2024.</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inkt-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Subsidiaries of MiNK Therapeutics, Inc.</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inkt-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of KPMG LLP, independent registered public accounting firm.</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inkt-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inkt-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inkt-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inkt-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inkt-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Policy for Recoupment of Executive Incentive Compensation in the Event of an Accounting Restatement.</span></a></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ Indicates management contract or compensatory plan.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16. Form</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 10-K Summary</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"/>
    <td style="width:5.04%;"/>
    <td style="width:3.04%;"/>
    <td style="width:46.46%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">MiNK Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 21, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jennifer S. Buell, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jennifer S. Buell, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">President, Chief Executive Officer and Director</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33%;"/>
    <td style="width:1.04%;"/>
    <td style="width:43.3%;"/>
    <td style="width:1.04%;"/>
    <td style="width:21.62%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jennifer S. Buell, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President, Chief Executive Officer and Director</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 21, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jennifer S. Buell, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Christine M. Klaskin</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Treasurer (Principal Financial Officer and Principal</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 21, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Christine M. Klaskin</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounting Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Garo H. Armen, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairman of the Board of Directors</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 21, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Garo H. Armen, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Peter Behner</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 21, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Peter Behner</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Brian Corvese</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 21, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Brian Corvese</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Barbara Ryan</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 21, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Barbara Ryan</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ulf Wiinberg</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 21, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ulf Wiinberg</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>inkt-ex4_2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<html>
 <head>
  <title>EX-4.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 4.2</font></p></div>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.796%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">THIS NOTE, AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ACT</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), OR THE APPLICABLE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE PLEDGED, SOLD, ASSIGNED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION UNDER SUCH LAWS OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL, IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, TO THE EFFECT THAT SUCH PLEDGE, SALE, ASSIGNMENT OR TRANSFER IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ALL APPLICABLE STATE SECURITIES LAWS.</font></p>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.2%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">MiNK THERAPEUTICS, INC.</font></p>
  <p style="margin-left:0.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Convertible Promissory Note</font></p>
  <p style="margin-left:0.187%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">UP TO $5,000,000                                                                                                 February 12, 2024</font></p>
  <p style="margin-left:2.04%;text-indent:6.919%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.796%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For value received, MiNK Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), hereby promises to pay to the order of Agenus Inc. (hereinafter together with its successors in title and assigns referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Holder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), on demand by the Holder on or after January 1, 2026 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Maturity Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the principal amount outstanding under this note, together with interest thereon as set forth below (such aggregate amount, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amount Due</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), unless earlier repaid or converted pursuant to the terms and conditions set forth below. The principal amount of this Note is for up to FIVE MILLION DOLLARS ($5,000,000), which may be drawn down from time to time with the Holder&#x2019;s consent and in any increment, either in the form of advancements or payments made by the Holder on the Company&#x2019;s behalf. Interest shall accrue from the date funds are paid or advanced.</font></p>
  <p style="margin-left:2.04%;text-indent:6.917%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.769%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Convertible Promissory Note (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Note</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is being issued by the Company pursuant to that certain Convertible Promissory Note Purchase Agreement, dated as of the date hereof, by and among the Company and the Holder (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Purchase Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Purchase Agreement.</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 4.2</font></p></div>
  <div style="margin-left:2%;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.5846938775510204%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="x__interest"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Intere</font><font id="x_this_note_shall_bear_simple_interest_a"></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Note shall bear simple interest at an annual rate of two percent (2%). Interest shall be computed on the basis of a 360-day year for the actual number of days elapsed but in no event shall the rate of interest exceed the maximum rate, if any, allowable under applicable law. Interest shall accrue and not be payable until converted as provided in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> hereof or paid in connection with repayment in full of the principal amount of this Note.</font></div></div>
  <div style="margin-left:2%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6.803061224489796%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="x__amount_due_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amount Due</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;" id="x_1_payments"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Payment of principal and interest shall be made in immediately available funds in lawful currency of the United States of America, unless the Parties agree in writing prior to or at the time of payments to allow payment in the form of equity. Payments are to be made at the offices of the Holder or at such other place as the Holder hereof shall have designated to the Company in writing. Payment shall be credited first to any costs, expenses or charges then payable to the Holder, then to accrued interest then due and payable, and then to principal.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.2</font><div style="width:100%;display:inline;" id="x_2_prepayment"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Prepayment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Note may be prepaid without the written consent of the Holder, with no prepayment penalty.</font></div></div>
  <div style="margin-left:2%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6.803061224489796%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="x__conversion_of_the_notes"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Conversion of the N</font><font id="x"></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">otes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:8.667%;display:flex;margin-top:0.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;min-width:0.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.551115150055293%;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;" id="x_1_definitions"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Note shall be convertible according to the following terms: &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to any specified Person, any other Person who or which,</font></div></div>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.787%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">directly or indirectly, controls, or is controlled by, or is under common control with such specified Person. For purposes of this definition, &#x201c;control,&#x201d; &#x201c;controlled by&#x201d; and &#x201c;under common control with&#x201d; means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</font></p>
  <p style="margin-left:2.04%;text-indent:6.921%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.833%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the merger or consolidation of the Company into or with another Company (other than a wholly-owned subsidiary of the Company in a merger in which the Company is the surviving Company and the Certificate of Incorporation remains unchanged), the sale, lease, exclusive license, transfer or other disposition of all or substantially all of the assets or intellectual property of the Company (other than to a wholly-owned subsidiary of the Company), a transfer of more than fifty percent (50%) of the voting power of the Company, in a single transaction or series of related transactions and the closing of the initial public offering of the Company&#x2019;s Common Stock; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, that a Qualified Financing or other equity financing shall not constitute a &#x201c;Change of Control&#x201d;.</font></p>
  <p style="margin-left:2.04%;text-indent:7.505%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.843%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Equity Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Common Stock or Preferred Stock issued upon conversion of the Note under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="margin-left:2.04%;text-indent:6.921%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.833%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Qualified Financing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the first bona fide sale (or series of related sales) by the Company of its Equity Securities after the date of the Purchase Agreement resulting in aggregate proceeds to the Company (excluding the Note) of at least fifty million dollars ($50,000,000).</font></p>
  <p style="margin-left:2.04%;text-indent:6.926%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.898%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any individual, corporation, partnership, trust, limited liability company, association or other entity.</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 4.2</font></p></div>
  <p style="margin-left:2.04%;text-indent:7.505%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.843%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Preferred Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the preferred stock, par value $0.00001 per share, of the Company (or any similar equity security to be issued in connection with the Qualified Financing) to be authorized immediately prior to the closing of the Qualified Financing.</font></p>
  <div style="margin-left:2%;text-indent:6.925%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.2</font><div style="width:100%;display:inline;" id="x_2_financing_payment_conversion"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Financing Payment/Conversion</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Upon a Qualified Financing, the outstanding Note and all accrued and unpaid interest thereon shall, at the Holder&#x2019;s election, either be paid in full or converted into shares of the Equity Securities issued in the Qualified Financing. The number of shares of Equity Securities to be issued upon such conversion shall be equal to the quotient obtained by dividing (i) the Amount Due on the date of conversion by (ii) eighty percent (80%) of the per share price of the Equity Securities sold in the Qualified Financing. The Holder hereby agrees, as a condition to such conversion, to execute and become party to all agreements that the Company reasonably requests in connection with such Qualified Financing.  In the event that there is a material change in the financial position of the Company, such material change commensurate in financial scope to a Qualified Financing, at the request of the Holder, the parties shall discuss and consider in good faith an early payment of the outstanding Note and all accrued and unpaid interest thereon. </font></div></div>
  <div style="margin-left:2%;text-indent:6.925%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.3</font><div style="width:100%;display:inline;" id="x_3_change_of_control"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. In the event of a Change of Control of the Company, at the closing of such Change of Control, in full satisfaction of the Company&#x2019;s obligations under this Note, the Company will pay the Holder an amount equal to (x) one and a half (1.5) times the principal then outstanding under this Note and (y) the amount of accrued interest then outstanding under this Note immediately prior to the closing of such Change of Control.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.4</font><div style="width:100%;display:inline;" id="x_4_fractional_shares"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Fractional Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. No fractional shares of any of the Company&#x2019;s Equity Securities will be issued in connection with any conversion of this Note.</font></div></div>
  <div style="margin-left:2%;text-indent:6.925%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.5</font><div style="width:100%;display:inline;" id="x_5_certificate"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. As promptly as practicable after the conversion of this Note, the Company at its expense will issue and deliver to the Holder, upon surrender of the Note, a certificate or certificates for the number of full shares of Equity Securities issuable upon such conversion.</font></div></div>
  <div style="margin-left:2%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.5846938775510204%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;" id="x__demand__default"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Demand; Defa</font><font id="x_this_note_shall_automatically_become_i"></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ult</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Note shall automatically become immediately due and payable, without any notice or demand required by the Holder, upon the occurrence of any of the following events of default (individually, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Event of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Events of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;):</font></div></div>
  <div style="margin-left:8.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.2996616775973635%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__the_liquidation__dissolution_or_inso"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the liquidation, dissolution or insolvency of the Company, or the appointment of a receiver or custodian for the Company of all or substantially all of its property, if such appointment is not terminated or dismissed within thirty (30) days; or</font></div></div>
  <div style="margin-left:8.667%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.2996616775973635%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__the_institution_by_or_against_the_co"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the institution by or against the Company of any proceedings under the United States Bankruptcy Code or any other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generall</font><font id="xc___"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">y.</font></div></div>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.889%;text-align:justify;" id="upon_the_occurrence_of_an_event_of_defau"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upon the occurrence of an Event of Default, the Holder shall have then, or at any time thereafter, all of the rights and remedies afforded by the Uniform Commercial Code as from time to time in effect in the Commonwealth of Massachusetts or afforded by other applicable law.</font></p>
  <div style="margin-left:2%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.5846938775510204%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;" id="x__no_set_off"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Set-Of</font><font id="x_all_payments_by_the_company_under_this"></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">f</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. All payments by the Company under this Note shall be made without set-off or counterclaim and be without any deduction or withholding for any taxes or fees of any nature,</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 4.2</font></p></div>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">unless the obligation to make such deduction or withholding is imposed by law.</font></p>
  <div style="margin-left:2%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6.803061224489796%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;" id="x__general"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">General.</font></div></div>
  <div style="margin-left:8.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.2996616775973635%;display:inline-flex;justify-content:flex-start;">6.1</font><div style="width:100%;display:inline;" id="x_1_transfers__successors_and_assigns"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Transfers; Successors and Assigns.</font></div></div>
  <div style="margin-left:2%;text-indent:13.87%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.857142857142857%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__this_note__and_the_obligations_and_r"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Note, and the obligations and rights of the parties hereunder, shall be binding upon and inure to the benefit of the Company, the holder of this Note, and their respective heirs, successors and assigns; provided, however, that the Company may not transfer or assign its obligations hereunder, by operation of law or otherwise, without the consent of the Holder.</font></div></div>
  <div style="margin-left:2%;text-indent:13.85%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.857142857142857%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="xii__notwithstanding_anything_else_in_th"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything else in this Note to the contrary, the right of any Holder (or transferee) to receive principal or interest payments under this Note may be transferred only through the surrender of the current Note and reissuance of a new note by the Company pursuant to the provisions of this paragraph. The foregoing language is intended to cause the Note to be in &#x201c;registered form&#x201d; as defined in Treasury Regulations Sections 5f.103-1(c) and 1.871-14(c) and shall be interpreted and applied consistently therewith.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2</font><div style="width:100%;display:inline;" id="x_2_no_rights_or_liabilities_as_stockhol"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Rights or Liabilities as Stockholder; No Personal Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Note does not by itself entitle the Holder to any voting rights or other rights as a stockholder of the Company. In the absence of conversion of this Note, no provisions of this Note, and no enumeration herein of the rights or privileges of the Holder, shall cause the Holder to be a stockholder of the Company for any purpose. Holder agrees that no stockholder, director or officer of the Company shall have any personal liability for the repayment of this Note.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.3</font><div style="width:100%;display:inline;" id="x_3_amendment"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Note may be amended or modified, or compliance with any term, covenant, agreement, condition or provision set forth herein may be omitted or waived, either generally or in a particular instance and either retroactively or prospectively, upon written consent of the Company and the Holder.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.4</font><div style="width:100%;display:inline;" id="x_4_notices"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient&#x2019;s next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their address as set forth in the Purchase Agreement, or to such e-mail address, facsimile number or address as subsequently modified by written notice given in accordance with this Section 6.4.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.5</font><div style="width:100%;display:inline;" id="x_5_severability"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severability. If one or more provisions of this Note are held to be unenforceable under applicable law, such provision shall be excluded from this Note and the balance of the Note shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.6</font><div style="width:100%;display:inline;" id="x_6_governing_law"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Note and the obligations of the Company hereunder shall be governed by and interpreted and determined in accordance with, the laws of the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by, and construed in accordance with, the internal laws of the Commonwealth of Massachusetts (excluding the laws and rules of law applicable to conflicts or choice of law).</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 4.2</font></p></div>
  <p style="margin-left:0.2%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.2%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Signature on following page]</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 4.2</font></p></div>
  <p style="margin-left:1.107%;text-indent:6.867%;font-size:10pt;margin-top:13pt;font-family:Times New Roman;margin-bottom:0;margin-right:2%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, this Note has been duly executed on behalf of the undersigned on the day and in the year first written above.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">COMPANY</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">:</font></p>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">MiNK THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.04%;text-indent:-7.146%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:47.981%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">/s/ Jennifer Buell	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:2.04%;text-indent:-7.146%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:47.981%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Name: Jennifer Buell</font></p>
  <p style="margin-left:5.373%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Title: President &amp; CEO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">HOLDER</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">:</font></p>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">AGENUS INC.</font></p>
  <p style="font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.04%;text-indent:-7.146%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:47.981%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">/s/ Garo Armen	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:2.04%;text-indent:-7.146%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:47.981%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Name: Garo Armen</font></p>
  <p style="margin-left:5.373%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Title: Chairman &amp; CEO<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:5.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:30.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[Signature Page to Convertible Promissory Note]</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>3
<FILENAME>inkt-ex10_18.htm
<DESCRIPTION>EX-10.18
<TEXT>
<html>
 <head>
  <title>EX-10.18</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.18</font></p></div>
  <p style="margin-left:0.16%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT</font></p>
  <p style="margin-left:8.707%;font-size:10pt;margin-top:11.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">THIS  CONVERTIBLE  PROMISSORY  NOTE  PURCHASE  AGREEMENT  (this</font></p>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.815%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is made as of February 12, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) by and between MiNK Therapeutics, Inc., a Delaware corporation with offices at 149 Fifth Avenue, New York, NY 10010 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and Agenus Inc., a Delaware corporation with offices at 3 Forbes Road, Lexington, MA 02421 and the parent company of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Purchaser</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="margin-left:2.04%;text-indent:6.92%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.815%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, the parties wish to enter into this Convertible Promissory Note Purchase Agreement (the &#x201c;2024 Note Purchase Agreement&#x201d;) pursuant to which the Company will issue and sell to the Purchaser a new convertible promissory note for up to a total of $5,000,000, all on substantially the same terms as prior promissory notes between the Parties.</font></p>
  <p style="margin-left:2.04%;text-indent:6.921%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.833%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, the parties hereby agree as follows:</font></p>
  <p style="margin-left:0.227%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="article_i__purchase__sale_and_terms_of_n"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE I</font></p>
  <p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PURCHASE, SALE AND TERMS OF NOTE</font></p>
  <div style="margin-left:2%;text-indent:6.925%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="x__cancelation_of_third_note__sale_and_i"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sale and Issuance of Note</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Subject to the terms and conditions of this Agreement, at the Closing (as defined below), the Company hereby agrees to issue and sell to the Purchaser, and, subject to and in reliance upon the representations, warranties, covenants, terms and conditions of this Agreement, the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Purchaser agrees to purchase from the Company, a convertible promissory note in the principal amount of up to  FIVE MILLION DOLLARS ($5,000,000) and in the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Note</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and together with any other Note issued pursuant to this Agreement, and with any exchange or replacement thereof, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Note shall work like a line of credit, whereby the Company may draw down amounts from time to time with the Purchaser&#x2019;s consent, and the Note will include a schedule that is updated from time to time to reflect all amounts advanced to the Company or paid on the Company&#x2019;s behalf, along with the date of all such advancements or payments so that the parties can appropriately keep track of all interest accruals. The Company shall use the proceeds from the issuance and sale of the Notes for working capital and other general corporate purposes.</font></div></div>
  <div style="margin-left:2%;text-indent:6.954%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="x__closing__delivery"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Closing; Delivery</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The purchase and sale of the Note shall take place at a closing (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Closing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) at such place and such time as the Company and the Purchaser shall agree. At the Closing, the Company shall issue and deliver to the Purchaser a Note, and the Purchaser shall pay the Company any additional principal amounts being drawn or advanced under the Note by wire transfer of immediately available funds in accordance with the instructions of the Company, by check, or by cancellation or conversion of indebtedness of the Company to Purchaser, or by any combination of such methods.</font></div></div>
  <div style="margin-left:2%;text-indent:7.022%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="x__no_usury"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Usury</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement and the Note issued pursuant to the terms of this Agreement are hereby expressly limited so that in no event whatsoever, whether by reason of deferment or advancement of loan proceeds, acceleration of maturity of the loan evidenced hereby, or otherwise, shall the amount paid or agreed to be paid to the Purchaser hereunder for the loan, use, forbearance or detention of money exceed the maximum interest rate permitted by the laws of the Commonwealth of Massachusetts. If at any time the performance of any provision hereof or the Note involves a payment exceeding the limit of the price that may be validly charged for the loan, use, forbearance or detention of money under applicable law, then automatically and retroactively, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ipso facto</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the agreed upon interest rate as set forth in the Note shall be reduced to such limit, it being the specific intent of the Company and the Purchaser that all payments under this Agreement or the Note are to be credited first to interest as permitted by law, but not in excess of (a) the agreed rate of interest set forth in the Note, or (b) that permitted by law, whichever is the lesser, and the balance toward the reduction of principal. The provisions of this paragraph </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.18</font></p></div>
  <div style="margin-left:2%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.065%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">shall never be superseded or waived and shall control every other provision of this Agreement and the Note.</font></div></div>
  <p style="margin-left:0.2%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="article_ii__representations_and_warranti"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE II</font></p>
  <p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</font></p>
  <p style="margin-left:2.04%;text-indent:10.387%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.815%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company represents and warrants to the Purchaser that the representations and warranties are true and correct as of the date hereof and as of the Closing, except as otherwise indicated:</font></p>
  <div style="margin-left:2%;text-indent:6.993%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.667%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="x__organization__good_standing__corporat"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Organization, Good Standing, Corporate Power and Qualification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as</font></div></div>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">presently conducted and as proposed to be conducted and to carry out the transactions contemplated by this Agreement. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a material adverse effect on the business or assets of the Company.</font></p>
  <div style="margin-left:2%;text-indent:6.925%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="x__capitalization"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Capitalization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. As of the date hereof, the Company has a total authorized capitalization consisting of 150,000,000 shares of Common Stock, par value $0.00001 per share (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), of which 34,599,047 shares are issued and outstanding. All the outstanding shares of capital stock of the Company have been duly authorized, are validly issued and are fully paid and non-assessable.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="x__subsidiaries"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subsidiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Except for its wholly-owned subsidiary in the United Kingdom,  the Company does not currently own or control, directly or indirectly, any interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity. The Company is not a participant in any joint venture, partnership or similar arrangement.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;" id="x__authorization"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. All corporate action required to be taken by the board of directors, officers, and stockholders of the Company for the execution and delivery of the Agreement and the Note, the performance of all obligations of the Company under the Agreement to be performed as of the Closing, and the issuance and delivery of the Note has been taken or will be taken prior to the Closing. The Agreement and the Note, when executed and delivered by the Company, shall constitute valid and legally binding obligations of the Company, enforceable against the Company in accordance with their respective terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors&#x2019; rights generally or (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.</font></div></div>
  <div style="margin-left:2%;text-indent:7.042%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;" id="x__validity"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Validity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement has been duly executed and delivered by the Company and constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms. The Note, when executed and delivered in accordance with this Agreement, will constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with its terms.</font></div></div>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.343%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;" id="x__governmental_approvals"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governmental Approvals</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Subject to the accuracy of the representations and warranties of the Purchaser set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE III</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, no registration or filing with, or consent or approval of or other action by, any federal, state or other governmental agency or instrumentality </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.18</font></p></div>
  <div style="margin-left:2%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">is or will be necessary for the valid execution, delivery and performance by the Company of this Agreement or the issuance, sale and delivery of the Notes, other than filings pursuant to Regulation D of the Securities Act of 1933, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and state securities laws (all of which filings have been or will be made by the Company) in connection with the sale of the Note, if any.</font></div></div>
  <p style="margin-left:0.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="article_iii__representations_and_warrant"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE III</font></p>
  <p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">REPRESENTATIONS AND WARRANTIES OF THE PURCHASER</font></p>
  <p style="font-size:10pt;margin-top:6.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.413%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">At the Closing, the Purchaser represents and warrants to the Company that:</font></p>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="x__authority"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Purchaser has full power and authority to enter into and perform this Agreement in accordance with its terms. This Agreement has been duly executed and delivered by the Purchaser and constitutes the legal, valid and binding obligation of the Purchaser, enforceable in accordance with its terms.</font></div></div>
  <div style="margin-left:2%;text-indent:7.153%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:4.796%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="x__purchase_for_investment"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Purchase for Investment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Purchaser is acquiring the Note purchasable by it hereunder and the shares of capital stock of the Company issuable upon conversion thereof</font></div></div>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) for its own account, for investment and not for, with a view to, or in connection with, any distribution or public offering thereof within the meaning of the Securities Act.</font></p>
  <div style="margin-left:2%;text-indent:6.964%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="x__unregistered_securities__legend"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unregistered Securities; Legend</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Purchaser understands that the Securities have not been, and will not be, registered under the Securities Act or any state securities law, by reason of their issuance in a transaction exempt from the registration requirements of the Securities Act and such laws, that the Securities must be held indefinitely unless they are subsequently registered under the Securities Act and such laws or a subsequent disposition thereof is exempt from registration, that the Securities shall bear a legend to such effect, and that appropriate transfer instructions may be issued. The Purchaser further understands that such exemption depends upon, among other things, the bona fide nature of the Purchaser&#x2019;s investment intent expressed herein.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;" id="x__status_of_the_purchaser"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Status of the Purchaser</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Purchaser has not been formed for the specific purpose of acquiring the Securities pursuant to this Agreement.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;" id="x__accredited_investor"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Accredited Investor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Purchaser understands the term &#x201c;accredited investor&#x201d; as used in Regulation D promulgated under the Securities Act and represents and warrants to the Company that the Purchaser is an &#x201c;accredited investor&#x201d; for purposes of acquiring the Securities being acquired by it hereunder.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;" id="x__knowledge_and_experience__economic_ri"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Knowledge and Experience; Economic Risk</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Purchaser has sufficient knowledge and experience in business and financial matters and with respect to investment in securities of privately held companies similar to the Company in terms of the Company&#x2019;s stage of development so as to enable it to analyze and evaluate the merits and risks of the investment contemplated hereby and is capable of protecting its interest in connection with this transaction. The Purchaser is able to bear the economic risk of such investment, including a complete loss of the investment.</font></div></div>
  <div style="margin-left:2%;text-indent:6.925%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;" id="x__access_to_information"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Access to Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Purchaser acknowledges that the Purchaser and its representatives have made an investigation of the Company and its business as it deemed necessary and had the opportunity to ask questions and receive answers from officers and representatives of the Company concerning the transactions contemplated by this Agreement and obtain any additional information that is necessary to verify the accuracy of the information regarding the </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.18</font></p></div>
  <div style="margin-left:2%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company or otherwise desired in connection with its purchase of the Securities being acquired by it hereunder.</font></div></div>
  <p style="font-size:10pt;margin-top:8.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;" id="x__rule_144"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rule 144</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Purchaser understands that the exemption from registration afforded by Rule 144 (the provisions of which are known to Purchaser) promulgated by the Securities and Exchange Commission under the Securities Act depends upon the satisfaction of various conditions and that such exemption is not currently available.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;" id="x__no_general_solicitation"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No General Solicitation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including through a broker or finder (a) engaged in any general solicitation or (b) published any advertisements in connection with the offer and sale of the Note.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;" id="x0__bad_actor"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Bad Actor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Purchaser represents that neither it nor any of its Rule 506(d) Related Parties is a &#x201c;bad actor&#x201d; within the meaning of Rule 506(d) promulgated under the Securities Act. For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rule 506(d) Related Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean a &#x201c;beneficial owner&#x201d; of the Purchaser&#x2019;s voting securities of the Company as provided under Rule 13d-3 under the Securities Exchange Act of 1934, of as amended.</font></div></div>
  <p style="margin-left:36.107%;text-indent:-0.048%;padding-left:0.013%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:35.926%;text-align:center;" id="article_iv__miscellaneous"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE IV MISCELLANEOUS</font></p>
  <div style="margin-left:2%;text-indent:7.013%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.935%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="x__no_waiver__cumulative_remedies"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Waiver; Cumulative Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. No failure or delay on the part of any party to this Agreement in exercising any right, power or remedy hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The remedies herein provided are cumulative and not exclusive of any remedies provided by law.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="x__amendments__waivers_and_consents"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendments, Waivers and Consents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Any provision in this Agreement to the contrary notwithstanding, changes in or additions to this Agreement or the Note may be made, and compliance with any covenant or provision herein or therein set forth may be omitted or waived, if the Company obtains consent thereto in writing from the Purchaser.</font></div></div>
  <div style="margin-left:2%;text-indent:6.925%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="x__addresses_for_notices__etc_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Addresses for Notices, etc.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be conclusively deemed effectively given upon the earlier of actual receipt or: (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient&#x2019;s next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their address as set forth in the first paragraph above, or to such e-mail address, facsimile number or address as subsequently modified by written notice given in accordance with this Section ARTICLE IV.</font></div></div>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.796%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;" id="x__binding_effect__assignment"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Binding Effect; Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Purchaser may assign its rights and obligations hereunder to an affiliate of such Purchaser. Such assignee shall be deemed a &#x201c;Purchaser&#x201d; for purposes of this Agreement; provided that such assignment of rights shall be contingent upon the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">assignor and assignee providing a written instrument to the Company notifying the Company of such </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.18</font></p></div>
  <div style="margin-left:2%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">assignment and the assignor agreeing in writing to be bound by the terms of this Agreement. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;" id="x__survival_of_representations_and_warra"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Survival of Representations and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. All representations and warranties made in this Agreement, the Note or any other instrument or document delivered in connection herewith or therewith, shall survive the execution and delivery hereof or thereof.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;" id="x__entire_agreement"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement, collectively with all exhibits hereto, the Note, the Third Note, the Second Note, the First Note, the Third Note Purchase Agreement, the Second Note Purchase Agreement and the First Note Purchase Agreement, constitutes the entire agreement between the parties with respect to the subject matter contained herein and supersedes any other prior negotiations, correspondence, duties, obligations, understandings or agreements concerning the subject matter hereof.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;" id="x__severability"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;" id="x__governing_law"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement and the obligations of the Company hereunder shall be governed by and interpreted and determined in accordance with, the laws of the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by, and construed in accordance with, the internal laws of the Commonwealth of Massachusetts (excluding the laws and rules of law applicable to conflicts or choice of law).</font></div></div>
  <div style="margin-left:2%;text-indent:6.925%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;" id="x__counterparts"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement may be executed in counterparts, which taken together shall constitute one and the same instrument, and either of the parties hereto may execute this Agreement by signing such counterpart. This Agreement may be executed and delivered by facsimile, or by e-mail in portable document format (.pdf) and delivery of the signature page by such method will be deemed to have the same effect as if the original signature had been delivered to the other parties.</font></div></div>
  <div style="margin-left:2%;text-indent:6.935%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.033673469387755%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;" id="x0__further_assurances"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Further Assurances</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. From and after the date of this Agreement, upon the request of the Purchaser or the Company, the Company and the Purchaser shall execute and deliver such instruments, documents or other writings as may be reasonably necessary or desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.843%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.133%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:8.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.18</font></p></div>
  <p style="margin-left:2.04%;text-indent:6.792%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have executed this Convertible Promissory Note Purchase Agreement as of the Effective Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">COMPANY</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">:</font></p>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">MiNK THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.04%;text-indent:-7.146%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:47.981%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">/s/ Jennifer Buell	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:2.04%;text-indent:-7.146%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:47.981%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Name: Jennifer Buell</font></p>
  <p style="margin-left:5.373%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Title: President &amp; CEO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PURCHASER</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">:</font></p>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">AGENUS INC.</font></p>
  <p style="font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.04%;text-indent:-7.146%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:47.981%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">/s/ Garo Armen	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:2.04%;text-indent:-7.146%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:47.981%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Name: Garo Armen</font></p>
  <p style="margin-left:5.373%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Title: Chairman &amp; CEO<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.18</font></p></div>
  <p style="margin-left:5.373%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:39.013%;text-indent:0.18%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:38.815%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A Form of Note</font></p>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.796%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[See Attached]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>inkt-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 21.1</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">List of Subsidiaries of MiNK Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.96%;"></td>
    <td style="width:1.06%;"></td>
    <td style="width:47.98%;"></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of Subsidiary</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </font></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jurisdiction of Organization</font></p></td>
   </tr>
   <tr style="height:9.35pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">AgenTus Therapeutics Limited</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </font></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">England and Wales</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">AgenTus Therapeutics SA</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </font></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Belgium</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>inkt-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1.13in;"><p style="font-size:10pt;margin-top:36pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit 23.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We consent to the incorporation by reference in the registration statement (No. 333-268143) on Form S-3 and registration statements (Nos. 333-266170 and 333-273906) on Form S-8 of our report dated March 21, 2024, with respect to the consolidated financial statements of MiNK Therapeutics, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">/s/ KPMG LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Boston, Massachusetts</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">March 21, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>inkt-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Jennifer S. Buell, certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of MiNK Therapeutics, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.38%;"></td>
    <td style="width:4%;"></td>
    <td style="width:4.22%;"></td>
    <td style="width:46.4%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 21, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jennifer S. Buell, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jennifer S. Buell, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">President, Chief Executive Officer and Principal Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>inkt-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Christine M. Klaskin, certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of MiNK Therapeutics, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"></td>
    <td style="width:4%;"></td>
    <td style="width:4.08%;"></td>
    <td style="width:46.46%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 21, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Christine M. Klaskin</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Christine M. Klaskin</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Treasurer and Principal Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>inkt-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of MiNK Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"></td>
    <td style="width:4%;"></td>
    <td style="width:4.08%;"></td>
    <td style="width:46.46%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 21, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jennifer S. Buell, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jennifer S. Buell, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">President, Chief Executive Officer and Principal Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>inkt-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of MiNK Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"></td>
    <td style="width:4%;"></td>
    <td style="width:4.08%;"></td>
    <td style="width:46.46%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 21, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Christine M. Klaskin</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Christine M. Klaskin</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Treasurer and Principal Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>10
<FILENAME>inkt-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1.04in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.083%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">MINK THERAPEUTICS, INC.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.493%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:1.827%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">POLICY FOR RECOUPMENT OF EXECUTIVE INCENTIVE COMPENSATION IN</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.093%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">THE EVENT OF ACCOUNTING RESTATEMENT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.493%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.443324104301831%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Introduction</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.05pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of MiNK Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has adopted this policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) providing for the Company&#x2019;s recoupment of certain incentive-based compensation received by Covered Executives (as defined below) in the event that the Company is required to prepare an accounting restatement due to material errors or noncompliance with any financial reporting requirement under the securities laws.  This Policy shall not be interpreted to limit the Company&#x2019;s ability to recoup compensation under other policies and equity plans.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.443324104301831%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administration</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.05pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administration and enforcement of this Policy is delegated to the Compensation Committee of the Board (as constituted from time to time, and including any successor committee, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Committee shall make all determinations under this Policy in its sole discretion. Determinations of the Committee under this Policy need not be uniform with respect to any or all Covered Executives and will be final and binding.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.443324104301831%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.05pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be effective as of June 14, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and shall apply only to Covered Compensation (as defined below) that is received by Covered Executives (including equity compensation that has a later vesting date but has been awarded) on or after the Effective Date, except as otherwise agreed to by any Covered Executive.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.443324104301831%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Covered Executives</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.05pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy covers each current or former officer of the Company subject to Section 16 of the Securities Exchange Act of 1934, as amended (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Covered Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.443324104301831%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Covered Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24.35pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy applies to any cash-based and equity-based incentive compensation, bonuses, and awards that are received by a Covered Executive and that were based, wholly or in part, upon the attainment of any financial reporting measure (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Covered Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). For the avoidance of doubt, none of the following shall be deemed to be Covered Compensation: base salary, a bonus that is paid solely at the discretion of the Committee or Board and not paid from a bonus pool determined by satisfying a financial reporting measure performance goal, and cash or equity-based awards that are earned solely upon satisfaction of one or more subjective, operational or strategic</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.04in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24.35pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">standards. This Policy shall apply to any Covered Compensation received by an employee who served as a Covered Executive at any time during the performance period for that Covered Compensation.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.443324104301831%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Financial Restatements; Recoupment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.05pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event that the Company is required to prepare an accounting restatement due to the material error or noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (such an accounting restatement, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the Committee shall review the Covered Compensation received by a Covered Executive during the three-year period preceding the Required Financial Restatement Date (as defined below) as well as any transition period that results from a change in the Company&#x2019;s fiscal year within or immediately following those three completed fiscal years. Regardless of whether the Company filed the restated financial statements, the Committee shall, to the full extent permitted by governing law, seek recoupment of any Covered Compensation, whether in the form of cash or equity, received by a Covered Executive (computed without regard to any taxes paid), if and to the extent:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0.05pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the amount of the Covered Compensation was calculated based upon the achievement of certain financial results that were subsequently the subject of a Restatement; and </font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0.05pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the amount of the Covered Compensation that would have been received by the Covered Executive had the financial results been properly reported would have been lower than the amount actually awarded (any such amount, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Erroneously-Awarded</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).   </font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.05pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To the extent Covered Compensation was based on the achievement of a financial reporting measure, but the amount of such Covered Compensation was not awarded or paid on a formulaic basis, the Committee shall determine the amount, if any, of such Covered Compensation that is deemed to be Erroneously-Awarded Compensation. The Company must maintain documentation of the basis of the determination of that reasonable estimate and provide such documentation to the listing exchange.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.05pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Policy, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Required Financial Restatement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; is the earlier to occur of:   	</font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.05pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0.05pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the date the Board, a committee of the Board, or any officer or officers authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare a Restatement; or  </font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.04in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0.05pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the date a court, regulator, or other legally authorized body directs the Company to prepare a Restatement. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.05pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For the avoidance of doubt, a Covered Executive will be deemed to have received Covered Compensation in the Company&#x2019;s fiscal period during which the financial reporting measure specified in the award is attained, even if the Covered Executive remains subject to additional payment conditions with respect to such award.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.443324104301831%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Method of Recoupment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.05pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Committee will determine, in its sole discretion, the method for recouping Erroneously-Awarded Compensation, which may include, without limitation:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0.05pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">requiring reimbursement of cash incentive compensation previously paid; </font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0.05pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">cancelling or rescinding some or all outstanding vested or unvested equity (and/or equity-based) awards;  </font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0.05pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">adjusting or withholding from unpaid compensation or other set-off to the extent permitted by applicable law; and/or </font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0.05pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">reducing or eliminating future salary increases, cash-based or equity-based incentive compensation, bonuses, awards or severance. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.443324104301831%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Impracticability Exceptions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.05pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Committee shall not seek recoupment of any Erroneously-Awarded Compensation to the extent it determines that:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0.05pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if after the Company has made a reasonable attempt to recover such Erroneously-Awarded Compensation without success, documented such reasonable attempt(s) to recover, and provided that documentation to the exchange, the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of Erroneously-Awarded Compensation to be recovered;  </font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0.05pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">based upon advice of local counsel to be documented and shared with the exchange, the Company has determined that recovery would violate home country law where that law was adopted prior to November 28, 2022; and/or  </font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0.05pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to Company employees, to fail to meet the requirements of Sections 401(a)(13) and 411(a) of the Internal Revenue Code of 1986, as amended, and the regulations thereunder. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.04in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.443324104301831%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.05pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For the avoidance of doubt, the Company shall not indemnify any Covered Executive against the loss of any Erroneously-Awarded Compensation or any Covered Compensation that is recouped pursuant to the terms of this Policy, or any claims relating to the Company&#x2019;s enforcement of its rights under this Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.443324104301831%;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.05pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If any provision of this Policy or the application of any such provision to any Covered Executive shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.443324104301831%;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendments</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.05pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Committee may amend, modify or terminate this Policy in whole or in part at any time and may adopt such rules and procedures that it deems necessary or appropriate to implement this Policy or to comply with applicable laws and regulations.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.204%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.443324104301831%;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Impairment of Other Remedies</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.24%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.05pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The remedies under this Policy are in addition to, and not in lieu of, any legal and equitable claims the Company may have, the Company&#x2019;s ability to enforce, without duplication, the recoupment provisions set forth in any separate Company policy or in any Company plan, program or agreement (each, a &#x201c;Separate Recoupment Policy&#x201d; and collectively, the &#x201c;Separate Recoupment Policies&#x201d;), or any actions that may be imposed by law enforcement agencies, regulators or other authorities.  Notwithstanding the foregoing, in the event that there is a conflict between the application of this Policy to a Covered Executive in the event of a Restatement and any additional recoupment provisions set forth in a Separate Recoupment Policy to which a Covered Executive is subject, the provisions of this Policy shall control.  The Company may also adopt additional Separate Recoupment Policies in the future or amend existing requirements as required by law or regulation.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.111%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">           </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adopted June 14, 2023</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img206969693_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img206969693_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #S L0# 2(  A$! Q$!_\0
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M -XT 6Z*J>:_]XT>:_\ >- %NBJGFO\ WC1YK_WC0!;HJIYK_P!XT>:_]XT
M6Z*J>:_]XT>:_P#>- %NBJGFO_>-'FO_ 'C0!;HJIYK_ -XT>:_]XT 6Z*J>
M:_\ >-'FO_>- %NBJGFO_>-'FO\ WC0!;HJIYK_WC1YK_P!XT 6Z*J>:_P#>
M-'FO_>- %NBJGFO_ 'C1YK_WC0!;HJIYK_WC1YK_ -XT 6Z*J>:_]XT>:_\
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MUE% '#S^.+RVDN1+9VR(IE6(M*1@I-''\YZ#_69SG'') Y&=:>-[VZNIF'E
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MGR_$*].EQWCZ?:1AI=O-T& &W=M(7)# \8QN_P!GJ!Z".E%% !1110 4444
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M:\(_\\;O_P "#1_PIKPC_P \;O\ \"#1]8@'U*IY'SG17T9_PIKPC_SQN_\
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M/_W];_&L^+Q-ID\:M'*Y=FP(V0HV/,\O/..-P-6X=6T^XBGEBNXFC@&Z5MV
MJ\_-GTX//3@T 2_8T_YZS_\ ?UO\:/L:?\]9_P#OZW^-5X]<TR5XT2\C+2-M
M5>0<YQ@^A)X&<9J-?$>CO;?:5OXC%D8;GG*[@<=<8!.>F ?2@"Y]C3_GK/\
M]_6_QH^QI_SUG_[^M_C5677]*A:0/>Q QD!L9/)(&!CKR0..Y%6GOK:.\BM'
MF47$JLZ(>I (!_\ 0A0 ?8T_YZS_ /?UO\:/L:?\]9_^_K?XUGS^)+2WNKR%
MX+C;: ^=*JJ0I";\8!W<C@';@GC.:/\ A(8P_D-87BWID$8M#Y>\Y4MNSOVX
MPK<[NV.M &A]C3_GK/\ ]_6_QH^QI_SUG_[^M_C5>76;*VM+:XNY/LHN"H1+
MCY&!/8@^F>:@OO$-KI^J1V$L4S2.(CO4I@>8Y1>"P8\@YP#@4 7_ +&G_/6?
M_OZW^-'V-/\ GK/_ -_6_P :S%\2PNA>.QO&5HFGA($8\^-2 S+E^GS*?FP2
M#P#3Y_$4%KI:7\]I=(K0O.(OD+B-$W%CAL8Z#KU8=* -#[&G_/6?_OZW^-'V
M-/\ GK/_ -_6_P :R_\ A*;%;07$D<Z+]J%J5^5L-M#%LJQ4J%Y)!XP>XQ5N
M?50-/U&XMXM[V1=661MH8JH8X(SQ@T 6?L:?\]9_^_K?XT?8T_YZS_\ ?UO\
M:L44 8%_KOA[2[MK6_UR*VN% +1RW>UAD9'&:K?\);X2_P"AEM?_  -_^O7B
MGQ>_Y*-??]<XO_0!7#5UQPZ<4[GGU,9*,G&VQ]2?\);X2_Z&6U_\#?\ Z]'_
M  EOA+_H9;7_ ,#?_KU\MT4_JT>Y'UZ78^I/^$M\)?\ 0RVO_@;_ /7H_P"$
MM\)?]#+:_P#@;_\ 7KY;HH^K1[A]>EV/J3_A+?"7_0RVO_@;_P#7H_X2WPE_
MT,MK_P"!O_UZ^6Z*/JT>X?7I=CZD_P"$M\)?]#+:_P#@;_\ 7H_X2WPE_P!#
M+:_^!O\ ]>OENBCZM'N'UZ78^I/^$M\)?]#+:_\ @;_]>C_A+?"7_0RVO_@;
M_P#7KY;HH^K1[A]>EV/J3_A+O"7_ $,UK_X&_P#UZ/\ A+O"7_0S6O\ X&__
M %Z^6C331]6CW']=EV/J;_A+_"/_ $,UK_X&_P#UZ/\ A+_"/_0S6O\ X&__
M %Z^5S24OJZ[C^N2['U3_P )AX1_Z&>U_P# W_Z])_PF'A#_ *&>T_\  W_Z
M]?*IIII?5UW*^N2['U9_PF/A#_H9[3_P-_\ KT?\)CX0_P"AGM/_  -_^O7R
MB:0T>P7<?UN78^KQXQ\($@#Q1:9/_3]_]>NA%K&P!$TY!Y!$S?XU\6FO7?A7
M\4'TV2#P]KDK/9.1':W#<F$G@(W^SZ'M].D3HV5T:4\1S.TCW;[&G_/6?_OZ
MW^-'V-/^>L__ '];_&K%%8'45_L:?\]9_P#OZW^-'V-/^>L__?UO\:L5%<7-
MO:1B2YGBA0L$#2.%!8G &3W)H 9]C3_GK/\ ]_6_QH^QI_SUG_[^M_C4Y. 2
M 3[#O63!X@@?>;FVN+-5F^S@S[#ODZ[1L9C0!?\ L:?\]9_^_K?XT?8T_P">
ML_\ W];_ !K/D\2Z>M@URD@>06WV@0@C)&T-C/3."#UZ'/2K%WK-C87#0W4P
MB(5"">=V[>0 !STC8].U %C[&G_/6?\ [^M_C1]C3_GK/_W];_&L^3Q-I\=T
MUON=G"LX*C*LH"'.[H/]8O7^HS))XATU)%C$YD=IEAQ&A;#,2 3@=,JPSTX/
MI0!<^QI_SUG_ ._K?XT?8T_YZS_]_6_QJDGB/2C LKWD<>81,0S?=4KOY(XS
MM.<9Z<]*L?VG#)8_:K1);M=^P)"!NW9P1\Q &.^2* )?L:?\]9_^_K?XT?8T
M_P">L_\ W];_ !K+@\46EPT/EVUT4D"_/L4A692P0@-DDA>P(Y'/-)+XH@@@
MEEFL+V/R7V2HPCRGRJW)WX)(884$L?2@#5^QI_SUG_[^M_C1]C3_ )ZS_P#?
MUO\ &K%% %?[&G_/6?\ [^M_C1]C3_GK/_W];_&K%% %?[&G_/6?_OZW^-'V
M-/\ GK/_ -_6_P :L44 5_L:?\]9_P#OZW^-'V-/^>L__?UO\:L44 5_L:?\
M]9_^_K?XT?8T_P">L_\ W];_ !JQ10 R*(1*0&=LG/SL6_G3Z** "BBB@#&\
M7_\ (E:]_P!@ZX_]%M7R]HNE-K.HBU69(5$;R/*X)5%4$DGTZ=3@>I%?4/B_
M_D2M>_[!UQ_Z+:OE.TO+JPN%N+.YFMYUR!)"Y1AG@\CFNO#_  NQYV-MSQN=
M>_PWO8Y)+=M0MOM08B.,*V'7SU@W;L8'S-TZXI7^';AG6/6["4[O+C\HEPS[
M9&VDKG:?W3=?4?2L;_A+]8.BW&F-=.\=R^^65W=G8[@W4G&<J.<9XQG%4I=>
MUB:42RZM?R2 @AGN7)R 0#G/8,P^A/K6UI]SF<J78UKS2-)DTG29;".X@NK]
M9&+WE]'Y2;&*D?ZM>N..?;FK-AH>@W&GZ;+>O=64EU<-#O>[C,<BHA+L,QC8
M"Y5022!DYSBN4>>:2**)Y9&CB!$:,Q(3)R<#MD\T\7UVKVSK=3AK7'V=A(<Q
M8.X;?[O))X[\U7*^Y*FKWL==>>&='T^ZUB&XCOMME:)<"5;N,A'D1"D3 1D.
M=[8+ @$ G'%<54\E[=RI,DEU,ZS.))0TA(D<9PS>IY/)]34%.*:W)DT]D%%%
M%,D*ZWX9?\E#TO\ [:_^BGKDJZWX9?\ )0]+_P"VO_HIZF?PLTI?''U1[AKR
M:@[:=_9TCI(MR7;&=C 1.=K_ .R3@>Q(/7%8UKJ.NLUI!]GNXUF#[S+ Q9-S
M28.[!&5PG4CZ$'CL:*\X]DY.QNM<6"W_ '=PYE,43M-$0R$QH3(0<8"XD!XY
M)%30WFMSZ9K#7,&V5(',$:1R!@^'X!VC=T7&TGGOR*Z:B@#C;O\ MV*>41_;
M)()KJX92N[=%B.0*..=A.TCT8>XJ>.WU&;295O3?#4%FB),,LBH4++]S:1P%
MR&SSG)/8UU=% #8T$4:QJ6(48!9BQ_$GD_C3J**8@JW9?\M/P_K52K%K*(R^
M5=LX^ZN:3&MRI=>&K.ZOC=/-.N9?.\M2H DVA2P.W<IP!T8#CIUJI%X+L88?
M+6ZNA^^\[>!$K;MJKQA!MX0<C#<GGFM[[2/^><O_ 'P:/M(_YYR_]\&I+,V/
MPW:1B8":X(E96P2ORXE:4 <=-S'KGC\Z?#H-O%IL^GM<7$MM+ +=5=E_=Q@$
M!5( Z ]3D].:O_:1_P \Y?\ O@T?:1_SSE_[X- &1-X7@N;N"ZN+Z\FEAD23
M+^7\Q1PP_@^7H =NW(ZYI5\+VL2P>1=W<,D$,<"2HR%MJ*R]U(Y#'/'88Q6M
M]I'_ #SE_P"^#1]I'_/.7_O@T 9$/A/3H+QKF,N':7SON1Y#;Q(?FV[B"P&0
M2?;'&-*72[.;48;^2WC:YB1D1RHR 2I_/Y1CTYJ7[2/^><O_ 'P:/M(_YYR_
M]\&@#,OO#=KJ-TTUU/<R*0X6+<N$W(4.&V[@,$G&[&><<"E_X1Z/?Y[7]XUX
M)!(+L^7O&%*[<;-N,,W&WOGK6E]I'_/.7_O@T?:1_P \Y?\ O@T 4[C1DN;2
MUMVN[D"W(8.=CLY'0L64]_3%1W_A^WU#41>2SSJVV)6C39M81N77DJ6'+'H1
M6A]I'_/.7_O@T?:1_P \Y?\ O@T 9UOX>M[<D"XN9(UA>WAC<KM@C8C(7"@_
MPK]XG&/K3I]"M[FVFMI)9?*DLOL2XQN1""&(.,9/R]L?**O_ &D?\\Y?^^#1
M]I'_ #SE_P"^#0!C?\(CITAD-S)<7 D,A=68("755)P@4?=0#\3ZU=T[2/[-
MDD9+^[E60[G27806V@;LA0<_+ZXJY]I'_/.7_O@T?:1_SSE_[X- $U%0_:1_
MSSE_[X-'VD?\\Y?^^#0!\[_%NWGD^(E\R0R,ICBY521]P5P_V.Y_Y]YO^^#7
MV!]I'_/.7_O@T?:1_P \Y?\ O@UTQQ'*DK'%/!\TG+FW/C_['<_\^\W_ 'P:
M/L=S_P ^\W_?!K[ ^TC_ )YR_P#?!H^TC_GG+_WP:?UKR(^H_P![\#X_^QW/
M_/O-_P!\&C['<_\ /O-_WP:^P/M(_P"><O\ WP:/M(_YYR_]\&CZUY!]1_O?
M@?'_ -CN?^?>;_O@T?8[G_GWF_[X-?8'VD?\\Y?^^#1]I'_/.7_O@T?6O(/J
M/][\#X_^QW/_ #[S?]\&C['<_P#/O-_WP:^P/M(_YYR_]\&C[2/^><O_ 'P:
M/K7D'U'^]^!\?_8[G_GWF_[X-'V.Y_Y]YO\ O@U]@?:1_P \Y?\ O@T?:1_S
MSE_[X-'UKR#ZC_>_ ^/C9W/_ #[S?]\&FFSNO^?:;_O@U]A_:1_SSE_[X-'V
MD?\ /.7_ +X-'UGR']1_O'QQ+#+%CS(W3/3<I&:C5&D8*BEF/0*,FOLO[2/^
M><O_ 'P:/M(_YYR_]\&CZSY#^I?WOP/C<V=U_P ^TW_?!I#9W7_/M-_WP:^R
M?M(_YYR_]\&C[2/^><O_ 'P:7UCR']3\SXT-G=?\^TW_ '[-(;.Z_P"?:;_O
M@U]F?:1_SSE_[X-'VD?\\Y?^^#2]OY#^J>9\9"QNV( M9R3P (S7O?PN^%RZ
M(D6N:Y"&U-AN@MV&1;CU/^W_ "^O3U+[2/\ GG+_ -\&C[2/^><O_?!J)U7)
M6-*>'4'=ZDU%0_:1_P \Y?\ O@T?:1_SSE_[X-9'035%<6UO=QB.Y@BF0,'"
MR(& 8'(.#W!I/M(_YYR_]\&C[2/^><O_ 'P: )JH#28!*LF^3*W1NAR/OE2N
M.G3!-6?M(_YYR_\ ?!H^TC_GG+_WP: ,'_A"M/RN;F[(6W^S@$ID+Y8CZ[,]
M!G&<9R<<UIW&C6]SJ27[O*)5"@!2-ORK*H[>DS?D/?-O[2/^><O_ 'P:/M(_
MYYR_]\&@#'7PG8JJA9[H (8S\R\J5B&#\O\ TQ0_7/KBDM_"5G;7,MPES=&6
M22.3<?+R"C,PY"\_?8$MDX[UL_:1_P \Y?\ O@T?:1_SSE_[X- &(/!]B+9+
M;[3=^0J@"/<N-PB\G?G;G.SCKCOBK\^C1S6%U:+<W,*W,IDD>-EW<D$@9!&#
MC'3H:N?:1_SSE_[X-'VD?\\Y?^^#0!FIX>A2YCG^V7.4VG:!&%9E4JK$!!R
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ML+WC]YR__"C?#/\ S_:O_P!_H_\ XW1_PHWPS_S_ &K_ /?Z/_XW74;?"/\
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M.BLS_A'=(_Y\(?RH_P"$=TC_ )\(?RHT#4TZ*S/^$=TC_GPA_*C_ (1W2/\
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M#!,XPH7D]3P.2<#GK5:M*:DH^_N8UG3<VZ2M$****LR"KFD?\AJP_P"OB/\
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MJ,1M3D#_ &16!Y,O_/)_^^37U6&:]C#T1^<9A%_6ZG^)_F,HI_DR_P#/)_\
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MR>@K,V(//G_Y\Y/^^U_QH\^?_GSD_P"^U_QJQ2*ZOG:P.#@X/0^E $'GS_\
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MXUYV?'NL?W;7_OV?\:8?'^L_W;7_ +]G_&C^S:_D/^W\'Y_<>C^?/_SYR?\
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M(5)+OL,J=5&5VMCYAQ)P<@5V]% '&K8>(8896_TJ220@LT+11R,XA558Y8C
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M<3[+'_>E_P"_S_XT?98_[TO_ '^?_&J!U^U74+FU>.5%MN)IVVB-/DW\_-N
MQ_$1C/&:3_A(;)KA(XVWHP7YP<;6+A,$'&#DUF;&A]EC_O2_]_G_ ,:/LL?]
MZ7_O\_\ C66/%&GM;W]TK,]K9HCM+&I;<&&1@8R?KTYSTJW)K6G0Q"22Z55)
M8#(.<AU0C&,YW,H^IH L_98_[TO_ '^?_&C[+'_>E_[_ #_XU2C\0Z3+&\B7
MT;*N,XSDY.  .I.01@=P10WB'25_Y?HS\BN-N6R&&1C'7(R?P/H: +OV6/\
MO2_]_G_QH^RQ_P!Z7_O\_P#C4D;I+&LD;!D8!E93D$'H13J (?LL?]Z7_O\
M/_C1]EC_ +TO_?Y_\:FHH A^RQ_WI?\ O\_^-'V6/^]+_P!_G_QJ:B@"'[+'
M_>E_[_/_ (T?98_[TO\ W^?_ !J:B@"'[+'_ 'I?^_S_ .-'V6/^]+_W^?\
MQJ:B@"'[+'_>E_[_ #_XT?98_P"]+_W^?_&IJ* ,RXO=+M)C#<7XBD'57N6!
M'ZU'_:VB?]!./_P*;_&N&\9_\C-<?[J?^@BL"O9HY;"=.,W)ZH^5Q.?UJ-:=
M-06C:Z]#UC^UM$_Z"<?_ (%-_C1_:VB?]!./_P "F_QKR>BM/[*I_P S,/\
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M@./^^?\ Z]']A:/_ - <?]\__7K7^U:7\K,/]6\1_.OQ_P CRNBO5/["T?\
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M/\: )J*A\\_\\)?R'^-'GG_GA+^0_P : )J*;&Y<$E&7V:G4 %%%% %'6?\
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M0G2C)K5I=6?%8S.,93Q$X0EHFULN_H=W_P +"B_Z!S_]_1_A1_PL*+_H'/\
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MGS-D@L2"0,E1D<T =O12*25!(P<<CTI: "BBB@ HHHH **** "BBB@"CK/\
MR M0_P"O:3_T$UX_7M-U;I=VDUM(6"2HT;%>H!&.*YO_ (0+2O\ GXO/^^U_
M^)KT\!BJ="+4^I\]G66U\74C*E;1=SSJBO1?^$"TK_GXO/\ OM?_ (FC_A M
M*_Y^+S_OM?\ XFN_^TJ'G]QXO^K^-[+[SSJBO1?^$"TK_GXO/^^U_P#B:/\
MA M*_P"?B\_[[7_XFC^TJ'G]P?ZOXWLOO//99I9V#2R/(P& 78DXH::5XUC>
M5VC3[JEB0/H*]"_X0+2O^?B\_P"^U_\ B:/^$"TK_GXO/^^U_P#B:7]HX?\
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M%S_WS'_\11]DF_Z"%S_WS'_\11RKO^8<\OY7^'^9:HJK]DF_Z"%S_P!\Q_\
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M%!'Y 5)4LM.Z"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img206969693_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img206969693_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %E M # 2(  A$! Q$!_\0
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MBC^OPN/^OQL>MTA( R2 /4UX!H]EXAU72K;Q!8Q%M3:XWG5)=7"[OFP8S$>
M.V*Z6'0K/Q#X^\8P:EY[1111.L23LJA]G7 /..W:AZ >MU6U&YELM.N+F&UD
MNI8HRZP18W2$#[HSW->&_P!LZK/\._"VGK/*\5W>RP3?Z1Y1D56^6,R?P@Y/
MY5KV^F:UH^C^*X9;86.E/IC/':#41<M#)Z@]0",_E0]+C6Z/6M,NY;[3+:ZG
MM);.66,.UO+]Z,GL?>K5>-6H.L'P-X?O[F:/2;C36FE5)2GG2 '"DCDXXX]Z
M[KP5:66FG5=.T_7'U*WM[G:L#Y8V?'^KW$G=3:U9)I2ZY<0:O?6LFDW2VEK:
M_:!>Y'ER'&2@]ZJ>&O&NG>*-$N=3LTE3[-N\V&3&]<#(Z'N.E<M<,W_"U/$Z
M[FV_V'TSQT%<IH,,OACP=IGBJT1VM+J"6SU2)>X+,$D^H.!_^NIOI_7F/K;^
MMD>BI\1].?0-+U<6=UY.HW?V2-/EW*V2,GGIQ6C>>+[2#Q3!X=MK:>\OG3S)
M?)QM@7U<D\?3Z>M>02&=?A1X6-J ;D:NWE ]"^YMOZXKLOAV[Z'XHUC0M<C0
M:]<O]J%WG/VE",D GTYX^OI56U_KLA7T_KN:5S\3A9W4%M<^%M<BFN&*0(\
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M20 X<=P#S3-/LM/T/X3KKTM[JJ7>H6\<+R6\W[S&_P"5$W<(.V?3- 'LE)D
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MX?[L32 .WT&<FI)Y/)@DEQG8I;'K@4= ZF"O@?0%TNRTT6;?9;*?[1 GG/\
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MR@VK++"K,!Z9(H?]?<D"T_KS/&9HK.X\&^ +W4HX9-UW]GGFG .80S?(Q/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(/\ 4)]*F1422H)/]>?]T?S-3U!)_KS_ +H_F:2W*EL)1115F84444 %%%%
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M,!2.,'W-=A;Z1;6E^US;(D*/%Y<D*( K<Y!^O6JLND7+ZH][#<QVA1=D*Q1
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MVWR/LUX(1.ENUUL'EJ[H'4'G/(/I5?1?$UWK7B>!%MIK73IM.:YB2783+^\
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M #J9%1W)*K#[S_[QJS58?>?_ 'C2B.6PM%%%60%%%% !1110 4444 %%&**
M"N<M_%$UW<%[?2)Y=-^TO:B[1P3O7(+%.H3((W?I71US=IX9OK"X,%MK#0Z5
M]I>Y^S+#^\)8DE"^?N9.<8SVS0B7?H0Z9XWLKFSAN-0,-F)88I%4.SMND+87
M 7_9X]:MGQ?I099A=0FQ-LUQYH+;^'V;0F,]>/7/&*R[#P";.XT^3^T@_P!D
M^S<>3C?Y1<^O&=_X8IK?#X/DMJ1#@2&-A#]UVG\Y6Z\@$8([^U7[ER+SL:S^
M--#CM4N6N)Q&697'V:0M#M(#>8,90#(SNQUJWHNK_P!KG4?W2HMI>/;*5;.\
M *0WX[JP=9\%:CKEOMO-=1I'BECE'V,"+Y\89$#<,,8W$L<9K<T#13HD-Y&;
M@3?:+DSY";=N55<=3_=_6E[MAWG?R-:BBBI- HHHH **** "BBB@ HHHH *D
M@_U"?2HZD@_U"?2ID5$DJ"3_ %Y_W1_,U/4$G^O/^Z/YFDMRI;"44459F%%%
M% !1110 4444 <)XSO[S3->-W8R%)XM'E*-MW -YT8SCH>":8=5UTZZ-%_M5
MP/[1,'VG[.F_RS;^9C&,<-WKOJ*?-I;^MR'%WO?^K'E$OC+6##I<YOIH[D1P
M-)&8U2.?=*48@;26X'/*A>.M#:EJ.D)>VT>JWJQG6ITNYG=0]NF"8_F92%#'
MN1CC QFO5Z*KF78GD?<XO4+B^N?"?AR>^=6NY-0M#*T.=K?/UZ#J,&L9->\2
M3VHG_M=D,MC>W6T6J?*T,A"@<=QUKTVBES>17+YGG7]OZ_=72/'J'D1O>V5M
MY2VZL LT*LQR1G().*KR>+-4M;1GO=0=/]"OXHI/* \V>.3;&< 8W[1TZ5Z;
M11S+M_5A*#[GG5OKVN--'+)?%X!J$%FUNT"X9'@#,2V,YW5F:9/J:RV]S9W\
ML%Y)H EMK8(HA=T=BR!,8Z#Z\UZQ4-W:QWMG+:RM(L<JE6,;E& /H1R*.?LO
MZL+V;ZO^KF1X2U.[UO1VU:Y)6*[F9[6(J 8X>B@^I."?QK=J*VMH;.UAM;>,
M1P0H$C0=%4# %2TG:^A<4TM0HHHI%!1110 4444 %/@Z/_O?T%,I\'1_][^@
MJ6..Y+5<_P"ND^H_E5BJY_UTGU'\J2W*EL%%%%60%%%% !1110 4444 %%%%
M ',:SKNI6^NMI^G_ &",06JW<K7K%1*"^W:K9 7&.ISU Q6+>^/KZSOKLQQ6
MES:+'=&':CKAH!D@N3\W<'"@#L37;7FE:=J,L,M[8VUS) VZ)I8PQ0^V>E4-
M2\*Z1J-O>K]BMX+F[C='NHHE$@W#:3GUQ5)KJ1)2>S,"7QCJ2>?9.+"._$L"
MPO&KRHXE0O@+D98;3U(&.?:LFW\9ZJTTNMJEN8DTN&:>U>1@I_?.C&,=F.._
ML*[J+PWHL6G?8/[+M&MRP=T,*X=P/O$>M+_PC6A[HF_L>RS#CRSY*_)@DC'X
MDG\:?-&^Q/+.VYQ-_KET+V:1);A8X'U0%/M#?-LB4KS_  XSQCIVJ>U\3ZQ8
MW.J7ES/#/IMJ+)GA93NABD0%G#9Y(SDYZ]>*[9]&TR1G9]/MF+F0L3&.2XP^
M?]X  ^M4]4\-V.HVD\,21VDD\ MI)XH5+F#O'D]L<>U"DK6L#C*][D^@:C/J
M^BP:A/"L)N-SQHN?]7D["<]RN#^-:5,ABCMX(X8E"QQJ$11V & *?4.U]#17
MMJ%%%% PHHHH **** "BBB@ J2#_ %?_  (_SJ.I(/\ 5_\  C_.ID5'<DJL
M/O/_ +QJS58?>?\ WC2B.6PM%%%60%%%% !1110 4HZTE%(#RK0[O7XM-77(
M?[1>*V%U+=RWEYO@N$7?M5(\DJ00.<#H>M;ESXRU>U@:22TT[=;V*7]POFN-
MT;MA4CS_ ! #DGC.!781Z?916+6,=K"MHP96@" (0V=PQ[Y.?K45QHVEW;VS
M7&GVTK6V! 7C!\L#H![<"KYDWJC-0:6C.4E\9:E/O-O;VL<%Q+<VMMN9O.CD
MB1FWN.F#M/ Z9%.T76;W1O!%K=W.G75XHL#>RW8F#*6*EL-N;?D\=!@9KJAH
MVF"^EOAI]M]KF4I)-Y8W.#P03[U8BMH(+5+6*%$MT3RUB"_*%QC&/3%*ZM9(
M:B[W;_K0\\UO7]:O[9=,9K."8W5EYDMK*^UXYB<)D<CD<XZCI6UKFJZCG3[#
M[-=Z5#<:@EH]V9$)>/:QRA!.W)4#)P>?6MZWT'2+6 06^F6D40E$VQ(@!Y@Z
M-]1V]*M7=G;7]L]M>6\=Q _WHY5#*?P-/F7;^M!*,NK.-DU^\TJXETJPU"VU
M.2%;BX:>]<@QI&%S"67[S_-U[#K38/'5_<2)<K80"P-W#;E"S>=^\B#@^G&<
M>]=0_AW19;*&S?2K-K:%MT41A&U#W('O4YTO3RY?[%!N,JSD[!_K%&%;Z@<
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MC:=.,26B']VD?4CY5.5Z'L>AZBFPZ'IEO%Y45E&B':<#/\+%E[]F)/XUH44
M9O\ 96D0/%FW@C9=BQ@MC[I)7C/."3^=1_V)HLEJ(Q!%Y#/\NV9@,X(PI!X&
M"1@<>U5=?\.G69Y9,6YS9-!'YHR5<N&W#CC@?6J%SX/EEO)G4PFU::1DMED:
M)45E0;A@'!RIZ8Z]10,U[_\ L=;BWL[JW5V2%O+55)$: IQ@=.=GY5/=PZ3%
M:3Q77D)!-.#(&?&96(P<YR&)QBL"3PG>-+)AK3I*!.2WFR[Y4<;^.P4CJ>U)
M_P (E>M>SSR-92!G5U4YPY6;S,D;?E^7([_K1V Z!=(TF.)XEMX0JH$<%NP;
M>-QSG[W.35:UT_0[^SFN8K1%BED8.Y)4@HYY!S\HW9(QCKFLI?"-PC2OOBED
M\WS-TLK$3KYF_9(NW ';/S=/3BKJ:!<)H%M9$6IDANS<&'GR74NS;#QT^8=N
MH'%(!]I;^'[^QW1VRQP!4&YLQX"LP7#9ZYW<@YY]Z+GPQ93:G:3Q2B 6RHR0
M1J!G825)YY )[Y^HK)_X0^]33_)_T-W CVH&*JI'F=,J1CYQP0<X/3BI_P#A
M$[OSYI6F@:9XL)+N8"-O*V;=F.5[]>_3- &U::;I]IHWV"1X9H)F;S&?:!,[
ML2QXXR23P*5-&T>".=!;0JI1UFW.3\KX+;B3WVCKZ5SC>$=0^R>6HLRXN'DC
M#R%EC#*HZ%,-RIXP.O!%3'PA-LO-QBGDD9F61YW4R R!\$;<#&, G<..F,BF
M!T5OI6G0WGV^WMXQ.P.)%)/#8SCG'.!G'6@:/IRAP+2,!R"W7G#EQ_X\2:31
MK.:PTBWM;@Q&5 =WE#"\DGC@>OH/H*OTQ%$Z-II,Q-G'^_SYG7YLMO.?^!<U
M'/H&DW,C/-8QNS.78Y(W$D$YP>>5!Q[5I44@N46T737C$;6<94*R@<\!FW''
MI\P!SZU:@@CMH%AA7;&O09)_4\FI** "BBBF 5)!_J_^!'^=1U)!_J_^!'^=
M3(J.Y)58?>?_ 'C5FJP^\_\ O&E$<MA:***L@**** "J-MI^F:>TS6\4$)8;
M9"&Z#KCD_*.2<# J]7&_\(C>2:FT\[VCP-*KNO/[P"82<KMP...IY[TNH=#?
MNCI=AIMHKQI]EBDB%NB'.#N 0KSS@D5$VDZ$+IFDM84DA<$ER57<<L#R<,?F
M/KUQ6./"5TC*%^Q.GFHRE\YMU6<R8CX[@@=NGI5S4/#3W^M3W<GV>2!RQ5)!
MG!,.P'&,=>:72X^MBX-&T&.!E$4 0/RYF.0P&,;LY''&,XQVK0>*TN4C1A%(
ML,@90&SL=>G3N*Y>'P8R7<#.MFUND"(T6W(,@B9"V,8ZD'/7BB'PG>6<UO-:
MM9@Q6\<9C)95=Q&Z.Q('7Y@<]\4V!T=Q9:=?72-.D,LZ+\OS\[=P;H#R,@&H
M)=%T:X/VB2U@;YS(9-Q +;MV20<'YAGGH:YZ#P3<1Z:L'GV\=SN8-<Q@[MI@
M$>,XS]X9QZ>]71X5<Z/-:[A$TLJ.T(G9X6 *$Y!4<X7L*!&I%I6B_:(IX8H#
M)" Z;9,@ 9PV,X.,G!/3-0W]GH4$%QJUS!'(NTR,RN6#8P25&<9.T=.N*R;K
MP;([,UJ;6#,]Q(0JD;T<J50X'W?EP1[\4VX\)7D\,Y"6 -PLJBV8DQ6Q?;AD
M^7K\O/ ZT#T-F^L-$B5;RZMHSF8'(S\SNXZ@'D;B.#P#4SVNC6MU%.Z6L<[W
M3,CDC)G9=IQ_M%1BL.7PMJ,EQ"!-:B&"21T;+;FWS))R,8&-I'7GBFV?A*]@
MNEGF-F^R:"4+DX8H7W'[ORDAA@<].O>@#=>QTC5&,DD2-).%8Y9DD.W(!QD$
M$ D9]#0NC:-,G[JV@*J1S$V,87;C*GT&,=^]<Z/!=PE@Z^; MUO0B>,$N%6-
ME(!Z\D]*GT'3KR6PUD?88M.-S''%"IC(4E8]I8J0#C/M^='<#<GT?1[JW$<M
MM \3.[#YL L_WN0><]Q52WTWPY/<.;>"&5I"X8JS,NX, PZX#9 ]SBLNV\)W
ML(<NMC,KL^V"9F9(PP3YQA1\P*GH!UZBI?\ A%+E!-Y,EK$ZB9K9U!XD:59$
M8C';&#UXH TVM]!BN/)*P13-*I4L2-T@W.-ISR1ECQZD5=TO3XM,LS;QN)',
MC2RO@ N[G<20.!DFN?7PEY+H\JP3PQNC2*RDLX\IDDQP>26R!WK2\*Z?<6.C
MAKPL;N=M\A=<-M VH"/4(%S[YH0F;=%%%, HHHH *D@_U"?2HZD@_P!0GTJ9
M%1)*@D_UY_W1_,U/3&B1SEE!/2I135T145)Y$7]P4>1%_<%5S$\I'14GD1?W
M!1Y$7]P4<P<I'14GD1?W!1Y$7]P4<P<I'14GD1?W!1Y$7]P4<P<I'14GD1?W
M!1Y$7]P4<P<I'14GD1?W!1Y$7]P4<P<I'14GD1?W!1Y$7]P4<P<I'14GD1?W
M!1Y$7]P4<P<I'14GD1?W!1Y$7]P4<P<I'14GD1?W!1Y$7]P4<P<I'14GD1?W
M!1Y$7]P4<P<I'14GD1?W!1Y$7]P4<P<I'14GD1?W!1Y$7]P4<P<I'3X.C_[W
M]!2^1%_<%.5%0848'6DW<:C8=5<_ZZ3ZC^56*8T,;-N902>]"&U<BHJ3R(O[
M@H\B+^X*?,3RD=%2>1%_<%'D1?W!1S!RD=%2>1%_<%'D1?W!1S!RD=%2>1%_
M<%'D1?W!1S!RD=%2>1%_<%'D1?W!1S!RD=%2>1%_<%'D1?W!1S!RD=%2>1%_
M<%'D1?W!1S!RD=%2>1%_<%'D1?W!1S!RD=%2>1%_<%'D1?W!1S!RD=%2>1%_
M<%'D1?W!1S!RD=%2>1%_<%'D1?W!1S!RD=%2>1%_<%'D1?W!1S!RD=%2>1%_
M<%'D1?W!1S!RD=20?ZO_ ($?YT>1%_<%/551=JC I-W&E86JP^\_^\:LU&88
MR22@R>M"=AM7(Z*D\B+^X*/(B_N"GS$\I'14GD1?W!1Y$7]P4<P<I'14GD1?
MW!1Y$7]P4<P<I'14GD1?W!1Y$7]P4<P<I'14GD1?W!1Y$7]P4<P<I'14GD1?
MW!1Y$7]P4<P<I'14GD1?W!1Y$7]P4<P<I'14GD1?W!1Y$7]P4<P<I'14GD1?
MW!1Y$7]P4<P<I'14GD1?W!1Y$7]P4<P<I'14GD1?W!1Y$7]P4<P<I'14GD1?
MW!1Y$7]P4<P<I'14GD1?W!1Y$7]P4<P<I'4D'^H3Z4>1%_<%/ "J !@#H*3=
MQI6%J+[0GHQ_X":EJJGW/Q/\Z$KC;L2^>O\ =?\ [Y-'GK_=?_ODTRBGRD\S
M'^>O]U_^^31YZ_W7_P"^33**.4.9C_/7^Z__ 'R://7^Z_\ WR:911RAS,?Y
MZ_W7_P"^31YZ_P!U_P#ODTRBCE#F8_SU_NO_ -\FCSU_NO\ ]\FF44<H<S'^
M>O\ =?\ [Y-'GK_=?_ODTRBCE#F8_P ]?[K_ /?)H\]?[K_]\FF446#F8_SU
M_NO_ -\FCSU_NO\ ]\FF44<H<S'^>O\ =?\ [Y-'GK_=?_ODTRBCE#F8_P ]
M?[K_ /?)H\]?[K_]\FF44<H<S'^>O]U_^^31YZ_W7_[Y-,HHY0YF/\]?[K_]
M\FCSU_NO_P!\FF44<H<S'^>O]U_^^31YZ_W7_P"^33**.4.9C_M" 9VO_P!\
MFI0<@$=#59_N-]#4Z?ZM?H*35AIW'5";A02 CG!QD"IJK+_%_O'^="0Y.P_[
M0/[DG_?-'V@?W)/^^:;13L1S,=]H']R3_OFC[0/[DG_?--HHL',QWV@?W)/^
M^:/M _N2?]\TVBBP<S'?:!_<D_[YH^T#^Y)_WS3:*+!S,=]H']R3_OFC[0/[
MDG_?--HHL',QWV@?W)/^^:/M _N2?]\TVBBP<S'?:!_<D_[YH^T#^Y)_WS3:
M*+!S,=]H']R3_OFC[0/[DG_?--HHL',QWV@?W)/^^:/M _N2?]\TVBBP<S'?
M:!_<D_[YH^T#^Y)_WS3:*+!S,=]H']R3_OFC[0/[DG_?--HHL',QWV@?W)/^
M^:/M _N2?]\TVBBP<S'?:!_<D_[YH^T#^Y)_WS3:*+!S,=]H']R3_OFI5(90
MPZ$9J ]*EB_U*?[HI-6*B[CZC,Z@D88X..%J2JP^\_\ O&A*XV[$GGK_ '7_
M .^31YZ_W7_[Y-,HI\I/,Q_GK_=?_ODT>>O]U_\ ODTRBCE#F8_SU_NO_P!\
MFCSU_NO_ -\FF44<H<S'^>O]U_\ ODT>>O\ =?\ [Y-,HHY0YF/\]?[K_P#?
M)H\]?[K_ /?)IE%'*',Q_GK_ '7_ .^31YZ_W7_[Y-,HHY0YF/\ /7^Z_P#W
MR://7^Z__?)IE%'*',Q_GK_=?_ODT>>O]U_^^33**.4.9C_/7^Z__?)H\]?[
MK_\ ?)IE%'*',Q_GK_=?_ODT>>O]U_\ ODTRBCE#F8_SU_NO_P!\FCSU_NO_
M -\FF44<H<S'^>O]U_\ ODT>>O\ =?\ [Y-,HHY0YF/\]?[K_P#?)H\]?[K_
M /?)IE%'*',Q_GK_ '7_ .^34BL'4,.AJ"I(/]0GTI-6&G<DJJGW/Q/\ZM55
M3[GXG^=$0D.HHHJR HHHH **** "BBB@ HHHH *@%Y";]K+<?/$8E*XXVYQU
MJ9EW(RY(R",CJ*Y.]@GT?5(6L]1DFNI(6$[7AWB.(<[R>V#V[UK2IJHVKZG-
MB:TJ*4DKJ^IT>HQQS6,D,ET;4.,"4.%*GUS61X;N)+TRW=UJ FN"3"L08 !5
M/WMOJ>N:BTG31?3_ &R[M?M$++E9[TEI)#V*IT1?;K6O/HFF7(Q)8P@]F1=C
M#Z$<UJW"FG3;_!?U^1SQ56M)5HJUNC;U[/:W>VCW)[V\BL+8W$^X(&"G:,G)
M.!_.K!&#S7*ZG9W=NUM8W5](^CS3 -*1F5#_  HS>A..:Z&RLEL8FC6:>7<V
MXF>0N1[9]*SG3C&":=V_Z^\WI5ISJ.+C9*WW_JMK/U+-%%%8G4%%%% !1110
M 4444 %%%% "/]QOH:G3_5K]!4#_ '&^AJ=/]6OT%3(J(ZJR_P 7^\?YU9JL
MO\7^\?YTHCEL+1115D!1110 4444 %%%% !1110 5D7>M21!C:V+7"AF4$RJ
MF\KUV \MBM>N7L+;4I],L@D4,B(YEAD:4J%.3C<N,MCV/-;48Q=W+^MSEQ,Y
MJT87UOLK]O7N:<&H:G<P1SQ:7$T<BAE/VP<@_P# :)]0U2WMY9WTF/9&A=L7
M8/ &?[M9OAW3([S0[>9[J^1LLI$=RRKPQ' [5H3:# \$BM>ZAM*$'==,1C'?
MVK62I1FXM;/S_P SFIRQ%2DIIO57WCV_PE4ZWJ<=C9WTMI9_9[EXU 25MP#]
M.V*Z$C!(KBUNWOH[;23+9QPVSP,DZE\2X[+QUKM3R348B"C;2V_W=#3!595+
MMRNM/OUN)1117.=X4444 %%%% !1110 4444 !Z5+%_J4_W141Z5+%_J4_W1
M4R*B/JL/O/\ [QJS58?>?_>-*(Y;"T4459 4444 %%%% !1110 4444 %9MI
MK=O=2Q)Y<L(GW>0\@&V7!P0,'@\=#S3M9@FGTXK KN5=7>-'*-(HZJ".A_PK
MDV:+380"9+O0[M\[NDEO)_1Q^O\ /IH48U(ON>=B\7.C-67N]?Z[=VMKJZMO
MWE%9.G:BWFQV=U('9UW6UR/NW">OLWJ*NWU]%I]MYTH9B2%2-!EI&/10/6L7
M3DI<IUQKPE#GO9+?R_K_ (8+V^AL(5>7<S.VR.-!EI&] *+&]6^BD=8WC:*0
MQ.CXRK#J,C@]:Y>^OKM=16*%!-K<Z[ %.4M$/\*_[7<FK.@Z?]GOD^QSRR10
M;A=3ESLF<_PHO3@\[JZ'AXQIW;U_K^EW]#ACC9SK\L5IM_7GU:Z+?4ZBBBBN
M0]0**** "BBB@ HHHH **** "I(/]0GTJ.I(/]0GTJ9%1)*JI]S\3_.K554^
MY^)_G2B.0ZBBBK("BBB@ HHHH **** "BBB@#.OM7CTV\BCNT\NUE4XN2?E#
M_P!TCMQWKGHGBUC5=P820WEZ02.C0PJ"%^A)!KIY-.MYM0BO90SR1(5C5CE5
MSU('K5'3-MIK.H6+*JEW^U0<=58 -CZ$5U4YPC%N*UM_7Z,\VO3J3J14W[M]
M/NZ^NJ^9?U"_CTZU\YU9V9@D<:=78]%%4@GB&4>89K"V)Y$)C:3'L6S_ "J3
M68)V6TN[:+SI+2;S3$.KK@@X]^:B_P"$FTP)]^?S.GD^0V_/IC%3"+Y4X1N^
MO4UJSC[1JK+E736U_G^G^8@F;5K+4-,OH%ANXX\.JG*D$95U/ID56LO$L,NG
MV,47^E:C*%1H$;!! ^8D]NF:1IKBW@U'6KN$PR3QK!;6Y^]CG;G_ &B3T[5>
MBT. Z396DX(EM@K"2,[6#CJ0?SK1^SBO>6E^G>VORO;_ #,(NM.5X/6SW6MK
M^[Z.U]U\C5HHHKC/4"BBB@ HHHH **** "BBB@!'^XWT-3I_JU^@J!_N-]#4
MZ?ZM?H*F141U5E_B_P!X_P ZLU67^+_>/\Z41RV%HHHJR HHHH **** "BBB
M@ HHHH *H:%_R!+3_</\S5^L/1[^6+2;9!IUW(%4C>@7!Y/3FM(Q;@[=U^IA
M.:C5BWV?YH=X3_Y%R#_?D_\ 0S4DK7]WJEU:P7<4$,4:<-!O+;@<\Y'I57P_
M++I]I::9=VD\,TCR;68#:>2W4'TJ_:_\A_4O^N</\FK:II4G+YKKU.6A[U"E
M!W6R>Z?PWMT9SD>HW5Q!IUI'?6[^;,L1B%H<1;3P0<\XP.*Z*REO5U6>SNKB
M.<+ DJLL6S!+,,=3Z5<G>&VMFE= (X@7P%''TJA9S)<:]+-'G8]C$RYZXWO1
M*:J1;4;+Y;W] A1=&<4YW;:ZO:SZ7?4U:***Y3T0HHHH **** "BBB@ HHHH
M #TJ6+_4I_NBHCTJ6+_4I_NBID5$?58?>?\ WC5FJP^\_P#O&E$<MA:***L@
M**** "BBB@ HHHH **** "LG4-%-TTQMIU@6Y&VX1H]ZO_M =F'K6M150G*#
MO$SJTH58\LT<QJ&FG3[G3HM/G>/]Z\B)+\\:LJ')QUY^N.358:G<:U-8W"R"
M"!+I(1Y0^<.T9).3Q@=,8K8UC_D)Z7]9_P#T77/:.BI:6@48']I0'\X:[Z;Y
MJ?-+5V_5GBUUR5O9PTBWMZ*+1NCPX(+AC9W)@BF0).=NZ5ADDX?L3GFMF&&.
MW@2&%%2)!M55Z 4^BN&=24_B9[%*A3I? K?U^ 4445!L%%%% !1110 4444
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ML"HL7V;;&5!8@9!^4GGG%:GV"\_Z"UQ_W[3_  J-])EF8&;49WX*Y$:*V#U
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M 'I4L7^I3_=%1'I4L7^I3_=%*141]5A]Y_\ >-6:K#[S_P"\:41RV%HHHJR
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
<* "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img206969693_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img206969693_2.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1R:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ''Z^<I0X0DE-! 0      &$< 5H  QLE1QP"   " ?\< E  "')R,C,P
M-S(X' (% $!-:6-R;W-O9G0@5V]R9" M($%C=&EV95\Y.#8Y-#8Q-%\Q,5]-
M:4Y+("T@4RTQ7T%M96YD;65N=" R7T1R869T #A"24T$)0      $$_Y*DB_
M#0Z*\7Y9EW S.]LX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q :V            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              &(   "J0         !
M      $              JD   &(                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     $?T    !    H
M %P   '@  "L@   $>$ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( %P H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MVC)V>HSU-@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" "L 2L# 1$  A$! Q$!_\0 '@ !  $$ P$!
M      D%!@<( 0,$ @K_Q !2$   !@$" @0)!@D* P@#   ! @,$!08'  @)
M$1(3&2$4%1@Q05A9F-86.5&7M]<B,S5A<W9YLK87,G%X@9&2L=CP(T*A"B0H
M-L'&T?$W4E/_Q  = 0$  @(# 0$              04&!P($" ,)_\0 .1$
M @(" 0,!! @#" ,!      $" P0%$082(3$'$T'P%")187&!D;$5,J$(%B,S
M0L'1X1<E4F+_V@ , P$  A$#$0 _ )L-LFUO,N^JW[V<EW/B.\0;$@4+?MN;
MPI4:'A#,E2JN/X&BX[M;5M66,;"SV-[4[:J-&;\69@1DTVQD&S?H-4E0656
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MN1T [(2X^UGXLOO#8V^Y'0#LA+C[6?BR^\-C;[D= .R$N/M9^++[PV-ON1T
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MHQD10!7I D*P-%UA2!02'!,3]$#] W1Y]$>0%9T T T T T T T T T T T
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MZM6Z!5X6HP2TR]R3N?;.Y52*@63!D>0<MV3)!=X*'A"J+1LDHH8B*92@2R:
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M*KN4?Q:ZRJ::BJI3G.0IC"4 +DT T T T!&_C/YU7=G_ %,]G/VH;J= 20:
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MMA+82YM5;C+'LG[F&/4X5^Z?;%RE.:CS*4GM-K'#9XT T T T T T T T T
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MKLG-=@',:DW0CG$+%KQZ#,A$FB+)5B@HT2:IIB*:;=- R9$4TQ$A$P*4HB4
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M]'@IR=DDY7.,5 D9* !SY<^\>8\PY=_=S'T>?_/6Q#S5\_@<Z : : : : :
M: ZE_P 0M^B4_<-H")3@:_-1;,_U!L_VG7G4+T_.7[L'DX0?Y XA/[5'>K_&
M,-J077OKP3FO/]]K<=5<38UMM<HU%NLA2)BRW'%["PIY1EODJ>MSZT9D'!>6
M%DJ?67+%XWG8A@JW93Z[V+<RK64!HQ9-7S\_/X D_B$WR,3%HRAVZDFE',DY
M%1HCX.U.^(V2*[.V0Z:G4-S. 4,BCUBG5IB4G3-T>D(%1T T T T!&_C/YU7
M=G_4SV<_:ANIT!)!H!H#@! >?+T#R_\ KZ= .8"(AZ0\_P#;YM <\P#SCRT!
MP @(<P'N^GT>G_+EWZ  8!\P\^0\O[?H_P"N@.AR[;,D%G3M=%LV;IF5<+KJ
M$2102(43J*K*J&*1--,@"<YSF I"@)C"!0YZF*<I*$4Y3DTHQBFY2;\)127,
MFWX27+Y\'"RRNF$[;9PJJKC*=EEDHPKKA%<RE.<FHPC%)MRDU%)-MHH5>N53
MMC55[6+'#3[-NJ9!=S$2+20106*/X22QVRJ@)J!R$>@?D(AW@ AK[9&+DXLU
M7DX]U$VN5&VN4)-?:E)+E?!\>C\/CSQT=?M]5MJ9Y&KV.%L**YNNRW#R:<F$
M)KGF$Y53DH27#?$N/'GT\GFE[Y28--4TU;:U$@F!NGXRG(QD)>X?YP.7*8AZ
M?^41#EWAKE7AY=O^5BY%GWPILDOO\J+2X^__ ).&7O-+@J3S=OK,11_F^DYV
M+2U^5EL7^7!I+D3?A#URR2U6Q_1E,C.6I181$FVL[*(C)NQN$R$8,FBQ8V4Y
MQ!WBR39U+$,=9, 7491LAT$2N,@CT?MK->\WNHIL47..-DRG5*,5R^;I0A8Z
M_$7+A0F^UMI-HU;;[<^CL?J>K1RHVNPU_P!*IQ;]OIH8>8ISL<4XX&/=EXL,
MM]THU0E+*HJG8_YU!=SIU/VT9JRK9H_*.YFZ,$;&S<'D*U3J<3PF#QZF<ITT
MV]1+)"YC(N;!!04GUV<,IJZ+G%08>>K3%4T2GA^/JM;BY4-AL9?WBVM4G+'^
MDURITFME_I>#K>5.^^OSSFYEDK9OS"JF/^&;TVG675FWU-W3/2]7_BWH[,K5
M6UAJLJK9>T#JRM^7'J3JSW5>-K\&WB,EH=!B0Q*$W&S.S+HO(>[M.QI2Z*BJ
M6N03=F[=#TG\JNHN_FI)4?YRLE,O57$D^4-Z3.7*G+F)2@4O(NK+)SLO+:]_
M=*48_P E<>(50X].RJ"C7'C[HI_>8KI^G--H836LP:Z;;O.1E62GD9V3+CS+
M*S;Y69.1-_&5MLON\%]%+RY\@Y<Q\W_KS]//\_FUU"\/K0&!]R>#X_<5A6^X
MAD),T$%QC$VS.>39(R)X>29/6TG&/_ EU$ <)(O6:)'2"3EHX79J.$4'C550
MJY*3J+2U=0:;8:BVV5"SJ'4KX14Y4SBU.NQ0DU&7;-)M<Q<H\KN3X:SSV8]=
M9?LTZZZ>ZUP\2&?9H\UWVX%ET\>O-QKJ;<;)QY6UJ3@YTW3=<W"R,+5"<JYQ
MBXO3S9)PXJKMBCIB2R(XJF6;Y(3*#^%F'%70\ I3-JB=N*=;\<*2#MM(RG,B
MTK)MP9*J)MV+(B9TV8KN,1Z']GF+TGCW1S+J=MEVW^^JR+,:,8XL8KB,<>-D
MK95SLY<KIQ:<FHI-J*;W1[>_[3&W]KN=KX:#$V/1^CP\*>-E8=.TE+)W%UTE
M*=FQLQ(8\+*,>*=>+C2][&/O+[)24K>V$FQ$B)]$"%  */=R#D!2\A    [N
M0>8  -;(X2X7V>GW?#]CRVVVVV^6_+;]6_M9VZD#0#0#0#0#0#0#0#0#0'4O
M^(6_1*?N&T!$IP-?FHMF?Z@V?[3KSJ%Z?G+]V#R<(/\ ('$)_:H[U?XQAM2#
MOXF4XA3K/B"X#)O*9*-:EE.'K%SAIK,S&6L-G>NJ%(Q.'7Q,-YUP@XK]8O;B
M)3D9?(5S>3=/J2]:8FD5:\9ZF\> 2P0:KA:$AUG:)&SI:+CU7+<CT9,C=PHT
M1.LB22,)C2!4E!,F5\8PB[ H.!$14YZ JF@&@.I<YB)'.4HF,4IC 4O\XPE*
M(@4O,0#F80 H<QY (\Q\V@/SO[(>+AN(W"9I+5KEBVE7B(N6%=R>7XC#>"XQ
M9IG;#$G@/<2?"D3C+)CW(.3VE/FK)D.'Z$^Q>RZ&)T6LN51FBT<QIB.P?/S_
M -?MR"^L?;K,D-N)-N;LZ>Q3> \D97:?M4AG%):EVQ?*N$;1&1-R;IK/RP.-
MR[>N^)9]22<LH<8VPR4IX7"2P2L9&-O%CF2 WX\LW+'LY-\O^':)_JTT \LW
M+'LY-\O^':)_JTT!B]WO<RZ?(L-!#@JS4MJ_=1R"V-+TUB3Y6,5WT ,!G%+N
M%II2;I<IQ78)QDS/1YD 2!Y)MUC.T66;:_IK7Y6E_B%N<ZKG798Y=T534X.:
M5=D6G-\**E+M;_FY43SSU-[6^IM+U]+IG$Z>JS,"O*Q,:-"JR);38PR*Z9RO
MP;5=71'EV25,94SK?NW[VVOF79F&*WFKS]QR!CZM[?LS3UUQ6>K$OD U0IZ+
MFOGNL,:>K)57+RSH1[SQK$)G>I^+WKSJ" *;P6[@>I#'7@8:Y3W&(^&U]6C,
MEZ>C[HT\>>&_"^'!M'^\V]DXJ'0V^\KGZ^9HJ^/Q[MB_P^"_/DM+*VZ?-D=6
M7+B VZY+QZJ1=#PBUWUI6)2&9-S=(IDT659LLPX%ZJIT 25D&Z4>BF"@JJ&7
M,V04M])I]1F9BJR=I7;%5RFJ:XVX\K&FDHNR^,4N$V^$^Z3C_P#/+,+Z_P"N
MNM='HOIFKZ1RL&V63539GYEF%LJ\2J<+&['BZ_)NDG*<8UJV[BB'?S).?;%X
ML\L[>&S@HHM:V+Y3S&=PR%;Y>U";Q?6ZV_$#K$(4D'>LD56>(X3!,A5U$VOB
MYP<P+,ES(F$J?RV^OT>OSK:(9>9="/#]W1"BQ0Y_T^_E;!-^C]'**;4N7QSW
M.B.I?:)U-H<;.OT>AP[+%9!9^TS-G@K+5<N(WUZW'UV9;7"2?$9N^-=LHRG7
M&-;35@/MV7$BF.DFAL5S13$3''_CQT'MZM[M,!Y  ]"3W:UQJ<Q0 !Y=$H&$
M0'GR[M4TLC!A+BG76W1]5/)V#A]W#IIQ'X^+2O\ CPI)KEY[3K.H\FGG/ZIP
M-==RO\+3=,RS8/\ ^DL_9;VB4.'X4I:EKE)]K3<5K=.[A=Y&9W^7,3M\<;PK
M#<L:)UUC?<?,L*;3:I L']P@&]OJ</8)XF])^Z7C)^$5;N7#R#+*JLFRQA<-
MP=)F8*11M<W!R:\K$PM/S0U.-4Z,YV6--OM^DSV%L:G)/CWD<:3CX<8)H^FT
MZ*Z;Z@UF5I]SU#U^Z]A2\>_+IV73%>)0I]J]\M/C=*8E^9&$HQG+#MWD(WP4
MJ??U2:LCX,(5;/R2TPZW ;!][2+(PLDX:H8=R3@)A&2 I@X%](6N<;[G,?RS
MLP"HW0BXMDB5NS KQ=P^>>%E;M^_M>J-GN'5S1_"*J/Y88F3*[(OG-.4W/(C
M37937%IJ,*FG+E2DTTHK&^DO9!T;T%'*E7L7UQFY[2G;N-(L#5X%%3DJ84:J
M>RS\?.RKHS[K[\ZJRNCM56-!J4[);K5&Y0%)4*YA.$QO .^('=*3;7:5:)<1
M#F('-+V;=W+29C@(B/3,Z$XB(CTN8ZK)9F9/S++R922\.61=+X?:Y\LRFKI[
MI^AV>XT.EQXVONG#'U6#3!OGGQ"NB,8KTX44E\.$BX'67#O;6RNSCA6[QS65
M@9NHVDBLMHB8D7:='P5R+5/=L1FHZ;= G@[E5N=9 2$ZLX= O1[,=OLX8T\.
M.9=]&GSW5N;?*ESW)2:<DGXY2:^/YUEO1'2=VWIWMFBU\MKCNMTY2I4'"57:
MJK'7!QJE;4HKW=DJW.'$5&2X35<KG$9GK5<L@X[KVP7>])7/%+BL-,@02;/:
MHBM6U[E!)V:M)N'+G=0@Q>#*02R4@F:,<O"($/U+H6[@#(%KO3Q\#*O/Q]2_
M/+-RQ[.3?+_AVB?ZM- /+-RQ[.3?+_AVB?ZM- /+-RQ[.3?+_AVB?ZM- 6+7
M.(S/6ZWY$H5<V"[WI.WXGD*[%9"A4V>U5!:M/[96V5NKS=PY=;J$&3PTE7))
ME)IGC'+U)%-<$')T'1%$" 7UY9N6/9R;Y?\ #M$_U:: >6;ECV<F^7_#M$_U
M:: >6;ECV<F^7_#M$_U:: L2E\1J=R)(9 BJ7L%WNSLABR\.,;WYL@SVJMC5
MR[M*]7+6X@7!W^ZAJF[72K]MKTD+J-.\CS)R:2)79G2+I! #(;3>/E1RZ;-U
M>'=O=8I.'"*"CUV7:5X*T(JH5,SESX-NN<./!T ,*JPH-UU@3*84D53]$A@-
MZ2F Q0,', 'T#Y^X>7H$0_ZZ ^M - - - - - =2_P"(6_1*?N&T!$IP-?FH
MMF?Z@V?[3KSJ%Z?G+]V#R<(/\@<0G]JCO5_C&&U(*KQ&FEDKU[Q'E:+<3K"
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M?%F@'EP[+?6ZVQ?7WBKXLT \N'9;ZW6V+Z^\5?%F@'EP[+?6ZVQ?7WBKXLT
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MA+0#LP^'%ZANT#W<\2?"6@'9A\.+U#=H'NYXD^$M .S#X<7J&[0/=SQ)\):
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M;QW9H2E/JH#^99,6EA3567)& 7A+<36AP1[$,EA3.*416#O47]T.SQ82I./
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MTUJ-FW3-F9P=1<S5LL^.B@9=0ZPI$**IA/TAU(,J: : : : : : : : : :
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GZ!UU%ES),V39!NF99554Q$P%10YQ$P@7!H!H!H!H!H!H!H!H#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img206969693_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img206969693_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %" JP# 2(  A$! Q$!_\0
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M> M>UC4KG4+'5%N9HK?:UO>SVC6[2J>H*GC(/I0M0>AW%%%% !1110 4444
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MR(RJ0Q*!NR3U)Y'OFNLHH 0   #H*6BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK1_7]?<#/4J*YWP;XDG\3Z7=7%U9+9W%M>26DD2R^8-R8R0<#UKHJ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ J _>/UJ>H#]X_6JB3(2BBBJ("BBB@ HHHH ****
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M<RRSV[J&2:)4DCR,X.WY6'H10*QL*Z-C:ZMGI@@YI=R_WEZXZ]Z\Y OM1NM
MN;)UBOH;>[FB2,;4D*R8V$>A''UJ.74Y=0@GOM-CWSOKL(CAF8J%D$9!5O3!
MZ_2E<?*>D/-%&</*B'_:8"A)8Y,^7(CXZ[6!Q^5<OI-K97WA^]:\B\_407-Z
M+@99)@#V[*!]W':H-/26P\%Z1)I*0PW-RD0E9=HDD7'.S=P7^M.X6.RHK$T[
M5=_ARXO9KP.UOYH>5X=I0KGAE'<=\<&L!?$VIVJWZ,[S%;2*XBDG1 4+OM+8
M4_=P<X/-%PL=U2!E8D*P)!P<'.#7':VVH06T< \0&1EOK8;XE59%5SR'QQCN
M*=)K4VF75_>2M&MC;ZBT-SA "5,:[6)]=V!^-%_Z^X+'845Q.H:WJMMIL;&[
M=;V.R-Y+%'$F!DDKN+'[N.,#FFRZO?V<^M:FMS)+LL+>:.U;!1"X.2!Z"BX6
M.XIB2QR,ZI(K-&<. <E3Z'TKD&UC6(()(7ED"RSP117MQ'&&CWD[B54D8XX)
M]:O^&D>/4?$*27'VAUNE!EP 6_=CKCC-*XK'0QR)*@>-U=#T93D&G5P6@W.H
MVFCZ)%;:@DBWPEA2'RU_<D!B&!ZG!'.?6MKPUK5WK=Q([D+#;0K#.@7K<Y._
M\N./>F-JQT=%%%,04444 .3[XJ:H4^^*FJ)%QV"BBBD4%%%% !1110 4444
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M+O;"JF<='(&":ZJG-["%Y76NG8Z*G-[*-WIV-&BBBN4YPHHIK@M&R@X)& :
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M4E% !1113 **** "BBB@ HHHH <GWQ4U0I]\5-42+CL%%%%(H**** "BBB@
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M\U"XLHK\>; KLS,C*C!/O[6(PVWO@\5+HGBO1_$)E73KHN\0#,DD;1MM;[K
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M<7TSRD(2BJ>W6KUE=_:%((PZ]?>ATVE<U<&E<M4445! 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5 ?O'ZU/4!^\?K51)D)1115$!111
M0 452U/5K#1K3[3J%RL$1;:I/)9O0 <D_2ETS5;'6;076GW*3PY*DKP5(Z@@
M\@_6D!<HI<'TIDSB""2:3(2-2S'V R:+@.HJE:ZK:7FBIJ\+.UF\1F5MAR5^
MG6K-M,EW:Q7$.XQRJ'4LI!P?4'I0!)12X/I5*YU2SM(C+)-N43"!O*!<JY.
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M3)[E5O;O)@BP26 ZGV'UJ_D^M,5SR#7(;F74[M=02_EU5=4MC#M5S#]G!7D
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M(ZY_&A:?UZ?Y W<****8AR??%35"GWQ4U1(N.P4444B@HHHH **** "BBB@
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M?UT-*BBBF(<GWQ4U0I]\5-42+CL%%%%(H**** "BBB@ HHHH **** "BBB@
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>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>inkt-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-21T12:40:06.7010+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://minktherapeutics.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:inkt="http://minktherapeutics.com/20231231">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" namespace="http://xbrl.sec.gov/country/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet" id="Role_StatementConsolidatedBalanceSheet">
        <link:definition>100010 - Statement - Consolidated Balance Sheet</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetParenthetical" id="Role_StatementConsolidatedBalanceSheetParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheet (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statement of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit" id="StatementConsolidatedStatementOfStockholdersDeficit">
        <link:definition>100040 - Statement - Consolidated Statement of Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfStockholdersEquityDeficitParenthetical" id="Role_StatementConsolidatedStatementOfStockholdersEquityDeficitParenthetical">
        <link:definition>100050 - Statement - Consolidated Statement of Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows" id="Role_StatementConsolidatedStatementOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlowsParenthetical" id="Role_StatementConsolidatedStatementOfCashFlowsParenthetical">
        <link:definition>100070 - Statement - Consolidated Statement of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness" id="Role_DisclosureDescriptionOfBusiness">
        <link:definition>995455 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalents" id="DisclosureCashAndCashEquivalents">
        <link:definition>995475 - Disclosure - Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipment" id="Role_DisclosureEquipment">
        <link:definition>995485 - Disclosure - Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995495 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities" id="Role_DisclosureAccruedLiabilities">
        <link:definition>995505 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquity" id="Role_DisclosureEquity">
        <link:definition>995515 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlans" id="Role_DisclosureShareBasedCompensationPlans">
        <link:definition>995525 - Disclosure - Share-based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreement" id="Role_DisclosureResearchAndDevelopmentAgreement">
        <link:definition>995535 - Disclosure - Research and Development Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>995545 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureOtherLongTermLiabilities" id="Role_DisclosureOtherLongTermLiabilities">
        <link:definition>995555 - Disclosure - Other Long-term Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurement" id="Role_DisclosureFairValueMeasurement">
        <link:definition>995565 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureContingencies" id="Role_DisclosureContingencies">
        <link:definition>995575 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureBenefitPlans" id="Role_DisclosureBenefitPlans">
        <link:definition>995585 - Disclosure - Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995595 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995605 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995615 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsTables" id="DisclosureCashAndCashEquivalentsTables">
        <link:definition>995625 - Disclosure - Cash and Cash Equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentTables" id="Role_DisclosureEquipmentTables">
        <link:definition>995635 - Disclosure - Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995645 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" id="Role_DisclosureAccruedLiabilitiesTables">
        <link:definition>995655 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables" id="Role_DisclosureShareBasedCompensationPlansTables">
        <link:definition>995665 - Disclosure - Share-based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" id="Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>995675 - Disclosure - Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995685 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesDetails">
        <link:definition>995695 - Disclosure - Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails" id="DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails">
        <link:definition>995705 - Disclosure - Cash and Cash Equivalents - Summary of Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentSummaryOfEquipmentNetDetails" id="Role_DisclosureEquipmentSummaryOfEquipmentNetDetails">
        <link:definition>995715 - Disclosure - Equipment - Summary of Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995725 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>995735 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails" id="Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails">
        <link:definition>995745 - Disclosure - Income Taxes - Income Taxes Recorded Differed from Amounts Computed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" id="Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails">
        <link:definition>995755 - Disclosure - Accrued Liabilities - Summary of Accrued liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" id="Role_DisclosureEquityAdditionalInformationDetails">
        <link:definition>995765 - Disclosure - Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" id="Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails">
        <link:definition>995775 - Disclosure - Share-based Compensation Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfFairValueOfOptionsGrantedUnderWeightedAverageAssumptionsDetails" id="Role_DisclosureShareBasedCompensationPlansSummaryOfFairValueOfOptionsGrantedUnderWeightedAverageAssumptionsDetails">
        <link:definition>995785 - Disclosure - Share-based Compensation Plans - Summary of Fair value of Options Granted Under Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" id="Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails">
        <link:definition>995795 - Disclosure - Share-based Compensation Plans - Summary of Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails" id="Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails">
        <link:definition>995805 - Disclosure - Share-based Compensation Plans - Summary of Non-vested Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>995815 - Disclosure - Share-based Compensation Plans - Summary of Stock Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails" id="Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails">
        <link:definition>995825 - Disclosure - Research and Development Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>995835 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureOtherLongTermLiabilitiesAdditionalInformationDetails" id="Role_DisclosureOtherLongTermLiabilitiesAdditionalInformationDetails">
        <link:definition>995845 - Disclosure - Other Long-term Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>995855 - Disclosure - Fair Value Measurement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureBenefitPlansAdditionalInformationDetails" id="Role_DisclosureBenefitPlansAdditionalInformationDetails">
        <link:definition>995865 - Disclosure - Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>995875 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="inkt-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet" xlink:href="inkt-20231231.xsd#Role_StatementConsolidatedBalanceSheet" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetParenthetical" xlink:href="inkt-20231231.xsd#Role_StatementConsolidatedBalanceSheetParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss" xlink:href="inkt-20231231.xsd#Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit" xlink:href="inkt-20231231.xsd#StatementConsolidatedStatementOfStockholdersDeficit" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfStockholdersEquityDeficitParenthetical" xlink:href="inkt-20231231.xsd#Role_StatementConsolidatedStatementOfStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows" xlink:href="inkt-20231231.xsd#Role_StatementConsolidatedStatementOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlowsParenthetical" xlink:href="inkt-20231231.xsd#Role_StatementConsolidatedStatementOfCashFlowsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness" xlink:href="inkt-20231231.xsd#Role_DisclosureDescriptionOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="inkt-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalents" xlink:href="inkt-20231231.xsd#DisclosureCashAndCashEquivalents" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipment" xlink:href="inkt-20231231.xsd#Role_DisclosureEquipment" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="inkt-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities" xlink:href="inkt-20231231.xsd#Role_DisclosureAccruedLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquity" xlink:href="inkt-20231231.xsd#Role_DisclosureEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlans" xlink:href="inkt-20231231.xsd#Role_DisclosureShareBasedCompensationPlans" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreement" xlink:href="inkt-20231231.xsd#Role_DisclosureResearchAndDevelopmentAgreement" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="inkt-20231231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureOtherLongTermLiabilities" xlink:href="inkt-20231231.xsd#Role_DisclosureOtherLongTermLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurement" xlink:href="inkt-20231231.xsd#Role_DisclosureFairValueMeasurement" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureContingencies" xlink:href="inkt-20231231.xsd#Role_DisclosureContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureBenefitPlans" xlink:href="inkt-20231231.xsd#Role_DisclosureBenefitPlans" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="inkt-20231231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="inkt-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="inkt-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsTables" xlink:href="inkt-20231231.xsd#DisclosureCashAndCashEquivalentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentTables" xlink:href="inkt-20231231.xsd#Role_DisclosureEquipmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="inkt-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" xlink:href="inkt-20231231.xsd#Role_DisclosureAccruedLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables" xlink:href="inkt-20231231.xsd#Role_DisclosureShareBasedCompensationPlansTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails" xlink:href="inkt-20231231.xsd#DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentSummaryOfEquipmentNetDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureEquipmentSummaryOfEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfFairValueOfOptionsGrantedUnderWeightedAverageAssumptionsDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureShareBasedCompensationPlansSummaryOfFairValueOfOptionsGrantedUnderWeightedAverageAssumptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureOtherLongTermLiabilitiesAdditionalInformationDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureOtherLongTermLiabilitiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureBenefitPlansAdditionalInformationDetails" xlink:href="inkt-20231231.xsd#Role_DisclosureBenefitPlansAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="inkt-20231231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="us-gaap_DebtInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DrBuellMember" xlink:label="inkt_DrBuellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits" xlink:label="inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_EmployeeBonusMember" xlink:label="inkt_EmployeeBonusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AccountingPoliciesTable" xlink:label="inkt_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_HK" xlink:label="country_HK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AtlantClinicalLtdMember" xlink:label="inkt_AtlantClinicalLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ForgivenessOfRelatedPartyLiabilityMember" xlink:label="inkt_ForgivenessOfRelatedPartyLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DirectorsOrOfficersMember" xlink:label="inkt_DirectorsOrOfficersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote" xlink:label="inkt_IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PurchasesOfPlantAndEquipmentInAccountsPayable" xlink:label="inkt_PurchasesOfPlantAndEquipmentInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan" xlink:label="inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ClosingBidPriceForTenTradingDays" xlink:label="inkt_ClosingBidPriceForTenTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_MinimumBidPrice" xlink:label="inkt_MinimumBidPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_MinimumValueOfListedSecurities" xlink:label="inkt_MinimumValueOfListedSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_LegalFeesPercentage" xlink:label="inkt_LegalFeesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ClinicalResearchServices" xlink:label="inkt_ClinicalResearchServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ServiceAgreementNoticePeriod" xlink:label="inkt_ServiceAgreementNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition" xlink:label="inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_InitialCompliancePeriod" xlink:label="inkt_InitialCompliancePeriod"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncomeTaxReconciliationUncertainTaxPositions" xlink:label="inkt_IncomeTaxReconciliationUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ValueAddedTaxAccruedLiabilitiesCurrent" xlink:label="inkt_ValueAddedTaxAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ImpactOfChangeInFairValueDisclosure" xlink:label="inkt_ImpactOfChangeInFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion" xlink:label="inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongtermDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_OtherLongtermDebtCurrentAndNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ConvertiblePromissoryNoteMember" xlink:label="inkt_ConvertiblePromissoryNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange" xlink:label="inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_InterestAccruedOnConvertibleAffiliatedNote" xlink:label="inkt_InterestAccruedOnConvertibleAffiliatedNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_GainOnForgivenessOfLiability" xlink:label="inkt_GainOnForgivenessOfLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PaycheckProtectionProgramLoanMember" xlink:label="inkt_PaycheckProtectionProgramLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DueToRelatedParty" xlink:label="inkt_DueToRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_RepayableAdvanceOfDevelopmentGranted" xlink:label="inkt_RepayableAdvanceOfDevelopmentGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NewIntercompanyServiceAgreementMember" xlink:label="inkt_NewIntercompanyServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_OtherLongTermLiabilitiesTextBlock" xlink:label="inkt_OtherLongTermLiabilitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncreaseDecreaseInRepayableAdvanceReceived" xlink:label="inkt_IncreaseDecreaseInRepayableAdvanceReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PurchaseAgreementMember" xlink:label="inkt_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NumberOfConsecutivetradingDays" xlink:label="inkt_NumberOfConsecutivetradingDays"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NonVestedSharesMember" xlink:label="inkt_NonVestedSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NetProceedsFromIssuanceOfCommonStock" xlink:label="inkt_NetProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering" xlink:label="inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AccruedContractManufacturingExpenseCurrent" xlink:label="inkt_AccruedContractManufacturingExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BE" xlink:label="country_BE"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ServicesMember" xlink:label="inkt_ServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AdditionalPeriodForMinimumValueOfListedSecurities" xlink:label="inkt_AdditionalPeriodForMinimumValueOfListedSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes" xlink:label="inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NasdaqMvlsNoticeMember" xlink:label="inkt_NasdaqMvlsNoticeMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ResearchServicesMember" xlink:label="inkt_ResearchServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_RepayableAdvanceOfDevelopment" xlink:label="inkt_RepayableAdvanceOfDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ChangeInFairValueOfConvertibleAffiliatedNote" xlink:label="inkt_ChangeInFairValueOfConvertibleAffiliatedNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation" xlink:label="inkt_StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_SecondCompliancePeriod" xlink:label="inkt_SecondCompliancePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_BusinessServicesAndOccupancyCostsMember" xlink:label="inkt_BusinessServicesAndOccupancyCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings" xlink:label="inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PeriodOfLicenseAgreement" xlink:label="inkt_PeriodOfLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_TwoThousandAndEighteenEIPMember" xlink:label="inkt_TwoThousandAndEighteenEIPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DepreciationExpenseOnPropertyPlantAndEquipment" xlink:label="inkt_DepreciationExpenseOnPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossMember" xlink:label="us-gaap_OperatingIncomeLossMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding" xlink:label="inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PercentageOfServiceCost" xlink:label="inkt_PercentageOfServiceCost"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AuthorizedCapitalStockIncreased" xlink:label="inkt_AuthorizedCapitalStockIncreased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AgenusIncMember" xlink:label="inkt_AgenusIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_WolfGreenfieldSachsPCMember" xlink:label="inkt_WolfGreenfieldSachsPCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" xlink:label="inkt_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncomeTaxLineItems" xlink:label="inkt_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PeriodForBreachOfPaymentObligations" xlink:label="inkt_PeriodForBreachOfPaymentObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AdditionalCompliancePeriod" xlink:label="inkt_AdditionalCompliancePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PaymentForServicesMember" xlink:label="inkt_PaymentForServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_InsuranceFinancingAgreement" xlink:label="inkt_InsuranceFinancingAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncomeTaxTable" xlink:label="inkt_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="us-gaap_DefinedBenefitPlanTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_TerminateLicenseAgreementPeriod" xlink:label="inkt_TerminateLicenseAgreementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_RepayableAdvanceReceivedNoncurrent" xlink:label="inkt_RepayableAdvanceReceivedNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AccruedResearchServicesCurrent" xlink:label="inkt_AccruedResearchServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IssuanceOfCommonStockForPaymentOfServices" xlink:label="inkt_IssuanceOfCommonStockForPaymentOfServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_MinimumValueOfListedSecuritiesPeriod" xlink:label="inkt_MinimumValueOfListedSecuritiesPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PercentageOfComputationOfInterest" xlink:label="inkt_PercentageOfComputationOfInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IndividualServicesMember" xlink:label="inkt_IndividualServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_TwoThousandAndTwentyOneEIPMember" xlink:label="inkt_TwoThousandAndTwentyOneEIPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_RepayableAdvanceReceived" xlink:label="inkt_RepayableAdvanceReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAbstract" xlink:label="us-gaap_LossContingencyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote" xlink:label="inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_CapitalizedExpensesAmortizationPeriod" xlink:label="inkt_CapitalizedExpensesAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_OtherIncomeExpenseNetMember" xlink:label="inkt_OtherIncomeExpenseNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AccountingPoliciesLineItems" xlink:label="inkt_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PercentageOfSharesOfCompanySCommonStockOutstanding" xlink:label="inkt_PercentageOfSharesOfCompanySCommonStockOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NasdaqMinimumBidPriceNoticeMember" xlink:label="inkt_NasdaqMinimumBidPriceNoticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IntercompanyAllocationIncludedInExpense" xlink:label="inkt_IntercompanyAllocationIncludedInExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises" xlink:label="inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_MinimumValueOfListedSecuritiesForTenTradingDays" xlink:label="inkt_MinimumValueOfListedSecuritiesForTenTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncomeTaxReconciliationReturnToProvisionAdjustment" xlink:label="inkt_IncomeTaxReconciliationReturnToProvisionAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_WorkOrderReceivedFromRelatedParty" xlink:label="inkt_WorkOrderReceivedFromRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible debt outstanding amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Convertible Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding at December 31, 2023, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Institutional Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option, vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instruments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_DrBuellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dr. Buell</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_DrBuellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dr. Buell [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_DrBuellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dr. Buell.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other operating assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development Tax Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets in process research and development tax credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 Employee Stock Purchase Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance, Deferred tax asset, increase (decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_EmployeeBonusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Bonus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_EmployeeBonusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Bonus [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_EmployeeBonusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Bonus.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Income (Expense), Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting Policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of shares for services, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_HK_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hong Kong</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_HK_lbl" xlink:role="http://www.xbrl.org/2003/role/label">HONG KONG</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options, Outstanding at Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options, Outstanding at Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant-date fair values of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AtlantClinicalLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Atlant Clinical Ltd [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AtlantClinicalLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Atlant Clinical Ltd [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AtlantClinicalLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Atlant Clinical Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AtlantClinicalLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Atlant Clinical Ltd</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ForgivenessOfRelatedPartyLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forgiveness of Related Party Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ForgivenessOfRelatedPartyLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forgiveness of Related Party Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ForgivenessOfRelatedPartyLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Forgiveness of related party liability member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive (loss) gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_DirectorsOrOfficersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Directors or Officers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_DirectorsOrOfficersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Directors or Officers [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_DirectorsOrOfficersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Directors or officers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options and employee share purchases, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised And Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares stock options exercised and employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of convertible affiliated note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Fair Value Of Convertible Affiliated Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation change in fair value of convertible affiliated note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign rate differential</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible debt issued, principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Issued, Principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PurchasesOfPlantAndEquipmentInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases of plant and equipment in accounts payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PurchasesOfPlantAndEquipmentInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases Of Plant And Equipment In Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PurchasesOfPlantAndEquipmentInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of plant and equipment in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested or expected to vest at December 31, 2023, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Including Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment, net of accumulated depreciation of $495,638 and $283,682 as of December 31, 2023 and 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split ratio, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested or expected to vest at December 31, 2023, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for issuance under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Reserved For Issuance Under Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares reserved for issuance under Employee Stock Purchase Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal services fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ClosingBidPriceForTenTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing bid price for ten trading days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ClosingBidPriceForTenTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Closing Bid Price For Ten Trading Days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ClosingBidPriceForTenTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Closing bid price for ten trading days.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_MinimumBidPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum bid price required for Listing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_MinimumBidPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Bid Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_MinimumBidPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum bid price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense related to stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Nonvested Shares, Outstanding at Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Nonvested Shares, Outstanding at Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_MinimumValueOfListedSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum value of listed securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_MinimumValueOfListedSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Value of Listed Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_MinimumValueOfListedSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum value of listed securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computed &#8220;expected&#8221; Federal tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_LegalFeesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legal fees percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_LegalFeesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal fees percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ClinicalResearchServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical research services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ClinicalResearchServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Research Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ClinicalResearchServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical research services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ServiceAgreementNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service agreement notice period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ServiceAgreementNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service Agreement Notice Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ServiceAgreementNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Service agreement notice period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value $0.00001 per share, 150,000,000 shares authorized, 34,599,119 and 33,856,428 shares issued and outstanding as of December 31, 2023 and 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant and recognition of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital share based compensation stock options grant and recognition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Note converted into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_InitialCompliancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial compliance period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_InitialCompliancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Compliance Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_InitialCompliancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial compliance period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncomeTaxReconciliationUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncomeTaxReconciliationUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Uncertain Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncomeTaxReconciliationUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation uncertain tax positions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ValueAddedTaxAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">VAT</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ValueAddedTaxAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Value Added Tax Accrued Liabilities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ValueAddedTaxAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value added tax accrued liabilities current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible affiliated note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Payable, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ImpactOfChangeInFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of change in fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ImpactOfChangeInFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impact Of Change In Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ImpactOfChangeInFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impact of change in fair value disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Shares, Retired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement of treasury shares, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued, vesting of non-vested stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of nonvested shares, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding at December 31, 2023, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory note principal balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, foreign income inclusion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective income tax rate reconciliation, foreign income inclusion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign income inclusion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (loss), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLongtermDebtCurrentAndNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Long-Term Debt [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Promissory Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Increase) reduction in income taxes benefit resulting from:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares options, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, foreign rate change.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign rate change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign rate change</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_InterestAccruedOnConvertibleAffiliatedNote_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest accrued on convertible affiliated note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_InterestAccruedOnConvertibleAffiliatedNote_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Accrued On Convertible Affiliated Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_InterestAccruedOnConvertibleAffiliatedNote_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest accrued on convertible affiliated note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible debt, interest rate terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options and employee share purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value stock options exercised and employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increasing amount of borrowing capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Per common share data:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_GainOnForgivenessOfLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on forgiveness of liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_GainOnForgivenessOfLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on forgiveness of liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_GainOnForgivenessOfLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain On Forgiveness Of Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_GainOnForgivenessOfLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain on forgiveness of liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PaycheckProtectionProgramLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paycheck Protection Program Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PaycheckProtectionProgramLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paycheck Protection Program Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PaycheckProtectionProgramLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Paycheck protection program loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic net loss per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash and Cash Equivalents [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_DueToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_DueToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_DueToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Due to related party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options, Vested or expected to vest at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_RepayableAdvanceOfDevelopmentGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development agreement amount granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_RepayableAdvanceOfDevelopmentGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayable Advance Of Development Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_RepayableAdvanceOfDevelopmentGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayable advance of development granted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of shares vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NewIntercompanyServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Intercompany Service Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NewIntercompanyServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Intercompany Service Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NewIntercompanyServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Intercompany Service Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted net loss per common share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Federal and state net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_OtherLongTermLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Long-Term Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_OtherLongTermLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Long Term Liabilities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_OtherLongTermLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for information about other long-term liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncreaseDecreaseInRepayableAdvanceReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayable advance received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncreaseDecreaseInRepayableAdvanceReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Repayable Advance Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncreaseDecreaseInRepayableAdvanceReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in repayable advance received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Benefit Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of shares for employee bonuses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax years open for examination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options, Exercisable at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NumberOfConsecutivetradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of consecutive trading days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NumberOfConsecutivetradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of ConsecutiveTrading Days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NumberOfConsecutivetradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of consecutive trading days.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Currency Transaction Gain (Loss), before Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign currency loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate loan proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Loans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NonVestedSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Vested Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NonVestedSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Vested Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NonVestedSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-vested shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Issuance Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NetProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from issuance of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage value of common stock sold in initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Value Of Common Stock Sold In Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage value of common stock sold in initial public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock option exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS' DEFICIT</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeiture of restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment, Excluding Long-Term Commitment [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AccruedContractManufacturingExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract manufacturing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AccruedContractManufacturingExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Contract Manufacturing Expense Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AccruedContractManufacturingExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued contract manufacturing expense current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_BE_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Belgium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_BE_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BELGIUM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Benefit Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of shares for employee bonuses, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued, payment for employee bonuses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, $0.00001 par value, for payment of employee bonuses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Nonvested Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at December 31, 2023, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair value of Options Granted Under Weighted Average Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AdditionalPeriodForMinimumValueOfListedSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum value of listed securities regain compliance period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AdditionalPeriodForMinimumValueOfListedSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Value of Listed Securities Regain Compliance Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AdditionalPeriodForMinimumValueOfListedSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum value of listed securities regain compliance period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share retirement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased and Retired During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average period of unrecognized share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Description of Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested or expected to vest at December 31, 2023, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares, employee benefit plan net of shares withheld for taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Benefit Plan Net of Shares Withheld for Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, payment for employee bonuses, net of shares withheld for taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NasdaqMvlsNoticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nasdaq MVLS Notice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NasdaqMvlsNoticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nasdaq MVLS Notice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NasdaqMvlsNoticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nasdaq MVLS notice.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ResearchServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ResearchServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ResearchServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research Services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_RepayableAdvanceOfDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayable advance of development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_RepayableAdvanceOfDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayable Advance Of Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_RepayableAdvanceOfDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayable advance of development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeiture of restricted stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance of shares for employee bonus, treasury shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock Issued During Period Shares Employee Benefit Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury stock issued during period shares employee benefit plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Anti-dilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ChangeInFairValueOfConvertibleAffiliatedNote_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of convertible affiliated note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ChangeInFairValueOfConvertibleAffiliatedNote_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Convertible Affiliated Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ChangeInFairValueOfConvertibleAffiliatedNote_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of convertible affiliated note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance of Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period additional shares share based compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Additional Shares Share Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in number of shares in share pool</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment, net of accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_SecondCompliancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second compliance period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_SecondCompliancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Compliance Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_SecondCompliancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second compliance period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Extinguishment of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_BusinessServicesAndOccupancyCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Services and Occupancy Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_BusinessServicesAndOccupancyCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Services And Occupancy Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_BusinessServicesAndOccupancyCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business Services and Occupancy Costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of treasury shares to satisfy tax withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Of Treasury Shares To Satisfy Tax Withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of treasury shares to satisfy tax withholdings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PeriodOfLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of license agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PeriodOfLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period Of License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PeriodOfLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_TwoThousandAndEighteenEIPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 EIP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_TwoThousandAndEighteenEIPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen E I P [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_TwoThousandAndEighteenEIPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2018 EIP.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_DepreciationExpenseOnPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_DepreciationExpenseOnPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Expense on Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_DepreciationExpenseOnPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Depreciation expense on property, plant, and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United Kingdom</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED KINGDOM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ratio of annual increase shares reserved for issuance under ESPP to number of shares of common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ratio Of Annual Increase Shares Reserved For Issuance Under E S P P To Number Of Shares Of Common Stock Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ratio of annual increase shares reserved for issuance under ESPP to number of shares of common stock outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments of Financing Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Financing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total anti-dilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at December 31, 2023, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PercentageOfServiceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of service cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PercentageOfServiceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Service Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PercentageOfServiceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of service cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AuthorizedCapitalStockIncreased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Authorized capital stock increased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AuthorizedCapitalStockIncreased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Authorized Capital Stock Increased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AuthorizedCapitalStockIncreased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Authorized capital stock increased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of convertible affiliated note to common stock, $0.00001 par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible affiliated note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Purchase Commitment, Category of Item Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding principal amount of notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AgenusIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Agenus Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AgenusIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agenus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AgenusIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agenus Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AgenusIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agenus Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_WolfGreenfieldSachsPCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Wolf, Greenfield &amp; Sachs, P.C.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_WolfGreenfieldSachsPCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wolf, Greenfield &amp; Sachs, P.C. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_WolfGreenfieldSachsPCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Wolf, Greenfield &amp; Sachs, P.C.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts, commissions and other offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts Commissions And Other Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts, commissions and other offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses from transactions with related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Costs and Expenses, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options excercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of nonvested shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PeriodForBreachOfPaymentObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period for breach of payment obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PeriodForBreachOfPaymentObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period For Breach Of Payment Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PeriodForBreachOfPaymentObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period for breach of payment obligations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Category of Item Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Category of Item Purchased [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AdditionalCompliancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional compliance period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AdditionalCompliancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Compliance Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AdditionalCompliancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional compliance period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PaymentForServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment For Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PaymentForServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment For Services Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PaymentForServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment For Services Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_InsuranceFinancingAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance financing agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_InsuranceFinancingAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Financing Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_InsuranceFinancingAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Insurance financing agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Retired, Cost Method, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement of treasury shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding at Beginning Balance, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at Ending Balance, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_TerminateLicenseAgreementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Terminate license agreement period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_TerminateLicenseAgreementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Terminate License Agreement Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_TerminateLicenseAgreementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Terminate license agreement period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term in years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of business segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Non-vested Stock Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_RepayableAdvanceReceivedNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayable advance received noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_RepayableAdvanceReceivedNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayable Advance Received Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_RepayableAdvanceReceivedNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayable advance received noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AccruedResearchServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AccruedResearchServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research Services Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AccruedResearchServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research services current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense related to non-vested shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, withheld to cover taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IssuanceOfCommonStockForPaymentOfServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock for payment of services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IssuanceOfCommonStockForPaymentOfServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock for payment of services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IssuanceOfCommonStockForPaymentOfServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, $0.00001 par value, for payment of services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible debt, annual interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate During Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_MinimumValueOfListedSecuritiesPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of trading days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_MinimumValueOfListedSecuritiesPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Value of Listed Securities Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_MinimumValueOfListedSecuritiesPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum value of listed securities period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PercentageOfComputationOfInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of computation of interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PercentageOfComputationOfInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Computation Of Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PercentageOfComputationOfInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of computation of interest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition of parent stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and local income benefit, net of Federal income tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IndividualServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Individual Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IndividualServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Individual Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IndividualServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Individual Services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other income (expense), net:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_TwoThousandAndTwentyOneEIPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 EIP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_TwoThousandAndTwentyOneEIPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand and Twenty One E I P [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_TwoThousandAndTwentyOneEIPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one E I P.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option grants, term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_RepayableAdvanceReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayable advance received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_RepayableAdvanceReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayable Advance Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_RepayableAdvanceReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayable advance received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense related to discretionary contribution to the Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable at December 31, 2023, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible affiliated note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Affiliated Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of convertible affiliated note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible affiliated note, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_CapitalizedExpensesAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized expenses amortization period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_CapitalizedExpensesAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized expenses amortization period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment, Excluding Long-Term Commitment [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_OtherIncomeExpenseNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income (Expense), Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_OtherIncomeExpenseNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income Expense Net [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_OtherIncomeExpenseNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Income (Expense), Net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Nonvested Shares, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional number of shares authorised in share pool</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting Policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures - non-cash activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expired, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PercentageOfSharesOfCompanySCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares of company's common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PercentageOfSharesOfCompanySCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Shares Of Company S Common Stock Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_PercentageOfSharesOfCompanySCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of shares of company's common stock outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, Expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NasdaqMinimumBidPriceNoticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nasdaq Minimum Bid Price Notice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NasdaqMinimumBidPriceNoticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nasdaq Minimum Bid Price Notice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_NasdaqMinimumBidPriceNoticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nasdaq minimum bid price notice.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IntercompanyAllocationIncludedInExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intercompany allocation included in expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IntercompanyAllocationIncludedInExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intercompany Allocation Included in Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IntercompanyAllocationIncludedInExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intercompany allocation included in expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from employee stock purchases and option exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Employee Stock Purchases And Option Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from employee stock purchases and option exercises.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of offering costs of approximately $6.2 million</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares grated as a result of equity incentive plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes Recorded Differed from Amounts Computed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_MinimumValueOfListedSecuritiesForTenTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum value of listed securities for ten trading days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_MinimumValueOfListedSecuritiesForTenTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Value of Listed Securities for Ten Trading Days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_MinimumValueOfListedSecuritiesForTenTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum value of listed securities for ten trading days.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of shares for services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding at Beginning Balance, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at Ending Balance, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncomeTaxReconciliationReturnToProvisionAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation return-to-provision adjustment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncomeTaxReconciliationReturnToProvisionAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Return-to-provision Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_IncomeTaxReconciliationReturnToProvisionAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Return-to-provision adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Salary and Wage, Excluding Cost of Good and Service Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Salary and Wage, Excluding Cost of Good and Service Sold, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_WorkOrderReceivedFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work order received from related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_WorkOrderReceivedFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Work Order Received From Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inkt_WorkOrderReceivedFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Work order received from related party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Nonvested Shares, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering, net of offering costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_DrBuellMember" xlink:to="inkt_DrBuellMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits" xlink:to="inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:to="inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_EmployeeBonusMember" xlink:to="inkt_EmployeeBonusMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_AccountingPoliciesTable" xlink:to="inkt_AccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_AtlantClinicalLtdMember" xlink:to="inkt_AtlantClinicalLtdMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_ForgivenessOfRelatedPartyLiabilityMember" xlink:to="inkt_ForgivenessOfRelatedPartyLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_DirectorsOrOfficersMember" xlink:to="inkt_DirectorsOrOfficersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:to="inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote" xlink:to="inkt_IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_PurchasesOfPlantAndEquipmentInAccountsPayable" xlink:to="inkt_PurchasesOfPlantAndEquipmentInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan" xlink:to="inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_ClosingBidPriceForTenTradingDays" xlink:to="inkt_ClosingBidPriceForTenTradingDays_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_MinimumBidPrice" xlink:to="inkt_MinimumBidPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_MinimumValueOfListedSecurities" xlink:to="inkt_MinimumValueOfListedSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_LegalFeesPercentage" xlink:to="inkt_LegalFeesPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_ClinicalResearchServices" xlink:to="inkt_ClinicalResearchServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_ServiceAgreementNoticePeriod" xlink:to="inkt_ServiceAgreementNoticePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition" xlink:to="inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_InitialCompliancePeriod" xlink:to="inkt_InitialCompliancePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_IncomeTaxReconciliationUncertainTaxPositions" xlink:to="inkt_IncomeTaxReconciliationUncertainTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_ValueAddedTaxAccruedLiabilitiesCurrent" xlink:to="inkt_ValueAddedTaxAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_ImpactOfChangeInFairValueDisclosure" xlink:to="inkt_ImpactOfChangeInFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesRetired" xlink:to="us-gaap_TreasuryStockSharesRetired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion" xlink:to="inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongtermDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_OtherLongtermDebtCurrentAndNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_ConvertiblePromissoryNoteMember" xlink:to="inkt_ConvertiblePromissoryNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange" xlink:to="inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_InterestAccruedOnConvertibleAffiliatedNote" xlink:to="inkt_InterestAccruedOnConvertibleAffiliatedNote_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:to="inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_GainOnForgivenessOfLiability" xlink:to="inkt_GainOnForgivenessOfLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_PaycheckProtectionProgramLoanMember" xlink:to="inkt_PaycheckProtectionProgramLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_DueToRelatedParty" xlink:to="inkt_DueToRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_RepayableAdvanceOfDevelopmentGranted" xlink:to="inkt_RepayableAdvanceOfDevelopmentGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_NewIntercompanyServiceAgreementMember" xlink:to="inkt_NewIntercompanyServiceAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_OtherLongTermLiabilitiesTextBlock" xlink:to="inkt_OtherLongTermLiabilitiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_IncreaseDecreaseInRepayableAdvanceReceived" xlink:to="inkt_IncreaseDecreaseInRepayableAdvanceReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_PurchaseAgreementMember" xlink:to="inkt_PurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_NumberOfConsecutivetradingDays" xlink:to="inkt_NumberOfConsecutivetradingDays_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_NonVestedSharesMember" xlink:to="inkt_NonVestedSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_NetProceedsFromIssuanceOfCommonStock" xlink:to="inkt_NetProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering" xlink:to="inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_AccruedContractManufacturingExpenseCurrent" xlink:to="inkt_AccruedContractManufacturingExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BE" xlink:to="country_BE_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_ServicesMember" xlink:to="inkt_ServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_AdditionalPeriodForMinimumValueOfListedSecurities" xlink:to="inkt_AdditionalPeriodForMinimumValueOfListedSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes" xlink:to="inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_NasdaqMvlsNoticeMember" xlink:to="inkt_NasdaqMvlsNoticeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_ResearchServicesMember" xlink:to="inkt_ResearchServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_RepayableAdvanceOfDevelopment" xlink:to="inkt_RepayableAdvanceOfDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_ChangeInFairValueOfConvertibleAffiliatedNote" xlink:to="inkt_ChangeInFairValueOfConvertibleAffiliatedNote_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation" xlink:to="inkt_StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_SecondCompliancePeriod" xlink:to="inkt_SecondCompliancePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_BusinessServicesAndOccupancyCostsMember" xlink:to="inkt_BusinessServicesAndOccupancyCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings" xlink:to="inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_PeriodOfLicenseAgreement" xlink:to="inkt_PeriodOfLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_TwoThousandAndEighteenEIPMember" xlink:to="inkt_TwoThousandAndEighteenEIPMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_DepreciationExpenseOnPropertyPlantAndEquipment" xlink:to="inkt_DepreciationExpenseOnPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLossMember" xlink:to="us-gaap_OperatingIncomeLossMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding" xlink:to="inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_PercentageOfServiceCost" xlink:to="inkt_PercentageOfServiceCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_AuthorizedCapitalStockIncreased" xlink:to="inkt_AuthorizedCapitalStockIncreased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_AgenusIncMember" xlink:to="inkt_AgenusIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_WolfGreenfieldSachsPCMember" xlink:to="inkt_WolfGreenfieldSachsPCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" xlink:to="inkt_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_IncomeTaxLineItems" xlink:to="inkt_IncomeTaxLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_PeriodForBreachOfPaymentObligations" xlink:to="inkt_PeriodForBreachOfPaymentObligations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_AdditionalCompliancePeriod" xlink:to="inkt_AdditionalCompliancePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_PaymentForServicesMember" xlink:to="inkt_PaymentForServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_InsuranceFinancingAgreement" xlink:to="inkt_InsuranceFinancingAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDisclosures" xlink:to="us-gaap_LossContingencyDisclosures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="us-gaap_TreasuryStockRetiredCostMethodAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_IncomeTaxTable" xlink:to="inkt_IncomeTaxTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanTextBlock" xlink:to="us-gaap_DefinedBenefitPlanTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_TerminateLicenseAgreementPeriod" xlink:to="inkt_TerminateLicenseAgreementPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_RepayableAdvanceReceivedNoncurrent" xlink:to="inkt_RepayableAdvanceReceivedNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_AccruedResearchServicesCurrent" xlink:to="inkt_AccruedResearchServicesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_IssuanceOfCommonStockForPaymentOfServices" xlink:to="inkt_IssuanceOfCommonStockForPaymentOfServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_MinimumValueOfListedSecuritiesPeriod" xlink:to="inkt_MinimumValueOfListedSecuritiesPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_PercentageOfComputationOfInterest" xlink:to="inkt_PercentageOfComputationOfInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_IndividualServicesMember" xlink:to="inkt_IndividualServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_TwoThousandAndTwentyOneEIPMember" xlink:to="inkt_TwoThousandAndTwentyOneEIPMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_RepayableAdvanceReceived" xlink:to="inkt_RepayableAdvanceReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAbstract" xlink:to="us-gaap_LossContingencyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote" xlink:to="inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_CapitalizedExpensesAmortizationPeriod" xlink:to="inkt_CapitalizedExpensesAmortizationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_OtherIncomeExpenseNetMember" xlink:to="inkt_OtherIncomeExpenseNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="inkt_AccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_PercentageOfSharesOfCompanySCommonStockOutstanding" xlink:to="inkt_PercentageOfSharesOfCompanySCommonStockOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesMember" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_NasdaqMinimumBidPriceNoticeMember" xlink:to="inkt_NasdaqMinimumBidPriceNoticeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_IntercompanyAllocationIncludedInExpense" xlink:to="inkt_IntercompanyAllocationIncludedInExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises" xlink:to="inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_MinimumValueOfListedSecuritiesForTenTradingDays" xlink:to="inkt_MinimumValueOfListedSecuritiesForTenTradingDays_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_IncomeTaxReconciliationReturnToProvisionAdjustment" xlink:to="inkt_IncomeTaxReconciliationReturnToProvisionAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inkt_WorkOrderReceivedFromRelatedParty" xlink:to="inkt_WorkOrderReceivedFromRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DueToRelatedParty" xlink:label="inkt_DueToRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="inkt_DueToRelatedParty" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition" xlink:label="inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_22"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_23"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockRetiredCostMethodAmount" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesRetired" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_EmployeeBonusMember" xlink:label="inkt_EmployeeBonusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PurchasesOfPlantAndEquipmentInAccountsPayable" xlink:label="inkt_PurchasesOfPlantAndEquipmentInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PaymentForServicesMember" xlink:label="inkt_PaymentForServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote" xlink:label="inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_InsuranceFinancingAgreement" xlink:label="inkt_InsuranceFinancingAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_GainOnForgivenessOfLiability" xlink:label="inkt_GainOnForgivenessOfLiability"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings" xlink:label="inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises" xlink:label="inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IssuanceOfCommonStockForPaymentOfServices" xlink:label="inkt_IssuanceOfCommonStockForPaymentOfServices"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncreaseDecreaseInRepayableAdvanceReceived" xlink:label="inkt_IncreaseDecreaseInRepayableAdvanceReceived"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_InterestAccruedOnConvertibleAffiliatedNote" xlink:label="inkt_InterestAccruedOnConvertibleAffiliatedNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ChangeInFairValueOfConvertibleAffiliatedNote" xlink:label="inkt_ChangeInFairValueOfConvertibleAffiliatedNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inkt_EmployeeBonusMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="inkt_PurchasesOfPlantAndEquipmentInAccountsPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inkt_PaymentForServicesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="inkt_InsuranceFinancingAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inkt_GainOnForgivenessOfLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="inkt_IssuanceOfCommonStockForPaymentOfServices" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="inkt_IncreaseDecreaseInRepayableAdvanceReceived" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inkt_InterestAccruedOnConvertibleAffiliatedNote" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inkt_ChangeInFairValueOfConvertibleAffiliatedNote" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlowsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_EmployeeBonusMember" xlink:label="inkt_EmployeeBonusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PaymentForServicesMember" xlink:label="inkt_PaymentForServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ServicesMember" xlink:label="inkt_ServicesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inkt_EmployeeBonusMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inkt_PaymentForServicesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inkt_ServicesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DirectorsOrOfficersMember" xlink:label="inkt_DirectorsOrOfficersMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="inkt_DirectorsOrOfficersMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlans" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreement" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureOtherLongTermLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongtermDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_OtherLongtermDebtCurrentAndNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_OtherLongTermLiabilitiesTextBlock" xlink:label="inkt_OtherLongTermLiabilitiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLongtermDebtCurrentAndNoncurrentAbstract" xlink:to="inkt_OtherLongTermLiabilitiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurement" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAbstract" xlink:label="us-gaap_LossContingencyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyAbstract" xlink:to="us-gaap_LossContingencyDisclosures" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureBenefitPlans" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="us-gaap_DefinedBenefitPlanTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedBenefitPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AccountingPoliciesTable" xlink:label="inkt_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AgenusIncMember" xlink:label="inkt_AgenusIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AccountingPoliciesLineItems" xlink:label="inkt_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DepreciationExpenseOnPropertyPlantAndEquipment" xlink:label="inkt_DepreciationExpenseOnPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_AccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inkt_AgenusIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inkt_AccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_AccountingPoliciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_AccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="us-gaap_Depreciation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_AccountingPoliciesTable" xlink:to="inkt_AccountingPoliciesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="inkt_DepreciationExpenseOnPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NonVestedSharesMember" xlink:label="inkt_NonVestedSharesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inkt_NonVestedSharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentSummaryOfEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncomeTaxLineItems" xlink:label="inkt_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncomeTaxTable" xlink:label="inkt_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BE" xlink:label="country_BE"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_HK" xlink:label="country_HK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_CapitalizedExpensesAmortizationPeriod" xlink:label="inkt_CapitalizedExpensesAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_IncomeTaxLineItems" xlink:to="us-gaap_OpenTaxYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="inkt_IncomeTaxTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BE" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_IncomeTaxTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_IncomeTaxTable" xlink:to="inkt_IncomeTaxLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_IncomeTaxLineItems" xlink:to="inkt_CapitalizedExpensesAmortizationPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inkt_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits" xlink:label="inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncomeTaxReconciliationUncertainTaxPositions" xlink:label="inkt_IncomeTaxReconciliationUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange" xlink:label="inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion" xlink:label="inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote" xlink:label="inkt_IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncomeTaxReconciliationReturnToProvisionAdjustment" xlink:label="inkt_IncomeTaxReconciliationReturnToProvisionAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="inkt_IncomeTaxReconciliationUncertainTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="inkt_IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="inkt_IncomeTaxReconciliationReturnToProvisionAdjustment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AccruedResearchServicesCurrent" xlink:label="inkt_AccruedResearchServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AccruedContractManufacturingExpenseCurrent" xlink:label="inkt_AccruedContractManufacturingExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ValueAddedTaxAccruedLiabilitiesCurrent" xlink:label="inkt_ValueAddedTaxAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="inkt_AccruedResearchServicesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="inkt_AccruedContractManufacturingExpenseCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="inkt_ValueAddedTaxAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AuthorizedCapitalStockIncreased" xlink:label="inkt_AuthorizedCapitalStockIncreased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" xlink:label="inkt_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NetProceedsFromIssuanceOfCommonStock" xlink:label="inkt_NetProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="inkt_AuthorizedCapitalStockIncreased" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="inkt_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="inkt_NetProceedsFromIssuanceOfCommonStock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_TwoThousandAndEighteenEIPMember" xlink:label="inkt_TwoThousandAndEighteenEIPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_TwoThousandAndTwentyOneEIPMember" xlink:label="inkt_TwoThousandAndTwentyOneEIPMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes" xlink:label="inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PercentageOfSharesOfCompanySCommonStockOutstanding" xlink:label="inkt_PercentageOfSharesOfCompanySCommonStockOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation" xlink:label="inkt_StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan" xlink:label="inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding" xlink:label="inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inkt_TwoThousandAndEighteenEIPMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inkt_TwoThousandAndTwentyOneEIPMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inkt_PercentageOfSharesOfCompanySCommonStockOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inkt_StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfFairValueOfOptionsGrantedUnderWeightedAverageAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_RepayableAdvanceOfDevelopmentGranted" xlink:label="inkt_RepayableAdvanceOfDevelopmentGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_OtherIncomeExpenseNetMember" xlink:label="inkt_OtherIncomeExpenseNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_RepayableAdvanceOfDevelopment" xlink:label="inkt_RepayableAdvanceOfDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_RepayableAdvanceReceived" xlink:label="inkt_RepayableAdvanceReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_RepayableAdvanceReceivedNoncurrent" xlink:label="inkt_RepayableAdvanceReceivedNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inkt_RepayableAdvanceOfDevelopmentGranted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="inkt_OtherIncomeExpenseNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inkt_RepayableAdvanceOfDevelopment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inkt_RepayableAdvanceReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inkt_RepayableAdvanceReceivedNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PeriodOfLicenseAgreement" xlink:label="inkt_PeriodOfLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AgenusIncMember" xlink:label="inkt_AgenusIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NewIntercompanyServiceAgreementMember" xlink:label="inkt_NewIntercompanyServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossMember" xlink:label="us-gaap_OperatingIncomeLossMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_TerminateLicenseAgreementPeriod" xlink:label="inkt_TerminateLicenseAgreementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AtlantClinicalLtdMember" xlink:label="inkt_AtlantClinicalLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IndividualServicesMember" xlink:label="inkt_IndividualServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PeriodForBreachOfPaymentObligations" xlink:label="inkt_PeriodForBreachOfPaymentObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_WolfGreenfieldSachsPCMember" xlink:label="inkt_WolfGreenfieldSachsPCMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_BusinessServicesAndOccupancyCostsMember" xlink:label="inkt_BusinessServicesAndOccupancyCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DrBuellMember" xlink:label="inkt_DrBuellMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ResearchServicesMember" xlink:label="inkt_ResearchServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PercentageOfServiceCost" xlink:label="inkt_PercentageOfServiceCost"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ForgivenessOfRelatedPartyLiabilityMember" xlink:label="inkt_ForgivenessOfRelatedPartyLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ServiceAgreementNoticePeriod" xlink:label="inkt_ServiceAgreementNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IntercompanyAllocationIncludedInExpense" xlink:label="inkt_IntercompanyAllocationIncludedInExpense"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DueToRelatedParty" xlink:label="inkt_DueToRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_WorkOrderReceivedFromRelatedParty" xlink:label="inkt_WorkOrderReceivedFromRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ClinicalResearchServices" xlink:label="inkt_ClinicalResearchServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering" xlink:label="inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PercentageOfComputationOfInterest" xlink:label="inkt_PercentageOfComputationOfInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_LegalFeesPercentage" xlink:label="inkt_LegalFeesPercentage"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_PeriodOfLicenseAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inkt_AgenusIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="inkt_NewIntercompanyServiceAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingIncomeLossMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_TerminateLicenseAgreementPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inkt_AtlantClinicalLtdMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="inkt_IndividualServicesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_PeriodForBreachOfPaymentObligations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inkt_WolfGreenfieldSachsPCMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="inkt_BusinessServicesAndOccupancyCostsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inkt_DrBuellMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="inkt_ResearchServicesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_PercentageOfServiceCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inkt_ForgivenessOfRelatedPartyLiabilityMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_ServiceAgreementNoticePeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_IntercompanyAllocationIncludedInExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_DueToRelatedParty" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_WorkOrderReceivedFromRelatedParty" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_ClinicalResearchServices" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_PercentageOfComputationOfInterest" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LegalFees" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_LegalFeesPercentage" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureOtherLongTermLiabilitiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="us-gaap_DebtInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PaycheckProtectionProgramLoanMember" xlink:label="inkt_PaycheckProtectionProgramLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inkt_PaycheckProtectionProgramLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLoans" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ImpactOfChangeInFairValueDisclosure" xlink:label="inkt_ImpactOfChangeInFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inkt_ImpactOfChangeInFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureBenefitPlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AgenusIncMember" xlink:label="inkt_AgenusIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ConvertiblePromissoryNoteMember" xlink:label="inkt_ConvertiblePromissoryNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PurchaseAgreementMember" xlink:label="inkt_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NasdaqMvlsNoticeMember" xlink:label="inkt_NasdaqMvlsNoticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NasdaqMinimumBidPriceNoticeMember" xlink:label="inkt_NasdaqMinimumBidPriceNoticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_MinimumValueOfListedSecurities" xlink:label="inkt_MinimumValueOfListedSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_MinimumValueOfListedSecuritiesPeriod" xlink:label="inkt_MinimumValueOfListedSecuritiesPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AdditionalPeriodForMinimumValueOfListedSecurities" xlink:label="inkt_AdditionalPeriodForMinimumValueOfListedSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_MinimumValueOfListedSecuritiesForTenTradingDays" xlink:label="inkt_MinimumValueOfListedSecuritiesForTenTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_MinimumBidPrice" xlink:label="inkt_MinimumBidPrice"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NumberOfConsecutivetradingDays" xlink:label="inkt_NumberOfConsecutivetradingDays"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_InitialCompliancePeriod" xlink:label="inkt_InitialCompliancePeriod"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ClosingBidPriceForTenTradingDays" xlink:label="inkt_ClosingBidPriceForTenTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AdditionalCompliancePeriod" xlink:label="inkt_AdditionalCompliancePeriod"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_SecondCompliancePeriod" xlink:label="inkt_SecondCompliancePeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inkt_AgenusIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inkt_ConvertiblePromissoryNoteMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="inkt_PurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="inkt_NasdaqMvlsNoticeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="inkt_NasdaqMinimumBidPriceNoticeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ConvertibleDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_MinimumValueOfListedSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_MinimumValueOfListedSecuritiesPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_AdditionalPeriodForMinimumValueOfListedSecurities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_MinimumValueOfListedSecuritiesForTenTradingDays" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_MinimumBidPrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_NumberOfConsecutivetradingDays" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_InitialCompliancePeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_ClosingBidPriceForTenTradingDays" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_AdditionalCompliancePeriod" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_SecondCompliancePeriod" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition" xlink:label="inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockRetiredCostMethodAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesRetired" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_EmployeeBonusMember" xlink:label="inkt_EmployeeBonusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PurchasesOfPlantAndEquipmentInAccountsPayable" xlink:label="inkt_PurchasesOfPlantAndEquipmentInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PaymentForServicesMember" xlink:label="inkt_PaymentForServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote" xlink:label="inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_InsuranceFinancingAgreement" xlink:label="inkt_InsuranceFinancingAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_GainOnForgivenessOfLiability" xlink:label="inkt_GainOnForgivenessOfLiability"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings" xlink:label="inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises" xlink:label="inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IssuanceOfCommonStockForPaymentOfServices" xlink:label="inkt_IssuanceOfCommonStockForPaymentOfServices"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncreaseDecreaseInRepayableAdvanceReceived" xlink:label="inkt_IncreaseDecreaseInRepayableAdvanceReceived"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_InterestAccruedOnConvertibleAffiliatedNote" xlink:label="inkt_InterestAccruedOnConvertibleAffiliatedNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ChangeInFairValueOfConvertibleAffiliatedNote" xlink:label="inkt_ChangeInFairValueOfConvertibleAffiliatedNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inkt_EmployeeBonusMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="inkt_PurchasesOfPlantAndEquipmentInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inkt_PaymentForServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="inkt_InsuranceFinancingAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inkt_GainOnForgivenessOfLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="inkt_IssuanceOfCommonStockForPaymentOfServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="inkt_IncreaseDecreaseInRepayableAdvanceReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inkt_InterestAccruedOnConvertibleAffiliatedNote" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inkt_ChangeInFairValueOfConvertibleAffiliatedNote" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlowsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_EmployeeBonusMember" xlink:label="inkt_EmployeeBonusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PaymentForServicesMember" xlink:label="inkt_PaymentForServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ServicesMember" xlink:label="inkt_ServicesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inkt_EmployeeBonusMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfFinancingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inkt_PaymentForServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inkt_ServicesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DirectorsOrOfficersMember" xlink:label="inkt_DirectorsOrOfficersMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="inkt_DirectorsOrOfficersMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AccountingPoliciesLineItems" xlink:label="inkt_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AccountingPoliciesTable" xlink:label="inkt_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AgenusIncMember" xlink:label="inkt_AgenusIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DepreciationExpenseOnPropertyPlantAndEquipment" xlink:label="inkt_DepreciationExpenseOnPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="inkt_AccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inkt_AccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inkt_AgenusIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inkt_AccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inkt_AccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="inkt_DepreciationExpenseOnPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inkt_AccountingPoliciesLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NonVestedSharesMember" xlink:label="inkt_NonVestedSharesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inkt_NonVestedSharesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncomeTaxLineItems" xlink:label="inkt_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncomeTaxTable" xlink:label="inkt_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BE" xlink:label="country_BE"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_HK" xlink:label="country_HK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_CapitalizedExpensesAmortizationPeriod" xlink:label="inkt_CapitalizedExpensesAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inkt_IncomeTaxLineItems" xlink:to="inkt_IncomeTaxTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inkt_IncomeTaxLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inkt_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BE" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inkt_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inkt_IncomeTaxTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inkt_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inkt_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inkt_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inkt_IncomeTaxLineItems" xlink:to="inkt_CapitalizedExpensesAmortizationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inkt_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AuthorizedCapitalStockIncreased" xlink:label="inkt_AuthorizedCapitalStockIncreased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" xlink:label="inkt_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NetProceedsFromIssuanceOfCommonStock" xlink:label="inkt_NetProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="inkt_AuthorizedCapitalStockIncreased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="inkt_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="inkt_NetProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_TwoThousandAndEighteenEIPMember" xlink:label="inkt_TwoThousandAndEighteenEIPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_TwoThousandAndTwentyOneEIPMember" xlink:label="inkt_TwoThousandAndTwentyOneEIPMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes" xlink:label="inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" xlink:label="inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PercentageOfSharesOfCompanySCommonStockOutstanding" xlink:label="inkt_PercentageOfSharesOfCompanySCommonStockOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation" xlink:label="inkt_StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan" xlink:label="inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding" xlink:label="inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inkt_TwoThousandAndEighteenEIPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inkt_TwoThousandAndTwentyOneEIPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inkt_PercentageOfSharesOfCompanySCommonStockOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inkt_StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_RepayableAdvanceOfDevelopmentGranted" xlink:label="inkt_RepayableAdvanceOfDevelopmentGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_OtherIncomeExpenseNetMember" xlink:label="inkt_OtherIncomeExpenseNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_RepayableAdvanceOfDevelopment" xlink:label="inkt_RepayableAdvanceOfDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_RepayableAdvanceReceived" xlink:label="inkt_RepayableAdvanceReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_RepayableAdvanceReceivedNoncurrent" xlink:label="inkt_RepayableAdvanceReceivedNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inkt_RepayableAdvanceOfDevelopmentGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="inkt_OtherIncomeExpenseNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inkt_RepayableAdvanceOfDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inkt_RepayableAdvanceReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inkt_RepayableAdvanceReceivedNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PeriodOfLicenseAgreement" xlink:label="inkt_PeriodOfLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AgenusIncMember" xlink:label="inkt_AgenusIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NewIntercompanyServiceAgreementMember" xlink:label="inkt_NewIntercompanyServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossMember" xlink:label="us-gaap_OperatingIncomeLossMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_TerminateLicenseAgreementPeriod" xlink:label="inkt_TerminateLicenseAgreementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AtlantClinicalLtdMember" xlink:label="inkt_AtlantClinicalLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IndividualServicesMember" xlink:label="inkt_IndividualServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PeriodForBreachOfPaymentObligations" xlink:label="inkt_PeriodForBreachOfPaymentObligations"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_WolfGreenfieldSachsPCMember" xlink:label="inkt_WolfGreenfieldSachsPCMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_BusinessServicesAndOccupancyCostsMember" xlink:label="inkt_BusinessServicesAndOccupancyCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DrBuellMember" xlink:label="inkt_DrBuellMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ResearchServicesMember" xlink:label="inkt_ResearchServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PercentageOfServiceCost" xlink:label="inkt_PercentageOfServiceCost"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ForgivenessOfRelatedPartyLiabilityMember" xlink:label="inkt_ForgivenessOfRelatedPartyLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ServiceAgreementNoticePeriod" xlink:label="inkt_ServiceAgreementNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IntercompanyAllocationIncludedInExpense" xlink:label="inkt_IntercompanyAllocationIncludedInExpense"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DueToRelatedParty" xlink:label="inkt_DueToRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_WorkOrderReceivedFromRelatedParty" xlink:label="inkt_WorkOrderReceivedFromRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ClinicalResearchServices" xlink:label="inkt_ClinicalResearchServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering" xlink:label="inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PercentageOfComputationOfInterest" xlink:label="inkt_PercentageOfComputationOfInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_LegalFeesPercentage" xlink:label="inkt_LegalFeesPercentage"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_PeriodOfLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inkt_AgenusIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="inkt_NewIntercompanyServiceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingIncomeLossMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_TerminateLicenseAgreementPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inkt_AtlantClinicalLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="inkt_IndividualServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_PeriodForBreachOfPaymentObligations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inkt_WolfGreenfieldSachsPCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="inkt_BusinessServicesAndOccupancyCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inkt_DrBuellMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="inkt_ResearchServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_PercentageOfServiceCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inkt_ForgivenessOfRelatedPartyLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_ServiceAgreementNoticePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_IntercompanyAllocationIncludedInExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_DueToRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_WorkOrderReceivedFromRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_ClinicalResearchServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_PercentageOfComputationOfInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LegalFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inkt_LegalFeesPercentage" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureOtherLongTermLiabilitiesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PaycheckProtectionProgramLoanMember" xlink:label="inkt_PaycheckProtectionProgramLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inkt_PaycheckProtectionProgramLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLoans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ImpactOfChangeInFairValueDisclosure" xlink:label="inkt_ImpactOfChangeInFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inkt_ImpactOfChangeInFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AgenusIncMember" xlink:label="inkt_AgenusIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ConvertiblePromissoryNoteMember" xlink:label="inkt_ConvertiblePromissoryNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PurchaseAgreementMember" xlink:label="inkt_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NasdaqMvlsNoticeMember" xlink:label="inkt_NasdaqMvlsNoticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NasdaqMinimumBidPriceNoticeMember" xlink:label="inkt_NasdaqMinimumBidPriceNoticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_MinimumValueOfListedSecurities" xlink:label="inkt_MinimumValueOfListedSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_MinimumValueOfListedSecuritiesPeriod" xlink:label="inkt_MinimumValueOfListedSecuritiesPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AdditionalPeriodForMinimumValueOfListedSecurities" xlink:label="inkt_AdditionalPeriodForMinimumValueOfListedSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_MinimumValueOfListedSecuritiesForTenTradingDays" xlink:label="inkt_MinimumValueOfListedSecuritiesForTenTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_MinimumBidPrice" xlink:label="inkt_MinimumBidPrice"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_NumberOfConsecutivetradingDays" xlink:label="inkt_NumberOfConsecutivetradingDays"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_InitialCompliancePeriod" xlink:label="inkt_InitialCompliancePeriod"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ClosingBidPriceForTenTradingDays" xlink:label="inkt_ClosingBidPriceForTenTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AdditionalCompliancePeriod" xlink:label="inkt_AdditionalCompliancePeriod"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_SecondCompliancePeriod" xlink:label="inkt_SecondCompliancePeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inkt_AgenusIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inkt_ConvertiblePromissoryNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="inkt_PurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="inkt_NasdaqMvlsNoticeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="inkt_NasdaqMinimumBidPriceNoticeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ConvertibleDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_MinimumValueOfListedSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_MinimumValueOfListedSecuritiesPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_AdditionalPeriodForMinimumValueOfListedSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_MinimumValueOfListedSecuritiesForTenTradingDays" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_MinimumBidPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_NumberOfConsecutivetradingDays" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_InitialCompliancePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_ClosingBidPriceForTenTradingDays" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_AdditionalCompliancePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="inkt_SecondCompliancePeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="inkt_DueToRelatedParty" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DueToRelatedParty" xlink:label="inkt_DueToRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inkt_GainOnForgivenessOfLiability" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inkt_InterestAccruedOnConvertibleAffiliatedNote" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inkt_ChangeInFairValueOfConvertibleAffiliatedNote" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="7" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="8" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inkt_IncreaseDecreaseInRepayableAdvanceReceived" order="11" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="12" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote" xlink:label="inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings" xlink:label="inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_GainOnForgivenessOfLiability" xlink:label="inkt_GainOnForgivenessOfLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises" xlink:label="inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_InterestAccruedOnConvertibleAffiliatedNote" xlink:label="inkt_InterestAccruedOnConvertibleAffiliatedNote"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ChangeInFairValueOfConvertibleAffiliatedNote" xlink:label="inkt_ChangeInFairValueOfConvertibleAffiliatedNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncreaseDecreaseInRepayableAdvanceReceived" xlink:label="inkt_IncreaseDecreaseInRepayableAdvanceReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentSummaryOfEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits" xlink:label="inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="inkt_IncomeTaxReconciliationUncertainTaxPositions" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="inkt_IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="inkt_IncomeTaxReconciliationReturnToProvisionAdjustment" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="8" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="9" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncomeTaxReconciliationUncertainTaxPositions" xlink:label="inkt_IncomeTaxReconciliationUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion" xlink:label="inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange" xlink:label="inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote" xlink:label="inkt_IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_IncomeTaxReconciliationReturnToProvisionAdjustment" xlink:label="inkt_IncomeTaxReconciliationReturnToProvisionAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="inkt_AccruedResearchServicesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="inkt_ValueAddedTaxAccruedLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_AccruedResearchServicesCurrent" xlink:label="inkt_AccruedResearchServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inkt-20231231.xsd#inkt_ValueAddedTaxAccruedLiabilitiesCurrent" xlink:label="inkt_ValueAddedTaxAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="inkt_IncomeTaxLineItems" name="IncomeTaxLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_WolfGreenfieldSachsPCMember" name="WolfGreenfieldSachsPCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_GainOnForgivenessOfLiability" name="GainOnForgivenessOfLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan" name="TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_IndividualServicesMember" name="IndividualServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_PaymentForServicesMember" name="PaymentForServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_ImpactOfChangeInFairValueDisclosure" name="ImpactOfChangeInFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_IntercompanyAllocationIncludedInExpense" name="IntercompanyAllocationIncludedInExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_InterestAccruedOnConvertibleAffiliatedNote" name="InterestAccruedOnConvertibleAffiliatedNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_MinimumValueOfListedSecurities" name="MinimumValueOfListedSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_IncomeTaxReconciliationUncertainTaxPositions" name="IncomeTaxReconciliationUncertainTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_AdditionalPeriodForMinimumValueOfListedSecurities" name="AdditionalPeriodForMinimumValueOfListedSecurities" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_TerminateLicenseAgreementPeriod" name="TerminateLicenseAgreementPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering" name="PercentageValueOfCommonStockSoldInInitialPublicOffering" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inkt_AgenusIncMember" name="AgenusIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_PercentageOfServiceCost" name="PercentageOfServiceCost" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_NetProceedsFromIssuanceOfCommonStock" name="NetProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_RepayableAdvanceReceivedNoncurrent" name="RepayableAdvanceReceivedNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_TwoThousandAndEighteenEIPMember" name="TwoThousandAndEighteenEIPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_AtlantClinicalLtdMember" name="AtlantClinicalLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_NasdaqMinimumBidPriceNoticeMember" name="NasdaqMinimumBidPriceNoticeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_OtherLongTermLiabilitiesTextBlock" name="OtherLongTermLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_AdditionalCompliancePeriod" name="AdditionalCompliancePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_IncomeTaxTable" name="IncomeTaxTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_AuthorizedCapitalStockIncreased" name="AuthorizedCapitalStockIncreased" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation" name="StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_InitialCompliancePeriod" name="InitialCompliancePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_MinimumBidPrice" name="MinimumBidPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_ForgivenessOfRelatedPartyLiabilityMember" name="ForgivenessOfRelatedPartyLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_BusinessServicesAndOccupancyCostsMember" name="BusinessServicesAndOccupancyCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_ServicesMember" name="ServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_OtherIncomeExpenseNetMember" name="OtherIncomeExpenseNetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_PurchasesOfPlantAndEquipmentInAccountsPayable" name="PurchasesOfPlantAndEquipmentInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange" name="EffectiveIncomeTaxRateReconciliationForeignRateChange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion" name="EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_PercentageOfSharesOfCompanySCommonStockOutstanding" name="PercentageOfSharesOfCompanySCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes" name="StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_DrBuellMember" name="DrBuellMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_PeriodForBreachOfPaymentObligations" name="PeriodForBreachOfPaymentObligations" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_IssuanceOfCommonStockForPaymentOfServices" name="IssuanceOfCommonStockForPaymentOfServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_PercentageOfComputationOfInterest" name="PercentageOfComputationOfInterest" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_NewIntercompanyServiceAgreementMember" name="NewIntercompanyServiceAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_ConvertiblePromissoryNoteMember" name="ConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote" name="ProceedsFromIssuanceOfConvertibleAffiliatedNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_RepayableAdvanceOfDevelopmentGranted" name="RepayableAdvanceOfDevelopmentGranted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_TwoThousandAndTwentyOneEIPMember" name="TwoThousandAndTwentyOneEIPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" name="StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_SecondCompliancePeriod" name="SecondCompliancePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_MinimumValueOfListedSecuritiesPeriod" name="MinimumValueOfListedSecuritiesPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan" name="SharesReservedForIssuanceUnderEmployeeStockPurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_InsuranceFinancingAgreement" name="InsuranceFinancingAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_WorkOrderReceivedFromRelatedParty" name="WorkOrderReceivedFromRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_AccountingPoliciesTable" name="AccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote" name="IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_PurchaseAgreementMember" name="PurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_ResearchServicesMember" name="ResearchServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_ClosingBidPriceForTenTradingDays" name="ClosingBidPriceForTenTradingDays" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_RepayableAdvanceOfDevelopment" name="RepayableAdvanceOfDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_ChangeInFairValueOfConvertibleAffiliatedNote" name="ChangeInFairValueOfConvertibleAffiliatedNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_MinimumValueOfListedSecuritiesForTenTradingDays" name="MinimumValueOfListedSecuritiesForTenTradingDays" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_DueToRelatedParty" name="DueToRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding" name="RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_AccruedContractManufacturingExpenseCurrent" name="AccruedContractManufacturingExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises" name="ProceedsFromEmployeeStockPurchasesAndOptionExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_PeriodOfLicenseAgreement" name="PeriodOfLicenseAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_AccruedResearchServicesCurrent" name="AccruedResearchServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits" name="DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_NasdaqMvlsNoticeMember" name="NasdaqMvlsNoticeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_RepayableAdvanceReceived" name="RepayableAdvanceReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_EmployeeBonusMember" name="EmployeeBonusMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_NumberOfConsecutivetradingDays" name="NumberOfConsecutivetradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_IncreaseDecreaseInRepayableAdvanceReceived" name="IncreaseDecreaseInRepayableAdvanceReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" name="UnderwritingDiscountsCommissionsAndOtherOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_IncomeTaxReconciliationReturnToProvisionAdjustment" name="IncomeTaxReconciliationReturnToProvisionAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_PaycheckProtectionProgramLoanMember" name="PaycheckProtectionProgramLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_CapitalizedExpensesAmortizationPeriod" name="CapitalizedExpensesAmortizationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_DepreciationExpenseOnPropertyPlantAndEquipment" name="DepreciationExpenseOnPropertyPlantAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_ValueAddedTaxAccruedLiabilitiesCurrent" name="ValueAddedTaxAccruedLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_LegalFeesPercentage" name="LegalFeesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings" name="PurchaseOfTreasurySharesToSatisfyTaxWithholdings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_ServiceAgreementNoticePeriod" name="ServiceAgreementNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inkt_NonVestedSharesMember" name="NonVestedSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inkt_ClinicalResearchServices" name="ClinicalResearchServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" name="StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inkt_DirectorsOrOfficersMember" name="DirectorsOrOfficersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206346752752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 15, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MiNK Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001840229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,699,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INKT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2142067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">149 Fifth Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">994-8250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the 2024 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2023, are incorporated by reference into Part III of this Report.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206346704352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,367,229<span></span>
</td>
<td class="nump">$ 19,635,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">53,111<span></span>
</td>
<td class="nump">298,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">177,964<span></span>
</td>
<td class="nump">470,300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,598,304<span></span>
</td>
<td class="nump">20,404,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment, net of accumulated depreciation of $495,638 and $283,682 as of December 31, 2023 and 2022, respectively</a></td>
<td class="nump">953,977<span></span>
</td>
<td class="nump">1,066,910<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,552,281<span></span>
</td>
<td class="nump">21,471,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,911,973<span></span>
</td>
<td class="nump">5,823,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">5,037,361<span></span>
</td>
<td class="nump">4,238,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">2,453,251<span></span>
</td>
<td class="nump">2,621,611<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,402,585<span></span>
</td>
<td class="nump">12,683,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">48,072<span></span>
</td>
<td class="nump">108,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_DueToRelatedParty', window );">Due To Related Party</a></td>
<td class="nump">11,157,073<span></span>
</td>
<td class="nump">9,081,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.00001 per share, 150,000,000 shares authorized, 34,599,119 and 33,856,428 shares issued and outstanding as of December 31, 2023 and 2022, respectively</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">115,772,085<span></span>
</td>
<td class="nump">110,829,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(430,947)<span></span>
</td>
<td class="num">(292,468)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(133,396,933)<span></span>
</td>
<td class="num">(110,939,074)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(18,055,449)<span></span>
</td>
<td class="num">(401,303)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 4,552,281<span></span>
</td>
<td class="nump">$ 21,471,602<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_DueToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Due to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_DueToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206346754032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Equipment, net of accumulated depreciation</a></td>
<td class="nump">$ 495,638<span></span>
</td>
<td class="nump">$ 283,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">34,599,119<span></span>
</td>
<td class="nump">33,856,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">34,599,119<span></span>
</td>
<td class="nump">33,856,428<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206440923248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 15,489,997<span></span>
</td>
<td class="nump">$ 23,115,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,431,108<span></span>
</td>
<td class="nump">7,834,155<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(22,921,105)<span></span>
</td>
<td class="num">(30,949,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest Income (Expense), Net</a></td>
<td class="nump">463,256<span></span>
</td>
<td class="nump">253,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (loss), net</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">2,704,743<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,457,859)<span></span>
</td>
<td class="num">$ (27,991,212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per common share data:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share</a></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share</a></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic</a></td>
<td class="nump">34,359,945<span></span>
</td>
<td class="nump">33,672,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted</a></td>
<td class="nump">34,359,945<span></span>
</td>
<td class="nump">33,672,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive gain (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation gain (loss)</a></td>
<td class="num">$ (138,479)<span></span>
</td>
<td class="nump">$ 332,801<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (22,596,338)<span></span>
</td>
<td class="num">$ (27,658,411)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206343424352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders' Deficit - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 23,776,469<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
<td class="nump">$ 107,349,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (625,269)<span></span>
</td>
<td class="num">$ (82,947,862)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,476,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(27,991,212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,991,212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) gain</a></td>
<td class="nump">332,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of nonvested shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of nonvested shares, Shares</a></td>
<td class="nump">60,595<span></span>
</td>
<td class="nump">60,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1,595<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">258,648<span></span>
</td>
<td class="nump">258,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeiture of restricted stock</a></td>
<td class="num">$ (75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition', window );">Grant and recognition of stock options</a></td>
<td class="nump">3,089,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,089,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Recognition of parent stock options</a></td>
<td class="nump">96,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of shares for employee bonuses</a></td>
<td class="nump">$ 136,329<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">293,522<span></span>
</td>
<td class="num">$ (157,194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of shares for employee bonuses, shares</a></td>
<td class="nump">125,199<span></span>
</td>
<td class="nump">125,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of shares for employee bonus, treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="nump">$ 157,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,665)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="num">(401,303)<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
<td class="nump">110,829,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(292,468)<span></span>
</td>
<td class="num">(110,939,074)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,856,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(22,457,859)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,457,859)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) gain</a></td>
<td class="num">$ (138,479)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138,479)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of nonvested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of nonvested shares, Shares</a></td>
<td class="nump">175,196<span></span>
</td>
<td class="nump">175,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">105,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan', window );">Exercise of stock options and employee share purchases</a></td>
<td class="nump">$ 70,466<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">70,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan', window );">Exercise of stock options and employee share purchases, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares for services</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Share retirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition', window );">Grant and recognition of stock options</a></td>
<td class="nump">3,698,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,698,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Recognition of parent stock options</a></td>
<td class="nump">131,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of shares for employee bonuses</a></td>
<td class="nump">$ 533,723<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">1,011,356<span></span>
</td>
<td class="num">$ (477,639)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of shares for employee bonuses, shares</a></td>
<td class="nump">603,830<span></span>
</td>
<td class="nump">603,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of shares for employee bonus, treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(205,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="nump">$ 477,637<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 477,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(205,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="num">$ (18,055,449)<span></span>
</td>
<td class="nump">$ 346<span></span>
</td>
<td class="nump">$ 115,772,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (430,947)<span></span>
</td>
<td class="num">$ (133,396,933)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,599,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital share based compensation stock options grant and recognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options exercised and employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value stock options exercised and employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury stock issued during period shares employee benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206346885776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (22,457,859)<span></span>
</td>
<td class="num">$ (27,991,212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">204,617<span></span>
</td>
<td class="nump">121,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,860,366<span></span>
</td>
<td class="nump">3,026,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_GainOnForgivenessOfLiability', window );">Gain on forgiveness of liability</a></td>
<td class="num">(266,780)<span></span>
</td>
<td class="num">(2,790,809)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">245,589<span></span>
</td>
<td class="num">(296,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,917,557)<span></span>
</td>
<td class="nump">2,660,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued liabilities and other current liabilities</a></td>
<td class="nump">2,025,124<span></span>
</td>
<td class="nump">3,424,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other operating assets and liabilities</a></td>
<td class="nump">2,543,988<span></span>
</td>
<td class="nump">2,977,838<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,762,512)<span></span>
</td>
<td class="num">(18,866,843)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="num">(73,561)<span></span>
</td>
<td class="num">(250,046)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(73,561)<span></span>
</td>
<td class="num">(250,046)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings', window );">Purchase of treasury shares to satisfy tax withholdings</a></td>
<td class="num">(477,639)<span></span>
</td>
<td class="num">(157,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises', window );">Proceeds from employee stock purchases and option exercises</a></td>
<td class="nump">70,466<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(407,173)<span></span>
</td>
<td class="num">(155,599)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(25,250)<span></span>
</td>
<td class="nump">19,385<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash</a></td>
<td class="num">(16,268,496)<span></span>
</td>
<td class="num">(19,253,103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of period</a></td>
<td class="nump">19,635,725<span></span>
</td>
<td class="nump">38,888,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of period</a></td>
<td class="nump">3,367,229<span></span>
</td>
<td class="nump">19,635,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">27,509<span></span>
</td>
<td class="nump">10,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures - non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_PurchasesOfPlantAndEquipmentInAccountsPayable', window );">Purchases of plant and equipment in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_InsuranceFinancingAgreement', window );">Insurance financing agreement</a></td>
<td class="nump">109,000<span></span>
</td>
<td class="nump">444,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inkt_EmployeeBonusMember', window );">Employee Bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures - non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock, $0.00001 par value, for payment of employee bonuses</a></td>
<td class="nump">1,011,360<span></span>
</td>
<td class="nump">$ 293,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inkt_PaymentForServicesMember', window );">Payment For Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures - non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock, $0.00001 par value, for payment of employee bonuses</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_GainOnForgivenessOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on forgiveness of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_GainOnForgivenessOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_InsuranceFinancingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_InsuranceFinancingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from employee stock purchases and option exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of treasury shares to satisfy tax withholdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_PurchasesOfPlantAndEquipmentInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of plant and equipment in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_PurchasesOfPlantAndEquipmentInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inkt_EmployeeBonusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inkt_EmployeeBonusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inkt_PaymentForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inkt_PaymentForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206346749600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inkt_EmployeeBonusMember', window );">Employee Bonus</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">0.00001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inkt_PaymentForServicesMember', window );">Payment For Services</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inkt_EmployeeBonusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inkt_EmployeeBonusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inkt_PaymentForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inkt_PaymentForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206435394608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (22,457,859)<span></span>
</td>
<td class="num">$ (27,991,212)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206340216304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements - Directors or Officers<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=inkt_DirectorsOrOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=inkt_DirectorsOrOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206444415776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK Therapeutics, Inc. (&#8220;MiNK&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company pioneering a novel platform of living medicines based on a rare and potent class of immune cells called invariant natural killer T (&#8220;iNKT&#8221;) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. MiNK's proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, MiNK believes that its approach represents a highly versatile application for therapeutic development in cancer and immune diseases. MiNK is leveraging its platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of both native and engineered iNKT cells.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its inception in 2017, MiNK has incurred losses and expects to continue incurring operating losses and negative cash flows in the future until it is able to generate sales and profits. As of December 31, 2023, MiNK had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">133.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and cash and cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK believes that its cash and cash equivalents balance along with the additional funding received subsequent to year end from its parent, Agenus Inc. (&#8220;Agenus&#8221;), and funding planned from a third party will be sufficient to satisfy its liquidity requirements for more than one year from when these financial statements were issued. Because the additional funding is influenced by external uncertainties, in accordance with the relevant accounting guidance, the Company is required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Annual Report on Form 10-K. The financial statements have been prepared on a basis that assumes MiNK will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management continually monitors MiNK's liquidity position and adjusts spending as needed in order to preserve liquidity. Potential sources of additional funding for the Company include: (1) seeking strategic partnerships and collaborations, as well as out-licensing opportunities, for the Company's portfolio programs and product candidates, (2) exploring avenues for securing non-dilutive financing, such as grants and collaborations to strengthen the Company's balance sheet, and (3) potential of equity or debt financing options. If additional funding is not obtained through these sources, Agenus has indicated a willingness to loan MiNK additional funds to finance its operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK&#8217;s product candidates are in various stages of development and additional expenditures will be required if the Company starts new trials, encounters delays in its programs, applies for regulatory approvals, continues development of its technologies, expands its operations, and/or brings its product candidates to market. The eventual total cost of each clinical trial is dependent on a number of factors such as trial design, length of the trial, number of clinical sites, and number of patients. The process of obtaining and maintaining regulatory approvals for new therapeutic products is lengthy, expensive, and uncertain. Because all of the Company&#8217;s programs are at an early stage of clinical development, the Company is unable to reliably estimate the cost of completing its research and development programs or the timing for bringing such programs to various markets or substantial partnering or out-licensing arrangements, and, therefore, when, if ever, material cash inflows are likely to commence</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206441877744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2) Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(a) Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and include the accounts of MiNK and its subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(b) Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK is managed and operated as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> business segment. The entire business is managed by a single executive operating committee that reports to the chief executive officer. The Company does not operate separate lines of business with respect to any of its product candidates or geographic locations. Accordingly, the Company does not prepare discrete financial information with respect to separate product areas or by location and does not have separately reportable segments as defined by Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 280, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(c) Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases those estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(d) Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments purchased with maturities at acquisition of three months or less to be cash equivalents. Cash equivalents consist primarily of money market funds.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(e) Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equipment is carried at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, typically </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Additions are capitalized, while repairs and maintenance are charged to expense as incurred. Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">205,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">122,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(f) Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:0.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.3553803871825076%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities. </span></div></div><div style="margin-left:0.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.3553803871825076%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></div></div><div style="margin-left:0.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.3553803871825076%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s cash and cash equivalents are carried at fair value (a Level 1 measurement), determined according to the fair value hierarchy described above. The carrying values of the Company&#8217;s, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(g) Foreign Currency Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gains and losses from the Company&#8217;s foreign currency-based accounts and transactions, such as those resulting from the remeasurement and settlement of receivables and payables denominated in foreign currencies, are included in the consolidated statements of operations within other income (expense). The Company recorded de minimis foreign currency losses for the years ended December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(h) Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include the costs associated with the Company&#8217;s internal research and development activities, including salaries and benefits, share-based compensation, occupancy costs, clinical manufacturing costs, related administrative costs and research and development conducted for the Company by outside advisors. Research and development expenses also include the cost of clinical trial materials shipped to the Company&#8217;s research partners. Research and development costs are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(i) Share-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK accounts for share-based compensation in accordance with the provisions of ASC 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Share-based </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compensation expense is recognized based on the estimated grant date fair value. Compensation cost is recognized on a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">straight-line </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">basis over the requisite service period of the award. Forfeitures are recognized as they occur. See Note 8 for further discussion on share-based compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(j) Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the asset and liability method with deferred tax assets and liabilities recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and net operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such items are expected to be reversed or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statement of operations in the period that includes the enactment date. Deferred tax assets are recognized when they are more likely than not expected to be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(k) Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic income or loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted income per common share is calculated by dividing net income attributable to common stockholders by the weighted average number of common shares outstanding plus the dilutive effect of outstanding instruments such as stock options. Because the Company reported a net loss attributable to common stockholders for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of December 31, 2023 and 2022, as they would be anti-dilutive: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.78%;"></td>
          <td style="width:1.6%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.2%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.6%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.82%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,945,716</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,148,447</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested shares</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">789,503</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">726,163</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(l) Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. As the Company has a single reportable segment, MiNK expects the adoption of this standard to result in increased disclosures in the notes to its consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. For the Company, ASU 2023-09 is effective for fiscal years beginning after December 15, 2025. Early adoption is permitted for any annual periods for which financial statements have not been issued or made available for issuance. The Company is currently evaluating the impact that ASU 2023-09 will have on its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No other new accounting pronouncement issued or effective during the year ended December 31, 2023 had or is expected to have a material impact on the Company&#8217;s consolidated financial statements or disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206346570896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3) Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents consisted of the following as of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:58.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.268%;"></td>
        <td style="width:1.719%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.715%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.719%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.715%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.719%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.715%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.719%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.715%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Institutional money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206342087968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4) Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equipment, net, consisted of the following as of December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.627%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.377%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.036999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,351</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">496</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">284</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">954</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,067</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206444415776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5) Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to taxation in the United States and in various state, local and foreign jurisdictions. The Company remains subject to examination by U.S. Federal, state, local and foreign tax authorities for tax years </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bf9d2624-e5f8-4332-8ece-0d2f7a8edc9c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2019 through 2022</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. With few exceptions, the Company is no longer subject to U.S. Federal state, and foreign examinations by tax authorities for the tax year 2019. However, net operating losses from the tax year 2017 would be subject to examination if and when used in a future tax return to offset taxable income. The Company&#8217;s policy is to recognize income tax related penalties and interest, if any, in its provision for income taxes and, to the extent applicable, in the corresponding income tax assets and liabilities, including any amounts for uncertain tax positions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had available net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">52.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for Federal and state income tax purposes, which are available to offset future Federal and state taxable income, if any. $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">52.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of these Federal net operating loss carryforwards do not expire, while the remaining net operating loss carryforwards expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e22d9b5d-ce5f-4f3e-922e-62300307dbb9;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2037</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company&#8217;s ability to use these net operating losses is limited by change of control provisions under Internal Revenue Code ("IRC") Section 382 and may expire unused. The Company also has foreign net operating loss carryforwards, which do not expire, available to offset future foreign taxable income of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million generated in the United Kingdom and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in Belgium. The potential impacts of these provisions are among the items considered and reflected in the Company&#8217;s assessment of its valuation allowance requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beginning January 1, 2022, the Tax Cuts and Jobs Act (the "Tax Act") eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to IRC Section 174. The capitalized expenses are amortized over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period for domestic expenses and a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period for foreign expenses. We have included the impact of this provision, which results in additional deferred tax assets of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 and 2022 respectively.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax effect of temporary differences and net operating loss carryforwards that give rise to significant portions of the deferred tax assets and deferred tax liabilities as of December 31, 2023 and 2022 are presented below (in thousands).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Federal and state net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,804</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,819</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,224</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">341</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">269</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,515</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,154</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">926</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">427</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,674</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,674</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the net operating loss and tax credit carryforwards can be utilized or the temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. To fully realize the deferred tax asset, the Company will need to generate future taxable income sufficient to utilize net operating losses prior to their expiration. Based upon the Company&#8217;s history of not generating taxable income, the Company believes that it is more likely than not that deferred tax assets will not be realized through future earnings. Accordingly, a valuation allowance has been established for the full value of the deferred tax assets. The valuation allowance on the deferred tax assets increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax benefit was nil for the years ended December 31, 2023 and 2022. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes recorded differed from the amounts computed by applying the U.S. Federal income tax rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% in 2023 and 2022 to loss before income taxes as a result of the following (in thousands). </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computed &#8220;expected&#8221; Federal tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,716</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,878</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Increase) reduction in income taxes benefit resulting from:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,987</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,028</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign rate change</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">842</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign income inclusion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">530</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State and local income benefit, net of Federal income tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,693</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Return-to-provision adjustment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign rate differential</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">286</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">840</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">348</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206435348000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(6) Accrued Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consist of the following as of December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payroll</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,655</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">642</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,681</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract manufacturing costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">261</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,037</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206441877744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7) Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s authorized capital stock consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">155,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, all with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, of which:</span></p><div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares are designated as common stock; and</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares are designated as preferred stock.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206441877744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation Plans</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(8) Share-based Compensation Plans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) provided for the grant of incentive stock options intended to qualify under Section 422 of the IRC, nonstatutory stock options, restricted stock, unrestricted stock and other equity-based awards, such as stock appreciation rights, and stock units including restricted stock units for up to approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of the Company&#8217;s common stock (subject to adjustment in the event of stock splits and other similar events). As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares remain available for issuance under the 2018 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Company&#8217;s initial public offering (&#8220;IPO&#8221;), MiNK&#8217;s board of directors adopted the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan provides for the grant of incentive stock options intended to qualify under Section 422 of the Code, nonstatutory stock options, restricted stock, unrestricted stock and other equity-based awards, for an initial share pool of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of the Company&#8217;s common stock (subject to adjustment in the event of stock splits and other similar events). The initial share pool will automatically increase on January 1st of each year from 2024 to 2031 by the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> percent of the number of shares of the Company&#8217;s common stock outstanding as of the close of business on the immediately preceding December 31st and (ii) the number of shares determined by the Company&#8217;s board of directors on or prior to such date for such year. In January 2022 and 2023, the 2021 Plan share pool increased by approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares, respectively. As of December 31, 2023, there were approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares reserved for issuance under the 2021 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Company&#8217;s IPO, MiNK&#8217;s board of directors adopted the MiNK Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP provides eligible employees the opportunity to acquire the Company&#8217;s common stock in a program designed to comply with Section 423 of the Code. There are approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares reserved for issuance under the ESPP, plus an automatic annual increase on January 1st of each year from 2024 to 2031 equal to the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> percent of the number of shares of the Company&#8217;s common stock outstanding as of the close of business on the immediately preceding December 31st and (ii) the number of shares determined by the Company&#8217;s board of directors on or prior to such date for such year, up to a maximum of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares in the aggregate.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company primarily uses the Black-Scholes option pricing model to value options granted to employees and non-employees, as well as options granted to members of the Company&#8217;s Board of Directors. All stock option grants have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> terms, service conditions, and generally vest ratably over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-year period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each option granted during the period was estimated on the date of grant using the following weighted average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term in years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected term of stock options granted is based on historical data and other factors and represents the period of time that stock options are expected to be outstanding prior to exercise. The risk-free interest rate is based on U.S. Treasury strips with maturities that match the expected term on the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of option activity for 2023 is presented below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,148,447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,002,743</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61,883</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.01</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,945,716</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.03</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.32</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,227,555</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested or expected to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,945,716</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.03</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.32</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,227,555</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,999,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.56</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,227,545</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant-date fair values of options granted during the years ended December 31, 2023 and 2022, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.78</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and  $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. During both 2023 and 2022, all options were granted with exercise prices equal to the market value of the underlying shares of common stock on the grant date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value in the table above represents the difference between the Company's closing stock price on the last trading day of fiscal 2023 and the exercise price, multiplied by the number of in-the-money options that would have been received by the option holders had all option holders exercised their options on December 31, 2023 (the intrinsic value is considered to be zero if the exercise price is greater than the closing stock price). This amount changes based on the fair market value of the Company's stock. The total intrinsic value of options exercised during the year ended December 31, 2023, determined on the dates of exercise, was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized share-based compensation expense related to stock options granted to employees, consultants and directors which, if all milestones are achieved on outstanding performance based awards, will be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.9</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. For awards with performance conditions, expense is recognized if the achievement of underlying performance conditions is deemed probable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of non-vested stock activity for 2023 is presented below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nonvested<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">726,163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.01</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,563,324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">804,234</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">695,750</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.03</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">789,503</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized share-based compensation expense related to these non-vested shares which will be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. The total intrinsic value of shares vested during the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company issues new shares upon option exercises the vesting of non-vested stock and purchases under the ESPP. During the years ended December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">105,187</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">258,648</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively, were issued as a result of stock option exercises. During the years ended December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">175,196</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60,595</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively, were issued as a result of the vesting of non-vested stock. During the year ended December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">39,340</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were issued under the ESPP. Additionally, during the years ended December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">603,830</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">125,199</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were issued as payment for certain employee bonuses, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">205,879</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">43,665</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of those shares being withheld to cover taxes, resulting in a net share issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">397,951</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">81,534</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock based compensation expense also includes expense related to awards granted to employees of the Company from the Agenus 2019 Equity Incentive Plan. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The impact on the Company&#8217;s results of operations from share-based compensation for the year ended December 31, 2023 and 2022, was as follows (in thousands): </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">541</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">435</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,289</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,592</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,027</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206435495344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research and Development Agreement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(9) Research and Development Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2018, the Company entered into an agreement with the Belgium Walloon Region Government ("Walloon Region") in which the Walloon Region agreed to provide a grant of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and a repayable advance of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the development of one of the Company&#8217;s research programs. During 2020, the Company discontinued research efforts related to this program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other current liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 and December 31, 2022, respectively, represent the remaining amount of the advance received.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2022, the Company received notice that the Walloon Region had obtained a default judgment seeking repayment of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the advance based upon the Company allegedly not providing required notification that research and operations in the region were discontinued. In the year ended December 31, 2022, the Company reduced the recorded liability from the prior total of all amounts received under the advance from the Walloon Region, to the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million repayment that would be due based on the default judgment, and recorded a gain of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in &#8220;other income (expense), net&#8221; on its consolidated statement of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206347431856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(10) Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until the completion of its IPO, the Company relied on Agenus for all of its working capital requirements. For the periods presented, certain of the Company&#8217;s operations were fully integrated with Agenus, including, but not limited to, corporate functions such as finance, human resources, information technology and legal functions. The Company&#8217;s consolidated financial statements reflect all costs of doing business related to these operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 2021, the Company entered into an Intellectual Property Assignment and License Agreement with Agenus (the &#8220;New Assignment and License Agreement&#8221;), upon which the prior intercompany agreement between Agenus and MiNK was terminated. Pursuant to the New Assignment and License Agreement, Agenus assigned to the Company certain patent rights and know-how related to its iNKT cell platform, product candidates and other patents and know-how related to its business. In addition to the patent rights assigned to the Company by Agenus, the Company also received an exclusive, royalty-free, sublicensable license to research,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacture and commercialize certain licensed technology in the field. The New Assignment and License Agreement further provides for the Company to grant Agenus a field-limited, non-exclusive, royalty-free license under the assigned patent rights, subject to MiNK&#8217;s discretion and provided such access would not reasonably result in a disruption of planned MiNK activities. Agenus has also agreed to provide the Company with Agenus&#8217; biological material upon written request in order for the Company to use such material in its development activities of a combination therapy. Agenus may withhold the transfer of biological material, including, but not limited to, checkpoint modulating antibodies, for various reasons, including if such transfer would reasonably result in a disruption of planned Agenus activities. For any materials Agenus does share with the Company, the parties have agreed to enter into a separate agreement governing the transfer and providing for joint ownership of the data. Agenus has agreed that during the full term of the New Assignment and License Agreement, and for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thereafter, it will not develop, manufacture or commercialize an iNKT cell therapy, directly or indirectly by transferring such technology. The Company has the sole responsibility to develop, manufacture and commercialize products under this New Assignment and License Agreement. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may terminate the New Assignment and License Agreement without cause upon </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days&#8217; prior written notice to Agenus. Either party may terminate if they believe there has been a material breach which has not been cured within 90 days (or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days for breach of payment obligations) of receiving such notice.</span></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective April 1, 2022, the Company entered into an Amended and Restated Intercompany Services Agreement (the &#8220;New Intercompany Agreement&#8221;) with Agenus, which amended and restated the Intercompany General &amp; Administrative Agreement between the Company and Agenus dated September 10, 2021 (the &#8220;Prior Intercompany Agreement&#8221;). Under the New Intercompany Agreement, Agenus provides the Company with certain general and administrative support, including, without limitation, financial, facilities management, human resources and information technology administrative support (the &#8220;Agenus Services&#8221;), and the Company and Agenus provide each other with certain research and development services (the &#8220;R&amp;D Services&#8221;) and other support services, including legal and regulatory support (the &#8220;Shared Services&#8221;). The Company is required to pay </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of Agenus&#8217; costs related to the Agenus Services, and the costs of R&amp;D Services are based upon pass-through costs related to such services plus an allocation of the costs of the employees performing the services. No payment will be due from either party for the Shared Services, provided that the services provided by each party are proportional in scope and volume. The Company is also entitled to use Agenus&#8217; business offices and laboratory space and equipment (inclusive of a cGMP site) in exchange for the Company contributing a proportionate payment for the use of such facilities and equipment, and the Company will be covered by certain Agenus insurance policies, subject to certain conditions, including the Company paying the cost of such coverage. Either party may terminate the New Intercompany Agreement upon </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days&#8217; prior written notice and individual services upon </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days&#8217; prior written notice.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Allocated Agenus services primarily include payroll related expenses, facility costs, insurance and stock-based compensation, and are included in the accompanying financial statements based on certain estimates and allocations described above. Under the Prior Intercompany Agreement, the allocation methods primarily included time devoted to activities and headcount-based allocations. Agenus business services and occupancy costs were allocated to the Company based on the Company&#8217;s headcount as a percentage of Agenus&#8217; and the Company was required to pay </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">105</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of Agenus&#8217; costs for these business services and occupancy costs. Research services were charged between the entities based on hours recorded by Agenus employees as time spent on specific projects, applied to hourly wage rates, and the Company paid </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of Agenus&#8217; costs for these research services. As such, these allocations may not be indicative of the actual amounts that would have been recorded had the Company operated as an independent, publicly traded company for the periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Allocation of Agenus Services, net, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023 and 2022, respectively, is included in Operating expenses in the Company&#8217;s statement of operations and comprehensive loss and Due to related parties, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023, in the Company&#8217;s consolidated balance sheet. Agenus has agreed to not require repayment of this balance prior to March 31, 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, the Company's CEO (&#8220;Dr. Buell&#8221;), became an employee of Agenus in the role of Chairman of the Executive Council. As an employee of Agenus, Dr. Buell is paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> annually and was granted an option to acquire </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">750,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Agenus common stock that vest over a period of four years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective April 12, 2022, the Company entered into a Master Services Agreement with Atlant Clinical Ltd. (&#8220;Atlant&#8221;), a subsidiary of Agenus, to provide clinical trial support services to the Company, including an eTMF platform, medical monitoring and data manager services. The Company&#8217;s Audit and Finance Committee approved the engagement under its related-party transactions policy for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in services. As of December 31, 2023, the Company had entered into work orders with Atlant totaling approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">167,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, plus out of pocket expenses which are to pass through to Company at cost. For the years ended December 31, 2023 and 2022, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">106,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> related to these services is included in &#8220;Research and development&#8221; expense in the Company&#8217;s consolidated statements of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Buell's spouse is a partner in the law firm of Wolf, Greenfield &amp; Sachs, P.C. (&#8220;Wolf Greenfield&#8221;), which provided legal services to the Company during the years ended December 31, 2023 and 2022, and continues to do so. In the years ended December 31, 2023 and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company expensed Wolf Greenfield fees totaling approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">225,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">343,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Dr. Buell&#8217;s spouse does not receive direct compensation from the fees paid to Wolf Greenfield by the Company and the fees paid by the Company to Wolf Greenfield in the period was an insignificant amount of Wolf Greenfield&#8217;s revenues. The Company&#8217;s Audit and Finance Committee approved these services under its related-party transactions policy.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206341143296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAbstract', window );"><strong>Loss Contingency [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(11) Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may currently be, or may become, a party to legal proceedings. While the Company currently believes that the ultimate outcome of any of these proceedings will not have a material adverse effect on its financial position, results of operations, or liquidity, litigation is subject to inherent uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450-20/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450-30/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206444415776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTextBlock', window );">Benefit Plans</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(12) Benefit Plans</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s employees are eligible to participate in the Agenus Inc. 401(k) Savings Plan in the United States and a defined contribution Group Personal Pension Plan in the United Kingdom (the &#8220;Plans&#8221;) for all eligible employees, as defined in the Plans. Participants may contribute a portion of their compensation, subject to a maximum annual amount, as established by the applicable taxing authority. Each participant is fully vested in his or her contributions and related earnings and losses. For the years ended December 31, 2023 and 2022, the Company expensed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">172,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">131,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, related to the discretionary contribution to the Plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 715<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482236/912-715-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206435348000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(13) Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Note</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 12, 2024, the Company and Agenus entered into a Convertible Promissory Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) pursuant to which the Company issued to Agenus a Convertible Promissory Note in the principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the &#8220;Note&#8221;). The Purchase Agreement sets forth the terms and conditions, including representations and warranties, for the Company&#8217;s issuance and sale of the Note to Agenus.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may draw down on the principal amount of the Note from time to time with Agenus&#8217;s consent in any increment, either in the form of advancements or payments made by Agenus on the Company&#8217;s behalf. The Note carries an annual rate of interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% (the &#8220;Interest Rate&#8221;) that accrues from the date funds are paid or advanced by Agenus to the Company. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest shall accrue and not be payable until converted or paid in connection with the repayment in full of the principal amount of the Note. The Note provides that the Company will pay Agenus on demand the principal amount outstanding, together with any unpaid interest, on or after January 1, 2026.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In the event of a qualified financing event, as described in the Note, at Agenus&#8217;s election, the Company must pay the principal amount outstanding and any unpaid interest, either in full or in the form of equity securities. In March 2024 MiNK received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from Agenus and the Note was fully drawn.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nasdaq MVLS Notice</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 23, 2024, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying it that for the previous </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consecutive trading days the Company&#8217;s Minimum Value of Listed Securities (&#8220;MVLS&#8221;) was less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, as required by Nasdaq Listing Rule 5550(b)(2) (the &#8220;MVLS Rule&#8221;).  Nasdaq has provided the Company with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">180</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> calendar days, or until August 21, 2024, to regain compliance. To regain compliance, the Company&#8217;s MVLS must meet or exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for a minimum of ten consecutive trading days.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event the Company does not regain compliance with the MVLS Rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Hearings Panel. The Company will continue to monitor its MVLS and consider its available options to regain compliance with the MVLS Rule. However, there can be no assurance that the Company will be able to regain compliance with the MVLS Rule.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nasdaq Minimum Bid Price Notice</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 26, 2024, the Company received a letter (the &#8220;Minimum Bid Price Notice&#8221;) from Nasdaq notifying the Company that its common stock, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value per share (the &#8220;Common Stock&#8221;), failed to comply with the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Price Rule&#8221;) based upon the closing bid price of the Common Stock for the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consecutive trading days prior to the date of the Minimum Bid Price Notice from Nasdaq.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has been provided an initial compliance period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">180</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> calendar days, or until August 26, 2024, to regain compliance with the Minimum Bid Price Rule which requires that the closing bid price of the Common Stock meet or exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for a minimum of ten consecutive trading days.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the Company is unable to regain compliance with the Minimum Bid Price Rule, the Company may be eligible for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">180-day</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Rule, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for the second compliance period or fails to regain compliance during the second </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">180-day</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period, Nasdaq will notify the Company of its determination to delist the Common Stock, at which point the Company would have an opportunity to appeal the delisting determination to a Hearings Panel.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will continue to monitor the bid price of the Common Stock and consider its available options to regain compliance with the Minimum Bid Price Rule. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Rule.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206440930752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(a) Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and include the accounts of MiNK and its subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(b) Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK is managed and operated as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> business segment. The entire business is managed by a single executive operating committee that reports to the chief executive officer. The Company does not operate separate lines of business with respect to any of its product candidates or geographic locations. Accordingly, the Company does not prepare discrete financial information with respect to separate product areas or by location and does not have separately reportable segments as defined by Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 280, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(c) Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases those estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(d) Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments purchased with maturities at acquisition of three months or less to be cash equivalents. Cash equivalents consist primarily of money market funds.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(e) Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equipment is carried at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, typically </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Additions are capitalized, while repairs and maintenance are charged to expense as incurred. Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">205,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">122,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(f) Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:0.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.3553803871825076%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities. </span></div></div><div style="margin-left:0.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.3553803871825076%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></div></div><div style="margin-left:0.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.3553803871825076%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s cash and cash equivalents are carried at fair value (a Level 1 measurement), determined according to the fair value hierarchy described above. The carrying values of the Company&#8217;s, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(g) Foreign Currency Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gains and losses from the Company&#8217;s foreign currency-based accounts and transactions, such as those resulting from the remeasurement and settlement of receivables and payables denominated in foreign currencies, are included in the consolidated statements of operations within other income (expense). The Company recorded de minimis foreign currency losses for the years ended December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(h) Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include the costs associated with the Company&#8217;s internal research and development activities, including salaries and benefits, share-based compensation, occupancy costs, clinical manufacturing costs, related administrative costs and research and development conducted for the Company by outside advisors. Research and development expenses also include the cost of clinical trial materials shipped to the Company&#8217;s research partners. Research and development costs are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(i) Share-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MiNK accounts for share-based compensation in accordance with the provisions of ASC 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Share-based </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compensation expense is recognized based on the estimated grant date fair value. Compensation cost is recognized on a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">straight-line </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">basis over the requisite service period of the award. Forfeitures are recognized as they occur. See Note 8 for further discussion on share-based compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(j) Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the asset and liability method with deferred tax assets and liabilities recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and net operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such items are expected to be reversed or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statement of operations in the period that includes the enactment date. Deferred tax assets are recognized when they are more likely than not expected to be realized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(k) Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic income or loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted income per common share is calculated by dividing net income attributable to common stockholders by the weighted average number of common shares outstanding plus the dilutive effect of outstanding instruments such as stock options. Because the Company reported a net loss attributable to common stockholders for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of December 31, 2023 and 2022, as they would be anti-dilutive: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.78%;"></td>
          <td style="width:1.6%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.2%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.6%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.82%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,945,716</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,148,447</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested shares</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">789,503</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">726,163</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(l) Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. As the Company has a single reportable segment, MiNK expects the adoption of this standard to result in increased disclosures in the notes to its consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. For the Company, ASU 2023-09 is effective for fiscal years beginning after December 15, 2025. Early adoption is permitted for any annual periods for which financial statements have not been issued or made available for issuance. The Company is currently evaluating the impact that ASU 2023-09 will have on its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No other new accounting pronouncement issued or effective during the year ended December 31, 2023 had or is expected to have a material impact on the Company&#8217;s consolidated financial statements or disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206341078800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of December 31, 2023 and 2022, as they would be anti-dilutive: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.78%;"></td>
          <td style="width:1.6%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.2%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.6%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.82%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,945,716</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,148,447</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested shares</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">789,503</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">726,163</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206444512480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents consisted of the following as of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:58.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.268%;"></td>
        <td style="width:1.719%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.715%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.719%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.715%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.719%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.715%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.719%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.715%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Institutional money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206346999744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equipment, net, consisted of the following as of December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.627%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.377%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.036999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,351</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">496</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">284</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">954</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,067</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206347179296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax effect of temporary differences and net operating loss carryforwards that give rise to significant portions of the deferred tax assets and deferred tax liabilities as of December 31, 2023 and 2022 are presented below (in thousands).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Federal and state net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,804</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,819</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,224</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">341</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">269</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,515</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,154</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">926</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">427</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,674</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,674</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Income Taxes Recorded Differed from Amounts Computed</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes recorded differed from the amounts computed by applying the U.S. Federal income tax rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% in 2023 and 2022 to loss before income taxes as a result of the following (in thousands). </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computed &#8220;expected&#8221; Federal tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,716</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,878</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Increase) reduction in income taxes benefit resulting from:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,987</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,028</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign rate change</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">842</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign income inclusion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">530</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State and local income benefit, net of Federal income tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,693</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Return-to-provision adjustment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign rate differential</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">286</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">840</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">348</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206347086864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consist of the following as of December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payroll</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,655</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">642</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,681</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract manufacturing costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">261</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,037</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206435318864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Summary of Fair value of Options Granted Under Weighted Average Assumptions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each option granted during the period was estimated on the date of grant using the following weighted average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term in years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of option activity for 2023 is presented below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,148,447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,002,743</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61,883</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.01</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,945,716</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.03</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.32</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,227,555</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested or expected to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,945,716</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.03</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.32</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,227,555</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,999,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.56</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,227,545</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Summary of Non-vested Stock Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of non-vested stock activity for 2023 is presented below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nonvested<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">726,163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.01</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,563,324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">804,234</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">695,750</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.03</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">789,503</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.18</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Share-based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The impact on the Company&#8217;s results of operations from share-based compensation for the year ended December 31, 2023 and 2022, was as follows (in thousands): </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">541</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">435</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,289</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,592</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,027</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206435537328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 133,396,933<span></span>
</td>
<td class="nump">$ 110,939,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,367,229<span></span>
</td>
<td class="nump">$ 19,635,725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206346378768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 204,617<span></span>
</td>
<td class="nump">$ 121,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_DepreciationExpenseOnPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="nump">$ 122,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_DepreciationExpenseOnPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation expense on property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_DepreciationExpenseOnPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206346886992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">6,945,716<span></span>
</td>
<td class="nump">6,148,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inkt_NonVestedSharesMember', window );">Non-Vested Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">789,503<span></span>
</td>
<td class="nump">726,163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inkt_NonVestedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inkt_NonVestedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206435461056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents - Summary of Cash Equivalents (Details) - Institutional Money Market Funds - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cost</a></td>
<td class="nump">$ 2,899<span></span>
</td>
<td class="nump">$ 18,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">$ 2,899<span></span>
</td>
<td class="nump">$ 18,664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206456080176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equipment - Summary of Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment</a></td>
<td class="nump">$ 1,450,000<span></span>
</td>
<td class="nump">$ 1,351,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(495,638)<span></span>
</td>
<td class="num">(283,682)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment, net</a></td>
<td class="nump">$ 953,977<span></span>
</td>
<td class="nump">$ 1,066,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206347054096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax years open for examination</a></td>
<td class="text">2018 2019 2020 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 52,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Net operating loss carryforwards, Expiration date</a></td>
<td class="text">Dec. 31,  2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, Deferred tax asset, increase (decrease)</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research expenses</a></td>
<td class="nump">$ 6,515<span></span>
</td>
<td class="nump">$ 4,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 52,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_CapitalizedExpensesAmortizationPeriod', window );">Capitalized expenses amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 52,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_CapitalizedExpensesAmortizationPeriod', window );">Capitalized expenses amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Belgium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_CapitalizedExpensesAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized expenses amortization period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_CapitalizedExpensesAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206347262528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">U.S. Federal and state net operating loss carryforwards</a></td>
<td class="nump">$ 13,804<span></span>
</td>
<td class="nump">$ 11,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign net operating loss carryforwards</a></td>
<td class="nump">7,819<span></span>
</td>
<td class="nump">6,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits', window );">Research and development tax credits</a></td>
<td class="nump">341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research expenses</a></td>
<td class="nump">6,515<span></span>
</td>
<td class="nump">4,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">29,674<span></span>
</td>
<td class="nump">22,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">$ (29,674)<span></span>
</td>
<td class="num">$ (22,657)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets in process research and development tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206440931056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Taxes Recorded Differed from Amounts Computed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Computed &#8220;expected&#8221; Federal tax benefit</a></td>
<td class="num">$ (4,716)<span></span>
</td>
<td class="num">$ (5,878)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>(Increase) reduction in income taxes benefit resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">5,987<span></span>
</td>
<td class="nump">4,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange', window );">Foreign rate change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(842)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion', window );">Foreign income inclusion</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local income benefit, net of Federal income tax benefit</a></td>
<td class="num">(1,693)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_IncomeTaxReconciliationReturnToProvisionAdjustment', window );">Return-to-provision adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Permanent differences</a></td>
<td class="nump">840<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="num">$ (397)<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, foreign income inclusion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, foreign rate change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_IncomeTaxReconciliationReturnToProvisionAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation return-to-provision adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_IncomeTaxReconciliationReturnToProvisionAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206347303808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Summary of Accrued liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Payroll</a></td>
<td class="nump">$ 1,831,000<span></span>
</td>
<td class="nump">$ 1,655,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">398,000<span></span>
</td>
<td class="nump">642,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_AccruedResearchServicesCurrent', window );">Research services</a></td>
<td class="nump">302,000<span></span>
</td>
<td class="nump">1,681,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_AccruedContractManufacturingExpenseCurrent', window );">Contract manufacturing costs</a></td>
<td class="nump">2,430,000<span></span>
</td>
<td class="nump">261,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 5,037,361<span></span>
</td>
<td class="nump">$ 4,238,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_AccruedContractManufacturingExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued contract manufacturing expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_AccruedContractManufacturingExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_AccruedResearchServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research services current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_AccruedResearchServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206440956608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_AuthorizedCapitalStockIncreased', window );">Authorized capital stock increased</a></td>
<td class="nump">155,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_AuthorizedCapitalStockIncreased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Authorized capital stock increased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_AuthorizedCapitalStockIncreased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206336741792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Plans - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes', window );">Shares issued, payment for employee bonuses, net of shares withheld for taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,951<span></span>
</td>
<td class="nump">81,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair values of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.78<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation expense related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Intrinsic value of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,187<span></span>
</td>
<td class="nump">258,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued, vesting of non-vested stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,196<span></span>
</td>
<td class="nump">60,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Shares issued, payment for employee bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603,830<span></span>
</td>
<td class="nump">125,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares issued, withheld to cover taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,879<span></span>
</td>
<td class="nump">43,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized share-based compensation expense related to non-vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options excercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Stock option grants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10-year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued, vesting of non-vested stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,196<span></span>
</td>
<td class="nump">60,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Shares issued, payment for employee bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603,830<span></span>
</td>
<td class="nump">125,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inkt_TwoThousandAndEighteenEIPMember', window );">2018 EIP | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inkt_TwoThousandAndEighteenEIPMember', window );">2018 EIP | Maximum | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inkt_TwoThousandAndTwentyOneEIPMember', window );">2021 EIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_PercentageOfSharesOfCompanySCommonStockOutstanding', window );">Percentage of shares of company's common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares authorised in share pool</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan', window );">Shares reserved for issuance under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan', window );">Shares reserved for issuance under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding', window );">Ratio of annual increase shares reserved for issuance under ESPP to number of shares of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_PercentageOfSharesOfCompanySCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares of company's common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_PercentageOfSharesOfCompanySCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio of annual increase shares reserved for issuance under ESPP to number of shares of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares reserved for issuance under Employee Stock Purchase Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares, employee benefit plan net of shares withheld for taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inkt_TwoThousandAndEighteenEIPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inkt_TwoThousandAndEighteenEIPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inkt_TwoThousandAndTwentyOneEIPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inkt_TwoThousandAndTwentyOneEIPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206342149536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Plans - Summary of Fair value of Options Granted Under Weighted Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206347023824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Plans - Summary of Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding at Beginning Balance</a></td>
<td class="nump">6,148,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted</a></td>
<td class="nump">1,002,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised</a></td>
<td class="num">(105,187)<span></span>
</td>
<td class="num">(258,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited</a></td>
<td class="num">(61,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired</a></td>
<td class="num">(38,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding at Ending Balance</a></td>
<td class="nump">6,945,716<span></span>
</td>
<td class="nump">6,148,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Vested or expected to vest at December 31, 2023</a></td>
<td class="nump">6,945,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable at December 31, 2023</a></td>
<td class="nump">3,999,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at Beginning Balance, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted Average Exercise Price</a></td>
<td class="nump">2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise Price</a></td>
<td class="nump">0.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, Weighted Average Exercise Price</a></td>
<td class="nump">2.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, Weighted Average Exercise Price</a></td>
<td class="nump">3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at Ending Balance, Weighted Average Exercise Price</a></td>
<td class="nump">2.03<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest at December 31, 2023, Weighted Average Exercise Price</a></td>
<td class="nump">2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at December 31, 2023, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at December 31, 2023, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested or expected to vest at December 31, 2023, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at December 31, 2023, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at December 31, 2023, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 2,227,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested or expected to vest at December 31, 2023, Aggregate Intrinsic Value</a></td>
<td class="nump">2,227,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at December 31, 2023, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 2,227,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206341316144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Plans - Summary of Non-vested Stock Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested Shares, Outstanding at Beginning Balance | shares</a></td>
<td class="nump">726,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Nonvested Shares, Granted | shares</a></td>
<td class="nump">1,563,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Nonvested Shares, Vested | shares</a></td>
<td class="num">(804,234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Nonvested Shares, Forfeited | shares</a></td>
<td class="num">(695,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested Shares, Outstanding at Ending Balance | shares</a></td>
<td class="nump">789,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at Beginning Balance, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">$ 3.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">1.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">2.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">3.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at Ending Balance, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">$ 1.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206343287600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Plans - Summary of Stock Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 3,830<span></span>
</td>
<td class="nump">$ 3,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 3,289<span></span>
</td>
<td class="nump">$ 2,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206337022160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Agreement - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 2,621,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,453,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember', window );">Research and Development Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_RepayableAdvanceOfDevelopmentGranted', window );">Research and development agreement amount granted | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_RepayableAdvanceOfDevelopment', window );">Repayable advance of development | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember', window );">Research and Development Agreement | Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_RepayableAdvanceReceived', window );">Repayable advance received</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember', window );">Research and Development Agreement | Other Income (Expense), Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_RepayableAdvanceOfDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayable advance of development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_RepayableAdvanceOfDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_RepayableAdvanceOfDevelopmentGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayable advance of development granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_RepayableAdvanceOfDevelopmentGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_RepayableAdvanceReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayable advance received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_RepayableAdvanceReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=inkt_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=inkt_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206336955936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 12, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_DueToRelatedParty', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,157,073<span></span>
</td>
<td class="nump">$ 9,081,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,002,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_DueToRelatedParty', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_AgenusIncMember', window );">Agenus Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_PeriodOfLicenseAgreement', window );">Period of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_TerminateLicenseAgreementPeriod', window );">Terminate license agreement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_PeriodForBreachOfPaymentObligations', window );">Period for breach of payment obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may terminate the New Assignment and License Agreement without cause upon 90 days&#8217; prior written notice to Agenus. Either party may terminate if they believe there has been a material breach which has not been cured within 90 days (or 45 days for breach of payment obligations) of receiving such notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_IntercompanyAllocationIncludedInExpense', window );">Intercompany allocation included in expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_AgenusIncMember', window );">Agenus Inc | New Intercompany Service Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_PercentageOfServiceCost', window );">Percentage of service cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_ServiceAgreementNoticePeriod', window );">Service agreement notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_AgenusIncMember', window );">Agenus Inc | Individual Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_ServiceAgreementNoticePeriod', window );">Service agreement notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_AgenusIncMember', window );">Agenus Inc | Business Services and Occupancy Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_PercentageOfServiceCost', window );">Percentage of service cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_AgenusIncMember', window );">Agenus Inc | Research Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_PercentageOfServiceCost', window );">Percentage of service cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_AtlantClinicalLtdMember', window );">Atlant Clinical Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Expenses from transactions with related party</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_WorkOrderReceivedFromRelatedParty', window );">Work order received from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_AtlantClinicalLtdMember', window );">Atlant Clinical Ltd | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_ClinicalResearchServices', window );">Clinical research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,500<span></span>
</td>
<td class="nump">106,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_WolfGreenfieldSachsPCMember', window );">Wolf, Greenfield &amp; Sachs, P.C.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal services fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="nump">$ 343,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_DrBuellMember', window );">Dr. Buell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Compensation paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Dr. Buell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_ClinicalResearchServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical research services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_ClinicalResearchServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_DueToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Due to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_DueToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_IntercompanyAllocationIncludedInExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intercompany allocation included in expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_IntercompanyAllocationIncludedInExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_PercentageOfServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of service cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_PercentageOfServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_PeriodForBreachOfPaymentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for breach of payment obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_PeriodForBreachOfPaymentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_PeriodOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_PeriodOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_ServiceAgreementNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Service agreement notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_ServiceAgreementNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_TerminateLicenseAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Terminate license agreement period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_TerminateLicenseAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_WorkOrderReceivedFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Work order received from related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_WorkOrderReceivedFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481440/840-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479741/842-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_AgenusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_AgenusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=inkt_NewIntercompanyServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=inkt_NewIntercompanyServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=inkt_IndividualServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=inkt_IndividualServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=inkt_BusinessServicesAndOccupancyCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=inkt_BusinessServicesAndOccupancyCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=inkt_ResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=inkt_ResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_AtlantClinicalLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_AtlantClinicalLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_WolfGreenfieldSachsPCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_WolfGreenfieldSachsPCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_DrBuellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_DrBuellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206342206768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plans - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Expense related to discretionary contribution to the Plans</a></td>
<td class="nump">$ 172,000<span></span>
</td>
<td class="nump">$ 131,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140206340141856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 26, 2024</div></th>
<th class="th"><div>Feb. 23, 2024</div></th>
<th class="th"><div>Feb. 12, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | Nasdaq MVLS Notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_MinimumValueOfListedSecuritiesPeriod', window );">Number of trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_AdditionalPeriodForMinimumValueOfListedSecurities', window );">Minimum value of listed securities regain compliance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_MinimumValueOfListedSecuritiesForTenTradingDays', window );">Minimum value of listed securities for ten trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | Nasdaq Minimum Bid Price Notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_MinimumBidPrice', window );">Minimum bid price required for Listing</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_NumberOfConsecutivetradingDays', window );">Number of consecutive trading days</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_InitialCompliancePeriod', window );">Initial compliance period</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_ClosingBidPriceForTenTradingDays', window );">Closing bid price for ten trading days</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_AdditionalCompliancePeriod', window );">Additional compliance period</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_SecondCompliancePeriod', window );">Second compliance period</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | Maximum | Nasdaq MVLS Notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inkt_MinimumValueOfListedSecurities', window );">Minimum value of listed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | Convertible Promissory Note | Agenus | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Convertible debt issued, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Convertible debt, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Convertible debt, interest rate terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Interest shall accrue and not be payable until converted or paid in connection with the repayment in full of the principal amount of the Note. The Note provides that the Company will pay Agenus on demand the principal amount outstanding, together with any unpaid interest, on or after January 1, 2026.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_AdditionalCompliancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional compliance period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_AdditionalCompliancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_AdditionalPeriodForMinimumValueOfListedSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum value of listed securities regain compliance period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_AdditionalPeriodForMinimumValueOfListedSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_ClosingBidPriceForTenTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Closing bid price for ten trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_ClosingBidPriceForTenTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_InitialCompliancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial compliance period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_InitialCompliancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_MinimumBidPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum bid price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_MinimumBidPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_MinimumValueOfListedSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum value of listed securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_MinimumValueOfListedSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_MinimumValueOfListedSecuritiesForTenTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum value of listed securities for ten trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_MinimumValueOfListedSecuritiesForTenTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_MinimumValueOfListedSecuritiesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum value of listed securities period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_MinimumValueOfListedSecuritiesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_NumberOfConsecutivetradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_NumberOfConsecutivetradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inkt_SecondCompliancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Second compliance period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inkt_SecondCompliancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inkt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=inkt_NasdaqMvlsNoticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=inkt_NasdaqMvlsNoticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=inkt_NasdaqMinimumBidPriceNoticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=inkt_NasdaqMinimumBidPriceNoticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inkt_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inkt_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_AgenusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inkt_AgenusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=inkt_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=inkt_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "L@'58N*WD=. (  !%-P  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6;;6_J.!J&_XK%'(UFI%+R1DO/M)4HT%FVIY0MG!EU1_O!34R)3A*SME/:
M?[^/$TC(KF.2E?G2\I+G3G)A._<=.]=;RG[P-2$"?<11PF\Z:R$V7WL][J])
MC/DYW9 $OEE1%F,!;]E;CV\8P4%6%$<]Q[(N>C$.D\[M=?;9G-U>TU1$84+F
M#/$TCC'[O",1W=YT[,[^@^?P;2WD![W;ZPU^(PLBOF_F#-[U"I4@C$G"0YH@
M1E8WG:']=>RYLB#;XH^0;/G!:R1/Y972'_+--+CI6/*(2$1\(24P_'LG(Q)%
M4@F.X]\[T4ZQ3UEX^'JO?I^=/)S,*^9D1*,_PT"L;SJ##@K("J>1>*;;OY'=
M"?6EGD\CGOU%VWS;_D4'^2D7--X5PQ'$89+_QQ\[$ <% ZNFP-D5./]58'LU
M!>ZNP&U:X.T*O(Q,?BH9AS$6^/::T2UB<FM0DR\RF%DUG'Z8R-]](1A\&T*=
MN!U3/X6?42"<!&B2B%!\HFF2MR?YNW31]\48_?+E5_0%A0EZ#*,(/N;7/0$[
MEQ(]?[>CNWQ'3LV.; <]TD2L.>PE($%5H ='71RZLS_T.T>K.";^.7+M,^18
MCJLXH)&^_!&S<V3WLW)/43[6E_\]36#OEFKOE;-QBQ_"S?3<&KT1?2<,_35\
MY8)!9_B7BG"NX*D5Y CQE6^P3VXZ, 1PPMY)Y_;GG^P+ZS<5'9-B8T-B%7)>
M0<[3J9=->/FY(2IL^G+;ZCZH^&BKVO(Q)%;ATR_X]+4G. 0X00;H/L)O*D#Z
M^A6.N(KK2%O6EI AL0JABX+01;,6-"<LI'(<#!",ILK&=$1I/R;5#DK:^K;0
M#(E5H%T6T"Z;0;L/N8\C]$(P0_?PH?+BH->J@Z6M:@O+D%@%UJ" -6@%:]?0
M:G'IU>Y?5+"T-6UA&1*KP+HJ8%UI3V]G0Y[)6R@OAD!MAF-E9]3K/(:S![1<
M$X8W)!6AS\_ VOCG*G9:H;;L#(E5V-E6:>BL)O1&T-H8M+0IN*T/]$ ^E99-
M+V59ECWP+,>Y4C'3%[>%9DJM2NW !MN-J*6,R6[Z3#:4B3!Y0PN!A;J/'E%\
M(:JJD;ZJ-35#:E5J3DG-:4+M#QJEB8#8",-;1)B:EEYI1I6PM$6M81E2J\(J
M#;ZM=<&W1;H2A.5Q5YH,O&]S2FAZQ;HF9M3:FU*K4BO-O:VWY_L>>>@R=/[L
MB%RW:SM=UU9B,^KX3:E5L96>W]:;]EUCR_HC&@&K-\K4EP"]SHPF7>S[!&1
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M.'NY)AC:CMP OE]1*O9OY Z*)^=N_P-02P,$%     @ K(!U6!O*LZ9V!0
M1!0  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6RM6&UOVS80_BN$%ZP;
MX,1\$26Q<PPD3HH:Z]8@3K?/C,3$1"71%>FDW:\?*3FR+5&*A^5#8KW<G9XC
M[Y[GI.FS*K_JE1 &?,^S0I^/5L:LWT\F.EF)G.LSM1:%O?.@RIP;>UH^3O2Z
M%#RMG/)L@B$,)SF7Q6@VK:[=E+.IVIA,%N*F!'J3Y[S\<2DR]7P^0J.7"[?R
M<67<A<ELNN:/8BG,E_5-:<\F3914YJ+04A6@% _GHPOT?HZ)<Z@L_I+B6>\=
M Y?*O5)?W<DB/1]!ATAD(C$N!+<_3V(NLLQ%LCB^;8..FF<ZQ_WCE^@?JN1M
M,O=<B[G*_I:I69V/XA%(Q0/?9.96/7\4VX2HBY>H3%?_P?/6%HY LM%&Y5MG
MBR"71?W+OV\78L\!!3T.>.N CW4@6X=JY28ULBJM*V[X;%JJ9U Z:QO-'51K
M4WG;;&3AMG%I2GM76C\SFZM"JTRFW(@47/*,%XD RZJ 3L&7Y17XY>37Z<38
M)SG[2;*->EE'Q3U1KT1R!@@: PPQ\;C/CW?'A^X3FU^3)&Z2Q%4\TA/O8KF\
MOEOZTJC] K^?:Z'W>LT3<3ZR/:)%^21&LY]_0B'\S9?4&P4[2)$T*9*AZ+,Y
MURO BQ0D[D!\V\@GGHG":%_6=:BH"N7Z_&E&2!AAS*:3I_V$NG:(A81&F#:&
M!V"#!FPP"/:F%&LN4R"^6S;2PHNQCA#N/9L2A% +8=<*LS@,(S\^VN"C@_@^
MFY4H;?>5I5U!P+46_G6DG:>C*&)AT +9-0LB2"#T@PP;D.$@R#ME>'8$R+#S
M=$)93& ;9=<.PP &(<-^G%&#,QK$>6UK<6V)WXQ!85E%/5CJ3C;Y)JLH)Q6V
M&1+)*TZW]TX"1L<AB:M:/L$Q&8<QMMFY>Y861'YO=^:%62HCQQ%CJRAZ+2I)
MR'[X5B'J9,<H85'46H2N&8)AR%#/7L7-&L1'[%7_'L7="J$4X[A=[ET[C(+(
M4DC/'K$&'QLDR$^+B\O%I\7=XGH)+OZ\ LN[S_/?/W[^='5]NWP'KJX_+.:+
M.Q]P]I;\^4;!#E8 P9T0PL$]ND@2M;&$"=;\![_/A%?U8+>9&$(L(JV-\AC2
M&-N>[RDDM*?7Z#68Y<8V3B;YO<RDD7[ZW$8Y  !)1,)V27D, TQB2GLX'NU$
M%PT*7HM%7\.+NZ4=4()I!Z_',,0HW).&0[P[!47#$GI(J*_A)5VF0 '$-*9M
MP!Y+',8$A6$/XIV,HF$=K5<X4\7CJ1%E_BKFKEH&,8QP&W#7#,&8]I;N3E71
ML*Q>;02X4^!6U-1_PTOCY6KDT56$: 2[;=:U9#!&F+ >K#MQ1</J.E=Y+HV3
M+5V/5:HPLG@41=*WN(/Q_.P%O*/Q_P]TF/-.J%$TJ )+HY*O*Y6EHM3OW+N0
M3*3QYCJH^/^5]M\JVF'6.VE&P]KL=MK.'MHE/[;D7P([.=M*/8%GEJXA FO;
M8WK%2S$&B,*QO>;^ZDNV.#9FI4KYCTC'@ 1CRMC8"D)5,X2,8QJ. QR_&$NM
M'7>[F_:56AM[8(OJ#<8;U)T,2!"VN\5CU-LIN]$!#>KR[")-I9O>+'>ZH?Y4
M%O8=9"TMEWJ!,D]OTRC"L$N</E,88\;ZJ COQ!Z_*O;-"*IJG5*Y+:^5^T#Q
M)"RG:F^7XZZNGP8$LJ ]2/H,,<-!&/= WPT ^-4!8&]Z[NU1W-7U4T3L?H>,
MM&G4:XL@(PQ&00_>O7?OX3&@EE5]++?@KKZ?HAA2&@3MUU.?:0 1@:0'\VX4
MP,>, GMR6K7B\3ET7YS]\[S'L&>@G^Q]XG'?U_[@Y:,L-,C$@W6%9Y%5PK+^
M9%6?&+6NOOK<*V-47AVN!+?0G8&]_Z"4>3EQ'Y*:#X>S?P%02P,$%     @
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M7JJ]4]J.D;4[EA?2X"'OFB5>PZ!L +Y?2FD>._:D[R[V["]02P,$%     @
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MO.Z<@4%=LO9*7KI G#C@<,+![1S<H8,_X>!U#EXCM&76R+HCBJ0+P0](:&M
MTS=-;!IO4%,RG<8G)>#7$OQ4NN),\JK,B:(Y>E)P@1PIQ-?HKRT51(=:(L)R
MM.(UU$FA$[BGZ \N)7J'/C_=H3<_OUW8"JAH0#OK/GO;?M:=^"QVT2?.5"'1
M!Y;3_!S !@V]$/=5R*T[BWA'LVODX2OD.JYG(+3Z?G=WAH[7Q]5K\+P)O"YZ
M;(/H"RPY2>6-*4HMB&\&T4OX1FY)1I<6Q%Y2L:=6^LM/.'1^-2F\$-B97K_7
MZ\^AIX^ 2$16-+62TSWL#UM=22;1+5+4(.EM9I_BP(^3)(D6]OY4T-C0]3 .
ML$[PWD VZ,D&LV1_HPRR4S5<20ZKJI1*9VM/371;K/"$1>0##2<>L#78Q9Z/
M@\!,-NS)AK-DCY54P:(S$0Q''W[GNHD+%(,!18.EYR1^XD:QF634DXSFRUT5
M5*"29;RFZ$U7\F^O$*/*6/?1)>O^0F!GPN->>#R;G7NF** J=-]I_]!K_Y,:
MJS\>Y< //3<(!ZD:F[F!YTU5?M+33>:+Z2Q/NJ#:))F()N-BP<Z Y=C&C1P?
MUH>9)G:.;<F9)0K!FZSWSC4Z+W@_B.(@&? SFD9)@EWL3E \Z9QXMN8?()(0
MQQH.([(@@B)HHL18[1W0A<K]4FCGLMVC;'<V,[=$EIFNF28_:#N(@E%_BYB<
M9L&Y#H>[D]DLGJJE8RO&LYTOO2NKG3[>_!AG[_LX&\TF.1_;*9[OIU^:\R>0
M)GO8_C<4L5W]#+3A8';*7"(XFDL%C0P:Q)4^T):948T_6JB>[P5)XH\$&2R]
M,()^$DUH.G9=/-]V_Y^FO,V>4=6XY4ZI,EC.JSJV9QQ^1^O+SH['&YB?NNW5
MR'NVX__P?G AM'/]Q\Z/9_MK"M,4Y)7!L"($9=DW!$<I)JMF=/C/0$3C[1E[
ML1^-]O&Q(33#V,$3V3NV;SS?O\_'FLF.$YLZ3I"$GC<\!1I-HS"(?3PD:Y^,
M;345FV::E5!*.Z;:P:=_VT_,[YLY<?#^5D_2S3AXA&G'\$]$;$J8X"JZ!DCG
M.H)U(-K)MGU0?-L,A\]<P:C9W!:4Y%1H _A]S;EZ?= ?Z/^_D/X+4$L#!!0
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M#GQYW@:-&H.J):!J%$I-[!@#;D)FWD3KM&RMM-SP3I%5]V5/[":MT&=AX4V
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MK0]FY;E##JN<BY# ]1PLLU'0N#&H6@*J1J'4Q+XQH#-L1F>F\W^LPUG8<?W
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M"[IXOO%'OMDV^L9R=;$3&[B%YL_=38W?EJV7+"^A4KFL2 WKR\4'>G[-0SW
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M-L#?UU(VSU_T ]K_,[#Z#U!+ P04    " "L@'58@V][&38"  "_!0  &
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MF![&1G*]A/T-LRN. +X-$&+;Z7!/*0L=SG*)I3#Y).\Q40XEGO7&MY[L:)Y
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MR')?5(DPCJ)!6#$N@W3L8_<Z':O&"B[Q7H-IJHKI]RD*M9P$O6 =>."+TKI
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MJ#0Z.3L-0+=CI'6LJKUTY\K2(/!F29,7M4N@_4(INW;< =TL3_\ 4$L#!!0
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M:WC7F42A8"RR5$@MG'ED$(+CJYRDWM7AA2FMT6@\9]WX\WG<D;, =65F9]D
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M#"9AV/OT@V3'YL$"8]DLB*))[_ZURB(;8QA++#">A,R11'3>>]@@ A_H!):
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M/NUC!'67S?Z'586[X%TJ:U7F'C>"(]ZT -]7"@>YZ@=MT-SX7_T-4$L#!!0
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M#J[3 IP<D;J3D+FL8>0MZ%=TU:0VD75.1JT=V509:X#UDC@$-HB\KZ1%P]4
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M.[KKPV=.CRLTWH#6MUJ[;N #],^U]3]02P,$%     @ K(!U6/VD5@/2#
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MHV1RA#?I"IP$WN0-WK5Q#EZJ;.#WQ<J1Y:_ASZ%R6]CT,,QWR+FK18KSB%O
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M*D!%W%(Z421;\6NKL7.P&3I(KR<BWR,B#RTD?D90#H[:.))62/WW<;(,=))
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M.CJ9$O]T,WXU&ZMJ/_(LE*4!RB]7-+&B=@+TO5#*MAOGH)N!Y_\#4$L#!!0
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M-'A1NP(ZSY6RNXV[H!OER5]02P,$%     @ K(!U6#Y;;EO%!   ]@L  !D
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M]919+XQ<N<EN*@W-B>YU28,Y*BM YW,IS6YA#;2C_O@_4$L#!!0    ( *R
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M.[1)VU11L3U,>W"3V];"B8/MM/#O=^V$4" @'M:'QA_W')]SG7N3[(6\45L
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M\L;(1=%NOI7&R*RXG /'7\QV +Z?2FD>;^P$U3\6X_\!4$L#!!0    ( *R
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M1],PLJIO[D=I\!U0?Q;X5 -E#7!\)Z5Y;MC'0/?X6_T$4$L#!!0    ( *R
M=5A-**Z"Y0,  -L,   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;*U7
MVV[C-A#]%4*[6"3 .KK:EA-;0.)TT7U8-$AVVX>B#[0TLM252)6D[/3O.Z04
M^2:K"1 @B$1JYO"<(8<SGF^Y^"DS $6>RX+)A94I55W;MHPS**F\XA4P_))R
M45*%0[&V926 )L:I+&S/<29V27-F17,S]R"B.:]5D3-X$$3694G%OW=0\.W"
M<JV7B<=\G2D]84?SBJ[A"=2/ZD'@R.Y0DKP$)G/.B(!T8=VZUTO7UP[&XO<<
MMG+OG6@I*\Y_ZL'79&$YFA$4$"L-0?&Q@244A49"'O^TH%:WIG;<?W]!_V+$
MHY@5E;#DQ1]YHK*%%5HD@936A7KDVU^A%336>#$OI/E/MJVM8Y&XEHJ7K3,R
M*'/6/.ES&X@]!W=RQL%K';QCA^",@]\ZF,C9#3,CZYXJ&LT%WQ*AK1%-OYC8
M&&]4DS.]C4]*X-<<_53TE<6\!/*=/H,D(W(P?(28BP02<I^G*0A\204OR6W)
M:Z8D6?*RJA7.7MR#HGDA+Q'@Q],]N?AX23Z2G)'O&:\E98F<VPJYZA7MN.5U
MU_#RSO!R/?*-,Y5)\@M#"H< -HKLE'HO2N^\0<1[B*^([WXFGN/Y/826KW?W
M!NCX7>!]@^?_;^ QO#(NN*P%D#]O5U()/-M_]86L00SZ$77"7\N*QK"P,*,E
MB U8T:</[L2YZ9/[3F 'XH-.?#"$'G5'Y].'T/.<&WBN,*TA,4/WAGR!! 0M
MB,+HK(!!FJN^>#2+3,TB^K[:1*-@ZD[F]F9?:(_5.)R&G=6!@G&G8#RX?1>X
M?WAM2KC$RRRIFSLIUW]F6Y5)H)8Z6DB\57*V-@ETW2=E_)Y;^TY@!X&9=(&9
M#&]M1MD:="@VM*AI<U<76"THBZ%/>0,WV=N>\2R<'NWAJ5'@>&>V<-HQG0XR
MQ3* ESP6(ZJ Q(9V'[]!D+?NS/1$QR@,O'X=8:<C?)6.]NCAHZAUE>T3$YZN
M[[E'L3ZU&?M./\591W$V2/%)Z1AC)2 %CS&O6ZIM?GPF#/L5GG9IOTNBH>R?
MG6IQ)S/_2$V?E1/TRW&=7=5T!@4]@JH%&RD^J@3?Y*:IH<G?6*^QQ>EE.PSX
MUG/4HNW+<OT][8>R]IH!]_4ID315GZF<%KV*!K'>K,@]4>2%DS."O)T@;U#0
M V"KQU!#IR:&_F[$.UD^#)RCL]1CY =G;B%WUPBX@Z4V^DUE($P.]!+S3\N7
M/SN^'WNL/']VQ,S>:Q-+$&O3/4L2ZW:NZ:.ZV:Y#OS5]Z='\G>[<3?NY@VG:
M_F]4K',F20$I0CI74RQ%HNFDFX'BE6E&5UQA:VM>,_SU 4(;X/>4<_4RT MT
MOV>B_P!02P,$%     @ K(!U6'_"Z:'$ @  60@  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S@N>&ULK99=;YLP%(;_BL6FJ96Z\OVQCB"UB:9.VK2H6;>+
M:1<..02K!F>V2=I_/QL(HH6@:MI-L,UY7S_G&-N)#XP_B!Q HL>"EF)FY%+N
MKDQ3I#D46%RR'93J3<9X@:7J\JTI=ASPIA85U'0L*S +3$HCB>NQ)4]B5DE*
M2EAR)*JBP/SI!B@[S S;. [<D6TN]8"9Q#N\A17(^]V2JY[9N6Q( :4@K$0<
MLIEQ;5_-(QU?!_P@<!"]-M*9K!E[T)W/FYEA:2"@D$KM@-5C#W.@5!LIC#^M
MI]%-J87]]M']4YV[RF6-!<P9_4DV,I\9D8$VD.&*RCMVN(4V'U_[I8R*^A<=
MFMC0-5!:"<F*5JP("E(V3_S8UJ$GL+T3 J<5.*\5N*W K1-MR.JT%ECB).;L
M@+B.5FZZ4=>F5JML2*E7<26Y>DN43B;7:<HKV* O!*\))9* 0._1JEE3Q#)T
M#*"]@+,%2$RH.%>A]ZL%.GM['IM2T6A/,VUGOFEF=D[,O(#T$KGV!7(LQQV1
MSU\O=Y[+356#KA!.5PBG]G-?7X@+-*\XAU*B7]=K(;GZY'Z/Y=D8>^/&>AM>
MB1U.86:H?2: [\%(WKVQ ^OC6-;_R>Q9#=RN!NZ4>[+$3YQ1.I9C(PQKH3X9
M]HD=N;9E6;&Y[^./Q 6^WX][1N9U9-XT&6<9"'UT8(HR #'&V%@$O;G=#]$0
M<1@6>,Y)0K\C]"<)[]1J8)[F2"\*2<<)_2&AY0P)AV%V$-DG$8,.,9A$G+.R
M_HC5^5%6F6I4G)1;E#(A1VF# 8;CN=80=R0N.$T;=K3A).TWF0,?PPH'TX7!
M$&K2_!_W4=2A1Y/HWYG$H[LH&NP.WW)#-[!?P _C/,>-?-]_45*S=_#K2_<K
MYEM2"D0A4TKK,E1?$F\NLJ8CV:Z^"]9,JINE;N;J[@>N ]3[C#%Y[.CKI?LW
MD?P%4$L#!!0    ( *R =5C;7:[<M@(  /H'   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;*U576_3,!3]*U9 "*1MSD>33B.-U'5#5&*BV@0\(!Z\
MY+:QYL29[;0;OQ[;24,[TK A^M#XXYYSS[EQKN,-%W<R!U#HH6"EG#BY4M49
MQC+-H2#RA%=0ZITE%P51>BI66%8"2&9!!<.^ZT:X(+1TDMBN+402\UHQ6L)"
M(%D7!1&/Y\#X9N)XSG;AFJYR919P$E=D!3>@OE0+H6>X8\EH :6DO$0"EA-G
MZIW-QB;>!GREL)$[8V2<W')^9R;S;.*X1A P2)5A(/JQAADP9HBTC/N6T^E2
M&N#N>,O^P7K77FZ)A!EGWVBF\HESZJ ,EJ1FZIIO/D+K)S1\*6?2_J--$QN&
M#DIKJ7C1@K6"@I;-DSRT==@!>-$!@-\"_*> T0% T (":[119FU=$$626/ -
M$B9:LYF!K8U%:S>T-&_Q1@F]2S5.)9?W-56/Z!A-LXR:PA*&YF5S.DR9WUZ
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MFRP@?G_-\VK]13:PV6;RYO]02P,$%     @ K(!U6,ZKT3;E @  "0@  !D
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M',HO4LP%P^I;W$2R%>NMYW0@L%K9@[+LP0>W]."04AT(K":5;3U["NN=FKH
MKMW!3G^PU]8-44YWX.PUMEEQ12FPE3:+7%)9$Y&[A7*U-*1C;</VUB?*J&JW
M]0R3N]QKS%:QM$D)+"6D==:3MR[+C6,^$333WNN>"NGD]#"29AN8"I#OEY2*
MW41M4-IW_Q]02P,$%     @ K(!U6"51X\ 6!   D!4  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#4N>&ULS5C;;N,V$/T50ELL$F!KW7Q+UC;@6%DTP&8;
M)$W[4/2!EL:VL)2HDK2=+?KQ)2E%EA)9L5 ^Q \6*7'.S)P9#B^3/67?^09
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M%>/$:/WC>0RJ'Z8.NHKAV>V\D<?N2Z%^%J++8K5C_#V*2C4WCC;*: K9G]E
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MH0O&&=#[0FO<'9R#?HR7?P!02P,$%     @ K(!U6'UVML'C!@  "#P  !D
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MNM[1<EE]]3B36LNLVEP('@ME"M#Y>TD=0+UC/J3<?/P[^1=02P,$%     @
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M+HFB)'$C@+D=1!&&P-V((Y@#\( A452]![?>1\'R/16L?LL=_ 502P,$%
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MK[FL%X;YC_Z4O#KWAUWK3LIK+/NJOFC>'-YN'][,?_H-4$L#!!0    ( *R
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M4$L! A0#%     @ K(!U6 RY6>;' @  Y <  !@              ("!T!8
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( *R =5A<-NU#
M8 0  &L0   8              " @<T9  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " "L@'58+OPT^!()  ".30  &
M@(%C'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ K(!U
M6&J+/C/Q!@  /R   !@              ("!JR<  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( *R =5B#;WL9-@(  +\%   8
M      " @=(N  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" "L@'58L-IH(T0"  ";!0  &               @($^,0  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ K(!U6 S2[A96 @  H@8  !@
M             ("!N#,  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( *R =5A!&(-$*0D  ,,4   9              " @40V  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ K(!U6(3\A&A[#@
M""@  !D              ("!I#\  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " "L@'58.S_GJ'8"  #7!0  &0              @(%6
M3@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( *R =5AQ
MNW?G=P(  (4%   9              " @0-1  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ K(!U6!K1DED\"0  _1<  !D
M     ("!L5,  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *R =5C]I%8#T@P  (<D   9              "
M@89R  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ K(!U
M6.F=*N.O @  Z04  !D              ("!CW\  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " "L@'58N\#LDE\#  !8!P  &0
M        @(%U@@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( *R =5@@?C4R_ <  -P6   9              " @0N&  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ K(!U6'*K$3%6#P  P"X
M !D              ("!/HX  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " "L@'58,L%*/\@"  #X!0  &0              @('+G0
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( *R =5A_/\AN
M?@(  ,,%   9              " @<J@  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ K(!U6#OIIFR# @  CP4  !D
M ("!?Z,  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "L
M@'58-C.FG, $   /"P  &0              @($YI@  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( *R =5B-B#Z=L (  -8%   9
M          " @3"K  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#
M%     @ K(!U6#Y;;EO%!   ]@L  !D              ("!%ZX  'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "L@'58/-T20GT"  #T
M!0  &0              @($3LP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM
M;%!+ 0(4 Q0    ( *R =5A.V4%"9P,  /D.   9              " @<>U
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ K(!U6)KU
M@.;V @  T D  !D              ("!9;D  'AL+W=O<FMS:&5E=',O<VAE
M970S,BYX;6Q02P$"% ,4    " "L@'58SE>ONU@"  #A!0  &0
M    @(&2O   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M *R =5BN1EM"<P(  %<&   9              " @2&_  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ K(!U6*QO2KJ4!   O1@  !D
M             ("!R\$  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " "L@'58)U4\&TT#   ("@  &0              @(&6Q@  >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( *R =5A-**Z"Y0,
M -L,   9              " @1K*  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ K(!U6'_"Z:'$ @  60@  !D              ("!
M-LX  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "L@'58
MVUVNW+8"  #Z!P  &0              @($QT0  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( *R =5C06Z<I. D  ')2   9
M      " @1[4  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ K(!U6,ZKT3;E @  "0@  !D              ("!C=T  'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "L@'58TVT^P><$  !W&0
M&0              @(&IX   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( *R =5@Q7WE!3 ,  ,@*   9              " @<?E  !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ K(!U6"UQ>.(A
M P  R@L  !D              ("!2ND  'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " "L@'58)5'CP!8$  "0%0  &0
M@(&B[   >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( *R
M=5@EI%%#@0@  !-'   9              " @>_P  !X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ K(!U6'C5IH1R @  T@4  !D
M         ("!I_D  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
M    " "L@'58?7:VP>,&   (/   &0              @(%0_   >&PO=V]R
M:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( *R =5AW%J:]7 ,  -@5
M   -              "  6H# 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     X #@ /P\   T0 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>94</ContextCount>
  <ElementCount>273</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheet</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheet (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetParenthetical</Role>
      <ShortName>Consolidated Balance Sheet (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statement of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statement of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statement of Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit</Role>
      <ShortName>Consolidated Statement of Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statement of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statement of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipment</Role>
      <ShortName>Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Share-based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlans</Role>
      <ShortName>Share-based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Research and Development Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreement</Role>
      <ShortName>Research and Development Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureContingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureBenefitPlans</Role>
      <ShortName>Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsTables</Role>
      <ShortName>Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalents</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentTables</Role>
      <ShortName>Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Share-based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables</Role>
      <ShortName>Share-based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlans</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Cash and Cash Equivalents - Summary of Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails</Role>
      <ShortName>Cash and Cash Equivalents - Summary of Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Equipment - Summary of Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentSummaryOfEquipmentNetDetails</Role>
      <ShortName>Equipment - Summary of Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Income Taxes - Income Taxes Recorded Differed from Amounts Computed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails</Role>
      <ShortName>Income Taxes - Income Taxes Recorded Differed from Amounts Computed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Accrued Liabilities - Summary of Accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Summary of Accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Share-based Compensation Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails</Role>
      <ShortName>Share-based Compensation Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Share-based Compensation Plans - Summary of Fair value of Options Granted Under Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfFairValueOfOptionsGrantedUnderWeightedAverageAssumptionsDetails</Role>
      <ShortName>Share-based Compensation Plans - Summary of Fair value of Options Granted Under Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Share-based Compensation Plans - Summary of Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails</Role>
      <ShortName>Share-based Compensation Plans - Summary of Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Share-based Compensation Plans - Summary of Non-vested Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails</Role>
      <ShortName>Share-based Compensation Plans - Summary of Non-vested Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Share-based Compensation Plans - Summary of Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Share-based Compensation Plans - Summary of Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Research and Development Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails</Role>
      <ShortName>Research and Development Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="inkt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:OperatingLossCarryforwardsExpirationDate -  inkt-20231231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="inkt-20231231.htm">inkt-20231231.htm</File>
    <File>inkt-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img206969693_0.jpg</File>
    <File>img206969693_1.jpg</File>
    <File>img206969693_2.jpg</File>
    <File>img206969693_3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="364">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "inkt-20231231.htm": {
   "nsprefix": "inkt",
   "nsuri": "http://minktherapeutics.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "inkt-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "inkt-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    }
   },
   "keyStandard": 229,
   "keyCustom": 44,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 22,
   "memberCustom": 20,
   "hidden": {
    "total": 7,
    "http://fasb.org/us-gaap/2023": 4,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 94,
   "entityCount": 1,
   "segmentCount": 43,
   "elementCount": 551,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 364,
    "http://xbrl.sec.gov/dei/2023": 40,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet",
     "longName": "100010 - Statement - Consolidated Balance Sheet",
     "shortName": "Consolidated Balance Sheet",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetParenthetical",
     "longName": "100020 - Statement - Consolidated Balance Sheet (Parenthetical)",
     "shortName": "Consolidated Balance Sheet (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss",
     "longName": "100030 - Statement - Consolidated Statement of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statement of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit",
     "longName": "100040 - Statement - Consolidated Statement of Stockholders' Deficit",
     "shortName": "Consolidated Statement of Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_8de82880-160e-43df-8a06-7bd23e1206fe",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8de82880-160e-43df-8a06-7bd23e1206fe",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows",
     "longName": "100060 - Statement - Consolidated Statement of Cash Flows",
     "shortName": "Consolidated Statement of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlowsParenthetical",
     "longName": "100070 - Statement - Consolidated Statement of Cash Flows (Parenthetical)",
     "shortName": "Consolidated Statement of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_442d530a-bd9b-4549-9f81-dfaba599e462",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_4ed8c189-5338-453a-9f58-24dd7ab9d275",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4ed8c189-5338-453a-9f58-24dd7ab9d275",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness",
     "longName": "995455 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalents",
     "longName": "995475 - Disclosure - Cash and Cash Equivalents",
     "shortName": "Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipment",
     "longName": "995485 - Disclosure - Equipment",
     "shortName": "Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995495 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities",
     "longName": "995505 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquity",
     "longName": "995515 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlans",
     "longName": "995525 - Disclosure - Share-based Compensation Plans",
     "shortName": "Share-based Compensation Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreement",
     "longName": "995535 - Disclosure - Research and Development Agreement",
     "shortName": "Research and Development Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "longName": "995545 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureContingencies",
     "longName": "995575 - Disclosure - Contingencies",
     "shortName": "Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureBenefitPlans",
     "longName": "995585 - Disclosure - Benefit Plans",
     "shortName": "Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEvents",
     "longName": "995595 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995605 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995615 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsTables",
     "longName": "995625 - Disclosure - Cash and Cash Equivalents (Tables)",
     "shortName": "Cash and Cash Equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentTables",
     "longName": "995635 - Disclosure - Equipment (Tables)",
     "shortName": "Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995645 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables",
     "longName": "995655 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables",
     "longName": "995665 - Disclosure - Share-based Compensation Plans (Tables)",
     "shortName": "Share-based Compensation Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
     "longName": "995675 - Disclosure - Description of Business - Additional Information (Details)",
     "shortName": "Description of Business - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995685 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesDetails",
     "longName": "995695 - Disclosure - Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_dcf77660-1f56-4511-acbc-a3e5c157ebe0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dcf77660-1f56-4511-acbc-a3e5c157ebe0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails",
     "longName": "995705 - Disclosure - Cash and Cash Equivalents - Summary of Cash Equivalents (Details)",
     "shortName": "Cash and Cash Equivalents - Summary of Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_c81ea76b-898a-4328-bab5-6699b445169a",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c81ea76b-898a-4328-bab5-6699b445169a",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentSummaryOfEquipmentNetDetails",
     "longName": "995715 - Disclosure - Equipment - Summary of Equipment, Net (Details)",
     "shortName": "Equipment - Summary of Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995725 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "995735 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails",
     "longName": "995745 - Disclosure - Income Taxes - Income Taxes Recorded Differed from Amounts Computed (Details)",
     "shortName": "Income Taxes - Income Taxes Recorded Differed from Amounts Computed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails",
     "longName": "995755 - Disclosure - Accrued Liabilities - Summary of Accrued liabilities (Details)",
     "shortName": "Accrued Liabilities - Summary of Accrued liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
     "longName": "995765 - Disclosure - Equity - Additional Information (Details)",
     "shortName": "Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "inkt:AuthorizedCapitalStockIncreased",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
     "longName": "995775 - Disclosure - Share-based Compensation Plans - Additional Information (Details)",
     "shortName": "Share-based Compensation Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "inkt:StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "inkt:StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfFairValueOfOptionsGrantedUnderWeightedAverageAssumptionsDetails",
     "longName": "995785 - Disclosure - Share-based Compensation Plans - Summary of Fair value of Options Granted Under Weighted Average Assumptions (Details)",
     "shortName": "Share-based Compensation Plans - Summary of Fair value of Options Granted Under Weighted Average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails",
     "longName": "995795 - Disclosure - Share-based Compensation Plans - Summary of Option Activity (Details)",
     "shortName": "Share-based Compensation Plans - Summary of Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_eb7f200e-d650-4621-9cdf-076793f5da15",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails",
     "longName": "995805 - Disclosure - Share-based Compensation Plans - Summary of Non-vested Stock Activity (Details)",
     "shortName": "Share-based Compensation Plans - Summary of Non-vested Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_eb7f200e-d650-4621-9cdf-076793f5da15",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb7f200e-d650-4621-9cdf-076793f5da15",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails",
     "longName": "995815 - Disclosure - Share-based Compensation Plans - Summary of Stock Based Compensation Expense (Details)",
     "shortName": "Share-based Compensation Plans - Summary of Stock Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails",
     "longName": "995825 - Disclosure - Research and Development Agreement - Additional Information (Details)",
     "shortName": "Research and Development Agreement - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_eb7f200e-d650-4621-9cdf-076793f5da15",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_74e50261-4062-42c1-85a6-53221008391a",
      "name": "inkt:RepayableAdvanceOfDevelopmentGranted",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "995835 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "inkt:DueToRelatedParty",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_174c7e6c-f05b-4cd6-b218-630f2cf7c135",
      "name": "inkt:DueToRelatedParty",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureBenefitPlansAdditionalInformationDetails",
     "longName": "995865 - Disclosure - Benefit Plans - Additional Information (Details)",
     "shortName": "Benefit Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e483d8b6-b887-4adb-87ea-1ee972fb3247",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "995875 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a5913b2-d4ec-4aae-bf25-d4732ba15bdf",
      "name": "inkt:MinimumValueOfListedSecuritiesPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inkt-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inkt_AccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "AccountingPoliciesLineItems",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Line Items]",
        "label": "Accounting Policies [Line Items]",
        "documentation": "Accounting Policies."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_AccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "AccountingPoliciesTable",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Table]",
        "label": "Accounting Policies [Table]",
        "documentation": "Accounting Policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r586"
     ]
    },
    "inkt_AccruedContractManufacturingExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "AccruedContractManufacturingExpenseCurrent",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract manufacturing costs",
        "label": "Accrued Contract Manufacturing Expense Current",
        "documentation": "Accrued contract manufacturing expense current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "inkt_AccruedResearchServicesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "AccruedResearchServicesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research services",
        "label": "Accrued Research Services Current",
        "documentation": "Accrued research services current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r567"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentSummaryOfEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentSummaryOfEquipmentNetDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation expense",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "negatedLabel": "Less accumulated depreciation",
        "terseLabel": "Equipment, net of accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r140",
      "r448"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r90",
      "r146",
      "r444",
      "r461",
      "r462"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r31",
      "r374",
      "r377",
      "r404",
      "r457",
      "r458",
      "r683",
      "r684",
      "r685",
      "r689",
      "r690",
      "r691"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "inkt_AdditionalCompliancePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "AdditionalCompliancePeriod",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional compliance period",
        "label": "Additional Compliance Period",
        "documentation": "Additional compliance period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r475",
      "r689",
      "r690",
      "r691",
      "r730",
      "r746"
     ]
    },
    "inkt_AdditionalPeriodForMinimumValueOfListedSecurities": {
     "xbrltype": "durationItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "AdditionalPeriodForMinimumValueOfListedSecurities",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum value of listed securities regain compliance period",
        "label": "Minimum Value of Listed Securities Regain Compliance Period",
        "documentation": "Minimum value of listed securities regain compliance period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "inkt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant and recognition of stock options",
        "label": "Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition",
        "documentation": "Adjustments to additional paid in capital share based compensation stock options grant and recognition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of parent stock options",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inkt_AgenusIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "AgenusIncMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Agenus Inc",
        "terseLabel": "Agenus",
        "label": "Agenus Inc [Member]",
        "documentation": "Agenus Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r609",
      "r621",
      "r631",
      "r657"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r612",
      "r624",
      "r634",
      "r660"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r616",
      "r625",
      "r635",
      "r652",
      "r661",
      "r665",
      "r673"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r338"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total anti-dilutive securities",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r141",
      "r170",
      "r199",
      "r211",
      "r215",
      "r221",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r367",
      "r371",
      "r385",
      "r440",
      "r501",
      "r586",
      "r598",
      "r695",
      "r696",
      "r733"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r149",
      "r170",
      "r221",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r367",
      "r371",
      "r385",
      "r586",
      "r695",
      "r696",
      "r733"
     ]
    },
    "inkt_AtlantClinicalLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "AtlantClinicalLtdMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Atlant Clinical Ltd [Member]",
        "label": "Atlant Clinical Ltd [Member]",
        "documentation": "Atlant Clinical Ltd.",
        "verboseLabel": "Atlant Clinical Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r617"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r617"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r617"
     ]
    },
    "inkt_AuthorizedCapitalStockIncreased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "AuthorizedCapitalStockIncreased",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized capital stock increased",
        "label": "Authorized Capital Stock Increased",
        "documentation": "Authorized capital stock increased."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "country_BE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "BE",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Belgium",
        "label": "BELGIUM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_BusinessServicesAndOccupancyCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "BusinessServicesAndOccupancyCostsMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Services and Occupancy Costs",
        "label": "Business Services And Occupancy Costs [Member]",
        "documentation": "Business Services and Occupancy Costs."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_CapitalizedExpensesAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "CapitalizedExpensesAmortizationPeriod",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized expenses amortization period.",
        "label": "Capitalized expenses amortization period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r138",
      "r565"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "verboseLabel": "Cash and Cash Equivalents",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r442"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Estimated Fair Value",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total",
        "periodStartLabel": "Cash, beginning of period",
        "periodEndLabel": "Cash, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r97",
      "r167"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r97"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash Equivalents, at Carrying Value, Total",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cost",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r743"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures - non-cash activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inkt_ChangeInFairValueOfConvertibleAffiliatedNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "ChangeInFairValueOfConvertibleAffiliatedNote",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of convertible affiliated note",
        "label": "Change In Fair Value Of Convertible Affiliated Note",
        "documentation": "Change in fair value of convertible affiliated note."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r198",
      "r265",
      "r266",
      "r267",
      "r269",
      "r272",
      "r277",
      "r279",
      "r465",
      "r466",
      "r467",
      "r468",
      "r577",
      "r681",
      "r686"
     ]
    },
    "inkt_ClinicalResearchServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "ClinicalResearchServices",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical research services",
        "label": "Clinical Research Services",
        "documentation": "Clinical research services."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_ClosingBidPriceForTenTradingDays": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "ClosingBidPriceForTenTradingDays",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Closing bid price for ten trading days",
        "label": "Closing Bid Price For Ten Trading Days",
        "documentation": "Closing bid price for ten trading days."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Agreement",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r124",
      "r133"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r77",
      "r441",
      "r488"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r594",
      "r595",
      "r689",
      "r690",
      "r730",
      "r745",
      "r746"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetParenthetical",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r489"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r84",
      "r489",
      "r507",
      "r746",
      "r747"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value $0.00001 per share, 150,000,000 shares authorized, 34,599,119 and 33,856,428 shares issued and outstanding as of December 31, 2023 and 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r443",
      "r586"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r152",
      "r154",
      "r160",
      "r436",
      "r453"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note converted into common stock",
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ]
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt outstanding amount",
        "label": "Convertible Debt",
        "totalLabel": "Convertible Debt, Total",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r114",
      "r742"
     ]
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible affiliated note",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "inkt_ConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "ConvertiblePromissoryNoteMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Promissory Note",
        "label": "Convertible Promissory Note [Member]",
        "documentation": "Convertible promissory note."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureOtherLongTermLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r80",
      "r81",
      "r113",
      "r114",
      "r174",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r400",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r687"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory note principal balance",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r247",
      "r400",
      "r573",
      "r574"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt, annual interest rate",
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r73",
      "r259"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateTerms",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt, interest rate terms",
        "label": "Debt Instrument, Interest Rate Terms",
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt issued, principal amount",
        "label": "Debt Instrument, Issued, Principal",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureOtherLongTermLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r400",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r687"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureOtherLongTermLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r174",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r400",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r687"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureOtherLongTermLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r53",
      "r56",
      "r72",
      "r73",
      "r74",
      "r78",
      "r105",
      "r106",
      "r174",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r400",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r687"
     ]
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueRevenueRecognized1",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, revenue recognized",
        "label": "Deferred Revenue, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r729"
     ]
    },
    "inkt_DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "label": "Deferred Tax Assets In Process Research And Development Tax Credits",
        "documentation": "Deferred tax assets in process research and development tax credits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal and state net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r729"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r729"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r729"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r729"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_DefinedBenefitPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefit Plans",
        "label": "Defined Benefit Plan [Text Block]",
        "documentation": "The entire disclosure for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r421",
      "r581"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense related to discretionary contribution to the Plans",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Total",
        "verboseLabel": "Depreciation expense",
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r46"
     ]
    },
    "inkt_DepreciationExpenseOnPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "DepreciationExpenseOnPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation Expense on Property, Plant, and Equipment",
        "documentation": "Depreciation expense on property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_DirectorsOrOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "DirectorsOrOfficersMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors or Officers",
        "label": "Directors or Officers [Member]",
        "documentation": "Directors or officers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r296",
      "r327",
      "r328",
      "r330",
      "r583"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r617"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r617",
      "r653"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_DrBuellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "DrBuellMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dr. Buell",
        "label": "Dr. Buell [Member]",
        "documentation": "Dr. Buell."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_DueToRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "DueToRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties",
        "label": "Due To Related Party",
        "documentation": "Due to related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per common share data:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss per common share",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r188",
      "r190",
      "r192",
      "r193",
      "r194",
      "r196",
      "r381",
      "r382",
      "r437",
      "r454",
      "r568"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net loss per common share",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r190",
      "r192",
      "r193",
      "r194",
      "r196",
      "r381",
      "r382",
      "r437",
      "r454",
      "r568"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r346",
      "r361"
     ]
    },
    "inkt_EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation, foreign income inclusion.",
        "label": "Effective income tax rate reconciliation, foreign income inclusion",
        "terseLabel": "Foreign income inclusion"
       }
      }
     },
     "auth_ref": []
    },
    "inkt_EffectiveIncomeTaxRateReconciliationForeignRateChange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignRateChange",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation, foreign rate change.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign rate change",
        "terseLabel": "Foreign rate change"
       }
      }
     },
     "auth_ref": []
    },
    "inkt_EmployeeBonusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "EmployeeBonusMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Bonus",
        "label": "Employee Bonus [Member]",
        "documentation": "Employee Bonus."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period of unrecognized share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized share-based compensation expense related to non-vested shares",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized share-based compensation expense related to stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r134",
      "r156",
      "r157",
      "r158",
      "r175",
      "r176",
      "r177",
      "r179",
      "r185",
      "r187",
      "r197",
      "r222",
      "r223",
      "r280",
      "r331",
      "r332",
      "r333",
      "r357",
      "r358",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r404",
      "r457",
      "r458",
      "r459",
      "r475",
      "r532"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r609",
      "r621",
      "r631",
      "r657"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r606",
      "r618",
      "r628",
      "r654"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r71"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r384",
      "r416",
      "r417",
      "r418",
      "r573",
      "r574",
      "r579",
      "r580",
      "r581"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r285",
      "r290",
      "r384",
      "r417",
      "r573",
      "r574",
      "r579",
      "r580",
      "r581"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r416",
      "r417",
      "r418",
      "r573",
      "r574",
      "r579",
      "r580",
      "r581"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Option",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r14"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total",
        "terseLabel": "Foreign currency gains",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "verboseLabel": "Foreign currency loss",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r390",
      "r529"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Transactions",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "inkt_ForgivenessOfRelatedPartyLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "ForgivenessOfRelatedPartyLiabilityMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgiveness of Related Party Liability",
        "label": "Forgiveness of Related Party Liability [Member]",
        "documentation": "Forgiveness of related party liability member."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r613",
      "r625",
      "r635",
      "r661"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r613",
      "r625",
      "r635",
      "r661"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r613",
      "r625",
      "r635",
      "r661"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r613",
      "r625",
      "r635",
      "r661"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r613",
      "r625",
      "r635",
      "r661"
     ]
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "GB",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Kingdom",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "inkt_GainOnForgivenessOfLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "GainOnForgivenessOfLiability",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on forgiveness of liability",
        "negatedLabel": "Gain on forgiveness of liability",
        "label": "Gain On Forgiveness Of Liability",
        "documentation": "Gain on forgiveness of liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureOtherLongTermLiabilitiesAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "negatedLabel": "Gain on extinguishment of debt",
        "terseLabel": "Gain on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r48",
      "r49"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r511"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "country_HK": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "HK",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hong Kong",
        "label": "HONG KONG"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r617"
     ]
    },
    "inkt_ImpactOfChangeInFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "ImpactOfChangeInFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of change in fair value",
        "label": "Impact Of Change In Fair Value Disclosure",
        "documentation": "Impact of change in fair value disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r516"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r516"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r341",
      "r347",
      "r349",
      "r355",
      "r359",
      "r362",
      "r363",
      "r364",
      "r470"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax benefit",
        "terseLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r131",
      "r186",
      "r187",
      "r202",
      "r345",
      "r360",
      "r455"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase) reduction in income taxes benefit resulting from:",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inkt_IncomeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "IncomeTaxLineItems",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]",
        "documentation": "Income tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r343",
      "r344",
      "r349",
      "r350",
      "r354",
      "r356",
      "r464"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r346"
     ]
    },
    "inkt_IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "IncomeTaxReconciliationChangeInFairValueOfConvertibleAffiliatedNote",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of convertible affiliated note",
        "label": "Income Tax Reconciliation Change In Fair Value Of Convertible Affiliated Note",
        "documentation": "Income tax reconciliation change in fair value of convertible affiliated note."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign rate differential",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computed \u201cexpected\u201d Federal tax benefit",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "inkt_IncomeTaxReconciliationReturnToProvisionAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "IncomeTaxReconciliationReturnToProvisionAdjustment",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation return-to-provision adjustment.",
        "label": "Income Tax Reconciliation Return-to-provision Adjustment",
        "terseLabel": "Return-to-provision adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local income benefit, net of Federal income tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "inkt_IncomeTaxReconciliationUncertainTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "IncomeTaxReconciliationUncertainTaxPositions",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesIncomeTaxesRecordedDifferedFromAmountsComputedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax positions",
        "label": "Income Tax Reconciliation Uncertain Tax Positions",
        "documentation": "Income tax reconciliation uncertain tax positions."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_IncomeTaxTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "IncomeTaxTable",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "documentation": "Income tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Deferred Revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and other current liabilities",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total",
        "negatedLabel": "Other operating assets and liabilities",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "inkt_IncreaseDecreaseInRepayableAdvanceReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "IncreaseDecreaseInRepayableAdvanceReceived",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayable advance received",
        "label": "Increase Decrease In Repayable Advance Received",
        "documentation": "Increase (decrease) in repayable advance received."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r616",
      "r625",
      "r635",
      "r652",
      "r661",
      "r665",
      "r673"
     ]
    },
    "inkt_IndividualServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "IndividualServicesMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual Services",
        "label": "Individual Services [Member]",
        "documentation": "Individual Services."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_InitialCompliancePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "InitialCompliancePeriod",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial compliance period",
        "label": "Initial Compliance Period",
        "documentation": "Initial compliance period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r605",
      "r677"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r605",
      "r677"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r605",
      "r677"
     ]
    },
    "inkt_InsuranceFinancingAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "InsuranceFinancingAgreement",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance financing agreement",
        "label": "Insurance Financing Agreement",
        "documentation": "Insurance financing agreement."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_IntercompanyAllocationIncludedInExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "IntercompanyAllocationIncludedInExpense",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intercompany allocation included in expense",
        "label": "Intercompany Allocation Included in Expense",
        "documentation": "Intercompany allocation included in expense."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_InterestAccruedOnConvertibleAffiliatedNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "InterestAccruedOnConvertibleAffiliatedNote",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest accrued on convertible affiliated note",
        "label": "Interest Accrued On Convertible Affiliated Note",
        "documentation": "Interest accrued on convertible affiliated note."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Income (Expense), Net, Total",
        "label": "Interest Income (Expense), Net",
        "documentation": "The net amount of operating interest income (expense)."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r165",
      "r166"
     ]
    },
    "inkt_IssuanceOfCommonStockForPaymentOfServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "IssuanceOfCommonStockForPaymentOfServices",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for payment of services.",
        "label": "Issuance of common stock for payment of services",
        "terseLabel": "Issuance of common stock, $0.00001 par value, for payment of services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Fees",
        "terseLabel": "Legal services fee",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "inkt_LegalFeesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "LegalFeesPercentage",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal fees percentage",
        "label": "Legal fees percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r116",
      "r446",
      "r586",
      "r688",
      "r693",
      "r731"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r137",
      "r170",
      "r221",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r368",
      "r371",
      "r372",
      "r385",
      "r586",
      "r695",
      "r733",
      "r734"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increasing amount of borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Category of Item Purchased",
        "label": "Category of Item Purchased [Axis]",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased",
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyDisclosures": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDisclosures",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r233",
      "r234",
      "r235",
      "r292",
      "r420",
      "r456",
      "r480",
      "r481",
      "r540",
      "r542",
      "r544",
      "r545",
      "r547",
      "r561",
      "r562",
      "r571",
      "r577",
      "r582",
      "r587",
      "r697",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "inkt_MinimumBidPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "MinimumBidPrice",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum bid price required for Listing",
        "label": "Minimum Bid Price",
        "documentation": "Minimum bid price."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r233",
      "r234",
      "r235",
      "r292",
      "r420",
      "r456",
      "r480",
      "r481",
      "r540",
      "r542",
      "r544",
      "r545",
      "r547",
      "r561",
      "r562",
      "r571",
      "r577",
      "r582",
      "r587",
      "r697",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ]
    },
    "inkt_MinimumValueOfListedSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "MinimumValueOfListedSecurities",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum value of listed securities",
        "label": "Minimum Value of Listed Securities",
        "documentation": "Minimum value of listed securities."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_MinimumValueOfListedSecuritiesForTenTradingDays": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "MinimumValueOfListedSecuritiesForTenTradingDays",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum value of listed securities for ten trading days",
        "label": "Minimum Value of Listed Securities for Ten Trading Days",
        "documentation": "Minimum value of listed securities for ten trading days."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_MinimumValueOfListedSecuritiesPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "MinimumValueOfListedSecuritiesPeriod",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of trading days",
        "label": "Minimum Value of Listed Securities Period",
        "documentation": "Minimum value of listed securities period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Institutional Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "inkt_NasdaqMinimumBidPriceNoticeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "NasdaqMinimumBidPriceNoticeMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nasdaq Minimum Bid Price Notice",
        "label": "Nasdaq Minimum Bid Price Notice [Member]",
        "documentation": "Nasdaq minimum bid price notice."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_NasdaqMvlsNoticeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "NasdaqMvlsNoticeMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nasdaq MVLS Notice",
        "label": "Nasdaq MVLS Notice [Member]",
        "documentation": "Nasdaq MVLS notice."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r132"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss",
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net Loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r99",
      "r117",
      "r135",
      "r150",
      "r153",
      "r158",
      "r170",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r191",
      "r199",
      "r210",
      "r214",
      "r216",
      "r221",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r382",
      "r385",
      "r451",
      "r509",
      "r530",
      "r531",
      "r569",
      "r596",
      "r695"
     ]
    },
    "inkt_NetProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "NetProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of common stock",
        "label": "Net Proceeds From Issuance Of Common Stock",
        "documentation": "Net proceeds from issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_NewIntercompanyServiceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "NewIntercompanyServiceAgreementMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Intercompany Service Agreement",
        "label": "New Intercompany Service Agreement [Member]",
        "documentation": "New Intercompany Service Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r613",
      "r625",
      "r635",
      "r652",
      "r661"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "inkt_NonVestedSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "NonVestedSharesMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Vested Shares",
        "label": "Non Vested Shares [Member]",
        "documentation": "Non-vested shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of note",
        "terseLabel": "Outstanding principal amount of notes",
        "label": "Notes Payable, Fair Value Disclosure",
        "documentation": "Fair value portion of notes payable."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "inkt_NumberOfConsecutivetradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "NumberOfConsecutivetradingDays",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of consecutive trading days",
        "label": "Number of ConsecutiveTrading Days",
        "documentation": "Number of consecutive trading days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of business segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax years open for examination",
        "label": "Open Tax Year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses from transactions with related party",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Operating Costs and Expenses, Total",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r210",
      "r214",
      "r216",
      "r569"
     ]
    },
    "us-gaap_OperatingIncomeLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLossMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expenses",
        "label": "Operating Income (Loss) [Member]",
        "documentation": "Primary financial statement caption encompassing operating income (loss)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, Expiration date",
        "label": "Operating Loss Carryforwards, Expiration Date",
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r586"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation gain (loss)",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Other comprehensive (loss) gain",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r13",
      "r151",
      "r154",
      "r159",
      "r392",
      "r393",
      "r398",
      "r435",
      "r452",
      "r683",
      "r684"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive gain (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentLiabilitiesMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Liabilities",
        "label": "Other Current Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_OtherIncomeExpenseNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "OtherIncomeExpenseNetMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Income (Expense), Net",
        "label": "Other Income Expense Net [Member]",
        "documentation": "Other Income (Expense), Net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current liabilities",
        "terseLabel": "Due to related parties, current",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r586"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "inkt_OtherLongTermLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "OtherLongTermLiabilitiesTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureOtherLongTermLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Long-Term Liabilities",
        "label": "Other Long Term Liabilities [Text Block]",
        "documentation": "The entire disclosure for information about other long-term liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLongtermDebtCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLongtermDebtCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Long-Term Debt [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (loss), net",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net:",
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense), net:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r611",
      "r623",
      "r633",
      "r659"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r614",
      "r626",
      "r636",
      "r662"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r614",
      "r626",
      "r636",
      "r662"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "inkt_PaycheckProtectionProgramLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "PaycheckProtectionProgramLoanMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureOtherLongTermLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paycheck Protection Program Loan",
        "label": "Paycheck Protection Program Loan [Member]",
        "documentation": "Paycheck protection program loan."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_PaymentForServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "PaymentForServicesMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment For Services",
        "label": "Payment For Services Member",
        "documentation": "Payment For Services Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlowsParenthetical",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments of Financing Costs, Total",
        "terseLabel": "Offering cost",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Purchases of equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "inkt_PercentageOfComputationOfInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "PercentageOfComputationOfInterest",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of computation of interest",
        "label": "Percentage Of Computation Of Interest",
        "documentation": "Percentage of computation of interest."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_PercentageOfServiceCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "PercentageOfServiceCost",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of service cost",
        "label": "Percentage Of Service Cost",
        "documentation": "Percentage of service cost."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_PercentageOfSharesOfCompanySCommonStockOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "PercentageOfSharesOfCompanySCommonStockOutstanding",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of shares of company's common stock outstanding",
        "label": "Percentage Of Shares Of Company S Common Stock Outstanding",
        "documentation": "Percentage of shares of company's common stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_PercentageValueOfCommonStockSoldInInitialPublicOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "PercentageValueOfCommonStockSoldInInitialPublicOffering",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage value of common stock sold in initial public offering",
        "label": "Percentage Value Of Common Stock Sold In Initial Public Offering",
        "documentation": "Percentage value of common stock sold in initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_PeriodForBreachOfPaymentObligations": {
     "xbrltype": "durationItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "PeriodForBreachOfPaymentObligations",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period for breach of payment obligations",
        "label": "Period For Breach Of Payment Obligations",
        "documentation": "Period for breach of payment obligations."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_PeriodOfLicenseAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "PeriodOfLicenseAgreement",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of license agreement",
        "label": "Period Of License Agreement",
        "documentation": "Period of license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r489"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Prepaid Expense, Current, Total",
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r224",
      "r225",
      "r566"
     ]
    },
    "inkt_ProceedsFromEmployeeStockPurchasesAndOptionExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "ProceedsFromEmployeeStockPurchasesAndOptionExercises",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from employee stock purchases and option exercises",
        "label": "Proceeds From Employee Stock Purchases And Option Exercises",
        "documentation": "Proceeds from employee stock purchases and option exercises."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from initial public offering, net of offering costs of approximately $6.2 million",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "inkt_ProceedsFromIssuanceOfConvertibleAffiliatedNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "ProceedsFromIssuanceOfConvertibleAffiliatedNote",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of convertible affiliated note",
        "label": "Proceeds From Issuance Of Convertible Affiliated Note",
        "documentation": "Proceeds from issuance of convertible affiliated note."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Issuance of Long-Term Debt, Total",
        "terseLabel": "Proceeds from issuance of long-term debt",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r465"
     ]
    },
    "us-gaap_ProceedsFromLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLoans",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureOtherLongTermLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate loan proceeds",
        "label": "Proceeds from Loans",
        "documentation": "Cash received from principal payments made on loans related to operating activities."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r150",
      "r153",
      "r163",
      "r170",
      "r178",
      "r186",
      "r187",
      "r199",
      "r210",
      "r214",
      "r216",
      "r221",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r366",
      "r369",
      "r370",
      "r382",
      "r385",
      "r438",
      "r450",
      "r474",
      "r509",
      "r530",
      "r531",
      "r569",
      "r584",
      "r585",
      "r597",
      "r685",
      "r695"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r126",
      "r129",
      "r130"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentSummaryOfEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentSummaryOfEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "verboseLabel": "Equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r139",
      "r449"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentSummaryOfEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentSummaryOfEquipmentNetDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment, net of accumulated depreciation of $495,638 and $283,682 as of December 31, 2023 and 2022, respectively",
        "verboseLabel": "Equipment",
        "totalLabel": "Equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r439",
      "r449",
      "r586"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r126",
      "r129",
      "r447"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives of assets",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Agreement",
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]",
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r115"
     ]
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]",
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r115"
     ]
    },
    "inkt_PurchaseOfTreasurySharesToSatisfyTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "PurchaseOfTreasurySharesToSatisfyTaxWithholdings",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of treasury shares to satisfy tax withholdings",
        "label": "Purchase Of Treasury Shares To Satisfy Tax Withholdings",
        "documentation": "Purchase of treasury shares to satisfy tax withholdings."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_PurchasesOfPlantAndEquipmentInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "PurchasesOfPlantAndEquipmentInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases of plant and equipment in accounts payable.",
        "label": "Purchases Of Plant And Equipment In Accounts Payable",
        "terseLabel": "Purchases of plant and equipment in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r233",
      "r234",
      "r235",
      "r284",
      "r292",
      "r322",
      "r323",
      "r324",
      "r419",
      "r420",
      "r456",
      "r480",
      "r481",
      "r540",
      "r542",
      "r544",
      "r545",
      "r547",
      "r561",
      "r562",
      "r571",
      "r577",
      "r582",
      "r587",
      "r590",
      "r694",
      "r697",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r233",
      "r234",
      "r235",
      "r284",
      "r292",
      "r322",
      "r323",
      "r324",
      "r419",
      "r420",
      "r456",
      "r480",
      "r481",
      "r540",
      "r542",
      "r544",
      "r545",
      "r547",
      "r561",
      "r562",
      "r571",
      "r577",
      "r582",
      "r587",
      "r590",
      "r694",
      "r697",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ]
    },
    "inkt_RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ratio of annual increase shares reserved for issuance under ESPP to number of shares of common stock outstanding",
        "label": "Ratio Of Annual Increase Shares Reserved For Issuance Under E S P P To Number Of Shares Of Common Stock Outstanding",
        "documentation": "Ratio of annual increase shares reserved for issuance under ESPP to number of shares of common stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r606",
      "r618",
      "r628",
      "r654"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r408",
      "r409",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r506",
      "r508",
      "r539"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r408",
      "r409",
      "r410",
      "r411",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r506",
      "r508",
      "r539"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r732"
     ]
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transaction, description",
        "label": "Related Party Transaction, Description of Transaction",
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r142",
      "r401",
      "r402",
      "r403",
      "r407"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r516"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r408",
      "r409",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r506",
      "r508",
      "r539",
      "r732"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r409",
      "r412",
      "r471",
      "r472",
      "r473",
      "r514",
      "r515",
      "r516",
      "r536",
      "r538"
     ]
    },
    "inkt_RepayableAdvanceOfDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "RepayableAdvanceOfDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayable advance of development",
        "label": "Repayable Advance Of Development",
        "documentation": "Repayable advance of development."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_RepayableAdvanceOfDevelopmentGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "RepayableAdvanceOfDevelopmentGranted",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development agreement amount granted",
        "label": "Repayable Advance Of Development Granted",
        "documentation": "Repayable advance of development granted."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_RepayableAdvanceReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "RepayableAdvanceReceived",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayable advance received",
        "label": "Repayable Advance Received",
        "documentation": "Repayable advance received."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_RepayableAdvanceReceivedNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "RepayableAdvanceReceivedNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayable advance received noncurrent",
        "label": "Repayable Advance Received Noncurrent",
        "documentation": "Repayable advance received noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Agreement",
        "label": "Research and Development Arrangement [Member]",
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r340",
      "r741"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "inkt_ResearchServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "ResearchServicesMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Services",
        "label": "Research Services [Member]",
        "documentation": "Research Services."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r607",
      "r619",
      "r629",
      "r655"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r608",
      "r620",
      "r630",
      "r656"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r615",
      "r627",
      "r637",
      "r663"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r107",
      "r445",
      "r460",
      "r462",
      "r469",
      "r490",
      "r586"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r175",
      "r176",
      "r177",
      "r179",
      "r185",
      "r187",
      "r222",
      "r223",
      "r331",
      "r332",
      "r333",
      "r357",
      "r358",
      "r373",
      "r375",
      "r376",
      "r378",
      "r380",
      "r457",
      "r459",
      "r475",
      "r746"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r209",
      "r212",
      "r213",
      "r217",
      "r218",
      "r220",
      "r281",
      "r282",
      "r422"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalariesWagesAndOfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation paid",
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold",
        "totalLabel": "Salary and Wage, Excluding Cost of Good and Service Sold, Total",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Accrued liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Anti-dilutive Securities",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureCashAndCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Summary of Cash Equivalents",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureResearchAndDevelopmentAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Share-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes Recorded Differed from Amounts Computed",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Non-vested Stock Activity",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r512",
      "r513",
      "r516"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r61"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r105",
      "r106",
      "r107",
      "r143",
      "r144",
      "r145",
      "r198",
      "r265",
      "r266",
      "r267",
      "r269",
      "r272",
      "r277",
      "r279",
      "r465",
      "r466",
      "r467",
      "r468",
      "r577",
      "r681",
      "r686"
     ]
    },
    "inkt_SecondCompliancePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "SecondCompliancePeriod",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second compliance period",
        "label": "Second Compliance Period",
        "documentation": "Second compliance period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r477",
      "r478",
      "r479",
      "r541",
      "r543",
      "r546",
      "r548",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r564",
      "r578",
      "r590",
      "r698",
      "r744"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r218",
      "r570"
     ]
    },
    "inkt_ServiceAgreementNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "ServiceAgreementNoticePeriod",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service agreement notice period",
        "label": "Service Agreement Notice Period",
        "documentation": "Service agreement notice period."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_ServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "ServicesMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services.",
        "label": "Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option, vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Nonvested Shares, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Nonvested Shares, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested Shares, Outstanding at Beginning Balance",
        "periodEndLabel": "Nonvested Shares, Outstanding at Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at Beginning Balance, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at Ending Balance, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Nonvested Shares, Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfNonVestedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfFairValueOfOptionsGrantedUnderWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfFairValueOfOptionsGrantedUnderWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfFairValueOfOptionsGrantedUnderWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional number of shares authorised in share pool",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Exercisable at December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at December 31, 2023, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options excercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options, Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares options, granted",
        "terseLabel": "Options, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant-date fair values of options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair value of Options Granted Under Weighted Average Assumptions",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding at December 31, 2023, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, Outstanding at Beginning Balance",
        "periodEndLabel": "Options, Outstanding at Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at Beginning Balance, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at Ending Balance, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested or expected to vest at December 31, 2023, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested or expected to vest at December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested or expected to vest at December 31, 2023, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option grants, term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "documentation": "Description of terms of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r300",
      "r319",
      "r320",
      "r321",
      "r322",
      "r325",
      "r334",
      "r335",
      "r336",
      "r337"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Intrinsic value of shares vested",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfFairValueOfOptionsGrantedUnderWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at December 31, 2023, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at December 31, 2023, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding at December 31, 2023, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested or expected to vest at December 31, 2023, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued, price per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance, Shares",
        "periodEndLabel": "Ending Balance, Shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "terseLabel": "Shares issued, withheld to cover taxes",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_SharesReservedForIssuanceUnderEmployeeStockPurchasePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "SharesReservedForIssuanceUnderEmployeeStockPurchasePlan",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserved for issuance under ESPP",
        "label": "Shares Reserved For Issuance Under Employee Stock Purchase Plan",
        "documentation": "Shares reserved for issuance under Employee Stock Purchase Plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r168"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r29",
      "r134",
      "r156",
      "r157",
      "r158",
      "r175",
      "r176",
      "r177",
      "r179",
      "r185",
      "r187",
      "r197",
      "r222",
      "r223",
      "r280",
      "r331",
      "r332",
      "r333",
      "r357",
      "r358",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r404",
      "r457",
      "r458",
      "r459",
      "r475",
      "r532"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r477",
      "r478",
      "r479",
      "r541",
      "r543",
      "r546",
      "r548",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r564",
      "r578",
      "r590",
      "r698",
      "r744"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlowsParenthetical",
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r197",
      "r422",
      "r463",
      "r476",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r508",
      "r510",
      "r511",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r532",
      "r591"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlowsParenthetical",
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r197",
      "r422",
      "r463",
      "r476",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r508",
      "r510",
      "r511",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r532",
      "r591"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r610",
      "r622",
      "r632",
      "r658"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued",
        "terseLabel": "Issuance of common stock, $0.00001 par value, for payment of employee bonuses",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ]
    },
    "inkt_StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "StockIssuedDuringPeriodAdditionalSharesShareBasedCompensation",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period additional shares share based compensation.",
        "label": "Stock Issued During Period Additional Shares Share Based Compensation",
        "terseLabel": "Increase in number of shares in share pool"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible affiliated note, shares",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r28",
      "r53",
      "r107",
      "r257"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Benefit Plan",
        "terseLabel": "Issuance of shares for employee bonuses, shares",
        "verboseLabel": "Shares issued, payment for employee bonuses",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, shares, employee benefit plan net of shares withheld for taxes.",
        "label": "Stock Issued During Period, Shares, Employee Benefit Plan Net of Shares Withheld for Taxes",
        "terseLabel": "Shares issued, payment for employee bonuses, net of shares withheld for taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r83",
      "r84",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares for services, shares",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial public offering, net of offering costs, shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r83",
      "r84",
      "r107",
      "r465",
      "r532",
      "r549"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeiture of restricted stock, shares",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r83",
      "r84",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "verboseLabel": "Shares issued, vesting of non-vested stock",
        "terseLabel": "Vesting of nonvested shares, Shares",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total",
        "terseLabel": "Number of shares grated as a result of equity incentive plan",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r83",
      "r84",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansSummaryOfOptionActivityDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options, shares",
        "negatedLabel": "Options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Stock option exercises",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r83",
      "r84",
      "r107",
      "r306"
     ]
    },
    "inkt_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options and employee share purchases, Shares",
        "label": "Stock Issued During Period Shares Stock Options Exercised And Employee Stock Purchase Plan",
        "documentation": "Stock issued during period shares stock options exercised and employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion of convertible affiliated note to common stock, $0.00001 par value",
        "terseLabel": "Conversion of convertible affiliated note",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r29",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Benefit Plan",
        "terseLabel": "Issuance of shares for employee bonuses",
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares for services",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeiture of restricted stock",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r83",
      "r84",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of nonvested shares",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r83",
      "r84",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r29",
      "r107"
     ]
    },
    "inkt_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options and employee share purchases",
        "label": "Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan",
        "documentation": "Stock issued during period value stock options exercised and employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share retirement",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r83",
      "r84",
      "r107"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet",
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' deficit",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r87",
      "r88",
      "r101",
      "r491",
      "r507",
      "r533",
      "r534",
      "r586",
      "r598",
      "r688",
      "r693",
      "r731",
      "r746"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' deficit",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r169",
      "r264",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r280",
      "r379",
      "r535",
      "r537",
      "r550"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split ratio, description",
        "label": "Stockholders' Equity Note, Stock Split",
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r414"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r414"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r414"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r414"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r414"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r415"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "inkt_TerminateLicenseAgreementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "TerminateLicenseAgreementPeriod",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terminate license agreement period",
        "label": "Terminate License Agreement Period",
        "documentation": "Terminate license agreement period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "inkt_TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance of shares for employee bonus, treasury shares",
        "label": "Treasury Stock Issued During Period Shares Employee Benefit Plan",
        "documentation": "Treasury stock issued during period shares employee benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "terseLabel": "Retirement of treasury shares",
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r57",
      "r84"
     ]
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesRetired",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Shares, Retired",
        "terseLabel": "Retirement of treasury shares, shares",
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r84",
      "r107"
     ]
    },
    "inkt_TwoThousandAndEighteenEIPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "TwoThousandAndEighteenEIPMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018 EIP",
        "label": "Two Thousand And Eighteen E I P [Member]",
        "documentation": "2018 EIP."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_TwoThousandAndTwentyOneEIPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "TwoThousandAndTwentyOneEIPMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 EIP",
        "label": "Two Thousand and Twenty One E I P [Member]",
        "documentation": "Two thousand and twenty one E I P."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Employee Stock Purchase Plan",
        "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]",
        "documentation": "2021 Employee Stock Purchase Plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlows",
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "inkt_UnderwritingDiscountsCommissionsAndOtherOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "UnderwritingDiscountsCommissionsAndOtherOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting discounts, commissions and other offering expenses",
        "label": "Underwriting Discounts Commissions And Other Offering Expenses",
        "documentation": "Underwriting discounts, commissions and other offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r123",
      "r125",
      "r127",
      "r128"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance, Deferred tax asset, increase (decrease)",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "inkt_ValueAddedTaxAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "ValueAddedTaxAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VAT",
        "label": "Value Added Tax Accrued Liabilities Current",
        "documentation": "Value added tax accrued liabilities current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of common shares outstanding, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r194"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of common shares outstanding, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r194"
     ]
    },
    "inkt_WolfGreenfieldSachsPCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "WolfGreenfieldSachsPCMember",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wolf, Greenfield &amp; Sachs, P.C.",
        "label": "Wolf, Greenfield &amp; Sachs, P.C. [Member]",
        "terseLabel": "Wolf, Greenfield &amp; Sachs, P.C."
       }
      }
     },
     "auth_ref": []
    },
    "inkt_WorkOrderReceivedFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://minktherapeutics.com/20231231",
     "localname": "WorkOrderReceivedFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://minktherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work order received from related party",
        "label": "Work Order Received From Related Party",
        "documentation": "Work order received from related party."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481440/840-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450-20/tableOfContent"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450-30/tableOfContent"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715-20/tableOfContent"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-7"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-4"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "715",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482236/912-715-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0000950170-24-034672-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-034672-xbrl.zip
M4$L#!!0    ( *^ =5AS<N:E]U(  (5L   2    :6UG,C V.38Y-CDS7S N
M:G!G[+MU6%3KUS"\D59"$) >4I 0I9$8P$.+""@A"-(-DM)#""C2""C=W=TI
MW=W=W3W,?*,GU',\O_=YGNM[O^_]X\5K>\T]]^JU[A5[]H:/P>> F]+B4N(
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MOTHG!S#\M50.ME',)C(F'RJ$.NY=?RL3&.PN^$[H\TI\[3YV;ERFA!:+(F<
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M0\J_3"U9A(3-W37)VC*?%[QNH&#3>J&^KR<1;(]'^^41&UJ:PT<2:JK1;5C
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MN&J?<KV:OZ#N4$?2T)9,O-/@%.ZH"KA/>[PJF*6,T(06YDP-3?^J+Z*'B\.
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M_?,(O8K"6&W<:73']:*BX;O(^OI3<?D/B-&(-#.PRH5?5%2Y.FU]S2<45G3
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M>$#K,!_?3[F%?JXUC0(;S'T*K+GBN.S:)?YS<?3U]0W-X_N4'(YA94\_MJ@
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M.^I1Y\KE1\ (7"PJX]3_R;3]J.ML.UU+0U-#0Z(".1F'I;R/HLTV2!: $@]
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M2'W_-H=M+#)R6RV:D)]=()N'==-PK9M,(6FX#V-I,VPE<GZJ3N&<]-LU;Z<
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M";W3SN=+BW@%_?_Q$X9Q1GU_=9GZ8S?#%+L(IOR_.IC_N1D35,<O_\E^'X5
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M\4I*(8QG%EK!\<0!^WDNMJ\T\W_@F\AN;V^<*=]M;4LQ 'XUV;$-Y5($]:0
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M(*"N8"C$X3<3W!^:\Q#^(,?[(==S<G#\HP+GA^(LMI_B\YZ#LOD]!I2F$V$
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MM'3HKT-A('IA'D%N.SY^?GH1$1Y^(6$1$7XN>@$^?@%>OK.7"#>_D(2PB(2
M*/UOQ""#??8I!0/:2^@I*O\&=\9),_Q6+R\O+QXO01XHS(&77UQ<_-R-@ #W
M60ENN \$8>/-#8$S?G?RPX\B"&X'<[JXYT=_SMO80CT0T@P,V/1_H-_JY>KV
M$^AO$_C3\[GSL](2UV$@&P1(\>PM(\ GP,_-)\HM(&3 )R;!)\+))RPAR"?%
M^Z=B?^< "C. 0L$R.OH7@0KS ,%@>B,0#'X>LC"/ (_ '[S\5O9/;K2@0"=[
MG[_$(2XAR"_!+_S'4/Y0\L\^SEH2:(.P^9>\_+'LCVSS_BG=_]-F</M#>__2
M#&>*LV80_+49SH02.C HT,,.!).1MX-!;6T0](I.<(03& R"T?/S\?#S\(O0
MLQD[08!0+SB[%.\O%O_;P0/M?L;NY@$#7_14H!TO" PZOV\//XN?_]?X@782
M""<$^(_-\0-6'HSX5?I# 78Z1Y, VT <I!F\N7^['<$@\Y_^G(!>E$= D$>
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MF0=#=(D,A*^0F?GK (&8@3M("VCTKO%WQTCRDE]CDF=E$@C%.X(RW[PJ%*=
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M<4.WMJLFV,<<CJQ<()EVLW+HF"&^(]Z4*7/S)/TII_$) =7G*\#N(4KGA%,
M[V:J*$UI8RS)/0%E)^#!#1E;+JJ'Y<QPMGDUX^J:)\RA$8&59C>O&K$?/,]@
M+\EX:J[2^GR\@L5Q=7=]]^BHZ1V-2]D)H7&WON9DME'G>/U'I6D9MI:#^C=.
M@POT'PU]4RO7?.PKU+3F#FI7V=;[=LS#8*']=DDO[ NI^US*")(+*_U\\:;:
M11B=XQJ#%.?,&VK!T8]SX(B=!O4)F@77$>IXAL>'E;!Q5OCJ-5S5?%PA6HZ'
M$UQ!(4S>%8)-!A])M4"]85J=<LR#?W^QS:XP1ZRU3K%<6]742G]"N9QLM*S4
M<?AX"8"=K>=-P_KPB:CG;.=]3J%H29 FO!@@QWY(^Z+'7["C)R-L)=)@V5;]
M@5JK@)_H_N)5_C"+CJX/L2 "_>7Y=2%)KHVTM'I?_EQ/T[*V_,+P[2$'LAXA
M2\O2ZDFF89VB45%V+:;8V2+^MR(IV;,F3<7)WVYZZ($]LYO4I5VP"&0^%!OY
MXG%4Q<B+.E=0KHJ$LE1NS)?IMLFU18:A1F8F8BXV^%E(DT77?1BDK<M3P:]?
M!L6UM I_7EB0E,P4?Z,7DYW[93&O;^T@4V//:M)CDX*&T>(HR,8S(\GH*(CC
MJ/13-7D!JV^!?D$D&J+O*@U+V*ST?8]>([?%AZ&9K*#XCWM<7"!?_@@A3I'M
M?O>B6,>.<,70<,_- 38RH0'-0( .&T9 JB8#"]^#8!43P^IQC]CJ\<XNKMBX
M9=;N+-:UR6^)&19,,:HSM=[>]5_-^$IS2V@HJ'/UE4C?\!7G?XBSHU1F9XJQ
MNLU=/>D:;^G7V_X.#^E5'$;B$IW?"V29R(#^Z:?S\]L  !WDPV)7(N_6UR/W
MMBU\0" R^@+@6E\W;=WN[N['C^^NFEWLD?[-^Z$>VZ3IKT3,AHMC'PEP/=>J
M+HGDV=)M^S3F&Q407W<OLAR4^<$.[(.!!MK+'R!AZ!$[X%W+!FYBW-"#?6MH
M22K7PNC[^/GKR1L-]C?6,1ZP> P\N:HQN4_&X6RSDSJ8(T_QIL5,'G TQ 60
MUW=F)X?EZZ<NL$<P WBT+FX:$35%G'A8CI\"]*53O^5"<N34_N%JT/"+-@W9
MBNO<]YW=TCFX*5AD*+@ZA*FR"87)2X@Q8M6+]PV2JA[!\I#N(2Q3L_14-5>R
M#"*,6<KQ\#SFWU>/&Q6"_=0.AD6IU&;BYGDZXVR'LLPLU$?I;ME^F:UC-#E6
MZ6AR"9()&[IY"B"=@&Q/)\6U(EZ[[.U/$SQ?ZIV<R$A-87K1VC0CE!,S'5XO
M=L"X[#+6[^=D%// _[J';H+;(:N  "]KIOUP.A\5K$8<]_6;$_3@6Y \XFH^
M)GV.C()'V0)AF+MK6C'CB\8(N%V\A<VX!:/BB@$/XU1RLN46S.*SCY_;2]1;
M/*L/$-69K/C3>,E^#9"'=>+D&_S5Q&,:*880@;;RVTN4^V+&6^E@BRSQW%UV
MM4V1LK<.#W^]"7=%X^0:M)_]^/X[(O97HTL9X^EK>.F;$KNY5NFI39X$K)BR
M[;0* <Z1^P$1-E7TXUKMIP!675/B&CJ^AI3D]II0-:=EOEN>'49FXDSYE54%
MI3%ZU<'D'6,'\0/.+V*:2,,/7+[6Z:(-<J+=E1 'T2#5DDX,,2M7$2%9V>]'
MZ+.T"GKNP&+@L#31 HYO$P.Q@GK$ P/E$"L)MR4%966MX]$H<LNW(1!2G<['
M..ERB,)9\MD!DT7-QG8=_FZ].,UG@<%LE&\ +.+-F'J'W7:D3Y%9 (22<CXA
M?+L$QWOP=[0KF#/__?X"HZ/YE15H<?J]U#=Z.K>3-*0AP_"O_<M]Z2F/";R\
M OA7=@@^K[[SVSWXUI337%Y^94WRJM'[OG8B+XY'[16A88XZDH?C-3D<1&[]
MJUB!G0V//#,<"0&H>:3:]=D,:K2+F[.VIBG1U/1##"=5-1I?ZYVC4KA33@%+
M1%K;VW[,BW$OY!M;5[^!CFE#>U>56E,UU6M]J Y'7W9K<CD&Y&^D6+A$O6&O
MZ\A5UC+[DO&0V0K$;%_+%CYUQ\-2W$5_@$"M01X9R<Y%-Y_R*7-((!B*!E8(
M1%[WUA@,,5N5O_JR2X"BM]$/.!L4FN;][DM'S0F+XFAK5U;W\V\&M^Q6:@W3
MV#,Z1@9CRR>U*?;QU]H77:'A2Z3;=/Q5CTN"YT-*BHZ38[8EI3<WO:89^0,!
M/H'25]-W3P%EPTX)J2M_.N7PLTX!A#4K<=_>.OXKE^7M>#CA98*BC:96X(E,
M;G:E_(4NTGF<2+J82K_T\/C@8&?-X'OEUA#3<C0S+2$+D9@Z@3N(84_B9^9P
M01Q[0<\RK1G9J+Z^*%WAX3(=EU+D@ON084J3,MVI6^[VKP?NMB!)WN?&>%$@
MW--CU-/V E53,:2Q'D7ORSWI[FX1Z)-4UYT6^UQ[@N@L]427["'6DA'?R1P2
M7<>.'ODA3J)8P=T8S6L$3 WV_;H"VH,Z3U<BII#1-5_=AF9?J\V;<N]E3<R;
M^8PE)?IP27(BLZYQ-GQ)0-/@MEB91'" PAQ*%/^W"AJ[]9=4<6\_FI@\;BMX
MQ& <A:4T,:;S"*S<OY9\=;;SR]>O)[*.7:,U%H9NO9H])F^64VM4XDM=]=TE
ML8HF=XL%FP5PB[FJUV^VUA$=0!*;"8>_<$XU%QS4".AF"G@D9#_,&$H)M-QY
MH$0V^_@9_5A1].P)]RC?9._ZSL%-?B;*6<DK,"C _E:U3IN3699929(-_]=>
M@U9A,V"1&<>HW</4YL\NW.V%6, PO<8=*F?^15IFIM=G4\(IP XLDK$N*CEG
MW% %7R#G*K%$<3*_SFED<G\<4CM"@$K%"G_3\_:!1I; 0X[4LFF<.7''5(7"
M 4B*$HEO?GYQ#+W&R[\,Q?A9J$^9B41YY&XNMM\Z#,E)3$E,;Y*[#:H-=Y"*
M?U##*S2*NFR^?M=$[Y[9/(%1;6\>C6DY/8^)T#,4QR04HH9A&B8GI62/X$=R
M3 ,@N@@8=[>QC/M!TA#-"VM=_:C!6Z[!BPDKD=HR/!8;^85M[(9&N&Q%55C3
M=*QL 8^71J&VKAK[%,>\QU(KO84'QEP?G2QQ!@U4= Z(AS8^4UM(".PB\I/+
MRWV#6#EYL&:B'KK&9#=D4<X=&')"?+A;#;N*AS;4MXAKY#M&C%LLL=&,D&O?
M%!X@N."Z5%0<&TY0$B\*COS,1;#F#%<CE_7#SK@[9E_ ]7G(Y2UBON8HS'..
MVQY;&E]>/!Z;:3L%M!I;AL1N<:96)8QWI[\LUH-W;/GW:A/YY:;'3:ODWO\\
M0;>>SY$!6P&[OIP]%JI:7RQ^]7Z=[BTGM;1UR$,VY9R01,, E<%\_?Q4QVE7
M5\FYS)?-*P_4:8\L J5. K;V7$I6UX\20MX'.A((UC@*0 IJ.)Z'VZ^F.>#D
M/]-7(R6^%F<(,A"[@YFLR![YK)M>+RZ;!!, 'Z524^"!Q438IF:QKF3$NM9\
M4O-Q_12C59'FEE:MD#_+R57M7EPK+ZX-3YGC"S86B,MBR:1L$5>KC'%]3$.Z
M%87L@-6Q]IZM8[^A<A-\M[(1K-<KCS"+?TV==*S7X#Q6KML"R]!J5>?;&D,N
M8$*WD!BJ-_!]F=T/*>EH'7;EAY?S^\UH"?I_"HL-BM'F_W@W<?AC4)S/=I\4
M_,F^5WF3HS_&G>+Q_1"US3V);P4ZK[MZ,SA27.,A*_WBQI(R48_6],KL%CA*
MW"(6"IR)YV]J+)UX:33U37^;?H54,&_]AR'JWQR<+"U4.#WWG@R4 XVDJX#8
MTKQTH(1QX7O:GF;Y91R1K2FB#*E?6ZP%;6EP6RR[+6&F[,X*S36O;V33-X16
MP_@WR!"L^X>'^R=/U$2+BCMZ/)&ZG;7>1;KCD#?ZXK8K)C-T&+&Q];/D93,D
MNP[*=423#A)=(T&.RV &7,'D_+XD8PR@^KK64'&2?4O\6&=:.S#F3[^=H44$
MI:L\AE]5R9$S_5RP*$LS MRB2"'5LJK#?<QU8F733UUY/1N21QK&2I<2HFTD
M3E-A/Q;6X+VHF"*L!!IBL%^W!\W?G!^/3_3PWM.G6^<J5^?7>$*\VP6+=>:/
MT(];&+)-358JCE6I69-.$$E7*>D<WZA@'5?F8=8K[_ #B;LUN&3GYD@65^MD
M)P\55KL%6R2$3NT4O17FB@-'I&6BVU+I/6;\\&Q2!J]KR9Z5D%W*$/.U<!8_
MGOAGU4#>Z:>B#U@X4N><Y0+>DQ6UO'J_;V 9=YU1[:G>G(^GQDK2^+M]+4L9
M\AIJ)]FKYC(K7R+<K9- #9'9!^X;5IWNN^4>3][Y9_6PSSM]*KCU)/4=D&6^
M[5U9IJ1$B8OBER67:<027H?Z9'48C_ <;4.EI+::]B,A+AK-Y_KY9:TA)4;/
M1XON/;ACX.G5V=?#@V=$7.];_J9\=CXO#XJ#-B-^%<_S@U99/90FH]XW/7,\
MY$YTM(IK/$C%K-"CMH;94-0<:Y+=JT[;\^4H* 86]WR4M_/EL,C+]R]RETX!
MQ 7N0Q+3]@&-)9Q: 4:6(5PA"$-8SYA+:7&)M>$-LNO$A1PY\7M@YTP#CGSN
M(=>W+PKW=85I#.D&_$S3"@S%V"@2.X/- V)KB$(>0KJC38GC>R(,!ZKUGS,Y
MJ[!$I8?)M5%BC1GB0[SQUXV5;W=QNA:6]QB]F2PLIR*#BUEBB++IIT<N4N]R
MJ!U\\RRZ"YVV1(]2OR6SSAVEC7B2GN';1$)26.] @D) PV@<]UZZ_FM8V7KV
MUZW$L5;B)J5X5@QFZH(*]!-2V"=HD&.>00WE48/46QH(#[(L"1 C/RG-MSEE
M_XJM10)"7^*^NUK-"\:;40FZ3$-N+Z@'<+F* *3H,M+V=Y[W6$<UQ(L:!S7F
M4T]U:%2G#*>N5TQH?;8%WKB'0ZW51<!8_B4@<\;HQ7S'P<O>M;&;TT-6O17E
M$A5*FH9)1\N1!6N]*?IQMOG3SNR>4JF.O>J$4VLGT24-P5LF1C6*\.L;70_L
MG#FMK8$3*,[F<)Z8ZA;7=\S%1&]MB(NG[*6D3,)6:5%#((;=I5<_22!#Y N,
M*T;:J)8T9/%LLP<[?(2.(Q?7K_KFC$^]Y+\1]]7-9F\OP,BZTDR]WL%?^FT$
MUPEYE?BZM+'#E80^LG?%]_1NQ(-GJ;_L++;%8J8@;A3?1Z]%(9B! _(9#(KZ
MJ/'Y6_(HL^GWURPAFQ/22?:V#R*-A9)?-.;?\6$>($(:UE_# KE5UF\4)2?N
M+'3R8EA_5EM<>"-03M WTI+)&E>G$<4".@5$% S"95ZL]5"H>L*6\[)G/K+J
M=T69S6<-FKIZ)\H&BQSC6>@OJKO[P6\DO$T)["8:<#>-Y6[MYQ#LGN*+;?-F
MH26T;+9;B P:RVO,\H*R"G--3QH..Z^:+2J$E74R  U4%7W<:HQK)O1!YEH1
M?&4?@Y]!R#/P!3QZQ#H+/*FD#\:RR >?R,C0UL[ZBL,/6M;Q@U>^-FJ^C%B5
M*EJ:M([6UN;5]>@U !<W%KH\<Z4RL>3-2:,T*28I)E>@N?)DE5>-=7*9PE7P
M_@G/!$2I#)@_7+\,3HX+\;$(46XFTIIX_495VO9PPI[+G.4M*\.S^63FV744
MA'J8 P>81%>_()\NY@":LXIWWZH-@U6482H9%(6YT/ER@BTMNEPGJB'",A9"
MJ-W1M!B%+=6IV?NB/,!IJ^R@;]"W^/&TTYYO!"WNA*>/_@A7W61ZNA+%_+"=
MC[%)6=D\;4K.GC=[QSC3(CS" (N*#0!?[&OTB>);G)GN]J<+V!UIEAK>_4+[
M/Y\:;JV_%B^1G7%Q'[;0>NA:U2E,OGY-]7'YE/LM'&P?9?.%O'7XNC*0EB*!
M7#W=%-8R[S-V'[L&)-,P5B-0!$+*)->REI65#60ZN2;:WMR2R>:YII9%VR%.
M1LWX85/[R\,8SHKJZ]DY.E.]2-<9HDQRC!['I0DB?!705"[V*JC0>=DT8\^
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M^8OEV@<E:VRT)-Z\'Q=)6\G*=RXOZ/'LI1I/$_%X[]R76L=6)"<G=\-6*M)
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MS?+%=G04 ;+7SW.<^.!\K+1N<2S7J 7CZ:)2;J#2=:/U@3>*E-]AD8+<TC
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M/PZ!UZG)OSXVLP:/9WRM;@Y40$!E>?Y9P026FSO946W4[^^5VP6H4J?6_:Q
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M_]J/M(2#<8.:6ZRB?(>&.42Z2_%L^IW$RN<EX49T:M8WTQ>GV-MO'4(*3OX
M(HOBJ7-/N3%=BY#9^5+FF@\4BZ+Z^_KG*_,#FKH5.FQ<L*S!X1_B23TR'>'-
M.X955;D3%;C#CU9Q!$5#<ELI":'AY:2<-/6Z<6M+>9&KV,$PS+S/#$1OX_ 0
MU+)7A2_56'.__',?X=\ #3_V8J=-,B>VS$0/^+4H9HZ0GAYYH$O6R2,D T'R
M_80$,>[B=*^V@_KP?0(H,-?#T,\-H(]$8@C[-:VYRH6&3VC/92U8*Z?PB5-?
M.7Y\(,J]>@P=Q5.(-.J#! 2W'7%7PL-]Q/**U)B?59\A"1U+!!F @T4*_ ,
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MW,((,<I*XF79.E5+7:M"J>4GX4_;7:6]&LB-KO$I_[G:6^6$YS\/13H9JOX
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MO=$SWW9L?!3GA[#;$OCJG.8+C9Y[IZ6XB2GMK@NYNX_G:<)4X-B.:[$ :$D
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MM= #$=>'<!EELS+C?I&?B;).XTQ\+HM96E6 71^+>EOSD)Z^LB;3FRS[)C+
MRJMW80AH7C4=TR? [TV"45(@HKN<V [W0/'V?) 11FP:L>D)8-. W;BJELHF
MV U6,+!#$(W=('"(&S).8M!>B4,#UP*EB JQM;K/6YIAN9VCJ1!7> 95$$53
MEN@[3&F<9M*@O2GP>(HBVXIB=E,I?9.*V8WJ6VR5?+=!X3:R$VJQR",TQG0P
MK,!!+1?%/2'<P(N9?_^;ORW"W=!H=%P*6C7E0AKSE%WO61KU(\^!V[1#X@DG
MPJ!LH)VQYQ$O!O4SX'9DL:VEG5N?/O$X-B,_%CP,J$\LT^?$M4-!J!N$A#//
M"F.'<D:WUJ2[3RN\*?P/XN<9S2ZCY@? U\4'6GX5]?LFY_?KE=\@U0Q,RS-!
M&B'<-@'5;#,FL9.8) KL0-B@%$?6,_*?W7_D_"JJN3=4S59>O5-*BZ#  MV8
M^+8/4@!U*:&FR;!(A66R *X[WMJ0ZZWQGMP/MKE !)D51L1S'(R&=RB)$B\D
MMLMY )?&[6#K9!3!.# UGIZEO*'9 )L.TE*PNBBK3^6G)$F9*.\_;,4R'R'S
MSXI$[,4V"5P> (GT*0FY,(DO6!!Z+*#!]IHZ'CN4; N$22MP62!\1A+3BXG+
MN$]BVPJ)[YB)S9* 6<[67M^U44?K7GHJ'OXX\I/002^2"-$3X9HDC$Q*0!!T
M3-_G%G6V-A1L&WG4!J_&,0,_8JY',*N9N '():%M!\0S7<MW@@18U]9EZ6U3
M2,P6D+S(-P,:P<Q1'*,$Z,2@;+&( &Y%H?!]SW'OO0++/5_AHR1TW4\:"0NQ
M0)D? P4,L>*('9*8QA[Q_2B*7=>S_&AK?>M;IQIO-%TY%,S'(E,,;L.-F$]H
M$,!?0 E=;CG<HUMKA?J+%PD3(@P]W[5)PBPLT6%[)'8<EYA^$IO4Y)806XM2
MWZK3> !/JSIE^ZJ6_[.\/^[X+(BBB #Z 4GD-"$TEG7,0>DR/1?8VM;*[->I
M7"W^O2WRYGEJ6TPD/(SLF'A.$*K07<H9IOJXKD--,TRVMSCV$\B)?"3C/;4H
ML[R$L, !_I>$(4B6 2?<CJGGV3YUDZTU$G^+G+XO2I&>YL^9F@K7LAD05.(E
M;H!!NR#(T-@E@>4&B<U-YL1;6P3@N67>/0X">Y9+X>X9(#!ZWSQ&29PD0*1]
M[ .1)$X<W'MJS??)\3(2Q_(V(<=;//)=P7W"0C2ZQY%%0M"""0^I97$_M/CV
MNKBVSJ#Q./ +MV<FS$3K.T8;FJ&+\GQ$3-=T0YZ(P-KBU+"QD/^U:#ZLS7^G
M@+O8B1W.;.+QQ,*LE(3$MLV([UE)) )AN^[6JNO;5VEJ"\06SI( $P&)E7@^
M,"T+5 D6,T(=X8$T&HA8;&W(R+V*+7\U:TX@?)\''K!M@37DA"E0_6!$Q-3W
M6&("4XBV%1"VN.3[)MUY0>)$/+%)Y)H,W7FR;UM$$MN+0,F@V,GOB=_00Z51
M;S#:)+9#X7"X9R[-UG$LS3"@!H:F[V)HI;F]]38VJK9_<U8LZ]G!P2^B."WI
M?(HQ8FI2W39U]^V[)X"*7A!S+\;Z*B9P31\-<#06)(C,@*'!!K2@;;WT;3&=
M/HZ2P^+$=9D# DZ"_8LX:.I4N*"DQ_"$^B+VS:V-V]N8O^E&J'JK@KQ/4_9A
M/.$)%6BJL3!KU0/P$%Y,;"_VW22")_RI1V,\:*#,!OWV-^ML^NA&M2T 8L^)
M0\'-@##NNEC#-" A\^$J?.I0*^1.$&YOZO5VJ^;?Q:HVUIG-=6WN.28E,8]B
M4,W=B$1):!$@53'UHDBX_M92I4<4,NY'XK-L[B> 0:!\V2#QB<@FH1>;Q,(*
MZXEEFO[VJL?WGBUUXY5L?3+)(T5/)TGB,9L2[GD1EL,5:(3#P)K(%=QBMKV]
M0NFW:S;V>0TW#(&_1W!ZWF4:X]!WPL##5&2.K3\8, S;)$E@)5[$'#.D]VZ*
M>!I:8!+;+J/4(C9FY;DT B;+(A28;-^);.8Q=VM=75ML[-R@W!]Y@0A-&A+N
M8ERH!Q)02(5)@M &)<!W6!)MKS2[)<[(^V^3^US=G"*V+5]@\2HOD08!!UL+
M4B!4EG H\WD2;ZV;<\M,[1N4P87EQ)X-5#NT!*91P\!QZ#A $RS;#!PKM/C6
M]AZ_5@:7V"\S+-1K6NK^*#96"FBL]7*[< <1F92ZC/ (G3M4"!+&04" -+ H
M-JD3LJWUCF^-87 +)&,LG^K%G),DQB@'%_1XRIA'*-:S"0/?CK:WK^@3R=7:
M()UG=@C71#D)L**":]M8U0ND0,>-?!K&(N'.UH:W/Y';VJ #'#2IF F0SQ,.
MNJ9,98TH4$OJ4W2 NQ'WMC:-9"L=X+^\W7X4=8, S<^<^#ZV9W:<@,268(31
M0%B1ZR?BR7O,'DR!W@9[2"@2P&,7O>(.X' 8$QHF'HD%$U2 ]FW;6YO+_$RC
M !\'$&(,_C1EIVX.K-<+90/V@)B>Z\:^!W3>W@9WZQ)1,WWBF)L@:CYE5F#&
M,3$=C@FM(B2Q$W$2N2%WW"2RHFAK.=EWF\(/RK>-R+Y%SFZ.A4\R%WICOMK(
M,AT6@/P3Q#[V7?,2$ODB(&YL4=ORO,#97@7CT7.A[T=$24SFV7:,-FG,:4%'
M.K5=2OR0>9$5N(X7;YWN?O\6V[&'TD8UU=CRH@2HB,<P.BFQ T)%:!(G"D+'
M%<(2T=;*3=^$A#[LYIN@L#47XCH)YUZ<8%%;+,XL\Y,"GS#ARGZD@H5/TT0\
MAFD\OG#,61A:EL5(@I4)7?2TQU; B<,9MY/02A+WJ=NE'K[X]>-<I2NBR#4M
MGT0)RFL<E!UJ@<+K^BX3<1+X<;1U61N/+1P\>ACF8_D.S,"- A,48>S*13W0
M"GW?)1&#VW6 V?C>UF6V/P"H;$D7]/L1(\(0Q @KB(@?8)HS]V-"$Q:3B-+
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M-41M(*^URB42.GPLB]YP>)J?RE=AQTS(@"/+-F15O\IX">.!&FI4#9L:U;3
M?'Q#M1>"W]!ZE12?T^HR'98_UGMX!0)FSHV7MMIC#,HL/(__@!W@^_)5^!&N
M0H^#]9@JN0BY2%K51F0:G"ZJB7$_)"I)G#@4+" F\T#C]WE"J&\SXOO4I&9B
MTM#=4&B_+K.HBDRAC:JF]:UKY]T)1O\MJI%4W814/?PQ?"RVZ23<D6A?)MJ2
ME@$9FZ5U#81/9$#.RD*VI<\6AC@3Y<(X1 LD=IH[$\8!K:DJ4[5"TOLQAD+K
M4 F'29M,I6H>D6/C)9K1@C>V8T\Z+1WD8:#T<RR=<M_T7:VW(]NB>G5?1)F[
M;A0'%B6>PUSB>J -T]ATB!]2D_G8-EEL2&X<7!3>DZ;1(U$>B?)(E+>?*)<K
MILX,MB$,RA@090S3XY).H9TS7_NM 5A&UCRH9D#+88ZRE=6 ULQ@_XL=E+EA
M,!!4\<!.C=.R.*^G[>,)B.!"KDQ:565149E)@J'_MOGFJO7)Q]:;]K5OOG#U
M^MH74>[6+U^QUO;-UNYKV3&Q6TUBJ#Y,OA_<GD>TZ-,IY&1Y$S<(;AD;ZIN3
M* QO^6,K@IG]V_YX8MZH+O+#!?QLRN%^2Z)Y%:S^MIYN;*PB\)9N^WMS6K=V
M@_? ^)_T>5Q=__BY[W!OQ.$GNL'[Q.$[UENZ2X3K0PMNMXPO@PO")S^]L%^,
M>QSWN*U[W HA]O&CUOW CB/?34@46B9Q3=\FU.:,.,R. V9[8>S[FRN97^X#
M.STMRL6:*$KYDF2T3+^TT8#*=>:#^V[?,3+ZI\#H_5%8?_([/+K*S/;<-[ZY
MFWU 7G1CO+TJ$B"T8NK1A%C ;H@;F"ZA9B*(1V/J1"&G,0LWP[0D7+UMJC07
M5;7Q=E.;:T([JB6W2WL9]S7N:]S7N*^_U+ZV0O6]3WGJ,>]_W->XK^>^KSN(
MMN_6AS@\B6T_*EMY.MJ9'9LBMA,?=++( >W,L4GLFY3$L6GQ(&)VR.Y<P%!I
M9RTP_2)A:5^!TA/0TKXS9_K)QNAL=4>Y6P>[)=>$E6%]V.O2X\KEV&09D2RX
MS).K"Z.I5$@:[%+D'$-YNX;7;?0O1@7C7-D")S]/86J8ULAAV06:O\[22EJW
M<YJSE&88B8(]QO#EJJ8YIR6O#&PJEO*K<MB=E_35VNBR[PTAO@WQ"#PS"JAM
MDM!U7>+Z(B)1"/\*G=BF 0VMQ/,V1#PN^G;BG^7AWD\[\?N+*;UK\]+G'VHZ
MR-?2IF$L:H41E[2N!3;80X@'X,>^IC M/95Y35WY9UI5HJKPJQ8A1)((&8.>
MZ\KC^,L40]-SP#9<9UED1@%\?8"$O56Z ;0N.U1S37=0>O2(EC&%8<FGBTPL
M9#K82\LS?I\<3?8G1F#[6*?T%6Z\WZ6N1!%G@$ #5$_2<J82!>#HYQ1? NH@
M2PEPN6+:\+36ZWH0O([C&!E_0)C 5M6Q9Y+8\T*L9^U9PDJ8&]T9KP]94N[A
MQHIRK[_>]QD]'3'["6!V8E1]5B3 [/?6[;V2]PZ)0X^4LKVFRF(L+C%G5>5=
MU=I0/].YCTDF4R+A*U:4I6B;]DF1H"PQ&[) G#M+BZ;*%BW*K9MU\@!8AZF1
MIO !S1(O(J['+, EZI @,3WF!:;#HN"N6'=0L 8W]#[-C^I9_0Y/8;\[FQ'[
MG@CV78\Z*&-*+"E 1%6 WL-_BZT#C)*\I\M(0^;+"IEN!SPV6U2I8ITYUO\"
M7DIBBE(KRK4BKQ13QJPX>"03J;O9ASC:,>G5CA]E-4RO*T'&/D.4[I:@)>DA
M2='9>JXYL<P#8@%=68^=CP^;?V4@7%<RJ9J*+&NU+^/EFBI)5V;+O!K+BMP@
M=6ZS#,E)J,N0#854".*:PB+4=TV2A''@<RZ".(XVY+E'P%AG$E+9/[")K+IM
MPY/[*[CQ5V0]>Y(9_'>3"\,Q=PS;M)T=B:P9%I6(=? %EI9HL7A-HYY944D2
M#T."V"4M) (M*R!M%#D*8!4#Z>O/AF(JM1J>GIX"-T%R,Y-5#G7%6YAC6 S7
M #B23$@F("8H",)/ULF,Y[3:-?[7W;*L[V".U/CV7N9(P^HUPGF)%<=^0 )F
MVX \@$91X 3$=WT[\:EM69?[8<:4Q<QT$A(SSD!J#(%!LR0@IN>ZL>\Q$=EK
M$.ZSU$+?9P6M7X">FZK1?C_Y_>C@A8&G#V_[+X \LW0&N/?3"^(MXV7>S @O
M:J+?>/&S;4Z\%B7:;3UBBC6\G<$*)H^W@K\&/3B>MMVV$,EDS>E*EUA8Q?HE
M1"V:6IHX96\N^8L/M&13P_(D47%EE80M0T_F",[B -$3<-3UA$UB"]MOVB(,
M+."6W+K4(]&S7)JX 2,,6"8J=134NR0FGL^CV,,J.8&[IJ:-/"IY4D?R2#_U
MQ[6$K^K AXAJ?@-/'7?'CZ(=T_.W!UNW!TMY>O;]@'95C7DO@COF(3&#T"-N
M3&T2)J9+1!QS:GLB8-:=RTZV^GQUF(.*-R]DO/S;!8PF2@$:VS$,_38#,'IA
M""#K<_A973;B9F[+1^L5>*<K/?BT__N'=Q^/CXS#C_N?OGS^]&7O^-V!\?;?
MQI=W[]]]>?=Q_]TWFH0\![K\&6W8NDK"%5+8@:ZE +KXY[*X6!A'K4D ]7 J
M;=.@;N.O)47>R_,&JTP+(1_!P)) 38N,@QJ_H]M/7++-H7>LZNJ822?82E$U
M-/%WNAZ2OK2JI!=M6+ZG+]ECN7MRF!2MBJJ*F4&36NN<,-LUY@<M6BX$+0WE
MM3L ,52R+\=JQ5DTD*0#?$*!LFPQ"G=4&)]!-#4.#P^[8D&J_-ADR9&\JA\
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M5A18H9]2  1R5#8R:$>GX(!JFDFM7KZ"5IQ8TE#4B( )R)P[#A0( VN0-M?
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M@X@@XQ0!(U6%<ZR+WD5\X &K^V="A@6A84:U#)0%;3-I/)3Q0FUQ6E7A.2]
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M> "KD'BPE$XK; W]RFBH.WM*K,16:CNRA8DN#9=V26$P$'#>LO.&2ED1T\$
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M'T9S2NIJTA,JJHP>(S7XN\'9#3_FRPVF""1QTZKD$?4+6SM>DTCN7]B-##<
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M0ZL%J7C)5E7G5%8'GTV:B!',#E#+;8>+)+B4"2*5W;(--@QBV$\&=O L,IE
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M:F7X'I"A;< LJDAUB.XGVPHK:6) 56::W>JQP3 31T 6>#K[E4GU:U;2Q!]
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MI 89$1.2KL!Z;Y\Q^=(Q&+DRY^"C3"1RY+:T+<O$(0/N4VQ^I@=WRHZTIO0
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M,TD=] 6$@?/>S4T^UUP2";S2[GXBON[15L3R+#/&>QX*)?:<^JZAZ<ED-)1
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MHA8!)YZ[H3;#,#4G]<W\RKCZ[M\@DUJ0IU"5DSFA"J(@&UOS33G"..-Q<JS
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M"%-G^P<6J'"X?;KS\8T9QXTC @SV#1ONM>.D-40!D><, 9'P>J37<X^_W5%
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M"E),N)@P3XZW@3KC$7%A,9MB-KKOG@@">6.Z'0U1VI#;4:+5) EEGM5B0,6
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M^IUL1\AM7A$\(X; +(V'Y6C^K?3>WE6QF#9^A75X\XJ09&%+"9QA?W,:G,0
M",>6XVH/[IIF)[H=+X,8X<  K_'(I "RDUZKV##^&2/QI^-Z"U:O8/7>$ZOW
MQX+5*UB][W7/F0($UVFY.J!):P>_:YB$J/CQ-@PXM?6]U"8II6' MS)Y4
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M0R2K@0H$81S2148BI0HRA$G7YPOB[31^U-\PET5>2TI$YNB7?_=/P1_PFU,
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M#SOA1$* X//V2OK7;WT87_%.(&<(*@J(>#KUHV'2))2O]&5<;68[SUS&#?;
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MFP]?JVP)EM$922Q+ZT@!:8PVMUF>)J8:AKS]N;7@GZ6%?@XVVP7KGL50>$>
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M&5=IO%,A=/<S6Q0?:E&+M!:%WX.U+OQ::([@$U414LSKTO3MU!(V3E&22B&
M!(D8E&$PKKNA,BM-%=-0 O-IA/DHM#*.SLHPVM5'7+.&\%1JM;' $.+UQ> &
M#XR.#0HG0[U3_2@IIY$H(_)#;[+C_ASJ]DN6RS56QU(9>PI>7J986"QSIT,G
MQ)M"VS++L 1C,P9X?89?,H9N[+G*&C-F*I!M95?$U>;+Y/ G<+TH.VJ8B40,
MC^*:=!-$'G1!^$L.=S; <HJT.7/YFGP])+*,S#@=0E^1Q'MY(#CR]LI#1,M=
M*TZ6KR3'VU.M497.)";S]*NK25V-!EFE[,*6W#A>+\6!!$+1FV&FQ$"51%$>
M7^B_"(0<"1Q 5XH\(%9T*L[/*EM+\]>19\&5R\Z-.,TB XP6TXCZVOW'8JO6
M[/'@*F.SU4;IOHDPS+7[%SM_8KU"?CGTC$$(I$RR2I"4/:WENU#.2)\)W)-E
M!)E;&EN"\]29,OPC?3Q&4A2/[^GLY 5K6;"6[XFU_&/!6A:LY?>Y90HB&E#*
M^=W1^XS^0 %O1T;-/EI'FX+[SFXSPGYD@A<4332B8-)T-*DTEA9RX&2/%.Q;
MJ%GWT\#?"HC-$Q5.A&%GKN*RB <,T5 ^'+#\UY;=+L;NJF3.V0/J>HJ1@DXY
M)=30?5="/"33/ 1+"3EMYF#J6R'JHZI.VVJ-W$1Z!"/D/!GX/*Q:Y6?GW'9'
MKVA_%@ +5>#TY\E^'"=[J2XIC\L?05)D^J70Q\1&/)43.00Y6_! +,D1-62/
M27#L[5-'=0,$.5.G[",4W_*,3D_T(\**I,J&]"N!0"54]AJL:C@I(<,V_(&"
MA(D2>R+= OL%-QK7).Q/,;2( YUQ3DYG8O0,'"#Q*#V]O!LBG3F!,EX(*.@;
M]$#2,1NJY$EA@HRVO>,[)N855B:'F9 S1=^#0CX]Y=8,3L\A='6<G?[^7.PV
M:96UV(]!!<R>.1 T\N,/RZ"4/YY$XOP%-ST&(57L"*U^RE#Z@)*]<<RU*#4.
M+2K8->*ZNV;HI7Y0*8,+CL"0S;R6Q+T+I;(MY&-B+A$,*$IX8_UO"7X/P@C#
MPB.FKW7Q#'< 6A*\WM17_B#T*Z7$\0.6. +)YSO9XRP)[28?@-#V*FP^E9&>
M:GM,;S[&6*MEK9=Z-">AFK!D*]8GDEOF[8C^'9C_S@9*^2F#?UU4Q;[UAV^1
M<$[00? _\#=6F<8TMFB?P_4C XMNZW_5PZZ?DC7E=F$%\-_O"3DJYW,2I.FA
MMC[ZX-0W'BO^VL=&HBDYD+"*W[J:00Y)J0IW]S586#S J\U7J4*+C=\D;$OO
M8-_6AP/BF7 -B8+*K;_\K=Z6HK>$SH?*GGW-847X]>(2$$UR=\N9D^,1(>2Z
M4;Q5M+^,_H_IA8>7P0%"[M%;'BX9(Q8\N=;NP+^"OTN-I^G^,7ES44SMF-R3
M,)L*)>CZKWDK#Z$->;O%8S</VKAAEOQKF]#XIP49#Q?$:G2MTC>9=)*/X-YN
M:7Z90]K1_Q^J,W]/.-Z2]:>J;?-+(*RR?V\!ELT^W_+NJ*N(#T"4AOP6,0C]
MQI%&L;P+H4L,;*:GC>7EB9\R6Y#-.FBSL5$-7X0/R?IM4^LDK^C[T#6JO$^D
MHP^[US,+?)YE,_35K(=BTJ2ES2WJA,K"1*IL(QC?D+)%8Q)"ID<>BF+O9M"5
MX.IA>ZO!-'(X.SH8:/(2M$;DJJ-$;: N8MZ)U-LMDCE4C.$ !.,0ET;.GZ!1
M)'[*LN\&PMC[?GCC]UII+C-&I1M5B2J2^/%TXTOO02<I\-\A/S<+EYDGZ>=Q
M_(O7UXYI#G'A4J].,MFY,\ON(<:9(?F,5Q=!XM(+V/F]FRD0E;E*,K1(SZ!.
M37V"M+:W]4 9O4H4FFT(5&?)EF*N0$]4F=X*;4S4@=_6XU0KX;GL0,:GQH.$
M;KB>'CL5NOD[<R] B["/5A9$^B]O*.'Y7;YLM)B$=BRQ(&\BVVT/^FI DA^W
M$UW>6_1*"9$M]/[H7F#Q\J5CWI DWZ?N))M+R(5U?XD/-E/EL94;P3N;_OPX
MC4?T)-)2SL/Y1-$V>RZ;PMRE1L^SD& $VPE@JK/T]H%-X'OG$-J_6I[GG0ZS
MMN]4=K.I-I$SC=9JV'LNJGF\VW4@B$K)UA=J/56:V<_J1/ )6B?VP?8PB99<
M6:8?YC(E1LJ4+O.=B@#,K2LP2U,-8.N-O8?W*E1=;?XW1@1T2/4@X&&GQ""<
M*1L.+I2K%BD%$BWN2(BEPQ<9P<UB][_88NW_YFPJ%IE$BI5>.0PHB$"9UXJJ
M!=6FK&1.RC,+^5X9QPJ=E3@P4)F%J( (DOU >482^PQ,O9].A$Y3]/ 2^Z*J
MVYPY6-6=*") :P1UF9#>:5>QU&Z?@N_^;KT(NP:$<K7W9A:N%2QE:2:4B08!
M&=BTXZD18B26>36UE:COABS602J"V\1V:63$J#/6A?D#MCW>=S"Q:*@Z@V(5
M:XI#1* R."N*H3"F0R2"?"7=K*#8C+H$GALT^%F&&<#+BP+4JQZ;[>;K8 ,D
M:O!K,D J>7SRT:=_?O4UH/6??/SI;ZH 'AOA<O]^]<V5%6NQ :LH=Y\9CDM3
M//@O!>AA])QU$Q'ZRA>$,(<X$O#?A*]WA$@C,%=[YJQ:_U5I"53UK'K,=%!0
M0[4"$19!*$6I_&(^QX<N!"85!$5+^D*ZF=1;T9O:!N%D[!-R(L<#(S97(GV9
M\11FB#-/).&11%JN_TB$,#;TQ#F.ZZ];:N/+RJP[4)IC#QN=C[VDGDLIDC]U
MA'RDKF.>QRG^>:L8/ZL $XCEG\XZ+,"^ NQ[OSO]W4<%V/=D@'W/<Z]D!!WY
M7HQBA[; ==^_T:".2L+*$A: Z5QZKIL!#!3>OP#-1U79NAL#$FLO$#V_#VDC
M/'9\TW"-BD?-KJF'1JN]G"LTDMN'2X-NA!3X6571Q'ZM]?NJKX(-<2UO$MX'
MJW1M]@NY ]ZR4!-$  C]L0-S,0G-QV>.=F(=,?\?<L!;B6&_,9N9OY//W\IX
MW*L JTPBDF\^?Z4!"0^SH[&^4Q1.E+&2BUN^J_P-E-CSQ[_1;Y@[!K';[8H"
M.L:+_<4.]0NJ!36G'A4>J>QP/TVCH3I1"X2*$2NT^5-V'"9$7*O$17_UW]CU
M![:]Q17$")=&/+92S87('LULL$*S!II:+%*MO7@A*+<906R_CN:MV;AP!%VZ
MN)9FC*U8 :U(LC7+L  EG6B@V^:*VSY6TIA%?MO?=&@O^;N\;DEO=4FS35=$
MVD:X;\. 8H37),Z<2?CI2$RET_MHD1T8HR 75VU\^'JDF@$'KI++!IG&"&-5
M09 M9(YC]5)_;[JC/+'.(X!, Y!D _3HM3JC2NTD3A8NA(&XB;G,NVCQ_-00
M-AJY.])CW\GH?<!EV_,89&YJ-CB(L 7AJ2<2?,\2*_HL?=+_B7Y@OK_CWOK=
M2=@%=BB_4V86!JJT%2^0LM'%!O"%LI\J9V]&OX3(826I&<W"(K76[9B^GZ+\
MMRWEF\0>!(<8HP3>2L^:VXZ)+.FL2*G$3-M;(SN2RGI1KAF5Q# Q3-J1XT,W
M"!^N11U!?5-[PJHZRL=5J'LR*8U5) O][4L=.7&?VGEXMR(NWL2\B!N50C'Q
M_LA:;MJ@8 D\JDB+!%[$5O"F)5IB] V+@T$SA/>F%3 ^[C+6OA^LZJTW(4/W
MT8:=C <8==[277LGSV.*Z9B!=J= ;O1_32^2]C8B)/*4E98/\&( %RE@+,+$
M_*9$%5'V@^ %GP(M7CBN,CC;R]T+)$AT]G9]?!PQ"*"%96Z#8N&6MS.9/?!K
MJY'B)MD?Q9:T>7=W6J4EAJ2[1]PP$7U1"',@SY RF4,A)_,P^X%?/9.AU/%\
MF>]R#4E\U6USY(/*Z:4;8DQ(!^!-KT3J2_!U_(C?U;:L7MVF<S>L4)/.7,Q:
M:QCY2>=]9 +8RJI#I29ST[(T? X0.^R"8$&QC:C:QG$*8I'""& +9OY\, +W
M5FDOR(6&%YKD!(%4)%LN>V:[\X?:'%SV7FAS]F^6Z9/OZJUB4>P6&K;*Q;Y?
M1:@9\UVPZ:&>:U:,H9?!SJFGXK:@'!P'$#-3WOKW/:&H*.?D?\L@QU.**)<&
MN3 0'>'SAICM#ZIZ4GM6E@9_Z2W_HN(J4A@YE6$)'$-@H=[E$AM>VYY?Z(PC
M^_-@_QJMU(<^L *C[3)6/-/F0CB4X)KFLJ]R4U5J\O8"[?6D5V"F&WQ\,[A;
M277M\"@J6)=X15>H1(UNM7VX=,S6_WO<UL= 8!_>BKRF\&HT7$7\Z7B PU])
MPK%!&6&[(RJ%$(H.+'B&!!&8EB!EO_<;F\CSKI\5&Y@)65+1M!RCTPIN3;;Z
M=X#E+%/09'K3L&4Q?HTRWF;L-;T-M=)9@82K)EO6%:LTPK+XUVMU9RXIZ%3R
MA>6,L PS\2S;3=_O*+^H])9_(J@0PPB?)5+H6:;JWV)M87A8T14(Y?8+:?,5
M&I2P8QO7E6[8*\[JBEKF/F2L"651;?[[BZ]?<N$.E4(KC&Y/&*6?L^>*K%9P
M]U$UW504B-EF&J1)K>N"2G[LUAE)+AB^Q+FR;9YX2>6^8*%',LEL 224=NS\
MBV@@D(EAD./M>0PS9Z@;!!P]00=)[F W2@!OV#[YSL$PLWX]7&Q1X4$4]/9\
MCW4K3'TG=Q,V&*%FY93!']K1WCCT':NUKY[%, M0]D!DD%2^>T2(9V;NW]UV
M@FXE3AVX+H6G5^?A7<-S^MKH4#991AM(SV/3]>8KD4="![+T:P$R8:(06&W%
M)5FM8-#RD><$8B,9$AD2;X]OI351G\YSS8,VFH!-4D*)>?PC9Y;I?WX!W_O9
MKS[NS^0!H[(FNBH7;2_LUAA#923%G(W.4I_+!:2L=)B^6 O=F:H6QW1OI6%W
MG@%UD2>$M/M(^!#<3]E8?@KE)UF%D2F6:_D+[N*5=7_1U=H)H#U-$Z,!@2;"
M0#! EUK/J N%?[2O:83J4L6L6,C/,D.3+M^L:2 .D>3E3AH-:?J0@796D8L;
MR9TS^5RZ\2=N[\=,>W[&W,;&7<+/3!P6@A ,.P#.-&='_-S?2G_P0<%+?Y4)
MBN#SSPVL$7(.=F!"I4<VG]%1OX[7_SI$=WRT7_WELZ]?_^HWFDV?^OZ-)A;^
M6K[T1O+)1Q__)[\;^FHH_(_)_C#7IIKW'X6)*&+\_.570KHS,M]2JYR.3\<9
M%.A>@>Z])W3OXP+=*]"][PW="ZT:< 333*C9/+H>/:Q*>#9V4M3$/B*[ >#6
M! $8M@T44%RC!&2RNQ);;=(ZIE]+4#=REULV8&'>R!2YS.X@X (DY:,TQK$,
MPPELAK'DL$X'*Y!=JD0B'?^%II3IKJDE,'=;M_OYU<0-"X"%[3#Y&SYS.J2J
M874W[JGEMMB/ UV!WZ\VOS;E0PA^9!)*L[_]ALN9"FOBBG@*]5$),=WN#6+0
M_[:MMV\2.&1+?7:(P*112=Q)%S5F?AK_,[6TD7]""C5WWK!WB63Q*__P+*I1
M<^L91[/^]>\,[OA:HJ1O;AOB!-@/]<$1N*A2P1_Z\L%14MB,!S(&?MH4X9U\
M!O OKI/HPW_@V4M8,P,L4"0G""1]S;OXBGLQY_A^'SRDH1#2'#=!.LBHYWZ1
M72<-DA#$0KU%>M4\SZTDW4K( ?3&<-=L3>5"/PMU J&-#D'YP5\/F+AS/&XG
MM?Z4X2H;\M.0R8TJS<9(.V5@K)*JNGB=.&DAJ]Q(0OB-C$Y'1<#TC=8LGBZ\
M</O-=*1?^MO][>]_]^DG'UU]M/$>LA7D!G_XNW\+RL ]H>9"L\(?K",?<IJ&
M#EPE0?W$;9V6^*4.3KIJ$N&Z.Q94N?5.$)JN!EW$5?W52GZ !W [ $6]6,_W
MIP$R $[2$I%(B3]6NH@F1.K]5YN7 2Q$F-)]W[;]/5W\GP;WMCGQ:R-5K.P;
M#L#+!!B*SRH>S_,OE23P!%9*WS4P!7H/\IB9)\Q!P\=?[,HKX9=QT_;7]L&G
MZ -V. FNX]J=[BG=REQJO@,V2PCBS ]W*C(>D/)4_Q,"D8^J7U;ARB3U\IX7
M=0N2&<%O@<&I[_<3K?7KZ(?@EN6"%Q..FB8QB[]N<'OO/E645'P"T?HLJ8!D
M 6(?DD7H;R4N0ET@VN$QAF8;0A<[Z)>FPC.=H5)Z^?%O]#.[-ZB1DO:4:.N9
MRH8/$1BJ3?QT_8&\\%;P=A;)A$! :M>=NY^U1 ]2@^TUDU=0!M5$=K0[D04$
M.'3DW@FR0,PGLF (C=>[SKUEAFVU.:.'/?2[@" +)%%1?B?2*W()BCOG@MI<
M7)'5Y)JZR,/K5QV YY$F6>2X++[RVL4:M1/1!XD'R<U0AZ%SHO:'$0W$;".]
M3WX43 $5I M6^M<XGW]&-3B7%C[K7NCV %9@5Z)T8!DH-=B:$;/-CV/HK"_(
M:[AV=#S)#'/PL7>CA2SIVL5-"R+J!NX8:5Z:4&@.=>!KEZC?G*XV9DIB!0.Z
MTO#,HB3B WR7IE4@,S1/-]X&HP4#FLGOP\H!O7+!BV>N<Q."S5H@$2+V[P7#
M47:&4)F1V#&$TC::!%&)=:W!#9(\[T+X)HW)N3U5LWTGPVBR!T#SX*.IT'%=
M@!,NH[FL/*-29MONH301.'IP%@9=76 $5V;3T6DY]G0^"IV:;0AC]L1O<])^
MMC<8@=F1M>WDLB%>"L40[.</A[;X8/&/:[OA:U#"OX[=4?+OKVV\B 7'5(0_
M QSP^8/_?@K *@33WI*8IZ-X-PQV899KI%G).C+>A\6&_)O?[ >']'R>L>E7
MW>;E=$,9YB<558C\_PH)*#G&+YN__97K=XB,)%%\>6 -*/K&:X?MVV_67,48
M_<\'YY025:0B7OJMLMU\S&=(AV$7/].NUM5F\W7*S86I@@!O7_XR7+I44D:^
M_F0V20DZ$?(E\"!PDOD@T^!&.,+N)X$VR2X8/'YE:8E9\8(OXW8Z\""%V6,2
MW3*%'IU7KB%Y1')3>K^QZQ?>$/U'>NN<NLK$G[W_A,?6SNV,^CBY+?CZ__FT
M^=//PEE_]1LS0ZA7J;^Q4!O.+F:MV]QM?7,+A=[Y;5WQ+1U)ZN3CCU!PX%N+
M%+:!13I"X6;/*"J>A(+=_(80C[ 6^G2DIF\]CB^4!W=Q#H2&X1$=6ZP/&HCO
MM\D433@=XH\PX>G])+U]K<'H@:XV?^L#BXS/,XA'%RY2D%3";BVS=K,'%K3Q
MC%IZO$+]R >*, 4^E "D4/27@'DS;OLCYP1WU-1TI2+PTU 891RF$)=31(U5
M$*9W!!6?+H1040186=R,D2O 97/T[V-B(0X-AG%/DH_G3?#VUBYHB)'I>M7V
MY (D0TJXV,/!O</^+O"?^E!\.C7$!;RXSNJ!BR2C3._T?]U;OW1.Y'R_],O4
MV[._GI/TL%[5A^NAV1$Y\]__.K\X/J6<97%<>E'_'\U#O^)$DKY;S/_'O]$_
M\7S]?+H.N2#+3/FLD2NS$DI2]AQCQRKA0#2QYPYU)C3]#"\B0+,@$7?LS>LM
M)XEQAVYBI=9_@;</$&,+6+GS$8";O(FH;I-UL)$U716B0G$*T+=W#X[50.<A
M!"&(^:>=NZ><FV]DE]R)%-9B$O[RI(0(54"O^H ,)2,B4UA>43Y$V$_*[&LN
ME?+CUFEY47K0(+KO._-D-"Z9A48:3;EJ)4"J3$#!P<>%""Y<(-[XL:T[[@PR
M=0SY(G9@X3Y2^LQZ3"7 &3DF"B"]'?S&W?&KUK.$+]"GK$U>T=0E'<A_G+Y7
MXZ7V?49@P#YUC634'&<DGC(*N^3ME,I%E9V0"@09*2N&DO!HH#(#L5N.4@QS
MT>4H$[Z.A7G+<J<:9:CX0J$0P("&MQ1*AT/%&(G?1<,,%>RP%\_-<&;@J2A8
MX!R;IT_(?Q?X6(&/O2=\[),"'ROPL1\.[RW[,%.+Z,:/T2]2[*2PR'O46V*D
MD-1UC,D)?DE FYKRE)W=S*>1-4:H-*Z,#VZE.'.EAXH^G+!I*H<:3DC[X?)2
MTVT .[I#I@WDA])FTY^JS'EX4^8\WUR^UD3"N>FDK:/P2([AKT7^:RL0LOCK
M\*L([!J$LW41@7WU4,M "B:YKD&47B$BDYUT4^:1K_R N,,HF>/)'G"/R$AK
M%<!"R^A7<79W+A)!^510*F^S*#U(.$X=%8"!DPG2&^\7W I]WT.Q[1/:VC]<
MM[$WMH]*7%C8XVK9]5[$&S2_&AQ&S4Z.*5Y\C+.-JRU$WU48CI?ZZ%#[2'Z"
M3 0=)4R5\+%[\-$0@UHM,H1C?7 :8F,7%$_0,#E0H+H#,W-( I&7Z94>2 &9
MVXN,0B4])5H<AL0I.A):##SA$@K#\^N8AZS$@.<3%"P(74/YY"5] "HGPW=#
M7Y@C+"BST8G7J\UGG)HPQ%4+>C*N)^$VZCC4]^;\Q*]WA@@STNI.?\^3Y82V
MX'$5J031 8# X[4>O)*.I?LK8DP=>1/&XU+/]H!Q(,UA"/?).0L&=CLN%@7$
MZ:@%U'2>A;OB9?7_),0?1NI;!PEU!?,;"OL>@>L [4;) <I<?L?F"""*P-3J
M)C!:Q1T<P2/Q"DM50OWKKWC+&O3T7'!1B 2< 6$\D?";.D3DV,H&'PG.DKU%
M_KO&X5G07IRK''T*5DOE(#R,VK@"H+,8Z'$=OTF?7+O.[<$^3]&/ZW!#+"Y
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M2/TPJ AZIK+L[WE@Y=+ZPP.:K8;X*.AH_I?^!RXZ>34KA5Z/\441*2[O#0E
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M6/&/Q(I_/6/%'PY6_$L]2[)8\C6@%ZOE )TRVP+#"&32T4,++4R)0AR"W4Y
M.,4M6LN\(I)\_EIX93B0J)%YB\QS&&<^*H__A3<F,DU2ZE=/!1X D_"9"G01
M.!"-^L^KFP9A@ T&,QPJMQ*=HO&<L#@3PM0P![IM %7KUG$\PP-S%0PZHP 4
M3R/# RE&#$^Y2"?\.-[2XXJ#'V6J%8-'+)X&S.2,7:A)")=>8_,8 C3 NV5W
M16!RAE?LRK6SXQ1']4T3X2W9C[]W&.3$V!E[P10X4R'J>#IX/O,3 9:";:P[
MH'PN5ZMV,).4<!EX*!+/"V!GA%I($+,!IA&V$645^(@OWN7%IXOPWT)CVB8J
M.A$.8ZO>%4LC@A?"W*D-41GD\#@16K3Z)-F34#/3@R83$)8Q@.3PL=;B_$!-
M0%BX#H\D0XEFZ?T4:0 [(20>6LJ6QE?"EJDT,7? ^PW3!@&#3=690+8%O59R
MH0'AFN5T,SNK'6+).< ]K%VW\J$ ZL>TKMIKJ>,R];HPOB1#4%-\I8N_$=OJ
MSL+I0OL5"-!#5)()*^X5J5#YK*<@A2U.C,)>$WZ_!T V.IUSX8_P*/&$BG>K
M[UW/5P<SZ2RT+-D@Q-%2"% -.#E* /W!2K 33IBK,"X?F(N(!F?P9OCT^7,"
MK/0!F!B_>!MNB:?\I.'67.7Y5''E*T87L*F%0F[@/V$+I:W(XEZMH?O,^\NE
ML'1L>#!?\*:=9>B;@^Z'$ 7]O6R;Q7_Y0QNT[HO%FYOK[Z\77[VZ*2OHJXJG
M^RNT[/]8+/ZWV_OCVCN'M]>+OPX.=$?Y&V_\FT?"AV+QZJ9RF\4/']QJP.FP
MUV1*:%;?LY'Y:_W5>W40+FAOH6;]E?X%/_>O>K/XJ:KV2]=NH[^U5//6N K!
M.SMT:&RP3(4=S%GYC\)HG)*S(U16YGXI_C"<:/(O=R!UA]^N$N5Y8\\ZJQ9P
MUHQQCJ_6M/%U%RND3^]P, 9K_/B_!3?HRK:D0;=B*CSA@9ZR>R_DIN8&9591
MX;ET-AF%6!@&=O@T82Q0:98W8889P5/(+*T7P6_2R'42_N"QY5T+,3:S?J=4
M_BM4R6*2/8%=Q6QH8]!3@V,UPYYX3X1CG9^XO%J+!0M"]86*2X;A5)Q>QW_S
M48H_D.CAH[JDRD-6P:"*".R^%2![4G$ ("6Y2;B&"ES1W#=&H]2R.7=["22_
MU!]/,D2<@<>)5!CY<AU!2.7#A:P>K8W'4,-&6(1[S3T,GJ'75>LD.Y/I0][2
MA1&\*V\S;M\AL9R>#):(QK^.;5ON#*H_?J.:?:A0)(JQML=T'CX#EL4@.;Z<
MG;4BL=2:^V5^"S=,\(N,W&6/BC(51OYY:V.' _9)/;#3=K0 Q6BA0R!:I_SL
M&L_FJ;!(-[*#.(W*;WU$(,@QCDN!:O\@[[!L(9/+;IBH:3(:V^Q0\'M3WC8P
M-\<$UWKI5+.-Y$EX.<+9'N4*<\3W$/F2^4V^PZ3S#4DGS;S)#S$:_<D"^2.A
MJT"$@H=#HIZ(].Q0+3$"*"/.,!"^T>\YI!R0*2>:G[8_*.Z"H7<+ (YT0"K6
MM!66>X+2E7>]S.JV<P[HV\MUC43V<NZ3KY=S'WT,K;O0!6)0Q(N:$X:'D##\
M!%$@@'^(%<="@0+;/L9*(BT&.@ KI(SU?^P'CAO\.0<U SSL?,[PS]>H5\!F
MB!(%@1@YFBAD%@#Y:/2CZ7Z0PRC=%UB?]>?@NZL__?E/Q-GX04ZS_$:#;W!I
M+;D8\H,0 :OVIO :\64S/(#3>_EC]BQ)42@(:+QM(Z*E"C@8MF6DH3=T=JR<
M>1$T7FTK+,3)8)$0H5@FAYJE9B ,-@I].D>W]H?/,6(=C/@*(1*K9EGG7XF_
M'4V*5:=T0&QL]-/TDOJZ_&?\RW2=G?&D"7:ZJ/GD<O#OO/'_0<B?NO(7Q%E7
MM?$(MYID0SC/MF,V<OI@35FHSS^&((A"'.:;[)$8;_TJ41@N5SX16 =U/CBF
MA#<T$A,!]'E=BIQ+XY/!I@XG&_[6]>(?3>O@.1 ?SM^^?UDL?OC'2U-C-4SG
M5HM'M$B&D9(2T7.UZZ[@TC Z&U8?@RW8+?[>-.O%*[GK-T$-9H.#U'BS>,1[
M%]*0/$ZLZ$D#1,HHECY _)5N:!DC*OI\? $7V,B(V<P[?WA)R%NT\AZ2^A2&
M>IQ410LF\I(*3(9 E,0RT397E=\O_!,J0(]UB'ZL]7C'[KEL%6S(9%-;4&::
M/B7PW39=/WHB%+>X]>@;P,=F!7S02!OX/7A,@(,N]-6\H]/#?[J083CQM>!^
M418S5HA:-S!/O"(:7.XEHS10,19^HX?HMQU11GGO#;Z_]O&:,-W./O;SMYAK
MX/K:(A?9VD&O,V,SD4,J C<(?<'V]'+?G*+P/1&7Q0RX$ATPA7R(G::BG0A#
MO,-I1R7]2T*67!$H&56LU"?1NI#GJ\"]"B.GP-H0]2?D?"%JQ/@ FPBF^$9L
MR-3U?@$NB23YJ>+#9SEBV67(*! O0 ^X*$YE?4F^<518( 8.\^L/9^/-V-$9
M._J1V-'G,W;TX6!''^7A>,H'8\/I3I@BL58$0MK$0L>\=T1&J6-)6(T04CH?
M)F\VUZB*/NRQH^4_RNP_=*C(.;%"-1Y2 Q5*>SR!M)51([7O6DI9/F0LWU._
M1?2?E4V7=317#<;5/"08LEI_9,4_[L_=>3I_G@/\;?8?=BMQHZ#$K+'A>?)Y
MMA <MF?>[XB2!*)?@0)IFWLVF=EDT&2,LJ>I;1E]>]+=G<UE-A=8*+88MD+4
M323!K-W@.B*]1;"WXGEKGAU" MWOX!.S(<V&A+PPNQARPN$^EMDAD*<^HPS*
M!\SZTBFLROE/-0#G_[VQ#A LDKKX5 TTY/PC4#^D8U D\V$CJ3,&C#]V'T_@
M$RZMP<D,@&#8620OU@V!0F++ZBI"/[!TQX;)O;50^.,FXI6/&\9,:2YPADL7
MB%-<!OMP9%Q]L8":!XZ7((8P1$@,_X,V<B:L,H=ES.M&J$LMHQ91RTBX=)G%
MB*<VN$\^+? F=H_M6+>>I%=?LO#O^1]TDW5H+E%GX8"\#&MKH.?1PJ!3"[V]
M(TO72,\YIHV7+KI]9]&[PE+LJD'!.1)<C(P3[UOE*.+.T,&5_ED3(2V]@Z$-
M3[55TZ.1#7P A/7-&5 S[D+B+YNR]TTEXXIF(JJ6COGXW5+#C;J$6\0+MX@U
M@&&7H9T[Z+\2$H;;!&2'*I08^S^0#*"6IYDO6K?#%O4":BOE..ZU@$49DK,-
M-P.I7X^_$MHC?''BTP-38N/1[6#V($+-87H(2U0))W?&8["'X$N0>->$OT&X
M#W4EZ4+X$T$5IVZZCKWJVL%,(/R=(  !/BQ+P)G'X;%)'/Q&YOQKP! E_Q=X
M1 H7X888ZXRB6Q3_GI$L#4W!^T0& 51%'?'-E#E.&+,P8!F+YAGRZ7ZBC34
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M/VX,K5Z6*X]PI'5=+H$;L&F9^1%RHVVU0J/=4UV$>"?M//V*N?Z9<%D8&AB
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M0KPG'3>S;&3*(R>QG-C\<#G65(1-2$7E3G^(1$4'V#3T)XE3L&<9J'HLXZ?
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MDL7!%?<9"3FY0@YAQ +C\Q/[@65LVY(:LKQ4"NB9OF.#SPAXXXG4 $@W!/;
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M><__!AU3 SWCZA?3+^#F.)?YRC:!X_;&_W=]C,#PWL1**A"4B_VP6T)[9K.
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M,2;!$28%;S#2)S:,YB>FO@(0(\H]F!(Z8@D?\4,O:*LT^Y"4CQ35A(F'_(#
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M'=XK3#[ Y0)(LUR)_@#>T7'*.60)WO0E90]OO[*;"L?)_-_Q_*3SMSQT$CU
MR8'B^$X$J_ 5@C>4AX7]8N!QP4<(^LTR&[9S)8E9EZM5TZXCWR:/"C/RH69!
M!FYK=U4_L.DK%T?B(V%]%D.&73D*V0CRVP<IWIC0@0, '6JTI1AX6;"&]-=(
M!1F>ZLH_D6(<QY$:28CDL*9M @TV0K8FB.,Q@5D%)4J!'PE9TDR\_;N-A%[=
ME$@S%"IS=7DW/0'L_P#FBL7BN*XH50 $9-Q('WEPED'%?]O[3H<.46:_2.M;
M0B^KM6$ZIO>?])WCEP<0O[Q$KFK,,$L1+"1WS5QX.18\PS<-KUY8C8';W96W
M%0ZCF8,M>]P4!CE1FXG?..ZG?K[E5F2[]ZO+4_,=M?OM'_2-F3J$SR!S,E;=
M>! $00*X:YAN$3%+D&Q# R>&2?+N@D\Q:1O',X_,3S[*\JIQ@J[B@5-G_&$7
MH2 C:@W[(9F*Y"(4\N)%=0JJ1'2($6H112>(5 -9,5%$%)@+ H91*"(8L@Z(
M#N0KCRC)$LFV()+VWZZ\.5Z]W<&.? GPCE7I8V@:\'CI/>E7\"'F8<W\77A9
MB\PQL<*'N:923"D7V51MUU,Q&:XBXFLX'VL_<B7896].5\ S)9_D1](=N][M
MH "$2CB7?9>^5.!<^TX;)9D$?*/DJA84N7.L/T<W(;\"BT<FK#(7DO-!AU$T
MB7=#$-;7U,X)XYP,CH9+!HIE@=_<W3A<I#3"]*=W)4,7PS>==W65:R=?>?X1
MZ;-A)!/*'L4*,NIN_;WL)&O J6O]<<6*1E^%ZW?YIR,!!N98#.;T/[]F-:\(
M3:H@HCO_9%P$ ^.1?_V(7V45?\(E<^KA-<KT=_04KZ,^.(1";!]=$"):-=M]
M]1\(YVDNRB\>5B8> 1-<-/[P;CB/9MEJ@WJ-'DKGW'ONSTCPDRSN;86MX8QW
MF(S8=D!:+BSCP]YPU=O6QH9&^PF 5D*]OVKHCG!@<D-UW-I(-F"2AO)VWL;Z
MJD;/4R*=_#0^\([ZJ%$N.GXMM*GV.;Y5RSL:@]XFQ]VC2].S7$1">OQT.VI_
MA>9:LE)%2HR(F)-:!!0/<CX5DW)&#L?B8I+_AP;;BD\DO^3$(.VHN:D4$.>*
M'"=W99ZL%MZ['#4H:"%@4KOA0M&2 +&,W*202;3%\.=G=,?%Z(X31.MD,3#P
MSTFVP2Z('6"E C5??$2!W"]F:IC=J S8RBC>;JA!RWNQ=^#%MD,=I^%8FJ*@
M)VV<]GD+%G1$V#S:?KMUUF3SUFI"BC-'O9JU3P'V-8X=PG&CG:>'$Q+/<- 9
M#OJ1<-#G,QQTAH/^HGOVGOL?J.WU[,G3K\=X$IJK[*BB>W0D$;->MY!;&"?>
MN<CAJD@4U\P50(K_N*(P(#U2FDCA=Z4A$J!AAJZ+Y,4PB,0U483HH+T*I$<5
MM'O"V(!PJ&$W$XY0T#[_NV15Q=0AQ6Q/V$RM,:VS@)U/D9R;UNLO3] ?SE'V
MQ6Z3:%_XXQG>"P;5;X<#)/XP\>S#VW:H$?-!IHECKIQ*=JOF8.K8MN$>H$/5
M1 >2<U2?:>[Y<D$N0VH =]B'-%<(3:EH6S,8#RP8*0'5?H_2DH/B@>1&II9^
M2I* A416S6XI(E8PED,;ZJ;T?T$<SSKW<_FQL5!;M8.>.A[=0 Y+*X(M_;T3
MSGS_RZ*2P$T%IG'$M_6JV6];;#GAVBWS8MA[#+'%9C.4Y CS%1P5=<)MR9?\
M @6O_N=;KK/$<W(+E"X)8$=ZGQ-/&9RC'?-O(C*,D9Y/H)4W<GG8X^/K):I_
M/VEVS0M<W#1W8M?8KJ9G"+/TG6 "DP=*3ZT8/UQ)F"FC0+:!W:'D0H3V<\RT
M(]0DL-%8'XF)2/J%JU!3S113#RA@S= _?.2Y;A)FS'-#\G?5D&0M,"*<5 "[
M !Q'C4$C9:XH?S:)3#F(YFH5+FD0Q5#GFIN&#^&X?L.^D/<]H-=(LW7C8#%4
M+0'SB.JH3)QA!J8C@EH#X..S8704T#797<5 C1_W5$;5 FI:UDC8&+"'Z,_H
ME5FG#Q_QG- !Y@-6E9\]88TC1:Y2';_K0[D#6^X:HT.UEH)H4DVO-E#&,S">
M%"Q&53^ <\'=@YWC(]P;Y.W0!F2L"6Z $71->$1]T( LDQE=>AX,>:7_I#*7
M$:#%3 -(.W&R.WYL@HH7;I4HV((87H:2,?>@4$OC"3[6FS;H^K+:*N8QN:]0
M=Q9B/N&)**W%V'NX(* )QQJ#KB\U#WR5:V>Z360GY1I*/Y@WB ;BFW<O0Z^-
M8#JQXMMH(RS=L>$,R)B@@)+W'8*G +G$H28RNQ+^(TYS*$/R459]S L:72_>
MO/LATB4+T? =##+IFH0MB'_R?;5?"UV!U-X#T75XKPNDE;S%]COQPE+3!D!.
M]A'+=>.>O5I%^!7*;I&>A&OQ(1F\[$&&H;-(DVY:KX>X 3C8Y=C7QD/>JV&0
M3?Y@;7E__3Y0,!Z><1 ?T[8SAQXCNNSSP-9CM?*QV=\K6"UNA>BD"V,SHJMM
MIAY 8JCKE0(YO ZN9/MK8(B;&2*3AR).9/JQ4(1+=RT-0"#9O6G:'BGD>R1W
MD":,@C5C"F321;,$!R]QE@>CO>)BC&FIFM>:F8=I YW=D&T[, #2C'%P2@>A
M_@=BAB$E1'U?$4FQHO"R&#W*WN9P]&%$733BR8Q>G)"!V\-SKNS+A="9(_Q:
M:%O.*QG;G$4VO!%4 $_F9MK!!Q&0A@(%:S%BCQ_'H35P G.0ZJ=*'OSM^Y>6
MTE\.,_[K)48RIGDSW6"U&^<?4"7C:Q(O@Y$&\,?W[;!=O,%ANU?F.(%E<\+U
M#LZ_?^*\']T2U%+]CS[]\[?/(SC0?Y7]ZN;JI_*#?V90@"42I"Y(-4-P.?&A
M*/0I<8UR[@X':OUCK1H"XK(+(0L>?4FTQ&(P6"HFJ(';_]P<W3H,7CI\!>,3
M3.'RL  NIF#LR 4ZMV.4X"@HB+B=Y!^I7JUG&88-3Y^G<3WJ8E" C>]=[(%[
MG/"NY>@Q6B<Z"0ZKXZ,*/\]''T=6$H1PY=Y?&)X#O'1\T*01B(^06!"KT97'
MD@XP).C<>WA(A7R!G[2(38>9OX0B"@M6/A@<Z#KN YQ_P.8/&A@^@MXBQX%Y
M41)R^!B.I&0GW]KHXA"24D42 OH ]5^[<EV#@YWX!B$;<'7^S6D"I&#]4+!L
MC0B-N0P89K<Y1N,%=H;*R" G4P@8@PG(ICU;9)8\3'%.B ^3X4NFZCBI38%'
M%DIWR.^I:8LVBP2I(8L"W&KNES(S"4'VUKHY_H@->0)_F6FCA!<0AMM^>4$O
M/*Y/>[#.P=6G#:YB@[7(-PM1XZ2;TPFEH7B_;^YJM]ZZ)*1B<9!Q<5 YR>80
MZ^&$6$F/2X"0$N=L. NTO+W9L0],GXDUE&?^P#ZN;IH[ /_Z/]8UQ16Q797;
MUCFF1(!:FR%Q"']BX*- .D&E=TLSE>8S-.( ;1ZFM0-F%<#XUP"3DCY5I*PX
MJF@;6";?I5J[8: H%MA](Z]VA^-L(5$1;;OQ60)<%T$$)FA (AODX_**C[,9
MC7S6Z,4:O_-)-H/G2$=VTQX@& <_6-?E$OZ;Z3%IV+;#X@,"+I)/O/KG:S(\
MHF0)NDE(<VX,LH!V6M6=4MNB\ T HR?V34B-L-BQ%_B#\#M278E_F/DR!'_/
MO=F;ZL#[9^B$EM7\@&0.Q U>UZ>H6:!1K=/\>B0TEHK"QU1EY>\ZD$XLCPL!
MUH/34- V" ;X7QYHX!-!_$<;N4(O-?#5Q*1J]N;DWG :",NE[]VA'^]WV+_L
M@!Q/8$?^PGU8P?<L6H 23P@0+?( ^Q8Z?&6H-J4Z?N+A6E0T/,[J-H@JA@<B
M:"'X4NM2;#93B&'AK?9)%ES!O NHRR%ZR7!_"&8&WL+#<48SR',&>7XDR/.;
M&>0Y@SQ_T3WS2</D:7=-BY'Q#1PZ14 Z." @0[=*]1T,)7Q4H1YU,HHL)? 0
M64[#V9"<'VD@FXD6/O)DF9A!Z%Q[6P&&CJ^R/KE:JWS*1;WM4&*ERBTB)43T
M"$15T5#Q(PWA78G*0"C?"M^$ @=^U3]*_/\WY=KHD*99Z3A1@4]B?XK3G(!A
M-8G$.94\4X'K7+VYHK@,*]%<U<EG)5SJ S^SNL&Y'YJ;XW\G-4X,2M#61#N"
M!5^2%ZRB,/*Y0'6/UVNM6,Q "8X"?'&1A'>$D A''.G%,':QI.!X@D3D981:
MMM)\>&NI\6%DP:'4Z!W9D-$\CPF]7$$,*7A@(TJJ_%0?6\/N43K#I$X@"0X8
MR<Z5D+!3"8!!*5.U),&^9.I)UBKZF[89MD)98--F?T^K<F!, 3D0[Z1NCIT2
M <34 $RP>-15&F\E%0JAP5E7T%8&LIEP!Y(/R=='/6FU3Y/J2]5DXO:N%Z^!
M7B%=F;FTXUG)P-&/C#=R"%!K(U;_# W_<85.7*%?,+<@<! ZU)')+Y$T-6=5
MBH5%ITM@!4.GN0,>T+TV2F#95D@IV;;'K$+7>:\=8(AV%#K.'*G=CXBB'>0Z
MK>U/R:,<N!T$8%V2O!9$$MTNJ57LM= 9V>ST(:[M&K0>R1PAC8H5?T6Q0F<_
M0/S*7J;L3MUC_*HFT9>K3UA@G4OMGZJ2G!%7(H4F%3J;J%A"\TM*1*1.W3;[
M+<E3#VQGP>A.Z4F/]*>MOO1<AW\(YRL1]C /;R##21UCEANGXK.7[,A4B;I0
M(0JL\@U+]X!K!*9"_T]L@""7OACVI!%#(:>6BB"FK/HAH3J.5PA^<I)1*(#D
MTA9F! \S?_!!9]W?8!P0 @NWQ^; N;V#QYEL'B[-R\SVE"_WZ]"(0(8C9(JB
M:C$!Y#Z^Q0IVP_)G'L59Q=+OE!AT+GHAN)$-$1^]$"-A--K8$S1+5O8^4HO/
M4<9'>:=M/8>E:>74% _A2TZ?<0LOI&OTYE,US*E',7X(8)"L4(X)-K'P 9E?
MF@W2HT_6$8B=>P"[XB.%B,T?Y(.SS,)C_5">[<?512H"B,=5P4UY/(*"KN+H
M]U B,-=O57J\ZW)7;ETP"\QZ8&:'Y]-.)):-H6R/@"#(.Q T=>/UC05!B[&(
M>(C'+!LX#5K"_D!U*"&/YSO37I^&TT;/_7[<\@^#9+WXE"SK:,[XV8-YSI^"
M<OU=GJH^I@'_9<SKJ']V+^;U(LW.[\NA;E38)%F8X.1/^,X3*J7N%Q"K7_:#
M]R18CU_!";IUUN ]8B6O2.:>[T^>?DY7(=X?&:?#?:(QTSI;+ + -](1GXG5
M'T^:\2-M#PP&X.TPX@%C@WVYXWD(V,5C;41(4'LC@)-4XI9#!5#/$J<7D(-+
MF,3@%\D4.C'/%@:H4BB9[M3$RF84T,/(/E[CV;#UL0!6YU%ST_QO8U1-&]D4
MOU<5GX+S5C2/"FZ*0P&&@UKG@Q6X(,_)T+\I P4=M_Q]'DMGCFGX[4C.PYCG
M6."3 000[T]NAT*U4 /?1=[.2W].;TV*HA,Q4)/S1XX_G"A/F-@-/FSN$7>*
M.4J4]^10'U@A6#>'/GK03;2U97R%)U8B3E^G299QWW1KRQ:15&N&4F!&Z>.$
M:NDW9.W*-5/@,9DU5!2&KCHKF*,/)JPW6NXB$J 7&6DL\*+@'9,PZ#SZ:<.C
M_\45M #4@>%(H439<*QS?WN^7KQ6QOR&4>B%"<@#6%+IV,;V0FS)H@U[P@!/
MN%PY;DU$,@;HGO"J6&%V@%[FX2CA06BC[6)S1-XZ!DH2UE[$22:0ZN^0<*%D
MJSX<0SYS*@#1>FX8L0W<#N<2EDB]-E:T.1'$?#2<>=LV=SX%?8@T!3,N9L;%
M?"0NYL6,BWDXN)@O-ADY5?+B<JS0)@"OO)"C 4S%Q!,WD%C/#8H'D2*\PU%U
M*,_"4<E%WPG*BDD<B:JS=*$4HM65D]_ TA-.6)H36@*G<48[PA\?(,GHF4I:
M9,=&K50?0/BHPWO J #UEP=Y\+.5@$7\Y<7UG[[]TQ_B4S\QN.SQ[H.LMO\.
M3>O*W\"N^PL$KS"Z-S+"L,*OK[_^\[=_^*VL\NOK%\^_>?[T^;,7+YY]\^3Y
MTQ?AMJL]K/P*[_[$[8+7_O;9LQ?JMLU#I=]X^N1)>M7?9M-=-*U,-/>(<QBP
M'NDW%)&B"/D!>%A+EV?2[V75&/4K_"'HMG3?!<N# RT<:[,%_JXLD+N@2:4=
MZ?NQ2('\TS#<U2,?O)JK:3V;8L5E]@SI.G V_2=\]X0,T7+HPV_!:8 CV6%H
M@@L.$6U0:-(R^0B-/F M(NYKSOM@W@>PT#M7Q+($+JD#AJ8YA4;)7!AAZ;2)
MAN2[_6E%C,Y:<DQ>2Q$--8-SA+@9Z_:67<0HD-G.9SO_]>T<)49R-JM,&I(7
M<!V78#15:S;&;*RSL7X28RV/A/X!_^L<98W-LN9NNO21B/K'2/G2Q(0@A<9T
MPK%A;X8]Y\7I=9#,!: [H?="K0?*68?]%)<S9\7S/ICW01*D9U'DENZNK'MO
M?@AH,J,2U&%<#V2VSD+AHP\!**\9^JA).[09P>A3Q9S9;&>S114-9&3@#K3!
M]"HK_9@W<E*:/':Y&#,T71@^S.9V5#B!6 4<,%+\1U'V;*>SG4[9::\RYD1F
MQHC6P%_3V3$D'[H"HS'ROBCY%A&CEFVOD 7Z]]GL9K,[;W;#'DVNNX&QC<3W
MY5RB]#QHYAN!'"LS8ETC@A6@&>0"$7V?<AQ., I;2?L4FC0;\VS,I\YZR=&,
M?,IIE<]% WV\,$WR5?='NEIWHQR-@//"@7;1.80/8<6+***GO\TPK.P5!#$(
MVT45(+O,>CO<1!;7W>5+'@1XO''AA$C2OGJNR\W[A_9/7/]54HT&<',*>N4V
MC;6H(K8G,#"5V(*# ,A/[319&6C<@W"#XGL[:>\;(.MLHK.)PD+C9ILAF<T[
M<M)/@0$C@,&2?1<*Z<"88R+@F UN-C@Q.)(UVP!HP?F';936#5''*;PST_?D
M_K+YF*JR%'$[U$W^0&9/BC&RUI$PS6S0LT&+04O J4[T_A$R10&( ?)7:^I;
MS>?"H5UH;5@!&S(1V752O%@[X+3RZ29HLEKM02Q=\$_<-""/CK"0@=L6JX:A
M] "ITQUQ+J[?<WR-A%8(YO!;* K"YXTR;Q1J>*2#P-AUEAGC27[3,-I,O'=R
M5*0DSMBZCCIMHDRV5Q8)RQQ1^Y^#P@JF>T1*%7X)20AHJ^7DHXC.K"1@'DV0
M_=RT!KPG(V6S[<^V3TUOH5+<EEM)XC)TU.A450.6AW*QX\%3Y>BRO<6C'IMM
MB\B<61S76(1>N?ZY7'$0E)&:4#B>\&5',AOF')EM>K9IMFD)UX.)"5UGGBFN
M<L;.R)SF>MEL4>>1\V)@,KINT<)F#IOYD&S42H.M@0!W1C/,%A<G;VHL2A]&
M],4@^&0&DKX#:YJM9K8:/?E6-PW 5>  %(QLF<F2$SE>GF)3-0KF7_-9"31S
M(?-.J>&,* ^PHAF71[/Y,'@/4F,1>@PK#Y-+8LB#B')@W2M>R?64K7^Q;,EO
MJ9M86M)L'-#R+V&U&DB6[ACSAXE46H8\[-.HLLW\!3-_P>/G+_C3S%\P\Q=\
MW%#_U$/X9]6][Q;_#,0W/PCK^C_P_/(^]Q_ @@E'W-^1%*98_&C*?^]BDEZ@
MWGFM/O@W("]X_%0%GYVUX2?+B,P'L.@W[X?=$GK/D6R7U,2X1,;,K L"VW=R
M2!O&+1]Q"</ >W_4LV#(+?,5P2QLC\2KA7P2"0T:_Q% B?Y[\,M'8;' #CO3
M8#R R.XG0E_>^,>)$3+/6AB*5Q^:'5 5 ZQ(NWB&1A<5RT/%MG<ET/<:D4SM
M H I(4$LP'P@CGX+O87Q;\"*E,.;Q<(!'U35=<'JX* R@<)\2DQ- 3^1[X')
MP?*#9"!J%OOP%7CKD'B/6R.:=/#/@&V3B<H/5<#0#3)X)#4>!DG,%@C%%-EA
M)%Y.DT^;6(*HV<2!-/V<$)<BXQVMOES=@/:F"/HPX2VV@HJX#T02M=Q@J?[#
MW*F8L\#Z'E"D_,6F2/_T2>E0]31$MV8G"/\KN+ZP28K%RJ?HP$E=&$E-^2YT
MSX00!EIEV(M0KFIL>: R+53[@ 8:J*V9ZYK]^!2U)/MHL\+(!N'R0'VS D)H
M^H[?3MUB6]TZU>2DCI_R2/K3Q;7-T*54^<C('='I*WD^M0B%I2.PA?_$BKON
M PB:HZZ[_;T-0UM\BH_@[8WU.K@%^)FFQ-Y6 H!O/:,"D+!"HI 4*?].$?%;
MF.'44L)GX?%W78525E#W@'AKJ(/2S727-[N[@>:\=]LC42->LD2T#]M9N]H
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M?O#!Z+YC87@,P;#B<SB EO<-(AO;I/(9Q32%E"+I+XXUPU=8_L*W("S7-G!
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M\ER*1F_+=EEZ'W'U^D/M#ZJ7!!-^]N3)L\573.#Z]O7_:[_)+*XJ=LYE/VP
M^47L!Q2D"S0_P*C1">T#MMS%_^T-]=_%]F F-BT7%$09."E!I%'X/9=N&"4
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ME[98[6,\MW= 4@PR>5!T*@]ST#<;E9"^L"PWZ0T1:8N@?U'TL*Z]#VNY_RP
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MM=4Q/SRNW%Z*6Z0.46%9HUO533>T;DQ0!J(0%VU+.*8EYK-G\]XQERHH6!E
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MJ2'Q-1M-@1%2'3IGD$"2-EG<J"Y;BM936@IH >0]U=7^\26<PT%FJ=/![6(
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M\/U=B]7&!8"&%7 O!&()O0I_C<LO2)%NS-(Y]#12"5,+&H1LKJ[DA1AQI,Q
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M82:F=U%#)Z0)1SH1 .DF[$+*?VD,0N];_?U1/DW"@=J)\Q&[-FE$'?D"5$
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M]<'^9Z0&TO0DF;/B5-2ZTD4=;(REUIGS:?WHKAH)GCIS/M)(%U;/))'VFM9
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MS3>34\ZS>S;?)5'4LG'.+;5<GK>(@9^@8/?V F9W56GJJ.=.:1]3LZ<LR(,
M]/IY@>>!:_^1XW*SICNK O?-\_LURG2I8;_DM%4B9(VJ'[F)3USL>]LL]_5I
M]%:(VUJUM>J'A1ZZ,:8N#L)MEOMKN#\/YAX&X_[,5]99IV>GS62XJ(B3P"4!
MM>+>&G%;8]YEZ3[#F'W?C;S8C;V!6;--\:RD+OMM*7]3PV^=G)VVDZ'B8NAY
MTLVQZ9SM$;8UY5V6[G-<'&G(Q*5X8,9LLS@K:<L?TKOIKF.K(G3KXJQJ**N>
MH6^8*:TH[,=GO_78BMV$8M>+DM=0F4=*"W9#:39#)2QH6-!X,= @+J&!B\/U
MI9QV!C1L6FHEC3HO)VQDW;3UF _>PV _O)S"U:0WQ-S7KUAXRD)L/?SZH4L2
MZE(:OXX";1<"6[?-@H@%D<<#O\#U)9#XC]^C&"*(-&Z<_"]<V-U]MN:%KLB:
MYQH:<9A^E_6$70I%*#1#$C3;^*EM ,%&FO%(_FL*K0^:UN45=#579/0YT"K+
MAU831<$]QZ7HZMY:8%GR?2-VI[HBE'JDBG3#50T4=%^!7M]WW1]*/0%F6(RG
M8F; AKJQWXC;;9IXPR_*EC$8YO8S<*<K*LQR^2)-2D.2HCLD3DK=RTNW3F?C
M.TW*9!I)SO:^4)1OL$1J6&.'F4[*\,U<M8NKV_:7^AM<P%*[SDB,+X$3-#?M
M,E17U.[+[7MJJ2]U_S=M^T[594QW$P;2>/FJJ^)&3\&T(%8+E0+]1D-]?RW_
MWOQ[V8(K28 HVX[G<H9ZJ'>NX;\"JD5XUG1LN#WVG/<B8]#&V<RFX=!7ZM9(
M:W'AI?2O2Q"+(ADQRZ68NC4]>]/PHQ*C0K6C <YWZ&4ZT]O>="AIY'LO%59+
M9]]T*-$TH'FC';K_F_QB^T'YZL9PM'ZH[];3%%H6*I8N4(RQT+H%3%P3I#O3
MJ^6N*C:^U*T%%$6?:NY:"?E"X:INGRX8$'2O!,I6G?"6JU-?J7YKT+\;EF%4
M_ 6]6W5GGVO5P6ZP)#X?"PD\;6>C Z:[[GT6M11\KPIB T8ZF'Y!"^3\;#R>
M0E,@#<'2#F;8^ENF?K=IAO,MI/R HLO8_56/@*Z%@QI+\U[5U /L736Z4<UB
MY?#T#7?5)>3)6\Q,,_H^BLGU43@WG=G$# 9K&F>YGP)N&?9._;J%W5(_']A"
M-,5@U[)'F7Z5R;\V7=!A(S 0O66M"K92S8_'SJG<GDP7=W^^-=;8B%CN"-)3
M+C+@3#7;0NX$;A# _Q.GOF*5=K\4\[04:@GS*+._7.B+PA:^?5,5F>:*\_&>
MY\&%/OT0O<U?JF;F2M$$K[L&H\WW7>FMP78C-1LT!9ZHFYY4NI,R-&P"_TSY
M6=?7A>G=U!%_M0/I>'@5.2R;Z2O^/8GVO*Y[AY1!=C7+ARZ^@O9V#D(["FC0
M5=ZT34TSY5@J/.A\4*@"DK)M5L\TD%FZ5,W+S4?56*7G6=SJWDECYP2:_312
MW'/^?(G5B/;P3"L30]4KWSX6DTY:X%O.?C&@'>GP8-K,2,MJ\1Q[?J),2T7C
MFMBP5-JP2&,Z1U\J5U>+?LGOU+=5YPGP<@L.?62EAZ=17C<C_^__2H*(_.+O
M!3-]:90B:M;5^8\FO8\V!([S&\BX=7Y;K[1KW?58IYJ6YO7[)/&5 1CCT4.'
MSG%M^YRP4[DYMM@]YU"W 9#/]M2SE9KK+8AWXQ)YKEK10;_K2=.FH^O;YC;=
MWL%N5-]'O9*\;ZC2;2VKIDMPK<)$Z;%#-[Z[96*!5XA*-;G2'GTK9=.C67'F
M_J]N$SPWZW9Q6-T2!>MY/M*,R*=-,R)/O65D*#,-GZWN/.S\9RH=>QUN=2T)
METP!Y*0#+-4@43HN3%J[\^\IOU1*8)XJPYRI5@FC/-CUDLB-?6PBWQMVURC-
MC.R.H8>F-"'S\_GGFY;/NDESPS-<P:PA8-(,ZKK5HODQ,US#"]#3IR,V,3JP
MC,/IG2XTGLC_M'K=A==/HT;O.8FP)S1CO3:!:,I&C8G)@00S U' V\23S:S
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MG',HTGNY$XJ;2>-<WGL*88Z->L-1 :@./V>-0Z+'2#7XD7C@]/IDG$A3@*B
M54JIY;[U1?X5?2Q+A1IG[79E6FAL3L[.$I1;@O(5"<IG"\XM0?F+$93O[*;T
MN..OC[G!^2[JO^3^+S5B!%K1]C_Z!-4'Q^A8XJOC[^\U@/Q9?MSYH,^4#>8^
M)<S8'%P>SK'N 23@X2!LOPM</TD_.&NBIR-S[K_E)[Q;V3 &PNZSHP-U*"N]
M[,:\LD9FO63#C9%98VY0\W+5YA=,YD%G/VYN1D77/.:Z#0/AJW[\2RU#P'KB
M\ )2-=/1!**6]-_:AW0AQ-!G;U_;3"BTP94[S%@']/K0I<F:CDWR_YK])=H2
MDB:MH4ZG\AQ.CM5 )NI(2B<-5.T4E&R,)S(H;9,PQL&4@?L5%'B *]U+6>FT
MASV4?275U"F?5I-FDL!+LT526O)#<%!1J*3@Y,KY<^]LSP0@D'W000-$ESW5
MEB%U5DB5J]LNL^I;O^[O?VK[S!H-KR$ 7:)OD+3HFB 9'=.JIY-+L!O!:]5I
M03V789K/*)GDW=0<*.OTR:4JY[OG2Y.9S-ODOG1:N]\N&4\E3*8!/M2<@O9/
M7O27U(HI.]#I8J8P )"@6PXX/2EJN3LK%%%-J0NA,L4ZQFLJKQ:7K&H3T,JL
M54$BJTM=+J9] E4?5E39]+I6T1\<MV63J6Z[+:&AAJ3;B"N $55S<#XS0&O
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M<S<!SB:D Z**H70E3>=:]XK_9DH"6D=4_>X+5#;V;+L+)>  4M<IZG&8XWM
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MUZ)^D.91C#(_C!#!)$1,\!S1*,AID/A1F"Y$<2L3!ASTO>"N/-Z Q8'!BG.
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M%B:(>(&/TB3*D1^)D,0Y];)P(35%(R]FU/,135-/1FU!BAC)*.*!1Q,116%
MQ+.CMJ=UU(QP*$,W.KC0S;8PMCAK<7:+<#8) C\)4A\Q3@DBW,L1\[( 13'!
M..*8^#B?Q]F,YSQG(D5AY M$2)@A)L(4X3"-2$[E;SA^)9Q-L$M)["81ME!K
MH=9"K87:]4&C8#G-DTR@+/08(CA))#2R%&419RQ/LYAG9!X:$RX2^4%/^JF>
MA,: YRAA7H1B"8F!\+$7Y<]W01_NY1ZX<1RY9(#.YVM4)#Y(7#&4BL03,7&
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MXL2"G@6]%P:]/,8XQP&*LRA%),U2E J"42:R*$Y)&H;$6R@2(4G DS1":9)
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M?TWKR<4-A>T8WV%-J(Q^^T'.&?TR^CTI^I&@>< 5<MP1Q)DG2 -ZH5 Y+#Q
MG+#B,OI5OBQ=)0B27H!>Z0$LE:DL\D:7P@;,J50/1;\;BN81T:LJVL-29(C,
M$'ET$)FMY^=SKI.!(P/'W@!'UJTR@F0$R0B2$63/$.1QDD\Q#KKDTB/)N$-<
M!X<T=@J%DCB!P0X,8>U$@%-+A'$.!2-*Q+FLD+96(!TC@V554D4?[.NZ;9%+
MAGN*/]H1]![A;DXYS0"< ?CY ["PGBL#V*LK0&$N+$6&5!9QPQ3S\(>4U64
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M8WC;H<'O  8?!U&NQ?_'%.)ONA_3C'_WS61<VXEW\8?3@5O]8NG*+:4Q]*C
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M]]0%MS#J8FGGX@:Y^MM\B_K^!W+UN-4@7\)XIN>#5ZYN1GU]\3+^"NJFBVT
MELITUNVK.O.K_>*?TV92AXO96].MR _<*S/\$8</3W@Y+Q#T8]?$O9E&=K6^
MZ^SQ^'-['$JJRA40 $)*!'4V-\E'^JMOK6VD PSSI>Y_UQ?-JY_^<IGR9F25
MUF(S33T)Z=Q:YN^$<.9+NK\4]+W=(C/LNVVLP=_K#_]9?/F/M[^??GK[QY?W
MKS_WBO<?7I\4IQ_>%)__^/7S^S?O3W]___;S0^!SRT.^C*>/L5?)N$G2YA^3
MX3^6I<T_YM+F'S-ILQ\[^^'CE[>?BR\?B]<?/WS^^-O[-Z=?WKXI]F@?W[W_
M</KA]?O3WXK/7V!L?W_[X<L^D]FRV+[]T^=F\H=I\G)U5K(PI28R*.1C[5=N
M>"Q@SBGRBFI12NN%*+=1I..#GDS'_F/X./+C5 &N^:GPC=4CN&8RGOK;H3F1
M]]<7[^E1W<6._D)>%&]@]N-ZE!P6PU#\.FWJ@6^:/:6[VVQ.^31[LPVQ<P9$
M.?)3L+X:$#L#>U+\$LTXBE_%W]-'\JH8CHO)F2^Z7UZWVG_WXXNB;@I=V'X]
M2"8<0/!77YAZ.#K3XW,8]329=D5G,Q0CV'</?!C#T<%Z^.;[,2=Q$CU$D1SZ
M];?XT[EWM8UT41C=@$$!M**+L1[[E+HX&L9)P#MUDY(:Z_/SZ< 7UO?[30$O
MZ\,=]>";'M<QV7$0.1!&\&<-/XR++_,IP@R_S&<1;XZSA/6H6XMF EH<O"2>
M'HS3:X?QY^YE*(XPV3I@*\1V8<U)$9_7#2*--/XTJ0=V4K1?P[A'TWX" 7A3
M?/;PW, D"P?CBT5"S_WY<'Q1C'TS IR 422'=ESZ."I7V(O)L'\!ZUD$GV E
MS?[2_-( 5@8S# &^GP]FLMCT0KMOL$2P8S#DN(WSK8C><UC(X5<_\'!=>\]%
M]+>GD<<QM0_OWMZ_*,Z&YSZM6QU]@D!/L1J8[7L]GAW 3*8POR:M93V(C=1@
M^;KU@J^:Z0@('';T;V-0G8MO?MQ,F^(_ALVD>-.N\4D1J?)_-<5H/!R-:S_1
ML%KS(0,=.A][K\%381A!V[I?1X6@ +CMIP6.KQE[N-M-;9U67 ^F<"%,(5)=
MG#0L%H+9H>;,]P,\$ C2CR] '6M@@/:LEX90&/C>?XMT$E>CGL ,8/!#;<_2
M\WT3+5Y8SS, )EB:.!?8]SB"T:@/_)!H(+1\-=\,!T_L#^<YN4N4UQ'X@M32
M(&#"?;AEK+_&P<=!S-<BWK0Z-Y XVL0%Z:B[>QF,\?O9,&[?\'M<.!B2_V'[
M ,KP\P6P(^A?D0%']0BF/$C;"$!V%O<=+FDSB0<P .#IR'5SJCNY(X@^Q"/R
M="CZN8ZD'9<^?FB%&FP=Q:3J*.5,I]^FX[@\_6$3V3HMVH\1,,#,=0*<.?7=
M=:F'6ZLMP*>E6P;^:[OH\\JR3<N0O@C3" ?%%![4A^$D3([T#4^/'#Q.7*#[
MW8. 4F$:32)JV,\WWOIS Z3&2 ^&3ME\Z XNC_Z>Z7G$K0AV/@ NIZ"^C>>G
M=UC2[7>:UY53VG-D<1"($Q>04A@C9X(TAI74KW?PO4_Q_]\!=X#>W5L]COWV
MFM/%^KQIEV?]-"0B$#RB7#X70>+6K2(9.^';.EO=AH($5_?CPD=B:JOHS#[X
M1;GNO202*9@E 11WHB*15,(A32J!9* 6")U8P>6V.D2<#BY7,#^=O-;C<72<
MII/YV]/)]0=H>TD<QR$ KM &KF8* ZI(E!FZ/P1TGRMXT1D8-P[TN# =1,<@
M*!+6 ]I'Q<@T\(BH%@">7X!"E7H&A?'PO)7ZH&T.)KWB%* >-*85-;[];J;E
M]M*89B^(M4"BS$\/TC",>NSBPR87,"Y05PW(C&F(B-:].NHP3;A(+^W7,"D8
M<U17X=.X=?(GG0:4/!^7 NP[4!C2>-,KOI_Y)*T:O_& H/@.*D21E$=W4OSJ
MK9XV_JK%J:/H"\!#L):N,!<@3R=^'*^81JTI(G34='JSXB9CEU9]H5![4)U2
M*90V7SL^\RM,*%[52U=T9DY\4S?#I%9V9<1\N]=Q:R;PF#B36.E_ N, /3M*
MW^&T4PR3UG6Q(NB3KOUUF/2R81QOJPSJK@E41,[YTB4W<AI1]';%GP(\L.WS
M"EO6%*>#P11>_[L?#<>3:"F]BQH@P>@_3Z*!MWFMSS3H$<;#A@ W1 +J;"PP
MM^J.CL&XFD8F2"2>".*Z\4?" B8#!3@QQWE411-'Q+4&+OT?/;/XX;E^TJG\
MB: Z@$[6WT)'3=PS/#^O)^V(.TT'=A+F WH_;-NX:?71SH5P)(BC!V"O)2.A
MVX]D?9T/091$ZZHSD1;\.1HVB7O2BFH7#ZK EAGYEI%@*T%W=\EB+M(A0Z34
M9,*,@43FCSDI/B6K.]$1++UMC<\-K-F9-0L&2HVT_<LB>G\:[_^,%S63J)-^
M!:LG @YHJ,U9/9IM>A^LM6'G+>O%$7Z/UC/\#3R%6I.D59(CQ4<1FCC]TGNC
MF0@_AR$(HZCQ?AWK\[GZ"_9?,NU=<B'#S;_0%U$EAPU,B_(-4-,W70R9;2VH
M6#+0U?UI4L'G2?6]9!;&P<$+!I--4TC0.0&,_CKI$'!IC#-Y /:FG[3X_ M[
MT;DXXF+'_!G8 ]A(&(SS #&+A/YALCA D7^_<2> DP=#@ 33*JSPYO%P^O6L
MP^!N%^=RH[547+1.X5J=6!Z>$CDKSJ _!$I/6'#I3>G7=DRM*32<NSJ/A",[
M5QFI7C4;B"LY@X"YHC]J".O<M/Z685@Q^%OFG"]L- _A :V39R:-YW*H#BL<
M!D\<3R(??R\F8Z"9)C853&(-^"KZ,/1%PL^D+'2<T&M=$1V1C_W7:,%$[U-R
M9'Q+#YGA?;,RTNAPBX:KMV<#6-^OB?E@O#J2PNK^)WK^"SS?1 YJ9@.XO$!
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MODGQ6T0<6+#6\9%%YU.+SEBCW<[@-P:YQ?T9Q>;$P_/SF?+=YO;W;==:U%R
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MZEH$J>^J$D5MV\%YU79?^\J"_S;^#!=CZZF%&1%1%;/:=IJ# [.HBGEA6J/
MBN!W8=OSK=%E2S7KDZSE9D$@XQP@(->Q3YC2E'#*4I*DG-)496&^.3'B7MA1
MG"FYF+0=\3=$J&WT93GC!+L*%_/+YUJ0?>*!BCC'!G3 >DT9-F]H8MID89D9
M,GQSX+#_EIJ4WUSU]+%63U/_(.73D3^F-Y8</_#S;!S'P8,KIX.'WB(=9^S!
MRW@:I,C&-+W;/5P-N:LA=Q6SC\0)#0AR1;.NC-P=BI9:;?.F?\^KG_ZSZ>!D
M?OZE,0[-+Q_!KKE5UI4[..[@//.#\\D,: 6[Q/SV!KZ CL(%GYC?,0W7_/"B
M+>YYZ<Z5.U?N7'4^FK;%M#DE[^'T%-.Z$.8WX^=WQ\7EF^\K[^5#O]/_?&/J
MVJT:[MPO9MB^R$!F7+G L L,WY"%R1+)DR0A+,,)"RP5)-511B@+\X!&L8[\
MC<"PRA,=^+XB,HY\PN* DDQ(C7'B) MU)#F-=MVKMG>D[224K2,;KAYPLF4"
M]HBR=,38TTNZ/-2Y<,)O<.'^_\=)P5L5Y' &H@\$(,^P)%1K15(6Q" 4E3"C
M3<-DHR3TP%)PK5UWZ^<Q+IX5V?@W^%')SW/ XC@DPP2W^5L,?U6U>5B70>.O
M)M#\)QUG3C@ZX7@+*_?H),@C* Q'!W=$W!%Q1^00Y4SFG8JIA$79N]['S]//
MUS$WZ=_57\^*&J ;Z%>;J^D$UI,P>)ZAZ-FYG1.)/*6^BD@L D%82 7A@J<D
M\6,_Y2J(PD@/;S+1KU59UP_V]]"1[P>CA(7.I''BSVWR<Q1_@6!9SI*<A$$8
MHK-;D1S=WD&2L4#1C GZ..*O?LADMCVX>JZ7G,$X2)W0=$+3&;E/5M0.B@[N
MB#C6>-)T>+3T'N<'PONT@,EY@IPI=*3"YP'<_^*>5:]W[+'#(Q5%E!,>ZI2P
M* 33BDE.=!XIX<=YG*C=U$EC'?3[NEXH^=9,7+8FDK%NZGZ1='?H'^XX\J,1
M39]>)/QV&22WRFMW0G/PN^V$YL.%G&"Y\G,:$ZI#3 [R-<D3R4C@BR#(I2_S
M;#--Z!#^HU;X#<:%Y(^#IS=ISMG'SCYV]O$@Z>".B&.-)TT'ETKTJ"ZD=V6E
M5>&2B9PU=+3"9_ N)$GCG$>A3X)4180)FI$,# CB)Q&-9)+HA&X,ICU$<E(C
M"Q;5TKQZ>#$:':7IT\M,<BXF)U2=4+V+$/19Q'T9!B0,(P%"T(](&J01D1G+
M<QJ&-(ZS0;B8MDC!0SN9@G'&GIP(=1:TLZ"=!3U(.K@CXECC2=/!Y2D]<I[2
MK*B<BVD?UM!]&ZX]'6AW,P6&(;X&[Z9*LR -59J1F&<Q82I.2)KZFJ@TUB(4
MBHM'2@*X,0< I(GYSN[<5&$Z8OZ>;:S[M_=SKJRG*;R?NF@^>L&[75#J/*(1
MTY1(3G%TCLI)3E5$ BG]3,18BS<,5]8627EH5U8X]JES93G)Z>ST)RMO!T4'
M=T0<:SQI.KA)\OOLJ!TZR>3,GN.4,;M/8_)]F@B>D#3&4<NI#DFNHYQPI3E+
MHRCF<B.-*8PB)63"29[KC# P=;!Z+B!9E/NAYJ%*?/\8.FIG+!HE-':6BQ-^
M;I.?H_!+0Q!>:28(XRDE+%8!X;Y2)%-IK@,1Q:&@ Q-^AW;U!&/_Z25^.H'I
M!.93$IC;A\/36 1<THSX-%2$"9&15*4)R7P6*JUB%L?^SCS<^<W2+K^SM.NF
MW/4&W.%LNU6A16HE7LE%A8/N=J=!DG&XG,2T0EXG_ISX&_XFNPDL.P2.B4QI
MSI.,<*U2PG3, /^EFH"PS$*>@6&9J8$!QVZHH9EGN H5/[_M0T#_)@@X"H)D
M%$61PX$/<-:Z\8<-<?]'U:#AO;+RU/>9$OCSO/0NX*_.=_MTU=$S0N-[TT)^
M , ]!BR?Y#%H(9%0DH$"(B)+?!&E>9BE@W!?V!-^,I6_- ?\2XE_<B[=X1\7
M)Q.?P28_*9FH62IT&A*0C2#?I ))IR* 6(E(E=(YS9)!Q+-NEHF/,#+1.7.=
MJ'2;/'!1N=V9F]%8)8#P0+HQ1I@/XHK'$8B]S$\B%K-,)+L;#O( 9^Z=Y=Q5
M/E[J?+S'>&"<5'0^WN-$DEF6@Q@-0Z(R =9UXH>$!Z$D7(;:YTE,@W C7#9,
M)'ER>EJI4X"'S@<\+!^P2]A=G7G!\XER3M^#%)D'XP!+5V6YP#UXGF7FVVGP
M5-4;"\ "T(C^LX PY8,(RN$?KI.,<D$#K9,AJ+>>:-B1ES@<95DVROP]3PF\
MEK<.61ON3 %G"CA3X"ZRDM,LCL(,^QK&$6%4<,+3/"$R#WSEBX@*.HA 6T]6
M'CI/F(Z9ZV[H)*?;Y"$+S.VNY214(N6I)CR.*2##*"4YS7(2B3R-(Q5$2;J[
M3A@/<"U?+>T.Z4..QU'L?,A._!WK)CO@N,L",Z[3.(L886GN$Y:+F*01I213
M,E!*^DR+C>YK]P:.NQ&EJSYBN@,G,7-.XDTG,?R,U-ZB(V1Q<:L7H@'\_KCN
MV[7%7/OP*RCTY4QYWQIM[7&KKKU3X%/@&S!!/,V+RKM UJN]4GNEY4][!7Q#
MFBFJWASN@FJ[]M14PI\W',8>GTK\(1AYWWCM=>*J_\)W>)L]5)Z*0";")XF?
M@72( @TR@6N2Z$!JQ7-&F1A"6\9?D>Y7]1DS'[Z%77L'F[8EI+0ORS*YVG/W
M^ QM.&UX# 8\(3G+,J+C-"4LB'V \YH1$3*MJ?#SF&VX=Q/ ]V&:1,1/8DF8
MGPB2Z< G.J$ZRD3H@SI[!@P6C -_0 PV\BI58V2WN%"3R[%G!TE[(-;/UD4=
MGTPZB?E-5:H3F]\*N%@U/B!OADX@$)W_!+,(:RU0FH*R^%/-K>1%P8M_6X!L
MK2:7^#3K9\</1'E^7B()2O&G!S_@A>8Q'LKO\0$/8E_M/FG]R=MXOE>T8*W9
MN,+NQ]P&4O/R0@'SP.-K["MI/I*%UL 94Z&\7,V_*66_@8>73R__M?;$I*S-
MCIL--JS2;O.$UW,/[&G35TGR2V0'7> 16S(B7K?*:"/O?#&9%[-) 8R87YHK
MIB:2@]_'S3A3!%A*77:\.S_C<^];N9A([PPP JP4EEF!CH<CT-W#7NR=E1/@
MTAHNE#W^[_[<KL6L#*!%^PBX9!,TO,#[;M"T1C%9%W [6YJ4*^]_555ZA=[R
MMG@Y[ YL3H6O80FWA:8OQ]Z7,[B6GY<+.#OB#.5E[1F WM+;8*%M!W.Y6^:.
M>"O8]'(.&[&^^AZ&6I)B#45=!:)&(#3A/8 5EVO"0V[D0'LW"[#X;%:5WT%^
MSD%&#4\;1DD"VD^"*HMP3E$0Y(1KGQ+->)9&G"6AW%WI^\,=^,LA15]P4V]*
MVVF47-Q7<B2Z><;U@)2<!U=/8 GC9R'$3\P)VG+>X(2!UAZDQ1+2),B"7!.5
M^W"$HLPGN4H%T3*DW)<BRW?3*.R7\]FDO%3JLZHN0$YN/U%_E-,+F_:&AZ<V
MIZ3_^9NRGO]1SO\_!2L1Y>D42 8X$41E<\YV=(;"\=659H<[0\A;BVG5O;@%
M;\2J%M&CDBFXG=:($2:\J;MM<-V:V0T?J&9?ZI%1AZ#2$;@;G2\+>-B\!&T+
MKR;.1J@9417#>F"30+/#9<#67)P5ZL*JDK+7H7&F*D-E@TG,(KG95= L\$*H
M;GOO I"F\OBF"V%FQ"6^^@,/S@_;@R*A#&4D(K"B@AQ8.=$1&.PJ)&!D@2W%
M.4"4#0T2Q*D2,8/+11X!^XN8\ 3,*Q;YC$D*-^3TT=C?ZI-W9=7\":_;93QD
M!PQ,Q]D-D9,#'"KC9AI[0+B&+:TQU6=:N%H:>@++MD<*H%V/:QNHV)P U/KV
MD';VU?;;X5VD@NLE@,8R1U1_.$JLJ&997&PY6S<IXZO.EA LU2(E@D7*^AVX
MA+,5AT$"_R\SQG<SHT2<*;F8J ^Z.T#F?)V@;5W,+[\@@;_ ,WZ>@!#\P5.@
M%&;P_7D%J.LIPQ&O7IS#RHQ!![M#+&T:7< ;ZJ"HL&82<&5C4Z(UIB;EMU<#
M,?N!N]1W,5E(M<JB$_6=6"T%Q^H5+&QQ/GTMBWHVX9>O\-/7,RY1&?4&N13V
MF4T&M_W#/Q;UO-"7[>/-5PE83Z_S\CN^!]SA59?W]WU ,<L=$'HSMO'X[_8X
M+)4&*Q$<#,AT(9RS+K5_!K##9NV#+0EK?<4GW_AE_?J'GU9XKV4L0XWM7'40
MYMDF;AZ/=6R4ZZ?^>1U@N<(=5-MMQ%,;^K/NN3:4:%=MY@#RQ;QL\X9Q*<@1
M\!YX.0%)!: 9[OY=R=?V2:D_]G]LKQ?H]Y[5ZE6M9KP".-_2PT2Z[:U_V%:B
M<E'415Y,0,*_:N]Q5>V)>6H<C[/T1V3SJZ^A8QK?=,E-GX?C\,'W&,?!0V\1
MC-,;WW;E\QM*@=*[5P)MY<U-[MZVP+M$S--!B&YKV<%*)_)V.O^J_('AO/HC
M# W9[1S)X^&$#LC_>U[]])\&S=?W9X[[#_,[+@9R)^3YG) VI&X.2!-7-S^;
MX+J'T77S*X;8/1-@<.?'-7L\T&2>8']II2Z)>/#YD2YW>*7'L*8T4LHGE%%-
MF!^&V-TQ)B+._%PJD*9AN.$5S1,=^+XB,HY\PN* DDQ(C0E=21;J2'(:[2QF
M_<L_%V TOI_6\VIA!I=^P/#EES,^;:)L'3C;4>%N$L0C&KN.94XD'N$FN[J*
M76:WBE )FBHB,JRK2$'$I;D.24*5THF@OK]EE,4P9>,CI;RZ&<VN6<^.CN2O
M-BG$Z:4GH9<<5'^X.M(LY[Z0*8E%H@C3641XD.0DI2J.@RCULW@W"0Q[4T>K
M91@/1NIT%,7A"%[!:1PG$]TF/TN9F"8IEP$@;5_EA F0B1F@=:+\B,:4990G
MAZUPO*-,'$1I&AW';K:%<\3OX-#:KK%.7SE]]>STU8M[)JO>3?_E2DK092')
M>1"B+M,DC[@D/.19F@<^MI8>MOZS(F)G-D'JLU$0/CV+X':.W9=.U#I1^^Q$
M[7;1&&1:I*'@1 9488.YD/!8!83F?I9$>2)IN+L&<X\@&@=A&@1CZOHL.?_^
M#@[MN[+2JG#6P2-TW;]]PN$ C]E.>NYOH\#1J[U'LC!X2'V>^43' BR,( 7E
MF.>*Z#Q0H"NU'^8;0\B'I48[2;,S(R/.HE$27=V^:=]G^)!]_9TAX@P19XC<
M18+&6>+[242)XM@D+Q2,I(HSPKGD@H69"I*!&R*-!%V H!R$%1*ZB;(N0/$8
ME0)N))@;">9&@NW8H(@#E229(%'$P:#(%:A#G\<D"426I7G*<[T1LGC4,3>/
M7W&09J-HWQK-#0IS GCHX2M7EW"[)HDZ\H,D!%LBC?$?/R5<I!1,BU"H, ]]
M*G<W[^%)U"7<E.]$]SRE\6C$JAL><9Q]4P,X^Q'+&>&)$H31 'T,N2!9+GRI
MM,J3-!]VW]3N3O9+ZQ)C9_V(!S7581>]5(%0\(=^0SW;1=]T21U2<],@SC*
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M9,'I!U=W]G&"\PX]4/L)W&T7U*V]4>'+PQ"B.TCGWZ 5OMSV-/A[UG'X3.H
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M&N3UEM/ZSU>\OM/.SK'QGF7D@/J&,'3E-3X:@7C]BXR]OW7&^-6OW7G<.[_
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M+_O;U#3)_#Q?E@7B=" SG6U96H\SFJMR,?,^@O@SC0(^8BHL_'G+O?X*#Y&
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M>,@L9AK,-J.LH;AG2(X\:8GN+:G><2(>_^4@$A",$V5*,>$%!Z<E19[$.N+
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MYZ=S'0D<[-@[[,@<['"PX_H&&X_F\<!ZU"^+>CN,H.D@O1>N'\;S.[F.!,=
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M.-3Q/%2N(X%#'?M'':X)L$,=UQ>C!8]>!_\>KCR?%AK(NUJ%-D+MGRO/1-E
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M/O!-GEDX3FFRC(,-=.IZ=;Q-@I 6!,"NDBVS^N./?_S#'_\(S^_<GL+_R,G
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M+ FHY6ODEBYI\%Q_Y>Q1>VK.P'@J*WV[=%:H4>4?2F4B%J3.A!J-Q<?'R_F
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M9/^>E2>H S_>->BM6X!!#J5F#3"V3^1+2VFG\L-YT)#=MK:(Z8TK-AS?@MT
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M]22(8 Z'OYA8I)D7$[^"KU?WWN<VEPWSC8T)#U&"=Y.^]1V'97>]\2%QT00
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M;IZ\JEW4SIM3J"0AH,+=%X5<+ABN2)82;T9Q%@RP^KX[TR47#FKQ*C"1'KV
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MSX)LY%O&I0\VQ)"?A2G(L[[/RR0W_![RV/\--B>1/R@:7E EDNR"",*$4R9
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M5J:J1]0C174N?+!F%MP!U\:/7AC\"P\X %.+6."K_, WO*XZ_*Y7YT'(S[/
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MA3--Q3TIH(=AL 5YF\17C2Y0XRZ;1:_." _32$5<V7;'<3H>K&8HLO:(UJ
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M9OUGY7><>);HA-UI[D60^"W=@ W20D9!V0 __U91O'83I&.#)U9D)R,^9K)
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MWEP&(;U(Z7I8XH",+%%TR2] F2!INY*B09[8E\5.-5-<F2WK B_<?N<L^@2
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M??^.RXZ,.8CSM#8\Y5VR*L0KRR:(:(.H1FQS>TL3_D*$G,#U4);UWPYZ[[1
M7#H*>LWP##Y@I@*T=AL'A=;@6+1FK-_2UGAC;6R-B1"=14]?KZ2?"]^I48(.
MD0.U_7E@-B2;4L2)HN[2;Z8M(+'>E6.(B";MTZ+!//JP,T&<M^);0$/A<&1
M<S$ZM?F=I?WZ4;R&/7ZC$_[WEN&"H2( @#\O^-B &6W#^?L"AH*972.V1Z3D
ME*0\L4\#MH4<TB81WS+W)$^Z)^7>V,JKH8("MR"^Z,G,QX&5AD!Y:.6;13F]
MZ+R??A&\ZT?G80/@ZJ#,4B]GJ07S3(;\#"NF%42H?2/"D)Z.$',7QJ!O.0U
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M-H";H?F6XG'7>+B?)OUK-'@I$&?.\H954?NL8Q9.  %2903JE&G@$"US+ A
MN)Z"GQ.TR8('?\/4:12FV;^!KQ_1ZR[*$BS,OW[@O1W7(6)6%")0<%ZP 6N
M.-<>R^";PXKZX$KZ@'05$, 3WI$+AT$0?9" [BX@USLB--Z'>18S"W3=-:P+
M!/?N)BYL9:LTQ=(NW?U=X&R[D@%_I/T[6]ZMJRC,&)H<;PP(LJ,5"S$ZNTUR
MV8\">ZS]$^BW.Z,9[;U3X(P#<1)UL8"FJD@B5DF&64]);!ICJT*318>5GL))
M5DFNZ,O7KC+ U%EM; 3&$61O"?H]PZ#<'FAL@A!-O,$P0!$Y-WN)BTSXM%8
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M*BN  /H1?13%\HCJ$4<A_J>+&@J^0KDCW35  /X4%P;]ANFF5D Y=BO!#!!
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M>[+1*ODI2J@]222$JLP# J# \Z11'$-_&1#@=VP!I<GPAN3Z%_5-9!%*FDN
M +O.];O%G)88HE"=]X,IMYW[HU-'27\]& BAQY03,!5QR]H/7*,4:[!]H42<
MHDL*UZ 0Z_V$$&^<8U\>T9P/XNQ^3@C=):F_QY3&E!S;(T!LNKH>M?%7>,-$
MXT$ )&I=D_^YT2! XPEA+P "Y%ZQ6:RA"$MS"\:# .C4WE*-9\ZXH=_,I^US
M:$Y^[3-*LSA\C:@3.&F99!E:O>X2,*C+"9P8OR+?\*%0M7:SP2<2)U+94F&>
M_7/]%L6_K6,/Q64F"U%NB[#B)R=NVPC59H XM8K8"K=Y>A07ONF.! '$B07
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MN@J"^]#S#[Z7.0%;ON<.,ZQDW/@Q<O'@9!VO-QM,(+% W^ /MGM'9#BM+H$
MVO(^?'_FC8=KH_0-2MS8IX"M-U=9XI/DHGG98-?QU@G]/^CV:E,S(;C0>VIL
MO1+<G*!Z=V2&-S-KVROIZJ3XC->;PH6. ># R1@(X\4S>K@MAS8#-<OH.EY?
M_I=LOW?BXWKSXF]#'[-"4O4FS^PD84$8UVZCVN\\N$%__[)6MOP)]HS5HO-X
MQ3B^PM_]C0.0XF08]UM^7"T=21$O9W^1ZSM<!#UPRC//X\ZR85#HGBB89+6L
M=G]?]8')KJ_Z?!@W6.WPN@$4BA@:XR+S@DUAO,F]?JGSN,+<>H226RR?9[/[
M"WMKZG=9:PD8UUGY(#NI$AJH.OO7N7.E\P#G5^=S;K)TM7'EEL:B&38[SW0W
M);NXPBDP+JK"X70R$@1(6-J5Y#==G<?-[.__.HMC^7,KGV?MEJJ4E%*_P$-7
M@W&WE8^W%1 R%(%+N_Q$.JG[%,_CPN=[EMSNSB"[7>](K2=,!/F>2+Z5^N55
MGP_CNK(/IY=SJ8:1I=U&=M5EHDG,[$VN0:*5)"I0GE% XA5HL! %]HT 6X83
M2:[TB8M:8P'*^[YJ[EO&&$Y=%0:[,$,HK>9*IV)[:4SG&:^.#XR8(6_0 051
M;N*H2\/.B?%P@!$S%LDDB]'Y =YI1'RR!]2(Y=$PH&NL (,AJ!U@.R1. TO+
MN]R4ZSTY<7IL!L7-[5:SH9#>:\DT:S>;MS/UFZVS I2;K7:(S;NMA:>EW6U:
M1J6LP31;\UT%15I4DBK-.S2FUU4RY>FM83ABE'<,O!NL. G&I1UT.E5XJ0)J
MEG9IJVH\7VEQ\!F*V!4$-5"RAU@XQ=HCS-J5[-D5SX%Q9U4.J/G(2O"PM!MZ
M'=%0.A3.+^"3% ZKMR\SD?-&6[N0G0TUR%$-@N8$&%=1<B#-6R@"?FE7\ J%
M:..G,S1\-RV.M/Y6ZL<=:X0LEE-C!7LF;7P\(?(:YR0U5PMFP+BK XZN97<6
MH>3L+W SD>(M0;]G>/';P_S"K[N[EQ4CX@VWYV_N[$CJ7^:.AW$K90?2KN#'
MA?WL+^"@=*9+6I.U>WKE)'ZRWG2V=LS_K^S2*DZVQX30ECR<S^@]BG5A4YMK
M#;2?26>WVR3U]T[*U4LZ@X#EWZB=@]I<>!D):M I3[=OG6JD\]Z'F&UE^_H@
M9%8JX5S[H#5LH#HL0GV^/1"C&.&7-[>6NVU_5^C1_PSR5&M%D >O9]''R?+D
MWWX2)0L)R5=EIKVWC1FCE_?WPAN^#UV\5_^ J/%"".:0E>PGCJC1*W>X-0!N
MG3@D_5;+,DEJ<,AFV2MG@3X:XE^,-8$,TTN#O:O!I[T,#*U0+U5>5=9>1O$Z
MO2H#:I+\,BJ.:6&NJR@LHKNN'HH4U9-%=!K4PYRZ]K.(KFQZR%/4K!;1$6D@
MYN2*VQC-9>:.O>$ZX2):SNAA4TF]G*Z[S&SP-DA_+?#XTP6/<@VW$H8O>H2Z
M'ETA[:)"G*"<5UB<0,N8DY^3%AJ_>#FG!^+%W2$O"T@G!;PSSP\R\K34+71O
M/TE78^21OM+D.<K*"J9=?B'U&IK_T!PYQACX/OO0"5D!R3ERC[,J(UE3M>"
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M)0GE3QF^5_@5P^_<WD\)J5QC7KZ-B&69/&3E[YX0PJ&K 3-7-"[, )-%?S;
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M0&?>C5LF=+9CCA9'+7)IBQ\8M0AD&9,6=)3%16!VU-8;YXVZ@38L2<C=&#4
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M**G0/$9U!X#!X&/@5AIY.D&P+@R+ZQ4*T<9/21KO&045M7(N0N\9I7[^Q-:
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M%858WR9O\(US'$ B_24L7L&JI,63$Z]CZAKSZ+XQ]FD,%M_I(9TYSL&4/%F
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M*)"9_UZZ4$GES Z4(WQ@&N@%^#<$_M O0"/YO*<"_?-=%+^@^."[NCV[.&M
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MZ>D^O'/\N.B.I<7KM.9#D_T8ILB3_1$SY7YC,+-+#:!95?D8&'-3Q;DR0Z1
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MOW\]!$E>,T+0FIT]$@@S*A.WGK&8VO3GJ#%8WN1QD)V+A5<^8>DN4L2[8!+
M(R 91VJ/0W^6-7 :LIP@O+X[RC"-% ==9' ^^ E6N[C14"HS)MT?OSNHTCS3
MRGMEHZP*?>JC5W^123&.M_.*0JRMDX?MQCD.()'^$A:O8)6Q_.3$ZYB:W3VZ
M;XQ]ZISG7DOYS'$.IN3) L170TP_*!EY &B,0H*/,_4/*!53@F2&\1ZW--^<
MI%@'/G&N\/D#;ZCQ/IQ1@H$M#T3I]DCGC,:V5! G&&UX7YAC1*&GLB?.R-E&
M;LG\2JW (J8+9R81#()@#XF'1X2"ABMB)G@017*80,0\.MY<&NA=&NA!;]IQ
M:?]F)\56ZBN9.2).,$36:<@\M\7,<:,C#DG<'Z Q<<E#UJ:%?MB)0!Z:PW50
MKV$M"-V2R(0S")97N@J#_56M8@5#&.],<"=2*VPA;_81X_:;.$\8%F]"+.'Y
M_&:.FA.D$J[S$#)*C+],4U4,FC APN!U$7EM9XXE,S>G\/E"QH6Q*S-!OY$)
M4V!TSK_G)(<,NW$6:;O#Z(2%RE6(PE>)6(",!^,$,D"*GWFS(D-T<B;-BI2Q
M,2 V9>:=BPP1"L-E/_/.17K/KT* S,S;&.D22AV ,_<V1<J0RP)_YMYF2!D1
MW BCN3<54L: /*)I[DV%!KRI$]$#1'&<%Z5EL/* ZP1N%C@3%#:MRRY@1A<%
MOD=>NV:A!D:I@<;NF(?'/IN/CX_OJ_/Y\:]__5MU.$FVSZL;?.?CO;!/I]E=
M(_3H\[R+ DPDR>WO&>U;U7_*&W.NLSBF 6NUZ^$#^=M=BFGL^[_^58%@+0-=
M = '<^6ZI/1%64)DGJ"ND@2E3($L_V6>4*G1:4/DI'+FS(#L'!!#98_1N^.7
M'6*[)_G#+( <PG\:EKRR25"SUL]\,2!F1G&&/ 'KG0>T?'[T%$?O^%2/3_B-
M3$GC8WS^[S3F!,T-2#4R;AA2\"V^#Z^==S^E$F#)M68&MI1A73O)#I\L^1^"
MEH,3(%*0*;UVXOB(I?XVE_ZQ 310B(=PK[RY63WQ,0K=SE7^<1;'K<:XNN!V
MV=8\8%6\T:Z;[3/J3J%@$UTF1CMBGC^@^Q#K#(BT<, ,;;UY=3YGA@/I]:8P
ML\7*O\T"0IWK[',ZL3, !@JM&DT_D\IX(?)NG3C$+#IIT/@-UK5=_YP/N:E)
MY)XO,@?+GZ3_"@I=ZMVH/5=G"CUK5.V@T@1ZFG1<53 [N;C2:1  ZG!@/@CE
M0&N;YEE0F!OG#+:W^9:FTMUL_J/ES4D0VAICMXN.RN6#=-WZIB/FEGO#+/8[
M9=J"F+MFCX50O81MSN&@7CS+)M/C66IX?(\SWB(QB4PQ')H23+%W%@HF%O:A
MR"?:NR]J5A3VK5&::PTTD6V$"8]@ A@@Q->?-]HF_](S8O"XFM8J=D]+19QB
M##1<IH1A36CMA#/(8MEFN6F B4J%B58E/ZZJSQ4">3/Z 0J=$ 1@$0K5']>;
M-7[/Z3YRJ!K7EUQ<(.$+#+;294RMEB HK7G/S-S!Q7F$VR8$+'M=@O"RY)6_
M(<UYHO<\EIO*^BR0OP,,<^>\&"9G%E)F=:R:%"QZ3.^B&,,;YJ^3VTSSP,1
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MFJEM\(-Q=/YD*=K8:,I)=0 &9&L6P*RE\="2WH/-&@37 ,Y':6U"P@'=6I5
M UYTIMIE^7N01_P2>( #Y_A."]<7C\:GW&J29.^H0/K6M. H;*!*>3TK6+"3
M0A@1 S TT+.0<:ZO\ :X"P"/6RF\'G3.7\ 7%GKXE*J[@ KP1_6L:N39"HH
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MITTB(WJL-N#,/'E)E9F3/R5U!M41DTDT6,$?.G6\/D+A$4X1C- \MIPCF[)
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MZEQ_I%3<QPSJF$*"781WPV*]SCV:6^Q'H)E=6II;L&I<5/I'-<,(%YC!_U/
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MJJHNZB%W;$<):W5=9#/:\)4,4R)@;:&53N>%A$EIK"]RF=$/B-WAVDVU9K4
M@7%9* Q,1VE9=+S)-)$5D)W)^+@6*3=O5C1:!:"L:J,D/5=,U#:K)C)' QI!
M?5'>,<'RUL">*1M$E\4SJ2G*_F,S-"Q![Y:P**4=^[Q)9R'C[%F0CF!&$IB)
M)E ]F+XR0IPCD4?]IJD)1REED)\92EL,*&VO3T.PKH$G0EI,'A5MVK!<)T4J
M(UON=P2+C)8DY9?=CG51(NKX"XW.T]SOF.5E-NYD[C+.#-2.^<GT5)[R"P[B
M1[L!T^SS LP8RC.;HLXXHB-!,(DTI7J5F.U6I976UX @F>10HI[ HT$JT*Y-
M2NJ0/J"M(!"_+E/ -' I$S)X>$29OX+%!27XIY@0EE2)<V-59*6/"Y3)J:1F
M*<-N2(8*-7_7ZP3HDSK[L6RD<JI3F)35.S&? Q?1!ANB\?-J;P-_@:'####,
M <1^",W$\>5A+6$U83P&15$0DXA(E1=96DH54:$$/!VCP6:REV&V3;F,"6X.
M3R]4"MUV-FH4V>YC09A,#J@NY28+CP"?(C5*8:8"$5B'&-4:S 40"QXY#S,Z
M;*FZ,M K<Y+9(O?E0%M /)QF,)E-)I^=L3@DEJ4VS?"%^5Q.1^WM@39)',4Z
MM>=9YK9,TKZ7V4S)6FEK?&\H,YWC*WP$BQ(8'P"+)*X22VJ39I1MI.7-J[28
M#(Q9[/?@0V5-5&S&"X;2L6K6JUTK2U!B:5%>VM/MRF]_T#G),^)6=@Q$[$N[
MZ/^J!3R^S4U^5;0K"YW<-SL%;/I:@SP:B)W[O<5X[A&AQZQ;$MJ<HWXTHHT
M31XY3CZ[]Y?(U-H[>R!P"HP*D F!WSEHA\IN9I?XW;0I1*5=[?Y>'2DO'!DO
M =.IVQ/'E3=?7>17@T]JWI#O&QAH=>!?2ROB\;+OK"A[0ZNRV.5.0(8I X3A
M=+I!$O1],N?+D/$R=[GG7CD;DD;(10\QH(&UP%I@+; 66 NL!=8":X&UP%I@
M+; 66 NL!=8":X&UP%I@+;#62-;^P+GH#[CO>_Y4],==<90XO(2D6]YZX$4.
M 8Y7X2 F(F.@BK1,#/5 U&N54S!(9FQ?7\SQL$6,*)4,0\LH",R@FJ=T7Z3P
M*@CSN>@:J(K'=<64>!6PZ^).X1T3=B8S/QI %X08K6Q8WQ2H-?%G[D)'5T&\
MNE5&HK9J]VG0<"+Y0"8FK<%<K<&/"Q6]%IF,Q#3'F #+;C*O;L1"\:9U7V>O
M6EY&%]FUO.8)EF_R4;%AGE"<*Y4M:=C-]J6EF3*VZC33JOC5E%I9<V0^QOID
M2ZB;E=29$+8E"J6,777I;B;_K;J6Q5!_%9G/52WH>BHIKDD*P7'AJZ8DI[F=
M-L,N7*Q\9*IS>J6E351\&5"/'\/R_O:JQ$!#,A-][N96PU9RC\BKIOYZ(U/J
MB] O(VS#"!-,72'CS6W2U5HUGZ"1+/:^7V(I$O^'=Q2AM^R%,HAE41-X;2QY
MIK1TJI:7MA0MU(0W,X.5,P,LH7R&P9J^);)8L8;0+HK![_C55+:A(!<.T\$9
M ;98)L;"BMB:(T9_33,)RB05(Y5+HP^1J@R;5[@P(A!)7.2+YDK+@PW!JI/,
M&7,F?WZA5L,"=5]#<X50NV>JX*(%;$3&3ITW3'%=>J0U)Z?FAME>%AJ!9TAO
MF<CK(A584"02INB3<4E^+S*I8VF,![(26K8X% 5W^7]NF;#Z,EC>J0:0N V%
MHU=<IQ8*P^N5Y$;:1168A C&G(QY[A8QN"V@4O";!_-CEK():"^3!K_4Q:V\
M44!\V;$PV8#D"-6%XWJILI8JA>:W&HRC;P^W:V3B_]-1/^&SABF8'QUM[#V?
M-<<L*JV-VGE"/>%M,548=(61M,D<H(04A!8 .NGD@IP./'<A*^)F#H&Q@DSI
M;=.3@R\Z4=G42A_%5*()YC8V^ <!;V'6KM%CKA:?A_VA(S4MDX>M;J%G*<>9
M5KE[:QDS+J&0/+,[B"=^,3/(YP*QQE0Z$SQ!)VW(/G"M>30NM,C!KGE%:<5E
MG2=ZD4I7%8D)3X9?L!!X(B-7_PX/F>!K3B92-%:8F&$>W CYA-\@G%BD"EHG
MT$K3\HQ//-(:I)UL4JXYT7 G(A6E+0L4F/-/Z.BHD: 5;E9VY2!17IE3=)I/
MA'?T8E:\122R"WGAW!:)L!0LFF,#1$,8D5HGP\(C[HN\>(<S1I&6J5LM>WAK
M<[L0LD!E.6F%\I3(U(]CK]K3>+A1/^BQ7"!A/$<@"8R@)U*1Q G(2&'MTEH>
M!;!)1?Y*"1E;D,KWF>84K&^)*J]J%POX43Y@Q88U'*V#:.08O+5O%./,@G)@
M2E21X0[8-*WUSJ*&=$L"UZF[WF'6/UD<E+&*ZR"VALOB@7"9/F238F_@7CG$
M VN#M6X4V:P_;32>4U*>-G"5<IVZ0ZQ%JT)TB?#L[L\H0]2J*7-Q!#IG[A6U
M)$0:+3/?0)&983KB&3Y16)-260U"M8:'!2;J.L/)6IVWIV8] A3ZT<!9H!!V
M=^ZC +YJ#NG2-%K,<?H2BMCV(R"R'6!8(T#N_GG1^] ]/?NA=\'.W[&KGTXO
MV<?NCSUV>G;5.[LZ/3_KOG__&WO?>W?%OG_?/?OY_VZ3X#/$'JP]Q3@P]X*9
M>]/>77T-?PL,@I8*# 8&'\+@UC,!-(1\YA!'&%@+K 76 FN!M<!:8"VP%E@+
MK 76 FN!M<!:8"VP%E@+K 76 FM_X'SF.U"=ZZ$[!X?;3P?T_(4[@Z\CG-,S
M]NOIU5GO\I+]^E/OHG?^KK4L9HR"J<I0+PIO.%$I%8K$V(F/F<*RM"J;WYX&
M5,:5]LJP_!^X7RXR7(]2D,/6R[A=N[F4FK-NGC?T]/S#Q^[9;^N+W#IZBB%Y
M9*S-8Q3:$T?:?)!G/[,KT&W=C[U?KDY/+EOL].QD!;6STSY\8HDT9676"CP>
MM#N[^PL%'G?:.W>'9CUL!=<BU'8/VH=O.E^L<?!UUL[W\Z-5(="?5:F\UJ_9
M?XLTE8C2\7TADN0_UE@()\RLAPOMC$_$T<(8WD>.>^V=@R<44"-D<27S!(3Q
M,1-:XM1@?^.3Z3$[Z9T'8_"&,?A"]YSF3.AG5=P??[DX^:E[V;L(]F!#[,'N
MC[VS7RZ##1AVZF_0!OR19XIULXE(@_WW;<TJ8_]5X_<'M_U.QEQF\)QG^@VR
M[]8WI[^)5(T0)A["Q -K@;7 6F ML!98"ZP%U@)K@;7 6F ML!98"ZP%U@)K
M@;7 6F#M!;'6Z##QKWM'L_[;XIW#]E9G9P'%$23V3'=X.V_:;SI[M3N\1N&X
MN5G39>]4-L$0=PR __IA,#6A==H'A_M/*+/'B>B?ET*P;I[S:"SBIN/8O=0K
MMK>O!RJ>?_>GMZ_'^23Y[O\!4$L#!!0    ( *^ =5CO/>TZ1 ,  *X7   /
M    :6YK="UE>#(Q7S$N:'1M[5A;3]LP%'[G5V0@MA?<)FPP2#(D-O&P&Y,&
MTO;JU"?)&8X=V0YM^/6SDX;1TE) Z[BLE=+4R;E^YV+WQ+DI^,&:%^= F;U[
ML4'#X>#H)]D.>D'<;Y>6H#^FB!/):D^;FL.[]8*J#$7HT<K(%UB44ADJ3%12
MQE!DH;=7CJ+U1BS#\XYI_)88689^;P=%5* @.6"6FS"PRT2.B,8+)R&1BH$B
M]HF5$Y>=B%0*XT@@#/S21*T9K<"H>9?2 GD=GF(!VCN&H?==%E1TA(DT1A:6
MUL#($,HQ$Z%RZIT2Q]_I&4@N5;CA-Y]HF*,!HDLZ@+!40(:*EJVZ86M\(CF+
MIFR[T1QKRQ"9R<,4#1E82A#.AJ-1C@D:KPV!DW 0]TM[610;-&\!1+"]2/E\
M+ ;6#%"/!(POJ(TG4^^D2C0RI HMFUU_Q>//WFD.5B]4!@=ZR_LH!KTK>-T2
MJ7NG#(?TWAG36K(P1G,P\::\-#3A,%F4Q%D7NL*,QD7DS' U97UPY(336E;&
M2AX!BUHM@>_W_,V.P?K"::DAU%!210UT8#2UTLINJML:H#KMYZAM[G(T==CQ
MCXDL%>NH6G4[?F]_=]-!V#=L#DW0\Q>1O'G;V]^;H+$_U+1A"1V<94I6@I%Q
MD-+F$PVMMR110,_"YINX![-#=]V1<U V]R@?IT2!C'&8UZNVEYAX,^V=ES\O
M-X)=/YIH+3/0G?*MM639??AA?+LY;D_ MUD9WVVISOSE9'_C&PIFK6NS>W'*
M7&4A#4]W'F@:UI^6^'AZ]=4-;5YDCFD!$[M4_62JZQ8PS-V'O$5>KC*DP^I3
MI5 S'!B4PF7*-Y51@1?4K>]8T?N]USM+J^GGUAD;WRP^5I!XM[Z]_ES]7.T
M_[3U'68@3BL]\0_$^X*%%<%6K?^_3HTCD7$JF.>N'Y2#7I7K@\=D9KF>'*XJ
M];_.BO? ,ZR*F^K3WMVT9!G#I#W+>I^SP5\8JET[1DS-:%,.(\)007-<=9.<
MJA 10UUR6H?N[66\NS#-FN3^JK3!M.X4-XP$!'N8$>]]  ZF '[UP<I*%+[:
MTE1HHD%A>I?#6C?!S2^;?DDS:/LYH:D!%5(^I+5NFG?<=]/V@[6XW\SI?P-0
M2P,$%     @ KX!U6-T+OQN+ @  W@L   \   !I;FMT+65X,C-?,2YH=&WM
M5FUOTS 0_KY?<6P2 JEIDV;J1A(J#;0AM!=-8Q)\=1VG.4CLR+[0AE_/.5VG
M D*P :M 1,J+=:_/DSO[LI+J:KH#6:E$SF_("*E2T^-WP3@>1MEHM62%T8U&
M-C-Y!XZZ2CW?K86=HTY M&0>8=T82T)3VH@\1SU/X+!9IKN]VQP_WAJA#DJ%
M\Y*2:!C%J%DE:];2PF@*''Y2210VE*XB!&2:))[PNA<7HL:J2ZZQ5@XNU *N
M3"WT6G=FB$R=A"FI)06BPKE.K _GXWC[=2AI*F.3O;"_TD6)I +7"*F2QJI@
M846S"K=8)3LS59Y^E=YF.D<6195Z= O,J4P*I$"R7&D?^7A9X@P)5K1ZNVDV
M:OAF9GJ&?H*!\ [P>]L-!B2GH>Q6*7AIM.,O, 6\UKEJ%#]X>:7FZ#@WE<-E
M.ZM0PI&4IM7$)00G:.L-NAZ J$H5]ZZ4^[#R5H&\(88,4*D M326>TD0&@VS
M#JPJF!XMO:C7L#UE-PJ.!*G:VS^Y,$.(XS@83PZC_?@IL/3$V!K>!#$(G7_'
MSGE#M[:<1 =AK]PO#^)GX633T:'_?::U[,NW.^3L)(=S864)XV@ XW"\/X %
M4LD:KE'R%I9':2I<&12HA9;,RV8:[/D<+T[ANE1,J6H)I1MPK<CAN@0>ZJ=P
MF6V]Z'XOHL=[T21,'Q;5K^TY]T$Y<B,XO3Q_!6=GEW\6:[C-/>.%<63T@-O.
M.2'+UBDB]P_C_7)[V3+0OZ\O_T/Z,:1OPMT%W,9T6U1J&>1H^>#C0S;AKFAK
MG>;HFDITB9>FFP,P3[_O6T=8=.L8O4[ LY%'=#L=EG8=H!%S%<RL$A\"4?#V
MFHAJ(3K7S]G9R$_GTQV>UOU<_QE02P,$%     @ KX!U6(B'N>BZ"   :CH
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M+'M-\_6'DU>]9O'%B;\!4$L#!!0    ( *^ =5A5D\S_704  !HA   /
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M/\-X56J+Y<ICI[0X$1T< 0%\S&=XH>R9V&V8;S9<_-1MV.]$_ U02P,$%
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MU:CO/!^MN\;#@&6I1DK4+9=X[50:LQ.ZGC25>-7!I8HG$J]>GU&LKB-S6<$
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M)CPA$K5Z!LU1Y^(:N[$QMTU:F$0J?BDDMF,5$"URK@7C&>,A$ =TP "T %P
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M!9VQA7I(<4>4%8FS"_04:;8!?!I'V&2V6_4#^,;-L-)&L:Z/Q"W%8*X%_WE
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M;-/D]?\ 4$L! A0#%     @ KX!U6'-RYJ7W4@  A6P  !(
M ( !     &EM9S(P-CDV.38Y,U\P+FIP9U!+ 0(4 Q0    ( *^ =5CG<N$_
M7($  +:2   2              "  2=3  !I;6<R,#8Y-CDV.3-?,2YJ<&=0
M2P$"% ,4    " "O@'58>;'^N&UB  #FN   $@              @ &SU
M:6UG,C V.38Y-CDS7S(N:G!G4$L! A0#%     @ KX!U6!IXL70 7P  +F@
M !(              ( !4#<! &EM9S(P-CDV.38Y,U\S+FIP9U!+ 0(4 Q0
M   ( *^ =5B@HG#'.ND" !26'  1              "  8"6 0!I;FMT+3(P
M,C,Q,C,Q+FAT;5!+ 0(4 Q0    ( *^ =5@89188G@4! /R>#P 1
M      "  >E_! !I;FMT+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( *^ =5C
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M   /              "  27!!0!I;FMT+65X,S)?,2YH=&U02P$"% ,4
M" "O@'5859/,_UT%   :(0  #P              @ &[Q@4 :6YK="UE>#,R
M7S(N:'1M4$L! A0#%     @ KX!U6& >M3M+'0  ?U<!  X
M ( !1<P% &EN:W0M97@T7S(N:'1M4$L! A0#%     @ KX!U6'S-Z'G?$0
M5[,   \              ( !O.D% &EN:W0M97@Y-U\Q+FAT;5!+!08
..#P / *,#  #(^P4    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>inkt-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:inkt="http://minktherapeutics.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="inkt-20231231.xsd" xlink:type="simple"/>
    <context id="C_dc1f8474-7a37-45c5-a06a-9ca912012dca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9a95821e-13b6-49df-9115-37827f9a727f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5a5913b2-d4ec-4aae-bf25-d4732ba15bdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">inkt:NasdaqMvlsNoticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-23</startDate>
            <endDate>2024-02-23</endDate>
        </period>
    </context>
    <context id="C_df7ebdbc-60ae-490c-baef-5224675cbc1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b4dec32d-a6b7-4422-b38c-c1ea75f485c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_8a02edeb-2a2b-41a7-856e-4ba72582b120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b6874be7-da49-437b-ba93-4e3f9f01d838">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8de82880-160e-43df-8a06-7bd23e1206fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b6d89eba-0f82-40fd-b984-843734274884">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b633005e-91ea-43eb-97fa-7e4b54c42a57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inkt:ResearchServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5c2d616e-4ddf-4064-8944-7301eb485567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4ce3db47-5730-4c1e-bcf4-44053fd9ff21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:WolfGreenfieldSachsPCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_51eb493f-bc2b-4fd9-b5aa-efa55fc34f2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7f88878f-2cfe-43e5-b0ca-654e225c9a1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AtlantClinicalLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_26d61948-a095-4072-b5b4-5cab95d54532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ae710cfd-3658-456e-8236-9910244a165d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b1cce805-eca1-48ac-8a3e-95ff6ff8052a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8b187843-724c-4035-a8bd-2721f3e23008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b4568e37-46c0-4e69-b2ec-5733ed214cac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_346638e3-eec6-429f-b5ff-617610cdae8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_84ae0517-023d-4ec4-b8be-679864cc08aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9e054ad4-ee65-43e9-bf29-ab336dac222b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inkt:PaymentForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ab635f33-5c9a-416d-95b3-be4679d91964">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inkt:NonVestedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_92993aa5-8d2c-43e1-861d-dafd88c0d11f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inkt:NewIntercompanyServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_732341c7-957d-4682-9e02-69f3f41bc8cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3f948c4b-dbf7-4fe1-80de-c2e6ec8ad0c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandAndEighteenEIPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0766000b-7486-4271-8d7f-0f025af31180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_30bfebaf-513a-4ffd-92f3-96640e11b431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:WolfGreenfieldSachsPCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_74e50261-4062-42c1-85a6-53221008391a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0acbebda-ba84-4b3e-97b5-988e9d80a5aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_25dc845e-01ae-44d3-831b-9b8aed9e8e67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inkt:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">inkt:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-12</endDate>
        </period>
    </context>
    <context id="C_e0540306-0080-4f2c-8d4d-23d53f4564e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inkt:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">inkt:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_8cc928c1-4773-48cd-b025-3a741ebaaee1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_eb7f200e-d650-4621-9cdf-076793f5da15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_92fa1c95-ab93-4332-a14e-01ee475bc615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_95392f28-5e39-4fdd-bb55-5bba87d291c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6bed87a6-106d-428e-a478-dc518b3adca0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_70150baa-d209-420b-b3f0-9727e2e8e91b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AtlantClinicalLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-12</endDate>
        </period>
    </context>
    <context id="C_5eaab94b-6260-4a4a-a00c-52210c750bbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4ed8c189-5338-453a-9f58-24dd7ab9d275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">inkt:DirectorsOrOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_419eb5b2-74d7-426a-8de0-6ec785c7a7e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inkt:PaymentForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_174c7e6c-f05b-4cd6-b218-630f2cf7c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b96f833e-9e89-4940-890a-3ad3066d1a3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_30769c45-3fd9-4704-8227-5041637f5332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9607a901-9bb0-4a3b-a4c9-d3098e66534e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c81ea76b-898a-4328-bab5-6699b445169a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_268ec649-4cb5-49c6-a775-45044d13d5a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ee885642-fc14-4425-b334-06fb0a0d1eea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d36c7999-649a-4daf-ab6e-976ec054bb05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inkt:EmployeeBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cefd892b-5378-4271-adcd-95443a008fca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6a1ac15f-c735-4f88-9b7d-d2ba5526a4fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e412c6c7-5f47-4066-aab4-7147f2d0c3b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inkt:NonVestedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_514af47c-c76d-45ca-bffb-56d9b5ff3b74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
        </entity>
        <period>
            <instant>2024-03-15</instant>
        </period>
    </context>
    <context id="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ed60fc07-4280-4084-b339-04048dfe71c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">inkt:NasdaqMvlsNoticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="C_8b3b3dc2-5df1-42cf-b22c-651f9e7e2441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dcf77660-1f56-4511-acbc-a3e5c157ebe0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7e66d751-8e58-4e0e-9b7c-eba65cf04289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b7f39df2-940c-4946-a3d9-f259147aae28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b28e3d23-d775-4bbd-9547-580645e3901f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b57bd5bc-4306-4671-aabe-7907cd2bac83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inkt:EmployeeBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cbf44c3c-afb7-4d6d-ae4b-5bcbfa6eb60d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cdfdfaeb-561e-445c-ae5b-25b64f9aebd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e483d8b6-b887-4adb-87ea-1ee972fb3247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_53b8ed07-cd44-46c7-8c61-16a3a18d3787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_442d530a-bd9b-4549-9f81-dfaba599e462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inkt:EmployeeBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_12d6f787-9426-4e92-85b0-11024f100689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AtlantClinicalLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1fff5c2a-d559-4ece-acb2-fc94ed1c220d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inkt:IndividualServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7b863875-076d-407c-9f20-f71f59c308af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fb24caa1-2baa-4a9a-bc97-8c26392c5c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_957e80a8-d4b5-459b-8ae0-7824ad63cf97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">inkt:NasdaqMvlsNoticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="C_eb216ed3-85fe-4453-894a-011e3ac6dfb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e13b52a1-81e9-4212-b833-7812073181d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">inkt:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8e90aa4c-d975-4aee-8b77-ed3c9b0a38c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_42c15bdd-fb56-4487-acc5-a92fa8762921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c28b56ad-700c-422d-b0b5-3496a8befd3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_24cbce9b-fd20-4704-9a75-a6a645e49d55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_477e462d-66f4-4337-b1ec-ca7e1946fed2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f8ef24c4-afb3-478b-a8f5-beceae45922e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bacbc03f-bcdc-458e-bcf7-0544b65ce927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_6ac170bb-03d4-44e8-b39d-948d34f91995">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:DrBuellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_9103c720-7b6a-415f-96e7-4b1a21557321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f0c522b1-1207-430a-a24a-68c5917435b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandAndEighteenEIPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cb159f01-5c87-4f27-ae80-397834ee1e9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandAndTwentyOneEIPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_43fdd5bf-5e30-46cf-b276-ce4dac22ec86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AtlantClinicalLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dc88111c-fde0-4875-b17d-3dcd2f81ff4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4e994016-9f6a-4ddc-a1f5-464cebf76b9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inkt:TwoThousandTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_42074970-bc84-4a58-b664-9c0013d5b65b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_88fdd179-67f1-4d6b-afcb-9aa725675bbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_56e9f88d-c09c-467c-a477-e97ed4507f16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">inkt:NasdaqMinimumBidPriceNoticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-26</instant>
        </period>
    </context>
    <context id="C_637388a5-8881-487e-b1c7-e3b9f34f5c6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">inkt:NasdaqMinimumBidPriceNoticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-26</startDate>
            <endDate>2024-02-26</endDate>
        </period>
    </context>
    <context id="C_396bcb04-2fa1-44c0-ba48-210a76d1239a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inkt:BusinessServicesAndOccupancyCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:AgenusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0247a7d4-1c63-48a2-b771-84ce9fed7ccf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inkt:DrBuellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <unit id="U_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Segment">
        <measure>inkt:Segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_d6829c8e-0a86-431c-914d-fc56ded86e08">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_56a93653-5ac0-43e1-a736-13ae28d9d6c5">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_b33ac35d-4c62-4f3b-8d5a-c4723b47fa1e">0001840229</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      id="F_1579128d-7e6a-4a6e-9792-dbbae8282bd9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      id="F_136c5469-8cc9-4126-a3dc-d9ccade676d2"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OpenTaxYear
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_bf9d2624-e5f8-4332-8ece-0d2f7a8edc9c">2018 2019 2020 2021</us-gaap:OpenTaxYear>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_e22d9b5d-ce5f-4f3e-922e-62300307dbb9">2037-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <dei:DocumentType
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_55350a1c-7232-4d1e-b476-1bbff8635a5d">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_e790b1b0-18b0-4dc1-9e78-439d673acd9a">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_51b54b92-074d-48ab-a6bf-3c4e6c713300">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_4ad87a5c-98ad-4396-b52c-caa3b5d7bcfa">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_f402a65e-3ae9-4571-b46e-5fc99fcdb352">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_61e6bb7a-06b2-4598-8d40-d63b00c62b0a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_cf56e26b-5257-417a-acfd-ee0fd95d5d0c">001-40908</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_d2442111-b6cc-4282-b58c-748bc4116464">MiNK Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_9642aa3f-c403-4d5c-98df-67e5bc9819ff">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_1fed25d3-2ecf-461e-a2f3-f1c69fc289fd">82-2142067</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_8975397e-b916-465d-a602-e0e226c2d3fe">149 Fifth Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_0dd2602b-5ff6-4007-a0ae-18751d75b5fa">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_56358a06-59fe-46a9-b917-912fce3f7780">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_d55a3ae6-10d2-4f4d-9b38-472c8a02f25b">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_70ed9cc6-e2a7-4ea4-98fa-17e684781563">10010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_f54e8596-e84f-4e4a-b43b-9d73c73189c1">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_6fcc688a-af73-4894-9200-8cf8540a0d22">994-8250</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_10b79cab-2903-4867-8494-3f550a6c94bb">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_c4a8363a-75d5-4007-a85d-a5abdb39764e">INKT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_373eb3f0-6dab-47e0-8a73-6202c3e653fc">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_a91a1519-5bf1-4169-8918-a8b722e7fe7c">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_94c0b34c-1273-42a0-b831-3e9c74cc251b">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_ff3b8ec7-0c5b-46df-a62c-66a0a0f0a84a">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_d449b71a-53c4-45f1-ab03-68a0c6d179eb">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_672b964f-9810-4062-a2dc-3c2b7c258b66">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_f81ba5af-172f-4704-a0fe-5aba398dabc8">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_2b0eb2f6-a093-4732-b60a-bb01d79c28c2">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_75097a20-8444-46e9-98e9-83b2a7a81f55">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_bbbc28c7-ce01-4b50-b558-b4351e1fc495">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_66a00e68-bf59-45c1-b8a3-7f05c5703c97">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_3fa4c5c1-8aee-40e1-a640-f8b76dde7bb9">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_bacbc03f-bcdc-458e-bcf7-0544b65ce927"
      decimals="-5"
      id="F_35f1bb67-7c22-4ab6-9737-6462f6a211fa"
      unitRef="U_USD">20500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_514af47c-c76d-45ca-bffb-56d9b5ff3b74"
      decimals="0"
      id="F_c3edcb77-7c67-45e2-b1e6-12e8713fad13"
      unitRef="U_shares">34699056</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_159d9bd8-0785-4ba2-8f04-ebbda25e7c1c">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Portions of the Registrant&#x2019;s Definitive Proxy Statement relating to the 2024 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the registrant&#x2019;s fiscal year ended December 31, 2023, are incorporated by reference into Part III of this Report.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_dc3937d1-0255-4145-a9a7-2b8283dd0f75">185</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_82f1997b-1bf5-4c8e-83aa-de041b85a085">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_1dce7d61-4987-491f-abbb-b90b8e553cdd">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_bd69bdda-bdf7-4c91-861e-740c19afaa94"
      unitRef="U_USD">3367229</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_93ff6a29-0ef1-40ac-9354-02ad7436db22"
      unitRef="U_USD">19635725</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_5ea555e2-4c9c-4c60-9cbb-4c0361abee5c"
      unitRef="U_USD">53111</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_bb5c6414-f452-4331-a60a-d85e67cf5355"
      unitRef="U_USD">298667</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_1e55019b-cb66-4c60-baf0-b7ccf75e1c02"
      unitRef="U_USD">177964</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_471d2c76-f28e-434c-b7a0-2008c5af407c"
      unitRef="U_USD">470300</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_f4cefbfd-2f05-4e0e-9d67-40495285e977"
      unitRef="U_USD">3598304</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_2550720d-3923-4999-b8ff-a7448031545a"
      unitRef="U_USD">20404692</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_7a2d591c-b327-40b1-8639-3b65b9d9f2a5"
      unitRef="U_USD">495638</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_4b5a4f53-d3b6-4bd3-ac4a-69667895cee3"
      unitRef="U_USD">283682</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_add793b5-1628-4358-8a85-1b5b6073a916"
      unitRef="U_USD">953977</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_1f48e5af-1e16-44c1-a798-ade3968d5ad7"
      unitRef="U_USD">1066910</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_1a7ccf3f-ae31-4dfe-93b1-74285fda7359"
      unitRef="U_USD">4552281</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_41897028-9a47-473c-b4c6-694a0fbf3fc4"
      unitRef="U_USD">21471602</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_73f21bbd-cb1b-41b5-88fa-982a5f58dba2"
      unitRef="U_USD">3911973</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_1fdccf34-1fa3-40bd-a123-209185ab439c"
      unitRef="U_USD">5823000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_d87caa01-5894-4d1b-a4cb-7f827515f88f"
      unitRef="U_USD">5037361</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_4ea7a5bf-fe5b-4984-8534-93437badc12a"
      unitRef="U_USD">4238555</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_e582aca6-a02d-4208-b8d4-1aec825887eb"
      unitRef="U_USD">2453251</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_b0c4d164-79fc-402b-9ba4-c26a52e8176b"
      unitRef="U_USD">2621611</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_94b4e06a-c0bc-4c69-8595-31a0e19f1455"
      unitRef="U_USD">11402585</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_698125a2-15e3-4dbf-abea-c7abbac96c01"
      unitRef="U_USD">12683166</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_47582a7d-349d-44ab-81ad-bebbd55f359c"
      unitRef="U_USD">48072</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_41ebf6e5-2dd2-49f6-bca5-760081c9ec9b"
      unitRef="U_USD">108500</us-gaap:OtherLiabilitiesNoncurrent>
    <inkt:DueToRelatedParty
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_fc1550ab-d035-4955-91a0-52ed306cdf13"
      unitRef="U_USD">11157073</inkt:DueToRelatedParty>
    <inkt:DueToRelatedParty
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_014b4794-a532-42dd-ac99-653807fccc23"
      unitRef="U_USD">9081239</inkt:DueToRelatedParty>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="5"
      id="F_333d0ddc-8bb0-4fca-be62-51f7fd3521e4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="5"
      id="F_338907ea-c72b-442c-be1d-65846c5573de"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="INF"
      id="F_acb5a297-c73e-4776-bed7-d9799098ae5f"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="INF"
      id="F_37c7670b-f89d-448b-b16d-bfbcc6036364"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="INF"
      id="F_16d73fc3-f2b0-4a82-82af-1efd429f51fb"
      unitRef="U_shares">34599119</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="INF"
      id="F_3f0e5e72-4e33-4f70-b8e9-cd5f6e2375d7"
      unitRef="U_shares">34599119</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="INF"
      id="F_98340c61-5dc4-4e63-bdd2-791195740f32"
      unitRef="U_shares">33856428</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="INF"
      id="F_55efc0cf-572a-4296-ab03-c05bdcd58b5b"
      unitRef="U_shares">33856428</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_176382a9-e2b6-46fc-a851-e7b1fd757cb6"
      unitRef="U_USD">346</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_d20c4fdb-e022-40a8-8fcd-5467e276c120"
      unitRef="U_USD">339</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_1588f373-1ec7-4e8a-888a-598e0aa17c82"
      unitRef="U_USD">115772085</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_8ad63aec-3136-4ef9-846c-a20cd0353f55"
      unitRef="U_USD">110829900</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_2fd5ee32-113b-4eae-b676-526469d14e74"
      unitRef="U_USD">-430947</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_07b699ea-924e-4cc6-b754-9ad9a94be75b"
      unitRef="U_USD">-292468</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_bd51a222-a838-4b16-abe8-11bbc3f6998b"
      unitRef="U_USD">-133396933</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_d4dc8fb2-95f9-4285-91c7-11ecdf205974"
      unitRef="U_USD">-110939074</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_bf8d8b33-8db4-4bb0-904b-728599cc7716"
      unitRef="U_USD">-18055449</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_0b295d57-e45c-486b-be66-ca1f3f64b1be"
      unitRef="U_USD">-401303</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_2629f79e-6d5e-44b7-b91c-b41fd3a8740c"
      unitRef="U_USD">4552281</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_c20583ca-3e29-417c-bd6d-6fd7a3c15ff0"
      unitRef="U_USD">21471602</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_8a72664b-8a0b-49aa-a7e7-cdcfff9febe9"
      unitRef="U_USD">15489997</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_ed795e6d-17ac-4603-a9e2-012627e35762"
      unitRef="U_USD">23115123</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_f9f8c42c-010f-4dec-a5fc-2b430c26fd92"
      unitRef="U_USD">7431108</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_192ed667-af3a-4527-86a0-3330bc2756f1"
      unitRef="U_USD">7834155</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_7edfe247-6b9c-4ad6-be48-7edb1eade498"
      unitRef="U_USD">-22921105</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_006367ef-7bee-42f9-b3fe-70677996cf33"
      unitRef="U_USD">-30949278</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_68e5ea3c-df4d-40aa-96b7-ebffd530cd69"
      unitRef="U_USD">463256</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_48107b0d-3ff2-42fa-b443-d85fad52fa73"
      unitRef="U_USD">253323</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_e18b97e6-2afc-4ffc-9993-f3cebc4d5fc7"
      unitRef="U_USD">-10</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_99bea7e4-2f3d-4687-89ea-d7d95cfbe3f8"
      unitRef="U_USD">2704743</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_1a0ee101-d485-44a0-b0fc-3a288b8d78d7"
      unitRef="U_USD">-22457859</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_590e816f-d111-4daa-bded-a56057ac3aac"
      unitRef="U_USD">-27991212</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="2"
      id="F_5481acc9-0008-4b89-915d-cf8903463a2e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="2"
      id="F_005d259b-3894-4070-8937-dd227608d615"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="2"
      id="F_897361ad-ffb0-4551-be27-71d710a1be18"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="2"
      id="F_ccc6e582-9060-43f0-b463-07394e081509"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_f4314942-afc5-48c7-b985-2c0a0eac7832"
      unitRef="U_shares">34359945</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_4c49cb50-90b3-4361-b903-68fb4e184eb3"
      unitRef="U_shares">34359945</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_c0031e83-edd7-4827-ba31-1d445f7d0fbd"
      unitRef="U_shares">33672927</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_9d69bdd4-de1b-4708-942d-4308068485fb"
      unitRef="U_shares">33672927</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_6913bf67-c156-4245-aedf-963f938165bb"
      unitRef="U_USD">-138479</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_fb5479d1-df69-4859-b814-0b916eb2aad4"
      unitRef="U_USD">332801</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_a22d3f6b-dfd5-4c61-958d-0c7691d87003"
      unitRef="U_USD">-22596338</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_98c5ebc7-50fc-48ab-912d-b956508f558d"
      unitRef="U_USD">-27658411</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_b4568e37-46c0-4e69-b2ec-5733ed214cac"
      decimals="INF"
      id="F_69f78996-5d0d-4ef5-bb3b-978d280be5cc"
      unitRef="U_shares">33476523</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b4568e37-46c0-4e69-b2ec-5733ed214cac"
      decimals="0"
      id="F_078755be-cc18-43c7-9852-d0ff06208cf6"
      unitRef="U_USD">335</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fb24caa1-2baa-4a9a-bc97-8c26392c5c44"
      decimals="0"
      id="F_74f08238-a74e-4ffa-9d1d-88f1e0f81053"
      unitRef="U_USD">107349265</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9607a901-9bb0-4a3b-a4c9-d3098e66534e"
      decimals="0"
      id="F_093d72b5-2b58-4031-b86f-16e547f90c56"
      unitRef="U_USD">-625269</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cdfdfaeb-561e-445c-ae5b-25b64f9aebd2"
      decimals="0"
      id="F_833183b1-ad94-4d0f-a0c3-674226d2412f"
      unitRef="U_USD">-82947862</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8de82880-160e-43df-8a06-7bd23e1206fe"
      decimals="0"
      id="F_eaf9f8ce-c50a-4288-a0ab-c6daafbc7dc4"
      unitRef="U_USD">23776469</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_0766000b-7486-4271-8d7f-0f025af31180"
      decimals="0"
      id="F_47614913-4583-475a-b813-3922b5cd8bec"
      unitRef="U_USD">-27991212</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_f9b0ce2c-d855-4b27-a38a-6648090d232e"
      unitRef="U_USD">-27991212</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_dc1f8474-7a37-45c5-a06a-9ca912012dca"
      decimals="0"
      id="F_8b21f4a6-3227-4209-a964-09edef719d3d"
      unitRef="U_USD">332801</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_216119d3-6f5a-49d6-a46d-cf1056a00e4f"
      unitRef="U_USD">332801</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b"
      decimals="INF"
      id="F_af9647ed-60d6-4f46-a8f1-a7c4e1cd0384"
      unitRef="U_shares">60595</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b"
      decimals="0"
      id="F_025dd20d-479c-4052-b1a2-bb7473d124ba"
      unitRef="U_USD">1</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_477e462d-66f4-4337-b1ec-ca7e1946fed2"
      decimals="0"
      id="F_ec2a3122-e99a-4dbf-aaa3-1a45a70866e9"
      unitRef="U_USD">-1</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_a3d4aa56-8c19-4c84-bd37-8715c823130e"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b"
      decimals="0"
      id="F_e4121279-022b-4587-9329-d723c0a8d8ac"
      unitRef="U_shares">258648</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b"
      decimals="0"
      id="F_c920117e-935a-4aa7-83d8-517e52a9a7ef"
      unitRef="U_USD">2</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_477e462d-66f4-4337-b1ec-ca7e1946fed2"
      decimals="0"
      id="F_7bca4319-1940-411f-a107-55b87b7d4ed8"
      unitRef="U_USD">1593</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_71ce9c15-f2ae-4661-b95b-372d16694f0d"
      unitRef="U_USD">1595</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b"
      decimals="0"
      id="F_c5792dfa-6b86-407b-8306-5b5793c5b953"
      unitRef="U_shares">20872</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_477e462d-66f4-4337-b1ec-ca7e1946fed2"
      decimals="0"
      id="F_fa4490e8-afe0-4fa5-9ef6-e1e4189f8047"
      unitRef="U_USD">75</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_1e4b49d1-5e6c-4f9b-b98b-3d0d4eb93fc9"
      unitRef="U_USD">75</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <inkt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
      contextRef="C_477e462d-66f4-4337-b1ec-ca7e1946fed2"
      decimals="0"
      id="F_8fe0640c-b54a-4633-aff9-9ea886a88e85"
      unitRef="U_USD">3089583</inkt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition>
    <inkt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_b554306f-b2e0-4cce-b2eb-729796505e8c"
      unitRef="U_USD">3089583</inkt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_477e462d-66f4-4337-b1ec-ca7e1946fed2"
      decimals="0"
      id="F_06fd159a-7ff8-438f-865c-5888fd47198a"
      unitRef="U_USD">96013</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_9cada9be-05c0-46bf-8789-950fb493eb83"
      unitRef="U_USD">96013</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b"
      decimals="0"
      id="F_78516f39-6dcc-4b17-8fc9-440e6baa3735"
      unitRef="U_shares">125199</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b"
      decimals="0"
      id="F_fe907362-9d1b-4d45-b9da-3ccf6f74d20b"
      unitRef="U_USD">1</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="C_477e462d-66f4-4337-b1ec-ca7e1946fed2"
      decimals="0"
      id="F_edcbd20b-69d4-45de-8a5a-5480b7e2a0fe"
      unitRef="U_USD">293522</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <inkt:TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="C_dc88111c-fde0-4875-b17d-3dcd2f81ff4a"
      decimals="0"
      id="F_6926898f-00c8-4a93-8fca-56cf14d34d00"
      unitRef="U_shares">-43665</inkt:TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="C_dc88111c-fde0-4875-b17d-3dcd2f81ff4a"
      decimals="0"
      id="F_d27f319b-9775-43fa-b255-f9ea9b032206"
      unitRef="U_USD">-157194</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_34b9d9ea-6d38-4f84-87a3-ef8d0521b869"
      unitRef="U_USD">136329</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="C_1d964ed6-c838-4b91-88e6-d8a11d681d1b"
      decimals="0"
      id="F_74380b1f-26bf-4d91-8d88-1bef72f66db6"
      unitRef="U_shares">-43665</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="C_dc88111c-fde0-4875-b17d-3dcd2f81ff4a"
      decimals="0"
      id="F_4eab3950-888e-4385-b4fd-03ccb2c52b4e"
      unitRef="U_shares">43665</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="C_dc88111c-fde0-4875-b17d-3dcd2f81ff4a"
      decimals="0"
      id="F_21c0bfb7-856f-4ed9-95b3-e34fc644b65d"
      unitRef="U_USD">157194</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_af79edf6-bdc2-44d4-bb8a-d3baa78ab5be"
      unitRef="U_USD">157194</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:SharesOutstanding
      contextRef="C_b7f39df2-940c-4946-a3d9-f259147aae28"
      decimals="INF"
      id="F_da39c648-feaf-4e86-b299-749c8016110a"
      unitRef="U_shares">33856428</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b7f39df2-940c-4946-a3d9-f259147aae28"
      decimals="0"
      id="F_1d6187d4-d685-47f2-8be1-622a2e91fd8e"
      unitRef="U_USD">339</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b6874be7-da49-437b-ba93-4e3f9f01d838"
      decimals="0"
      id="F_2512bb95-9d01-45a6-84e9-20dfb1049403"
      unitRef="U_USD">110829900</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c28b56ad-700c-422d-b0b5-3496a8befd3a"
      decimals="0"
      id="F_4aa5a08a-1f60-4d21-a6e1-789104c7340e"
      unitRef="U_USD">-292468</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5eaab94b-6260-4a4a-a00c-52210c750bbd"
      decimals="0"
      id="F_b6e1c56e-0086-43b9-a7e7-4abb5bd16ece"
      unitRef="U_USD">-110939074</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_2592d471-104d-4364-a340-87994d458235"
      unitRef="U_USD">-401303</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_8e90aa4c-d975-4aee-8b77-ed3c9b0a38c0"
      decimals="0"
      id="F_358d8cad-6922-42d9-99b2-3df25325020b"
      unitRef="U_USD">-22457859</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_3f722f23-7c6b-4bcb-be42-cec67b4b5540"
      unitRef="U_USD">-22457859</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_b1cce805-eca1-48ac-8a3e-95ff6ff8052a"
      decimals="0"
      id="F_00c1bf81-3257-4bdf-901e-5b583847b550"
      unitRef="U_USD">-138479</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_904f11f8-50a4-4c47-abf7-160f9dd30ae0"
      unitRef="U_USD">-138479</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_30769c45-3fd9-4704-8227-5041637f5332"
      decimals="INF"
      id="F_d83d4e00-024e-4d35-a617-49b118153a3f"
      unitRef="U_shares">175196</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_30769c45-3fd9-4704-8227-5041637f5332"
      decimals="0"
      id="F_7c1a8732-268e-4544-8347-a283f83d54e8"
      unitRef="U_USD">2</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_9a95821e-13b6-49df-9115-37827f9a727f"
      decimals="0"
      id="F_98878cc9-2ede-4fad-a7fe-fc97ff8ca678"
      unitRef="U_USD">-2</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <inkt:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="C_30769c45-3fd9-4704-8227-5041637f5332"
      decimals="0"
      id="F_0b561304-6a63-49d7-a509-c3a59bdbceb4"
      unitRef="U_shares">144527</inkt:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <inkt:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="C_30769c45-3fd9-4704-8227-5041637f5332"
      decimals="0"
      id="F_a41c8787-983a-43f5-9843-aed3bb122a59"
      unitRef="U_USD">1</inkt:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <inkt:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="C_9a95821e-13b6-49df-9115-37827f9a727f"
      decimals="0"
      id="F_db744a6a-2c98-498d-a738-54bd9c791b6f"
      unitRef="U_USD">70465</inkt:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <inkt:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_bff3e799-070a-4b07-b58f-fc251d22350e"
      unitRef="U_USD">70466</inkt:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="C_30769c45-3fd9-4704-8227-5041637f5332"
      decimals="INF"
      id="F_ee78ea52-2e7c-4531-82ec-e175c58f8502"
      unitRef="U_shares">-192</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_30769c45-3fd9-4704-8227-5041637f5332"
      decimals="0"
      id="F_40f2049c-336d-4770-8eee-a93b8aeb887a"
      unitRef="U_shares">25209</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_9a95821e-13b6-49df-9115-37827f9a727f"
      decimals="0"
      id="F_df789775-af71-4594-a8ca-053ba94a6d50"
      unitRef="U_USD">30000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_726f93f4-98a8-4292-9d8d-6a256a73ad30"
      unitRef="U_USD">30000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <inkt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
      contextRef="C_9a95821e-13b6-49df-9115-37827f9a727f"
      decimals="0"
      id="F_0c1a4494-f2c9-44f2-b6ba-071120c81e45"
      unitRef="U_USD">3698436</inkt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition>
    <inkt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_c63a7cd9-2e78-4f17-a075-cc2ca73ea804"
      unitRef="U_USD">3698436</inkt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_9a95821e-13b6-49df-9115-37827f9a727f"
      decimals="0"
      id="F_ddf35436-b499-479e-89bf-ef36daddf8f7"
      unitRef="U_USD">131930</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_16e3274d-5222-4025-871f-76509f456734"
      unitRef="U_USD">131930</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="C_30769c45-3fd9-4704-8227-5041637f5332"
      decimals="INF"
      id="F_4fc0d9b8-fbc6-49ea-a887-4e4df9715842"
      unitRef="U_shares">603830</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="C_30769c45-3fd9-4704-8227-5041637f5332"
      decimals="0"
      id="F_c4b8e88a-1af2-43c9-aa4c-1538e24db430"
      unitRef="U_USD">6</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="C_9a95821e-13b6-49df-9115-37827f9a727f"
      decimals="0"
      id="F_b00f7b2b-4978-4950-85b6-0c27103c3130"
      unitRef="U_USD">1011356</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <inkt:TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="C_92fa1c95-ab93-4332-a14e-01ee475bc615"
      decimals="0"
      id="F_67eebc98-fec3-4f93-8f22-9ebcc3bbaa4e"
      unitRef="U_shares">205879</inkt:TreasuryStockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="C_92fa1c95-ab93-4332-a14e-01ee475bc615"
      decimals="0"
      id="F_e540c983-e19c-41ed-9e0f-fc7ee81b0f32"
      unitRef="U_USD">-477639</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_5c8fd558-869c-427b-998b-9c46a88e1b9c"
      unitRef="U_USD">533723</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="C_30769c45-3fd9-4704-8227-5041637f5332"
      decimals="0"
      id="F_a1e26a67-8f7f-48f9-bfc8-fb2be83ac661"
      unitRef="U_shares">-205879</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="C_30769c45-3fd9-4704-8227-5041637f5332"
      decimals="0"
      id="F_8ecd572d-504e-4eed-82c8-6358732aab7e"
      unitRef="U_USD">-2</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="C_92fa1c95-ab93-4332-a14e-01ee475bc615"
      decimals="0"
      id="F_c062b36b-12f4-430c-8026-f8c9aa573936"
      unitRef="U_shares">205879</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="C_92fa1c95-ab93-4332-a14e-01ee475bc615"
      decimals="0"
      id="F_5204c675-589d-46d8-9501-a1d7bf13dab4"
      unitRef="U_USD">477639</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_7c702246-c797-4446-bc22-fce017e36431"
      unitRef="U_USD">477637</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:SharesOutstanding
      contextRef="C_eb216ed3-85fe-4453-894a-011e3ac6dfb1"
      decimals="INF"
      id="F_c85bcb76-9dc8-4749-a95a-d7fb9327daa2"
      unitRef="U_shares">34599119</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_eb216ed3-85fe-4453-894a-011e3ac6dfb1"
      decimals="0"
      id="F_b08d0721-06f2-41e4-b40e-403da170f3c4"
      unitRef="U_USD">346</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7e66d751-8e58-4e0e-9b7c-eba65cf04289"
      decimals="0"
      id="F_b1fa4f07-d4d1-43e1-adfb-f7d05eed35c5"
      unitRef="U_USD">115772085</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_42c15bdd-fb56-4487-acc5-a92fa8762921"
      decimals="0"
      id="F_00fa648e-834d-4afd-a0d9-f61d504f0ff2"
      unitRef="U_USD">-430947</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b96f833e-9e89-4940-890a-3ad3066d1a3f"
      decimals="0"
      id="F_5ce49b4d-a78e-45c2-b17c-4b393eb39887"
      unitRef="U_USD">-133396933</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_9c9f9297-4da9-4709-a44c-32878133a6a2"
      unitRef="U_USD">-18055449</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_59220876-8bab-4519-aa66-3218d0890bdf"
      unitRef="U_USD">-22457859</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_ceeeb0c4-fc0a-44e4-bd33-2a3f9b518c4f"
      unitRef="U_USD">-27991212</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_786627a7-da57-4968-973a-6c7748e1d05b"
      unitRef="U_USD">204617</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_0950b8ad-dbff-4ec4-bc40-7dd0797d662c"
      unitRef="U_USD">121749</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_c57c0091-fbd5-461a-9d30-5a4068fdaf41"
      unitRef="U_USD">3860366</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_427e6c47-6f76-4a84-909a-38635b7a57aa"
      unitRef="U_USD">3026846</us-gaap:ShareBasedCompensation>
    <inkt:GainOnForgivenessOfLiability
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_183f152b-e388-4dc2-ab55-c3b491f00f17"
      unitRef="U_USD">266780</inkt:GainOnForgivenessOfLiability>
    <inkt:GainOnForgivenessOfLiability
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_1517be72-e7f5-450a-8686-ad14468cb60c"
      unitRef="U_USD">2790809</inkt:GainOnForgivenessOfLiability>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_614734fc-8851-4841-9a2d-e9308c19181b"
      unitRef="U_USD">-245589</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_40127bdb-3cef-4c32-8cad-fbec9d0979cf"
      unitRef="U_USD">296945</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_d72af638-a465-494e-8153-e792742d5399"
      unitRef="U_USD">-1917557</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_510ee884-f707-4cb5-be9b-49e3fc3f698d"
      unitRef="U_USD">2660769</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_b0f2a7b2-7e12-45a7-ada7-414cb4e3fe47"
      unitRef="U_USD">2025124</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_5ebc53ab-a36b-4a73-840f-ecaa01982367"
      unitRef="U_USD">3424921</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_c9a57a35-ba90-49c0-b196-d2bfb6b56b24"
      unitRef="U_USD">-2543988</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_896b2fe9-68e6-43fc-9e7c-38534a3b9bbe"
      unitRef="U_USD">-2977838</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_35e32c59-801d-484c-8fd6-060faf305b42"
      unitRef="U_USD">-15762512</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_17094891-3f32-4f05-8f94-e0da8b3d45a1"
      unitRef="U_USD">-18866843</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_3f04885c-87f4-41ee-a769-5031a368141d"
      unitRef="U_USD">73561</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_a13e172e-1245-47f5-96f8-8b757b47e955"
      unitRef="U_USD">250046</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_a962d829-95cd-40e7-88c1-f024c13c25f3"
      unitRef="U_USD">-73561</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_64beb46a-df06-4217-9614-0e2001b85fe8"
      unitRef="U_USD">-250046</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <inkt:PurchaseOfTreasurySharesToSatisfyTaxWithholdings
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_2296ee7d-3039-4938-8058-6d276d771bbf"
      unitRef="U_USD">477639</inkt:PurchaseOfTreasurySharesToSatisfyTaxWithholdings>
    <inkt:PurchaseOfTreasurySharesToSatisfyTaxWithholdings
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_12f412e5-2b0c-412c-80c4-72431d764ada"
      unitRef="U_USD">157194</inkt:PurchaseOfTreasurySharesToSatisfyTaxWithholdings>
    <inkt:ProceedsFromEmployeeStockPurchasesAndOptionExercises
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_6d9586b8-4c5b-4d15-90ce-6b69c5a92246"
      unitRef="U_USD">70466</inkt:ProceedsFromEmployeeStockPurchasesAndOptionExercises>
    <inkt:ProceedsFromEmployeeStockPurchasesAndOptionExercises
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_0406c280-b076-45b1-a99d-ab8c4dfa509e"
      unitRef="U_USD">1595</inkt:ProceedsFromEmployeeStockPurchasesAndOptionExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_100713a2-acbf-410a-85c3-1dff7776d27f"
      unitRef="U_USD">-407173</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_ea9ff608-cdb8-408d-a0f2-e9e89b90f434"
      unitRef="U_USD">-155599</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_ec9cd058-8039-4e2c-b693-70b5113893df"
      unitRef="U_USD">-25250</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_e8dc15de-1f17-4021-bef9-a5be67f3626c"
      unitRef="U_USD">19385</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_08fe6876-5c1b-4e97-89f1-890d8994df01"
      unitRef="U_USD">-16268496</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_d8702cd7-57ee-47c8-b6ac-11d538035182"
      unitRef="U_USD">-19253103</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_3c1c7d42-cb7e-4c2f-b570-6eef1d337eb1"
      unitRef="U_USD">19635725</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_8de82880-160e-43df-8a06-7bd23e1206fe"
      decimals="0"
      id="F_154b9c4b-0d39-4d83-b391-f394e94e043a"
      unitRef="U_USD">38888828</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_fb8704a5-34d1-46a3-9e0a-a52b06884265"
      unitRef="U_USD">3367229</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="0"
      id="F_a45ad5d7-1397-4d86-bc4e-ce2ac3398330"
      unitRef="U_USD">19635725</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_a1c0fbed-89a4-478e-8ae9-840a4c988ee2"
      unitRef="U_USD">27509</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_4f3aa5aa-a854-434d-8710-bfb111ffe0e5"
      unitRef="U_USD">10820</us-gaap:InterestPaidNet>
    <inkt:PurchasesOfPlantAndEquipmentInAccountsPayable
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_cd81e407-17bd-4525-84c8-113ec534a452"
      unitRef="U_USD">177680</inkt:PurchasesOfPlantAndEquipmentInAccountsPayable>
    <inkt:InsuranceFinancingAgreement
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_783ae20b-f56a-4fff-9ba7-9436a5db81e3"
      unitRef="U_USD">109000</inkt:InsuranceFinancingAgreement>
    <inkt:InsuranceFinancingAgreement
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_a094fed5-4299-4b7e-98cb-595a4af8c660"
      unitRef="U_USD">444000</inkt:InsuranceFinancingAgreement>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_442d530a-bd9b-4549-9f81-dfaba599e462"
      decimals="INF"
      id="F_20cca5b2-11bd-459f-8d1b-cd54b377320b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssued1
      contextRef="C_d36c7999-649a-4daf-ab6e-976ec054bb05"
      decimals="0"
      id="F_f10aa0b2-29c1-45f7-b782-0d12532576ad"
      unitRef="U_USD">1011360</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="C_b57bd5bc-4306-4671-aabe-7907cd2bac83"
      decimals="0"
      id="F_c7d0f0e6-1967-4767-b23a-b449dd047414"
      unitRef="U_USD">293523</us-gaap:StockIssued1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_9e054ad4-ee65-43e9-bf29-ab336dac222b"
      decimals="INF"
      id="F_9751d715-0231-4f9e-b3cd-795962b360ce"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssued1
      contextRef="C_419eb5b2-74d7-426a-8de0-6ec785c7a7e5"
      decimals="0"
      id="F_77f14baa-0fca-4679-b6f7-1ad90bf011e2"
      unitRef="U_USD">30000</us-gaap:StockIssued1>
    <us-gaap:NatureOfOperations
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_5b6a18f9-ed7a-4b43-b342-e92a568ce556">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1) Description of Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;MiNK Therapeutics, Inc. (&#x201c;MiNK&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company pioneering a novel platform of living medicines based on a rare and potent class of immune cells called invariant natural killer T (&#x201c;iNKT&#x201d;) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. MiNK's proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, MiNK believes that its approach represents a highly versatile application for therapeutic development in cancer and immune diseases. MiNK is leveraging its platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of both native and engineered iNKT cells.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since its inception in 2017, MiNK has incurred losses and expects to continue incurring operating losses and negative cash flows in the future until it is able to generate sales and profits. As of December 31, 2023, MiNK had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;133.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and cash and cash equivalents of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;MiNK believes that its cash and cash equivalents balance along with the additional funding received subsequent to year end from its parent, Agenus Inc. (&#x201c;Agenus&#x201d;), and funding planned from a third party will be sufficient to satisfy its liquidity requirements for more than one year from when these financial statements were issued. Because the additional funding is influenced by external uncertainties, in accordance with the relevant accounting guidance, the Company is required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Annual Report on Form 10-K. The financial statements have been prepared on a basis that assumes MiNK will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Management continually monitors MiNK's liquidity position and adjusts spending as needed in order to preserve liquidity. Potential sources of additional funding for the Company include: (1) seeking strategic partnerships and collaborations, as well as out-licensing opportunities, for the Company's portfolio programs and product candidates, (2) exploring avenues for securing non-dilutive financing, such as grants and collaborations to strengthen the Company's balance sheet, and (3) potential of equity or debt financing options. If additional funding is not obtained through these sources, Agenus has indicated a willingness to loan MiNK additional funds to finance its operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;MiNK&#x2019;s product candidates are in various stages of development and additional expenditures will be required if the Company starts new trials, encounters delays in its programs, applies for regulatory approvals, continues development of its technologies, expands its operations, and/or brings its product candidates to market. The eventual total cost of each clinical trial is dependent on a number of factors such as trial design, length of the trial, number of clinical sites, and number of patients. The process of obtaining and maintaining regulatory approvals for new therapeutic products is lengthy, expensive, and uncertain. Because all of the Company&#x2019;s programs are at an early stage of clinical development, the Company is unable to reliably estimate the cost of completing its research and development programs or the timing for bringing such programs to various markets or substantial partnering or out-licensing arrangements, and, therefore, when, if ever, material cash inflows are likely to commence&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-5"
      id="F_ea7d9ae4-c0f5-41df-9900-dbf8bb362e01"
      unitRef="U_USD">-133400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-5"
      id="F_853c1fdb-19f5-475d-a175-8f2cacc1c548"
      unitRef="U_USD">3400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_d6dd51c9-5aa1-4881-88f6-af7956155eb3">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2) Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(a) Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include the accounts of MiNK and its subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(b) Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;MiNK is managed and operated as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; business segment. The entire business is managed by a single executive operating committee that reports to the chief executive officer. The Company does not operate separate lines of business with respect to any of its product candidates or geographic locations. Accordingly, the Company does not prepare discrete financial information with respect to separate product areas or by location and does not have separately reportable segments as defined by Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 280, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(c) Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases those estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(d) Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments purchased with maturities at acquisition of three months or less to be cash equivalents. Cash equivalents consist primarily of money market funds.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(e) Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equipment is carried at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, typically &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Additions are capitalized, while repairs and maintenance are charged to expense as incurred. Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;205,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(f) Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:0.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.3553803871825076%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:0.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.3553803871825076%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&#x2014;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:0.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.3553803871825076%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s cash and cash equivalents are carried at fair value (a Level 1 measurement), determined according to the fair value hierarchy described above. The carrying values of the Company&#x2019;s, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(g) Foreign Currency Transactions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Gains and losses from the Company&#x2019;s foreign currency-based accounts and transactions, such as those resulting from the remeasurement and settlement of receivables and payables denominated in foreign currencies, are included in the consolidated statements of operations within other income (expense). The Company recorded de minimis foreign currency losses for the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(h) Research and Development&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses include the costs associated with the Company&#x2019;s internal research and development activities, including salaries and benefits, share-based compensation, occupancy costs, clinical manufacturing costs, related administrative costs and research and development conducted for the Company by outside advisors. Research and development expenses also include the cost of clinical trial materials shipped to the Company&#x2019;s research partners. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(i) Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;MiNK accounts for share-based compensation in accordance with the provisions of ASC 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Compensation&#x2014;Stock Compensation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Share-based &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;compensation expense is recognized based on the estimated grant date fair value. Compensation cost is recognized on a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;straight-line &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;basis over the requisite service period of the award. Forfeitures are recognized as they occur. See Note 8 for further discussion on share-based compensation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(j) Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method with deferred tax assets and liabilities recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and net operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such items are expected to be reversed or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statement of operations in the period that includes the enactment date. Deferred tax assets are recognized when they are more likely than not expected to be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(k) Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic income or loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted income per common share is calculated by dividing net income attributable to common stockholders by the weighted average number of common shares outstanding plus the dilutive effect of outstanding instruments such as stock options. Because the Company reported a net loss attributable to common stockholders for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of December 31, 2023 and 2022, as they would be anti-dilutive: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.78%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.2%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.82%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,945,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,148,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;789,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;726,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(l) Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. As the Company has a single reportable segment, MiNK expects the adoption of this standard to result in increased disclosures in the notes to its consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. For the Company, ASU 2023-09 is effective for fiscal years beginning after December 15, 2025. Early adoption is permitted for any annual periods for which financial statements have not been issued or made available for issuance. The Company is currently evaluating the impact that ASU 2023-09 will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;No other new accounting pronouncement issued or effective during the year ended December 31, 2023 had or is expected to have a material impact on the Company&#x2019;s consolidated financial statements or disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_8d3edb34-d5a6-4892-a29f-dc184b26f5f3">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(a) Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include the accounts of MiNK and its subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_aad095a0-5f49-45c3-b0d0-ff74b238572e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(b) Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;MiNK is managed and operated as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; business segment. The entire business is managed by a single executive operating committee that reports to the chief executive officer. The Company does not operate separate lines of business with respect to any of its product candidates or geographic locations. Accordingly, the Company does not prepare discrete financial information with respect to separate product areas or by location and does not have separately reportable segments as defined by Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 280, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="INF"
      id="F_87e5951a-eca2-429d-bd33-573d16e52adb"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_a4ebe5bd-2761-446d-922d-44cf1fba7475">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(c) Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases those estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_c3774819-5a5d-47e4-a7a0-707ade9045ea">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(d) Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments purchased with maturities at acquisition of three months or less to be cash equivalents. Cash equivalents consist primarily of money market funds.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_d9acbe38-e5ed-41e7-a751-040ca5e72139">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(e) Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equipment is carried at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, typically &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Additions are capitalized, while repairs and maintenance are charged to expense as incurred. Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;205,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_26d61948-a095-4072-b5b4-5cab95d54532"
      id="F_0aec5014-44cd-4e62-af37-e2b225f8f82f">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_42074970-bc84-4a58-b664-9c0013d5b65b"
      id="F_eb59c53d-359a-44ae-a369-47a3113dc257">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <inkt:DepreciationExpenseOnPropertyPlantAndEquipment
      contextRef="C_8b187843-724c-4035-a8bd-2721f3e23008"
      decimals="0"
      id="F_5a6492e7-b8c9-41c0-8be3-d500d0444ce6"
      unitRef="U_USD">205000</inkt:DepreciationExpenseOnPropertyPlantAndEquipment>
    <inkt:DepreciationExpenseOnPropertyPlantAndEquipment
      contextRef="C_84ae0517-023d-4ec4-b8be-679864cc08aa"
      decimals="0"
      id="F_646548c3-6074-49b2-8ab1-62c9685253c1"
      unitRef="U_USD">122000</inkt:DepreciationExpenseOnPropertyPlantAndEquipment>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_89f23d92-ea5f-44a4-80c3-9c3b88d3b2d8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(f) Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:0.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.3553803871825076%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:0.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.3553803871825076%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&#x2014;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:0.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.3553803871825076%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s cash and cash equivalents are carried at fair value (a Level 1 measurement), determined according to the fair value hierarchy described above. The carrying values of the Company&#x2019;s, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_c55850dd-6d82-4790-b234-45d627836f8d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(g) Foreign Currency Transactions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Gains and losses from the Company&#x2019;s foreign currency-based accounts and transactions, such as those resulting from the remeasurement and settlement of receivables and payables denominated in foreign currencies, are included in the consolidated statements of operations within other income (expense). The Company recorded de minimis foreign currency losses for the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_6b479ebe-c8a9-4faf-aa11-750d2078233f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(h) Research and Development&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses include the costs associated with the Company&#x2019;s internal research and development activities, including salaries and benefits, share-based compensation, occupancy costs, clinical manufacturing costs, related administrative costs and research and development conducted for the Company by outside advisors. Research and development expenses also include the cost of clinical trial materials shipped to the Company&#x2019;s research partners. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_a6d7f527-a14d-40de-99a6-4a14a2005c98">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(i) Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;MiNK accounts for share-based compensation in accordance with the provisions of ASC 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Compensation&#x2014;Stock Compensation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Share-based &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;compensation expense is recognized based on the estimated grant date fair value. Compensation cost is recognized on a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;straight-line &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;basis over the requisite service period of the award. Forfeitures are recognized as they occur. See Note 8 for further discussion on share-based compensation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_48089223-12ce-4638-9d4e-09e2d23b2a29">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(j) Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method with deferred tax assets and liabilities recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and net operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such items are expected to be reversed or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statement of operations in the period that includes the enactment date. Deferred tax assets are recognized when they are more likely than not expected to be realized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_9226f532-95e4-4609-ac21-65f8db6a5aeb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(k) Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic income or loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted income per common share is calculated by dividing net income attributable to common stockholders by the weighted average number of common shares outstanding plus the dilutive effect of outstanding instruments such as stock options. Because the Company reported a net loss attributable to common stockholders for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of December 31, 2023 and 2022, as they would be anti-dilutive: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.78%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.2%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.82%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,945,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,148,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;789,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;726,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_711528de-011f-493c-8e6b-acaed1a9966b">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of December 31, 2023 and 2022, as they would be anti-dilutive: &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.78%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.2%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.82%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,945,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,148,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;789,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;726,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_dcf77660-1f56-4511-acbc-a3e5c157ebe0"
      decimals="0"
      id="F_02ba42c1-9394-4cda-81bc-6cf8237032ef"
      unitRef="U_shares">6945716</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f8ef24c4-afb3-478b-a8f5-beceae45922e"
      decimals="0"
      id="F_0927b3a7-f4e5-43c4-8dc9-ce93875790d7"
      unitRef="U_shares">6148447</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ab635f33-5c9a-416d-95b3-be4679d91964"
      decimals="0"
      id="F_6bd383b0-c5ab-4da2-a4e8-ec0249741e14"
      unitRef="U_shares">789503</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e412c6c7-5f47-4066-aab4-7147f2d0c3b8"
      decimals="0"
      id="F_1064ab54-0e85-42dd-bc36-b76a85797d13"
      unitRef="U_shares">726163</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_602a7e2a-a90d-4eec-a34d-9fd6a3aad355">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(l) Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires incremental annual and quarterly disclosures about segment measures of profit or loss as well as significant segment expenditures. It also requires public entities with a single reportable segment to provide all segment disclosures required by the amendments and all existing segment disclosures in Topic 280. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. As the Company has a single reportable segment, MiNK expects the adoption of this standard to result in increased disclosures in the notes to its consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires incremental annual disclosures around income tax rate reconciliations, income taxes paid and other related disclosures. For the Company, ASU 2023-09 is effective for fiscal years beginning after December 15, 2025. Early adoption is permitted for any annual periods for which financial statements have not been issued or made available for issuance. The Company is currently evaluating the impact that ASU 2023-09 will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;No other new accounting pronouncement issued or effective during the year ended December 31, 2023 had or is expected to have a material impact on the Company&#x2019;s consolidated financial statements or disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_318661fa-5e13-4eb7-95a1-55467c3269db">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3) Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents consisted of the following as of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as of December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:58.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:30.268%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.719%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.715%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.719%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.715%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.719%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.715%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.719%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.715%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Institutional money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_2e5e8264-a86f-4eb0-b54b-b69424362761">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents consisted of the following as of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as of December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:58.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:30.268%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.719%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.715%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.719%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.715%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.719%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.715%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.719%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.715%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Institutional money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_c81ea76b-898a-4328-bab5-6699b445169a"
      decimals="-3"
      id="F_dbe4b86f-9326-4f08-b2b0-724b193ca968"
      unitRef="U_USD">2899000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_c81ea76b-898a-4328-bab5-6699b445169a"
      decimals="-3"
      id="F_8e00464a-ee1c-4902-85ef-2888154a2e66"
      unitRef="U_USD">2899000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_6bed87a6-106d-428e-a478-dc518b3adca0"
      decimals="-3"
      id="F_23bba271-250c-48b4-b4a7-136122189151"
      unitRef="U_USD">18664000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_6bed87a6-106d-428e-a478-dc518b3adca0"
      decimals="-3"
      id="F_8a655a88-6fe4-4313-941c-4e6cb4864706"
      unitRef="U_USD">18664000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_e1dce775-1464-4135-b15a-c4c06ea07ceb">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4) Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equipment, net, consisted of the following as of December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.627%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.377%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.036999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_65d948d1-939e-455e-9acd-6a6b581e04d2">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equipment, net, consisted of the following as of December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.627%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.377%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.036999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_c13b02ab-7646-4965-9ed4-8c1cc5bf1b9b"
      unitRef="U_USD">1450000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-3"
      id="F_43ff30b4-d943-4873-8b86-582db88e34c0"
      unitRef="U_USD">1351000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_5584c452-5211-4384-a338-f9d0ba958b3f"
      unitRef="U_USD">496000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-3"
      id="F_16b357de-f7b8-4abf-8547-8d90a33e56d5"
      unitRef="U_USD">284000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_fa5b00a9-0717-49c1-9ecb-141ce21da128"
      unitRef="U_USD">954000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-3"
      id="F_3823d474-fbea-4435-b1ce-3466a658e067"
      unitRef="U_USD">1067000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_691d2950-8235-4771-abd8-8a53001b3591">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5) Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to taxation in the United States and in various state, local and foreign jurisdictions. The Company remains subject to examination by U.S. Federal, state, local and foreign tax authorities for tax years &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_bf9d2624-e5f8-4332-8ece-0d2f7a8edc9c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2019 through 2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. With few exceptions, the Company is no longer subject to U.S. Federal state, and foreign examinations by tax authorities for the tax year 2019. However, net operating losses from the tax year 2017 would be subject to examination if and when used in a future tax return to offset taxable income. The Company&#x2019;s policy is to recognize income tax related penalties and interest, if any, in its provision for income taxes and, to the extent applicable, in the corresponding income tax assets and liabilities, including any amounts for uncertain tax positions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had available net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for Federal and state income tax purposes, which are available to offset future Federal and state taxable income, if any. $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of these Federal net operating loss carryforwards do not expire, while the remaining net operating loss carryforwards expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_e22d9b5d-ce5f-4f3e-922e-62300307dbb9;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company&#x2019;s ability to use these net operating losses is limited by change of control provisions under Internal Revenue Code ("IRC") Section 382 and may expire unused. The Company also has foreign net operating loss carryforwards, which do not expire, available to offset future foreign taxable income of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million generated in the United Kingdom and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in Belgium. The potential impacts of these provisions are among the items considered and reflected in the Company&#x2019;s assessment of its valuation allowance requirements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Beginning January 1, 2022, the Tax Cuts and Jobs Act (the "Tax Act") eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to IRC Section 174. The capitalized expenses are amortized over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period for domestic expenses and a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;15-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period for foreign expenses. We have included the impact of this provision, which results in additional deferred tax assets of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023 and 2022 respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The tax effect of temporary differences and net operating loss carryforwards that give rise to significant portions of the deferred tax assets and deferred tax liabilities as of December 31, 2023 and 2022 are presented below (in thousands).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Federal and state net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the net operating loss and tax credit carryforwards can be utilized or the temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. To fully realize the deferred tax asset, the Company will need to generate future taxable income sufficient to utilize net operating losses prior to their expiration. Based upon the Company&#x2019;s history of not generating taxable income, the Company believes that it is more likely than not that deferred tax assets will not be realized through future earnings. Accordingly, a valuation allowance has been established for the full value of the deferred tax assets. The valuation allowance on the deferred tax assets increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income tax benefit was nil for the years ended December 31, 2023 and 2022. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes recorded differed from the amounts computed by applying the U.S. Federal income tax rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% in 2023 and 2022 to loss before income taxes as a result of the following (in thousands). &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computed &#x201c;expected&#x201d; Federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(Increase) reduction in income taxes benefit resulting from:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign rate change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign income inclusion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State and local income benefit, net of Federal income tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Return-to-provision adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_9103c720-7b6a-415f-96e7-4b1a21557321"
      decimals="-5"
      id="F_a923d698-506c-4bda-9de3-fbb49125d504"
      unitRef="U_USD">52300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_df7ebdbc-60ae-490c-baef-5224675cbc1f"
      decimals="-5"
      id="F_299b2a14-8e69-433c-a55a-647bbd05f968"
      unitRef="U_USD">52300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-5"
      id="F_fc8aea58-fc9c-4719-835a-18e7a7ef35d9"
      unitRef="U_USD">52100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_24cbce9b-fd20-4704-9a75-a6a645e49d55"
      decimals="-5"
      id="F_c4268e1e-51bb-44a6-a4be-55f887f59fd5"
      unitRef="U_USD">20500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_b28e3d23-d775-4bbd-9547-580645e3901f"
      decimals="-5"
      id="F_bd74f36c-f0af-46de-9ca3-64dbd6dac909"
      unitRef="U_USD">9100000</us-gaap:OperatingLossCarryforwards>
    <inkt:CapitalizedExpensesAmortizationPeriod
      contextRef="C_ee885642-fc14-4425-b334-06fb0a0d1eea"
      id="F_9558d9f1-d76b-45c8-bef1-b0bab16109de">P5Y</inkt:CapitalizedExpensesAmortizationPeriod>
    <inkt:CapitalizedExpensesAmortizationPeriod
      contextRef="C_6a1ac15f-c735-4f88-9b7d-d2ba5526a4fb"
      id="F_0e9954d7-fc3f-48e1-a627-a0c77aaf4949">P15Y</inkt:CapitalizedExpensesAmortizationPeriod>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-5"
      id="F_24a2fad6-0644-4e92-8ce6-9f4a4432336f"
      unitRef="U_USD">6500000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-5"
      id="F_a228c03b-9b28-4b98-ad27-2f9554d992b5"
      unitRef="U_USD">4200000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_35801499-bf4f-4e62-a60c-df0c98602444">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The tax effect of temporary differences and net operating loss carryforwards that give rise to significant portions of the deferred tax assets and deferred tax liabilities as of December 31, 2023 and 2022 are presented below (in thousands).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Federal and state net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_344c9df8-5d8b-4aec-80bd-62e0d0a67c0f"
      unitRef="U_USD">13804000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-3"
      id="F_531170fe-b478-47ba-8f03-d6a55d02a65c"
      unitRef="U_USD">11411000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_243a514f-55d4-40fc-9b59-5a282e5e0a0a"
      unitRef="U_USD">7819000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-3"
      id="F_edcd5e61-2eaa-4c32-94b9-65126a594afc"
      unitRef="U_USD">6224000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <inkt:DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_01fff03b-363c-4069-aeb6-cb3c72bf9f4e"
      unitRef="U_USD">341000</inkt:DeferredTaxAssetsInProcessResearchAndDevelopmentTaxCredits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_c32f0caf-d12e-4a98-beca-4e6507792e15"
      unitRef="U_USD">269000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-3"
      id="F_a418154f-9e75-465c-b8d1-82e89540d28f"
      unitRef="U_USD">441000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_686776dd-b54e-4acf-a75b-d6058ad8933f"
      unitRef="U_USD">6515000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-3"
      id="F_b681f85b-a277-40b2-a0aa-ccc39919483f"
      unitRef="U_USD">4154000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_4f0ea508-f2c9-402b-8f00-cbec8dfba4f4"
      unitRef="U_USD">926000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-3"
      id="F_7a482fc3-cf74-4852-a3a1-a82ee2df71c9"
      unitRef="U_USD">427000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_e75f5891-f3c4-4479-8962-0ec7d0e19513"
      unitRef="U_USD">29674000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-3"
      id="F_16d5ce12-ad2b-4f9c-830e-3b171cdbffe8"
      unitRef="U_USD">22657000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_cfacce62-ea69-4d8e-9338-48ee4175c319"
      unitRef="U_USD">29674000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-3"
      id="F_13b13bd6-e530-4174-8eab-602d0db98848"
      unitRef="U_USD">22657000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="-5"
      id="F_b7f1e4a6-9586-4738-a883-4b045631744e"
      unitRef="U_USD">7000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="-5"
      id="F_6c223909-914b-4ac2-b704-95f0632afed3"
      unitRef="U_USD">4000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_c2014581-8ed3-4915-91ec-2f047a3fd2e2">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes recorded differed from the amounts computed by applying the U.S. Federal income tax rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% in 2023 and 2022 to loss before income taxes as a result of the following (in thousands). &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computed &#x201c;expected&#x201d; Federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(Increase) reduction in income taxes benefit resulting from:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign rate change&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign income inclusion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State and local income benefit, net of Federal income tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Return-to-provision adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="INF"
      id="F_136947dc-fcec-4adc-943c-d1cc1e3496f9"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="INF"
      id="F_cbe56b93-6ece-4f23-a141-a56aceda366c"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="-3"
      id="F_f787dd91-ca1f-4913-ade7-759fc9332a0e"
      unitRef="U_USD">-4716000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="-3"
      id="F_634bc5dd-ec00-482c-b8d1-c7be41a09501"
      unitRef="U_USD">-5878000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="-3"
      id="F_05aa33dc-d8b2-4ff4-87c5-134bfe698bfa"
      unitRef="U_USD">5987000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="-3"
      id="F_afc335d4-aaca-4555-a939-ce0cd179de2d"
      unitRef="U_USD">4028000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <inkt:EffectiveIncomeTaxRateReconciliationForeignRateChange
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="-3"
      id="F_e8234358-63ba-4ded-8ee9-61d24e74d4b2"
      unitRef="U_USD">-842000</inkt:EffectiveIncomeTaxRateReconciliationForeignRateChange>
    <inkt:EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="-3"
      id="F_8d75e5a9-d115-4c3d-a514-a24a98b6ec37"
      unitRef="U_USD">-21000</inkt:EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion>
    <inkt:EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="-3"
      id="F_859eaf50-9f50-4878-ba9b-d3651a236687"
      unitRef="U_USD">530000</inkt:EffectiveIncomeTaxRateReconciliationForeignIncomeInclusion>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="-3"
      id="F_43749af1-1b68-4448-a078-8dfd5a13469a"
      unitRef="U_USD">-1693000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="-3"
      id="F_0a001fee-3238-4a3d-ba99-f94267fa2884"
      unitRef="U_USD">-104000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <inkt:IncomeTaxReconciliationReturnToProvisionAdjustment
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="-3"
      id="F_604b1013-e8c9-49b7-96a4-fb1181013888"
      unitRef="U_USD">1393000</inkt:IncomeTaxReconciliationReturnToProvisionAdjustment>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="-3"
      id="F_e8e344c0-09ba-47df-87c9-2dbea10d79cc"
      unitRef="U_USD">286000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="-3"
      id="F_edfdc3d5-bf1e-44a0-9668-1da7546b0db7"
      unitRef="U_USD">840000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="-3"
      id="F_bab35099-5468-47c1-acb1-9a6bf1c7e9ef"
      unitRef="U_USD">348000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="-3"
      id="F_eef8131c-9c16-40aa-b383-28844e83ebad"
      unitRef="U_USD">-397000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="-3"
      id="F_f51c27d4-31d3-42e0-bf8f-3c72cc9addf5"
      unitRef="U_USD">239000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_2397572f-c0a1-4211-b90c-6d5ef4581f32">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(6) Accrued Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued liabilities consist of the following as of December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Payroll&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contract manufacturing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_7461430e-1345-42ba-afc1-54f3d62689f3">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued liabilities consist of the following as of December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Payroll&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contract manufacturing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_08b3b4ec-27ae-4cde-81d3-6a4cc8ccbfbd"
      unitRef="U_USD">1831000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-3"
      id="F_97b505db-a363-4815-bba3-52b6cde1fbb8"
      unitRef="U_USD">1655000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_c66b5713-f03d-4488-b510-6f61808dcbfa"
      unitRef="U_USD">398000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-3"
      id="F_d90d11c0-3322-4830-83e2-0f26854e1779"
      unitRef="U_USD">642000</us-gaap:AccruedProfessionalFeesCurrent>
    <inkt:AccruedResearchServicesCurrent
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_fe06921a-57c9-4a39-bdc9-571d32caa4b5"
      unitRef="U_USD">302000</inkt:AccruedResearchServicesCurrent>
    <inkt:AccruedResearchServicesCurrent
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-3"
      id="F_1ffb5689-0501-40c4-b89f-2882c3455c66"
      unitRef="U_USD">1681000</inkt:AccruedResearchServicesCurrent>
    <inkt:AccruedContractManufacturingExpenseCurrent
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_9f6b9868-fd51-4d21-b457-51521fcc94cf"
      unitRef="U_USD">2430000</inkt:AccruedContractManufacturingExpenseCurrent>
    <inkt:AccruedContractManufacturingExpenseCurrent
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-3"
      id="F_31eaaf19-e5da-4d83-a091-3b09a94065f1"
      unitRef="U_USD">261000</inkt:AccruedContractManufacturingExpenseCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_febe64fd-c9c8-4923-9c1d-2942d5b535b7"
      unitRef="U_USD">76000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-3"
      id="F_a9741885-df69-4dcc-a8e1-ea2c75f01e46"
      unitRef="U_USD">5037000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="-3"
      id="F_7755227a-f388-476b-8530-a219e81f8cd8"
      unitRef="U_USD">4239000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_e7b584dd-f1c1-4a9d-a6f4-22ff2584aa5c">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7) Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s authorized capital stock consists of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, all with a par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, of which:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares are designated as common stock; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares are designated as preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <inkt:AuthorizedCapitalStockIncreased
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="INF"
      id="F_03993ac9-c2ac-49ee-a619-f073694b9935"
      unitRef="U_shares">155000000</inkt:AuthorizedCapitalStockIncreased>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="INF"
      id="F_1a9129de-5404-4290-a2b8-bb15919525f1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="INF"
      id="F_44734f6d-e75b-44b6-9603-b6389fe38365"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="INF"
      id="F_19088dbe-7fec-4b12-9c8c-4bafa5c97a7f"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_eac12b90-420d-4050-8333-d5af6cb1fef2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(8) Share-based Compensation Plans&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;) provided for the grant of incentive stock options intended to qualify under Section 422 of the IRC, nonstatutory stock options, restricted stock, unrestricted stock and other equity-based awards, such as stock appreciation rights, and stock units including restricted stock units for up to approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares of the Company&#x2019;s common stock (subject to adjustment in the event of stock splits and other similar events). As of December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares remain available for issuance under the 2018 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;), MiNK&#x2019;s board of directors adopted the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;). The 2021 Plan provides for the grant of incentive stock options intended to qualify under Section 422 of the Code, nonstatutory stock options, restricted stock, unrestricted stock and other equity-based awards, for an initial share pool of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares of the Company&#x2019;s common stock (subject to adjustment in the event of stock splits and other similar events). The initial share pool will automatically increase on January 1st of each year from 2024 to 2031 by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; percent of the number of shares of the Company&#x2019;s common stock outstanding as of the close of business on the immediately preceding December 31st and (ii) the number of shares determined by the Company&#x2019;s board of directors on or prior to such date for such year. In January 2022 and 2023, the 2021 Plan share pool increased by approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares, respectively. As of December 31, 2023, there were approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares reserved for issuance under the 2021 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the Company&#x2019;s IPO, MiNK&#x2019;s board of directors adopted the MiNK Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The ESPP provides eligible employees the opportunity to acquire the Company&#x2019;s common stock in a program designed to comply with Section 423 of the Code. There are approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares reserved for issuance under the ESPP, plus an automatic annual increase on January 1st of each year from 2024 to 2031 equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; percent of the number of shares of the Company&#x2019;s common stock outstanding as of the close of business on the immediately preceding December 31st and (ii) the number of shares determined by the Company&#x2019;s board of directors on or prior to such date for such year, up to a maximum of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares in the aggregate.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company primarily uses the Black-Scholes option pricing model to value options granted to employees and non-employees, as well as options granted to members of the Company&#x2019;s Board of Directors. All stock option grants have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; terms, service conditions, and generally vest ratably over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-year period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of each option granted during the period was estimated on the date of grant using the following weighted average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The expected term of stock options granted is based on historical data and other factors and represents the period of time that stock options are expected to be outstanding prior to exercise. The risk-free interest rate is based on U.S. Treasury strips with maturities that match the expected term on the date of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of option activity for 2023 is presented below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,148,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,002,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,945,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.32&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,227,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested or expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,945,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.32&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,227,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,999,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.56&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,227,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted average grant-date fair values of options granted during the years ended December 31, 2023 and 2022, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and  $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. During both 2023 and 2022, all options were granted with exercise prices equal to the market value of the underlying shares of common stock on the grant date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value in the table above represents the difference between the Company's closing stock price on the last trading day of fiscal 2023 and the exercise price, multiplied by the number of in-the-money options that would have been received by the option holders had all option holders exercised their options on December 31, 2023 (the intrinsic value is considered to be zero if the exercise price is greater than the closing stock price). This amount changes based on the fair market value of the Company's stock. The total intrinsic value of options exercised during the year ended December 31, 2023, determined on the dates of exercise, was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of unrecognized share-based compensation expense related to stock options granted to employees, consultants and directors which, if all milestones are achieved on outstanding performance based awards, will be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years. For awards with performance conditions, expense is recognized if the achievement of underlying performance conditions is deemed probable&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of non-vested stock activity for 2023 is presented below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Nonvested&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;726,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,563,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;804,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;695,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;789,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of unrecognized share-based compensation expense related to these non-vested shares which will be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years. The total intrinsic value of shares vested during the year ended December 31, 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company issues new shares upon option exercises the vesting of non-vested stock and purchases under the ESPP. During the years ended December 31, 2023 and 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,187&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;258,648&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, respectively, were issued as a result of stock option exercises. During the years ended December 31, 2023 and 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;175,196&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,595&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, respectively, were issued as a result of the vesting of non-vested stock. During the year ended December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,340&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were issued under the ESPP. Additionally, during the years ended December 31, 2023 and 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;603,830&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,199&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were issued as payment for certain employee bonuses, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;205,879&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,665&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of those shares being withheld to cover taxes, resulting in a net share issuance of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;397,951&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81,534&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock based compensation expense also includes expense related to awards granted to employees of the Company from the Agenus 2019 Equity Incentive Plan. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The impact on the Company&#x2019;s results of operations from share-based compensation for the year ended December 31, 2023 and 2022, was as follows (in thousands): &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_f0c522b1-1207-430a-a24a-68c5917435b0"
      decimals="INF"
      id="F_bfc601ed-bfc7-4f79-9d34-2abef4702402"
      unitRef="U_shares">13900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_3f948c4b-dbf7-4fe1-80de-c2e6ec8ad0c4"
      decimals="INF"
      id="F_f48fc724-6949-47d0-b5f3-50f81c6a85f5"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_cb159f01-5c87-4f27-ae80-397834ee1e9e"
      decimals="-5"
      id="F_f19d17f2-cd71-49e1-928a-bbc75151464d"
      unitRef="U_shares">6100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <inkt:PercentageOfSharesOfCompanySCommonStockOutstanding
      contextRef="C_ae710cfd-3658-456e-8236-9910244a165d"
      decimals="INF"
      id="F_dab9a481-00a4-47aa-bc95-6c2a0623644f"
      unitRef="U_pure">0.04</inkt:PercentageOfSharesOfCompanySCommonStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_53b8ed07-cd44-46c7-8c61-16a3a18d3787"
      decimals="-5"
      id="F_61f1c750-fb49-42e3-b388-865766e8dfc9"
      unitRef="U_shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_b4dec32d-a6b7-4422-b38c-c1ea75f485c6"
      decimals="-5"
      id="F_661c1c3e-7656-40b8-a994-f17e17162594"
      unitRef="U_shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_cb159f01-5c87-4f27-ae80-397834ee1e9e"
      decimals="-5"
      id="F_dcfcd7db-bfc2-4b82-a887-8e3b818f4ba4"
      unitRef="U_shares">8800000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <inkt:SharesReservedForIssuanceUnderEmployeeStockPurchasePlan
      contextRef="C_8b3b3dc2-5df1-42cf-b22c-651f9e7e2441"
      decimals="-5"
      id="F_8ba7a0ac-20a0-4038-a6d2-3572425a5446"
      unitRef="U_shares">1000000</inkt:SharesReservedForIssuanceUnderEmployeeStockPurchasePlan>
    <inkt:RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding
      contextRef="C_4e994016-9f6a-4ddc-a1f5-464cebf76b9f"
      decimals="INF"
      id="F_6eae9ef8-4a61-4a30-9dcd-81e07f6380bb"
      unitRef="U_pure">0.01</inkt:RatioOfAnnualIncreaseSharesReservedForIssuanceUnderESPPToNumberOfSharesOfCommonStockOutstanding>
    <inkt:SharesReservedForIssuanceUnderEmployeeStockPurchasePlan
      contextRef="C_4e994016-9f6a-4ddc-a1f5-464cebf76b9f"
      decimals="-5"
      id="F_dd42ca1a-cedd-43f7-837e-354b6955732b"
      unitRef="U_shares">3500000</inkt:SharesReservedForIssuanceUnderEmployeeStockPurchasePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="C_268ec649-4cb5-49c6-a775-45044d13d5a1"
      id="F_e16cfd15-fb48-46ad-87e0-3bb32fe334e2">10-year</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_cbf44c3c-afb7-4d6d-ae4b-5bcbfa6eb60d"
      id="F_b99b56cb-1e64-4c6c-8a92-670d44a857cc">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_8a02edeb-2a2b-41a7-856e-4ba72582b120"
      id="F_f7bdc51c-e365-47db-af4b-f62859af49de">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_cabe2a5b-946b-4e74-91a7-ba0cb2df68ce">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of each option granted during the period was estimated on the date of grant using the following weighted average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="2"
      id="F_45d09931-e409-4123-a83e-717c4c78b1d1"
      unitRef="U_pure">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="2"
      id="F_fc32c639-44d2-42cc-b999-a2118fab9458"
      unitRef="U_pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_5013ef72-4096-4fc8-951c-649c05943620">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      id="F_9b6c88c6-02bd-4bf9-8a18-f27f417dbfa4">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="3"
      id="F_a7e20017-4239-4b0e-b2ea-6fbeb68b2691"
      unitRef="U_pure">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="3"
      id="F_114bbe09-ad6e-4655-b69c-a7bc4da6ef8b"
      unitRef="U_pure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="2"
      id="F_94f41025-7e12-4799-b07a-12effd2e0e0b"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="2"
      id="F_d28789ee-57f6-4c83-b62d-24aec375c7a2"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_422d6b87-af60-4ef1-a148-78a118e93b4d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of option activity for 2023 is presented below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,148,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,002,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,945,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.32&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,227,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested or expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,945,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.32&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,227,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,999,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.56&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,227,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="INF"
      id="F_147da777-496a-448c-8f59-143b2156f502"
      unitRef="U_shares">6148447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="2"
      id="F_aa44486a-a9bd-4ffe-8426-49ec18f4b374"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="INF"
      id="F_5cb810e5-6c2c-431c-aca8-70608ae2535f"
      unitRef="U_shares">1002743</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="2"
      id="F_2c49b47b-3233-448e-b96a-27942e194c1f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="INF"
      id="F_9a5e551a-a3f8-453e-b4da-fb5ec06b67ed"
      unitRef="U_shares">105187</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="2"
      id="F_c4be0b16-1f36-490f-b7d4-20c22bd0db94"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="INF"
      id="F_d16ba530-28e5-4c19-9dec-07515d77f718"
      unitRef="U_shares">61883</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="2"
      id="F_045a0d32-335c-4c05-8285-d94bb1331669"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="INF"
      id="F_89283e89-6a96-4e67-880f-e86fc3ceac94"
      unitRef="U_shares">38404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="2"
      id="F_fb5154f1-da10-4eeb-b1e5-2dd09c6c49b9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="INF"
      id="F_d0017ca7-86f6-48f3-bf5b-aefa48556ad8"
      unitRef="U_shares">6945716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="2"
      id="F_8349789c-4a81-46e2-a0ee-9e8bf2c563c1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_16c2ad19-013e-4cc9-8e87-9043efe64660">P7Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_7d81ba79-afe8-4f64-958f-83d93a99459e"
      unitRef="U_USD">2227555</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="INF"
      id="F_0243e63e-7b68-4c71-93d9-c970c58b3981"
      unitRef="U_shares">6945716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="2"
      id="F_0f48cf83-2439-4dea-be5d-b7c8eefb1978"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_916e7b39-be44-40d2-a653-290754649c7f">P7Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_99b64933-e9c8-4703-a23d-ad3f0a761230"
      unitRef="U_USD">2227555</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="INF"
      id="F_9424adfa-1e92-4e0d-bb0d-af791ac12ff7"
      unitRef="U_shares">3999908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="2"
      id="F_a1965395-d965-41ca-a8b7-db20e0c51c11"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_73ec8a8f-a661-4e58-b19b-5cb865e25789">P6Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="0"
      id="F_8af86954-48b0-4bc6-8511-9ed2eed04fc4"
      unitRef="U_USD">2227545</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="2"
      id="F_83c2d7c0-7094-452f-9eaf-7f2dfeab414c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="2"
      id="F_ee9da499-f688-4260-a6f4-c34ff1c0b647"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="-5"
      id="F_577a6fd0-f55c-422b-af01-f4a985a473d0"
      unitRef="U_USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-5"
      id="F_317292bf-eb0c-4590-be8c-fd31a0dc9bd8"
      unitRef="U_USD">3600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_268ec649-4cb5-49c6-a775-45044d13d5a1"
      id="F_3d3d5c50-a2b9-47f5-9ee3-da40b6aabee0">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_3cc48fc8-c45e-407c-ade3-6327632d94a4">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of non-vested stock activity for 2023 is presented below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Nonvested&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;726,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,563,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;804,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;695,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;789,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="INF"
      id="F_7f115ee0-141f-4033-93d6-c690bdefff33"
      unitRef="U_shares">726163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_eb7f200e-d650-4621-9cdf-076793f5da15"
      decimals="2"
      id="F_ec3ec18e-c9b0-48df-8bf3-71eef7c10060"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="INF"
      id="F_f4ba0cd8-6c7e-4f95-a27b-81e662580964"
      unitRef="U_shares">1563324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="2"
      id="F_f878ad20-40eb-4c95-9c9b-e05161491a7c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="INF"
      id="F_beddd8b3-ba23-4adf-b5ad-a3a98b204933"
      unitRef="U_shares">804234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="2"
      id="F_29fc83ca-d21e-4e53-a6e2-1b0975b7d139"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="INF"
      id="F_ba310a90-f6c3-4286-bbbe-fb2e3d8f03be"
      unitRef="U_shares">695750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="2"
      id="F_69700751-ea88-43c4-8ea4-aadac439e279"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="INF"
      id="F_b62e779c-55a3-4be4-80a6-72c998b8abf3"
      unitRef="U_shares">789503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="2"
      id="F_3f502738-4868-4808-ac81-433ce3b301d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_355ecd7a-bbf9-4972-b4d2-95b03fa3e700"
      decimals="-5"
      id="F_243354b4-a7ec-4124-8ebc-9bc0defeb78b"
      unitRef="U_USD">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_2699b8a0-a507-48d8-aebe-0dbceac4496a">P4Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="-5"
      id="F_ab3a55ea-3d7f-4848-9e8a-c72a90ac8de4"
      unitRef="U_USD">1700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="INF"
      id="F_99101aae-5517-4ac0-a8bc-dd2524c5c019"
      unitRef="U_shares">105187</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="INF"
      id="F_6f7d9d1e-d529-419f-a96c-0aa5e6cef5cc"
      unitRef="U_shares">258648</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="INF"
      id="F_081d168f-974e-4a67-b671-efb585bf90e5"
      unitRef="U_shares">175196</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="INF"
      id="F_6e2f597e-b939-4337-9283-5ff763265631"
      unitRef="U_shares">60595</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_b6d89eba-0f82-40fd-b984-843734274884"
      decimals="INF"
      id="F_34a2522e-46db-479a-bc9c-54bdf95eecc5"
      unitRef="U_shares">39340</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="INF"
      id="F_c97a4672-e7df-436a-a7a0-ea988c28fda8"
      unitRef="U_shares">603830</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="INF"
      id="F_ce551908-4bc1-4e1c-9e9e-170da22393bd"
      unitRef="U_shares">125199</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="INF"
      id="F_ff1eef5b-b825-4448-b18c-4cc5533642f2"
      unitRef="U_shares">205879</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="INF"
      id="F_aa649482-39bf-401c-bbf7-f325d4c2133c"
      unitRef="U_shares">43665</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <inkt:StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="INF"
      id="F_fd907069-12a5-4d72-a9bd-58d47eb96f91"
      unitRef="U_shares">397951</inkt:StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes>
    <inkt:StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="INF"
      id="F_53fbf697-e509-46c3-be1d-adafb8aafdd5"
      unitRef="U_shares">81534</inkt:StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_88110e64-a768-4166-9f92-275b6a95019e">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The impact on the Company&#x2019;s results of operations from share-based compensation for the year ended December 31, 2023 and 2022, was as follows (in thousands): &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5c2d616e-4ddf-4064-8944-7301eb485567"
      decimals="-3"
      id="F_aeddaf04-4c84-4066-9a87-f64041fe9171"
      unitRef="U_USD">541000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_95392f28-5e39-4fdd-bb55-5bba87d291c1"
      decimals="-3"
      id="F_ffec692a-0b06-4cc4-9267-d5100954c75c"
      unitRef="U_USD">435000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_346638e3-eec6-429f-b5ff-617610cdae8c"
      decimals="-3"
      id="F_c46c0cbb-fd7e-44e2-a31e-b3a0bc8333e4"
      unitRef="U_USD">3289000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cefd892b-5378-4271-adcd-95443a008fca"
      decimals="-3"
      id="F_3677402e-61bd-4ee5-8ba9-f57a4c5a0d45"
      unitRef="U_USD">2592000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="-3"
      id="F_90dac4d6-ea7d-44c5-9c8d-3e10c81c5293"
      unitRef="U_USD">3830000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="-3"
      id="F_59c879d7-bd7c-439c-81d6-8f40e9e01fef"
      unitRef="U_USD">3027000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_04df2868-7aa4-46f2-b545-59a22be5a96d">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(9) Research and Development Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2018, the Company entered into an agreement with the Belgium Walloon Region Government ("Walloon Region") in which the Walloon Region agreed to provide a grant of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and a repayable advance of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the development of one of the Company&#x2019;s research programs. During 2020, the Company discontinued research efforts related to this program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other current liabilities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023 and December 31, 2022, respectively, represent the remaining amount of the advance received.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2022, the Company received notice that the Walloon Region had obtained a default judgment seeking repayment of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the advance based upon the Company allegedly not providing required notification that research and operations in the region were discontinued. In the year ended December 31, 2022, the Company reduced the recorded liability from the prior total of all amounts received under the advance from the Walloon Region, to the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million repayment that would be due based on the default judgment, and recorded a gain of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in &#x201c;other income (expense), net&#x201d; on its consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <inkt:RepayableAdvanceOfDevelopmentGranted
      contextRef="C_74e50261-4062-42c1-85a6-53221008391a"
      decimals="-5"
      id="F_c8845241-924c-48e7-83c8-c2a3525c797a"
      unitRef="U_EUR">1300000</inkt:RepayableAdvanceOfDevelopmentGranted>
    <inkt:RepayableAdvanceOfDevelopment
      contextRef="C_74e50261-4062-42c1-85a6-53221008391a"
      decimals="-5"
      id="F_5a350d64-47a1-4100-9ee8-7247d1c3e5d6"
      unitRef="U_EUR">8300000</inkt:RepayableAdvanceOfDevelopment>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_51eb493f-bc2b-4fd9-b5aa-efa55fc34f2c"
      decimals="-5"
      id="F_2a35cbb6-4d9a-42e2-bae8-72c68a58ffda"
      unitRef="U_USD">2300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0acbebda-ba84-4b3e-97b5-988e9d80a5aa"
      decimals="-5"
      id="F_f7333fb1-cfb4-4ef7-ab59-554697f010dc"
      unitRef="U_USD">2200000</us-gaap:OtherLiabilitiesCurrent>
    <inkt:RepayableAdvanceReceived
      contextRef="C_8cc928c1-4773-48cd-b025-3a741ebaaee1"
      decimals="-5"
      id="F_8d253712-df60-4a8e-bec9-b848d0efd972"
      unitRef="U_USD">2300000</inkt:RepayableAdvanceReceived>
    <inkt:RepayableAdvanceReceived
      contextRef="C_8cc928c1-4773-48cd-b025-3a741ebaaee1"
      decimals="-5"
      id="F_0179b70d-4c2b-4d38-8dea-c76f27adcae1"
      unitRef="U_USD">2300000</inkt:RepayableAdvanceReceived>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_e13b52a1-81e9-4212-b833-7812073181d6"
      decimals="-5"
      id="F_96d59295-a7e1-47b6-ad2b-a951897b6dc4"
      unitRef="U_USD">2700000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_740c8ef9-8af2-4635-81cd-9aab3c6d9c64">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(10) Related Party Transactions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Until the completion of its IPO, the Company relied on Agenus for all of its working capital requirements. For the periods presented, certain of the Company&#x2019;s operations were fully integrated with Agenus, including, but not limited to, corporate functions such as finance, human resources, information technology and legal functions. The Company&#x2019;s consolidated financial statements reflect all costs of doing business related to these operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 2021, the Company entered into an Intellectual Property Assignment and License Agreement with Agenus (the &#x201c;New Assignment and License Agreement&#x201d;), upon which the prior intercompany agreement between Agenus and MiNK was terminated. Pursuant to the New Assignment and License Agreement, Agenus assigned to the Company certain patent rights and know-how related to its iNKT cell platform, product candidates and other patents and know-how related to its business. In addition to the patent rights assigned to the Company by Agenus, the Company also received an exclusive, royalty-free, sublicensable license to research,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;develop, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;manufacture and commercialize certain licensed technology in the field. The New Assignment and License Agreement further provides for the Company to grant Agenus a field-limited, non-exclusive, royalty-free license under the assigned patent rights, subject to MiNK&#x2019;s discretion and provided such access would not reasonably result in a disruption of planned MiNK activities. Agenus has also agreed to provide the Company with Agenus&#x2019; biological material upon written request in order for the Company to use such material in its development activities of a combination therapy. Agenus may withhold the transfer of biological material, including, but not limited to, checkpoint modulating antibodies, for various reasons, including if such transfer would reasonably result in a disruption of planned Agenus activities. For any materials Agenus does share with the Company, the parties have agreed to enter into a separate agreement governing the transfer and providing for joint ownership of the data. Agenus has agreed that during the full term of the New Assignment and License Agreement, and for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thereafter, it will not develop, manufacture or commercialize an iNKT cell therapy, directly or indirectly by transferring such technology. The Company has the sole responsibility to develop, manufacture and commercialize products under this New Assignment and License Agreement. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company may terminate the New Assignment and License Agreement without cause upon &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; days&#x2019; prior written notice to Agenus. Either party may terminate if they believe there has been a material breach which has not been cured within 90 days (or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; days for breach of payment obligations) of receiving such notice.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective April 1, 2022, the Company entered into an Amended and Restated Intercompany Services Agreement (the &#x201c;New Intercompany Agreement&#x201d;) with Agenus, which amended and restated the Intercompany General &amp;amp; Administrative Agreement between the Company and Agenus dated September 10, 2021 (the &#x201c;Prior Intercompany Agreement&#x201d;). Under the New Intercompany Agreement, Agenus provides the Company with certain general and administrative support, including, without limitation, financial, facilities management, human resources and information technology administrative support (the &#x201c;Agenus Services&#x201d;), and the Company and Agenus provide each other with certain research and development services (the &#x201c;R&amp;amp;D Services&#x201d;) and other support services, including legal and regulatory support (the &#x201c;Shared Services&#x201d;). The Company is required to pay &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of Agenus&#x2019; costs related to the Agenus Services, and the costs of R&amp;amp;D Services are based upon pass-through costs related to such services plus an allocation of the costs of the employees performing the services. No payment will be due from either party for the Shared Services, provided that the services provided by each party are proportional in scope and volume. The Company is also entitled to use Agenus&#x2019; business offices and laboratory space and equipment (inclusive of a cGMP site) in exchange for the Company contributing a proportionate payment for the use of such facilities and equipment, and the Company will be covered by certain Agenus insurance policies, subject to certain conditions, including the Company paying the cost of such coverage. Either party may terminate the New Intercompany Agreement upon &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; days&#x2019; prior written notice and individual services upon &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; days&#x2019; prior written notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Allocated Agenus services primarily include payroll related expenses, facility costs, insurance and stock-based compensation, and are included in the accompanying financial statements based on certain estimates and allocations described above. Under the Prior Intercompany Agreement, the allocation methods primarily included time devoted to activities and headcount-based allocations. Agenus business services and occupancy costs were allocated to the Company based on the Company&#x2019;s headcount as a percentage of Agenus&#x2019; and the Company was required to pay &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of Agenus&#x2019; costs for these business services and occupancy costs. Research services were charged between the entities based on hours recorded by Agenus employees as time spent on specific projects, applied to hourly wage rates, and the Company paid &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of Agenus&#x2019; costs for these research services. As such, these allocations may not be indicative of the actual amounts that would have been recorded had the Company operated as an independent, publicly traded company for the periods presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Allocation of Agenus Services, net, of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended December 31, 2023 and 2022, respectively, is included in Operating expenses in the Company&#x2019;s statement of operations and comprehensive loss and Due to related parties, of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023, in the Company&#x2019;s consolidated balance sheet. Agenus has agreed to not require repayment of this balance prior to March 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2023, the Company's CEO (&#x201c;Dr. Buell&#x201d;), became an employee of Agenus in the role of Chairman of the Executive Council. As an employee of Agenus, Dr. Buell is paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; annually and was granted an option to acquire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;750,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Agenus common stock that vest over a period of four years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective April 12, 2022, the Company entered into a Master Services Agreement with Atlant Clinical Ltd. (&#x201c;Atlant&#x201d;), a subsidiary of Agenus, to provide clinical trial support services to the Company, including an eTMF platform, medical monitoring and data manager services. The Company&#x2019;s Audit and Finance Committee approved the engagement under its related-party transactions policy for up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in services. As of December 31, 2023, the Company had entered into work orders with Atlant totaling approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, plus out of pocket expenses which are to pass through to Company at cost. For the years ended December 31, 2023 and 2022, approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; related to these services is included in &#x201c;Research and development&#x201d; expense in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Dr. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Buell's spouse is a partner in the law firm of Wolf, Greenfield &amp;amp; Sachs, P.C. (&#x201c;Wolf Greenfield&#x201d;), which provided legal services to the Company during the years ended December 31, 2023 and 2022, and continues to do so. In the years ended December 31, 2023 and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Company expensed Wolf Greenfield fees totaling approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;343,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. Dr. Buell&#x2019;s spouse does not receive direct compensation from the fees paid to Wolf Greenfield by the Company and the fees paid by the Company to Wolf Greenfield in the period was an insignificant amount of Wolf Greenfield&#x2019;s revenues. The Company&#x2019;s Audit and Finance Committee approved these services under its related-party transactions policy.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <inkt:PeriodOfLicenseAgreement
      contextRef="C_88fdd179-67f1-4d6b-afcb-9aa725675bbd"
      id="F_b60e1f49-9dc9-413f-978b-a81be9cca043">P3Y</inkt:PeriodOfLicenseAgreement>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="C_88fdd179-67f1-4d6b-afcb-9aa725675bbd"
      id="F_e6d1a54f-6c4a-40d1-aaf1-28b24d39b68e">The Company may terminate the New Assignment and License Agreement without cause upon 90 days&#x2019; prior written notice to Agenus. Either party may terminate if they believe there has been a material breach which has not been cured within 90 days (or 45 days for breach of payment obligations) of receiving such notice.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <inkt:TerminateLicenseAgreementPeriod
      contextRef="C_88fdd179-67f1-4d6b-afcb-9aa725675bbd"
      id="F_a31fb919-9aa4-4dc4-bafe-d4bbff75d991">P90D</inkt:TerminateLicenseAgreementPeriod>
    <inkt:PeriodForBreachOfPaymentObligations
      contextRef="C_88fdd179-67f1-4d6b-afcb-9aa725675bbd"
      id="F_a0094a9f-58ae-47f3-be0c-82e628723eb6">P45D</inkt:PeriodForBreachOfPaymentObligations>
    <inkt:PercentageOfServiceCost
      contextRef="C_92993aa5-8d2c-43e1-861d-dafd88c0d11f"
      decimals="2"
      id="F_ee5dab80-3f84-4fe1-9d62-e2fe3126d34b"
      unitRef="U_pure">0.10</inkt:PercentageOfServiceCost>
    <inkt:ServiceAgreementNoticePeriod
      contextRef="C_92993aa5-8d2c-43e1-861d-dafd88c0d11f"
      id="F_25c6b887-ca72-4f3b-9658-5093061b3281">P60D</inkt:ServiceAgreementNoticePeriod>
    <inkt:ServiceAgreementNoticePeriod
      contextRef="C_1fff5c2a-d559-4ece-acb2-fc94ed1c220d"
      id="F_60af964f-49de-4660-b211-987fcab30eb1">P30D</inkt:ServiceAgreementNoticePeriod>
    <inkt:PercentageOfServiceCost
      contextRef="C_396bcb04-2fa1-44c0-ba48-210a76d1239a"
      decimals="2"
      id="F_9edde705-ba77-4d95-af96-9dfc082b0539"
      unitRef="U_pure">1.05</inkt:PercentageOfServiceCost>
    <inkt:PercentageOfServiceCost
      contextRef="C_b633005e-91ea-43eb-97fa-7e4b54c42a57"
      decimals="2"
      id="F_0fc7f7d2-3827-43fc-bbaa-e54a16bdfdd7"
      unitRef="U_pure">1.10</inkt:PercentageOfServiceCost>
    <inkt:IntercompanyAllocationIncludedInExpense
      contextRef="C_88fdd179-67f1-4d6b-afcb-9aa725675bbd"
      decimals="-5"
      id="F_2072e3bd-cb72-4e95-b61b-bb9a7a4cf34e"
      unitRef="U_USD">1000000</inkt:IntercompanyAllocationIncludedInExpense>
    <inkt:IntercompanyAllocationIncludedInExpense
      contextRef="C_732341c7-957d-4682-9e02-69f3f41bc8cb"
      decimals="-5"
      id="F_86dc3a1d-7fed-42db-98f3-471d328f8bad"
      unitRef="U_USD">2000000</inkt:IntercompanyAllocationIncludedInExpense>
    <inkt:DueToRelatedParty
      contextRef="C_174c7e6c-f05b-4cd6-b218-630f2cf7c135"
      decimals="-5"
      id="F_95296c96-3856-4faf-99e5-d04c2db90891"
      unitRef="U_USD">11200000</inkt:DueToRelatedParty>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="C_0247a7d4-1c63-48a2-b771-84ce9fed7ccf"
      decimals="0"
      id="F_3a9e9a84-05a6-44f4-aeff-b947cdc63846"
      unitRef="U_USD">150000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_6ac170bb-03d4-44e8-b39d-948d34f91995"
      decimals="INF"
      id="F_79208c37-63a6-4fc2-a997-76423d1dc234"
      unitRef="U_shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_70150baa-d209-420b-b3f0-9727e2e8e91b"
      decimals="0"
      id="F_8c59e66a-22b9-4f78-a1fd-9a87840be4fc"
      unitRef="U_USD">250000</us-gaap:OperatingCostsAndExpenses>
    <inkt:WorkOrderReceivedFromRelatedParty
      contextRef="C_7f88878f-2cfe-43e5-b0ca-654e225c9a1c"
      decimals="0"
      id="F_46217aaa-fcd8-40fd-8b49-83d8af75b62d"
      unitRef="U_USD">167000</inkt:WorkOrderReceivedFromRelatedParty>
    <inkt:ClinicalResearchServices
      contextRef="C_12d6f787-9426-4e92-85b0-11024f100689"
      decimals="0"
      id="F_99ef4ade-d4c4-4033-99c8-474521f97c8e"
      unitRef="U_USD">30500</inkt:ClinicalResearchServices>
    <inkt:ClinicalResearchServices
      contextRef="C_43fdd5bf-5e30-46cf-b276-ce4dac22ec86"
      decimals="0"
      id="F_c0ad08a4-96eb-4870-9426-51054cf221d7"
      unitRef="U_USD">106500</inkt:ClinicalResearchServices>
    <us-gaap:LegalFees
      contextRef="C_4ce3db47-5730-4c1e-bcf4-44053fd9ff21"
      decimals="0"
      id="F_69f5ad00-e0da-4247-85d6-6a22890d2c05"
      unitRef="U_USD">225000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="C_30bfebaf-513a-4ffd-92f3-96640e11b431"
      decimals="0"
      id="F_1ff0146e-423a-4e38-8023-28161e86b680"
      unitRef="U_USD">343000</us-gaap:LegalFees>
    <us-gaap:LossContingencyDisclosures
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_656f80b8-8c34-477b-9e7d-e4f9930f4caa">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(11) Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company may currently be, or may become, a party to legal proceedings. While the Company currently believes that the ultimate outcome of any of these proceedings will not have a material adverse effect on its financial position, results of operations, or liquidity, litigation is subject to inherent uncertainty.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LossContingencyDisclosures>
    <us-gaap:DefinedBenefitPlanTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_607bd66a-8f55-4c09-960d-9f5a776dae6c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(12) Benefit Plans&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s employees are eligible to participate in the Agenus Inc. 401(k) Savings Plan in the United States and a defined contribution Group Personal Pension Plan in the United Kingdom (the &#x201c;Plans&#x201d;) for all eligible employees, as defined in the Plans. Participants may contribute a portion of their compensation, subject to a maximum annual amount, as established by the applicable taxing authority. Each participant is fully vested in his or her contributions and related earnings and losses. For the years ended December 31, 2023 and 2022, the Company expensed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, related to the discretionary contribution to the Plans.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedBenefitPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      decimals="0"
      id="F_a8645872-ff41-4d3e-bf63-7c9581e99f3f"
      unitRef="U_USD">172000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_7b863875-076d-407c-9f20-f71f59c308af"
      decimals="0"
      id="F_7e616447-ecbc-4ebd-8674-582dd055ab7d"
      unitRef="U_USD">131000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_e483d8b6-b887-4adb-87ea-1ee972fb3247"
      id="F_2f79e023-3282-4e0c-a7e0-2af98a79785c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(13) Subsequent Events&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 12, 2024, the Company and Agenus entered into a Convertible Promissory Note Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) pursuant to which the Company issued to Agenus a Convertible Promissory Note in the principal amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (the &#x201c;Note&#x201d;). The Purchase Agreement sets forth the terms and conditions, including representations and warranties, for the Company&#x2019;s issuance and sale of the Note to Agenus.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company may draw down on the principal amount of the Note from time to time with Agenus&#x2019;s consent in any increment, either in the form of advancements or payments made by Agenus on the Company&#x2019;s behalf. The Note carries an annual rate of interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% (the &#x201c;Interest Rate&#x201d;) that accrues from the date funds are paid or advanced by Agenus to the Company. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest shall accrue and not be payable until converted or paid in connection with the repayment in full of the principal amount of the Note. The Note provides that the Company will pay Agenus on demand the principal amount outstanding, together with any unpaid interest, on or after January 1, 2026.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; In the event of a qualified financing event, as described in the Note, at Agenus&#x2019;s election, the Company must pay the principal amount outstanding and any unpaid interest, either in full or in the form of equity securities. In March 2024 MiNK received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from Agenus and the Note was fully drawn.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Nasdaq MVLS Notice&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 23, 2024, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) notifying it that for the previous &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; consecutive trading days the Company&#x2019;s Minimum Value of Listed Securities (&#x201c;MVLS&#x201d;) was less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, as required by Nasdaq Listing Rule 5550(b)(2) (the &#x201c;MVLS Rule&#x201d;).  Nasdaq has provided the Company with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; calendar days, or until August 21, 2024, to regain compliance. To regain compliance, the Company&#x2019;s MVLS must meet or exceed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for a minimum of ten consecutive trading days.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the event the Company does not regain compliance with the MVLS Rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Hearings Panel. The Company will continue to monitor its MVLS and consider its available options to regain compliance with the MVLS Rule. However, there can be no assurance that the Company will be able to regain compliance with the MVLS Rule.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Nasdaq Minimum Bid Price Notice&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 26, 2024, the Company received a letter (the &#x201c;Minimum Bid Price Notice&#x201d;) from Nasdaq notifying the Company that its common stock, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; par value per share (the &#x201c;Common Stock&#x201d;), failed to comply with the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the &#x201c;Minimum Bid Price Rule&#x201d;) based upon the closing bid price of the Common Stock for the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; consecutive trading days prior to the date of the Minimum Bid Price Notice from Nasdaq.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has been provided an initial compliance period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; calendar days, or until August 26, 2024, to regain compliance with the Minimum Bid Price Rule which requires that the closing bid price of the Common Stock meet or exceed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share for a minimum of ten consecutive trading days.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If the Company is unable to regain compliance with the Minimum Bid Price Rule, the Company may be eligible for an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;180-day&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Rule, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for the second compliance period or fails to regain compliance during the second &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;180-day&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period, Nasdaq will notify the Company of its determination to delist the Common Stock, at which point the Company would have an opportunity to appeal the delisting determination to a Hearings Panel.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company will continue to monitor the bid price of the Common Stock and consider its available options to regain compliance with the Minimum Bid Price Rule. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Rule.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="C_25dc845e-01ae-44d3-831b-9b8aed9e8e67"
      decimals="-5"
      id="F_91061339-6525-479f-be66-ee5633c24a79"
      unitRef="U_USD">5000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="C_25dc845e-01ae-44d3-831b-9b8aed9e8e67"
      decimals="2"
      id="F_78b27e6e-d0bc-4fe7-8bf2-6c828ac6f20c"
      unitRef="U_pure">0.02</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateTerms
      contextRef="C_25dc845e-01ae-44d3-831b-9b8aed9e8e67"
      id="F_0e7c9e7e-cbd2-4719-8074-0607ce3b3d94">Interest shall accrue and not be payable until converted or paid in connection with the repayment in full of the principal amount of the Note. The Note provides that the Company will pay Agenus on demand the principal amount outstanding, together with any unpaid interest, on or after January 1, 2026.</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:ConvertibleDebt
      contextRef="C_e0540306-0080-4f2c-8d4d-23d53f4564e5"
      decimals="-5"
      id="F_547ead0f-ad34-421d-88d4-cf5b95495dd6"
      unitRef="U_USD">5000000</us-gaap:ConvertibleDebt>
    <inkt:MinimumValueOfListedSecuritiesPeriod
      contextRef="C_5a5913b2-d4ec-4aae-bf25-d4732ba15bdf"
      id="F_27534214-3a7d-4597-b80f-511edca75fca">P30D</inkt:MinimumValueOfListedSecuritiesPeriod>
    <inkt:MinimumValueOfListedSecurities
      contextRef="C_957e80a8-d4b5-459b-8ae0-7824ad63cf97"
      decimals="-5"
      id="F_cb76f5a2-dbd3-454f-a179-eb649d7bd83b"
      unitRef="U_USD">35000000</inkt:MinimumValueOfListedSecurities>
    <inkt:AdditionalPeriodForMinimumValueOfListedSecurities
      contextRef="C_5a5913b2-d4ec-4aae-bf25-d4732ba15bdf"
      id="F_5bf23cda-25f0-4af0-ab06-e467875fab63">P180D</inkt:AdditionalPeriodForMinimumValueOfListedSecurities>
    <inkt:MinimumValueOfListedSecuritiesForTenTradingDays
      contextRef="C_ed60fc07-4280-4084-b339-04048dfe71c4"
      decimals="-5"
      id="F_a75307ff-d712-4a42-9cc8-478f33e7290e"
      unitRef="U_USD">35000000</inkt:MinimumValueOfListedSecuritiesForTenTradingDays>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_56e9f88d-c09c-467c-a477-e97ed4507f16"
      decimals="INF"
      id="F_cbf74ece-de20-4bfe-9de6-779857e11113"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <inkt:MinimumBidPrice
      contextRef="C_637388a5-8881-487e-b1c7-e3b9f34f5c6e"
      decimals="0"
      id="F_1f6d68d8-ccd8-4396-a0ae-3b57a4c011b5"
      unitRef="U_USD">1</inkt:MinimumBidPrice>
    <inkt:NumberOfConsecutivetradingDays
      contextRef="C_637388a5-8881-487e-b1c7-e3b9f34f5c6e"
      id="F_37b17795-6295-4eae-82bf-b823488524ea">P30D</inkt:NumberOfConsecutivetradingDays>
    <inkt:InitialCompliancePeriod
      contextRef="C_637388a5-8881-487e-b1c7-e3b9f34f5c6e"
      id="F_954fa9f3-c03a-4d1e-a097-eedc5e60cebc">P180D</inkt:InitialCompliancePeriod>
    <inkt:ClosingBidPriceForTenTradingDays
      contextRef="C_637388a5-8881-487e-b1c7-e3b9f34f5c6e"
      decimals="2"
      id="F_e4032214-aed1-48eb-9286-36ef8993bc06"
      unitRef="U_USD">1</inkt:ClosingBidPriceForTenTradingDays>
    <inkt:AdditionalCompliancePeriod
      contextRef="C_637388a5-8881-487e-b1c7-e3b9f34f5c6e"
      id="F_0e93e705-c8df-484c-91e9-5c852c039212">P180D</inkt:AdditionalCompliancePeriod>
    <inkt:SecondCompliancePeriod
      contextRef="C_637388a5-8881-487e-b1c7-e3b9f34f5c6e"
      id="F_e098b545-e4aa-4134-8a7a-b0332d0e2fc9">P180D</inkt:SecondCompliancePeriod>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_4ed8c189-5338-453a-9f58-24dd7ab9d275"
      id="F_b6d43e60-2abc-41d6-98bf-f136d7ce256d">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_4ed8c189-5338-453a-9f58-24dd7ab9d275"
      id="F_70045169-f010-4eea-adc3-3fad7e9f2d5c">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_4ed8c189-5338-453a-9f58-24dd7ab9d275"
      id="F_abc358ef-bbdb-4f0c-81df-3a16184fcb87">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_4ed8c189-5338-453a-9f58-24dd7ab9d275"
      id="F_f9342393-323f-4c82-8943-7abcedeae425">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
